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Abstract 
 
Cdc25 phosphatases play a crucial role in the regulation of the cell cycle, and overexpression 
of the three known isoforms has been directly correlated with poor cancer prognosis. 
Inhibition of this enzyme could prove to be an effective therapeutic strategy, but the most 
potent reported inhibitors lack specificity and an appropriate mechanism of action. 
Furthermore, more basic research is needed into the structure and precise cellular function of 
the different cdc25 isoforms. 
 
Following a literature survey, panels of novel inhibitors modelled on the natural product 
dysidiolide and reported quinonoid compounds were synthesised. Initial phosphatase assay 
results with cdc25A discouraged any further synthesis of related inhibitors. 
 
The untagged catalytic domain of each isoform was prepared, expressed and purified to carry 
out NMR structural studies. However, preliminary spectra showed a high degree of 
conformational flexibility that made further analysis prohibitively difficult. Extensive 
screening of crystallisation conditions also did not prove successful.  
 
As an alternative strategy, a ligand-based virtual screening approach using an optimised 
selection of reported inhibitors resulted in discovery of diarylthiazoles as novel, potent and 
drug-like inhibitors of cdc25 and the related phosphatase VHR. Some of these compounds 
also demonstrated potent anti-proliferative activity against a panel of cell lines.  
 
Parallel synthesis of a wide range of diarylthiazole analogues using a regioselective, 
sequential Pd-coupling approach proved moderately successful, identifying promising novel 
inhibitors for further development, although without significantly increasing the binding 
affinity. Screening of a wide range of commercially-available compounds chosen by a 
substructure analysis identified further promising inhibitors, which compare favourably with 
the best literature compounds. Attempts to develop novel methodology for the rapid and 
divergent synthesis of aminothiazoles ultimately proved unsuccessful with respect to various 
approaches to the difficult C-N bond formation, but simple conditions were found for the 
synthesis and Suzuki coupling of a highly electron-rich aminothiazole C4-triflate. 
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Abbreviations 
 
A alanine 
A549 an epithelial cell line 
Ac acetyl 
Ala alanine 
Am amyl 
AP alkaline phosphatase 
aq. aqueous 
Ar aryl 
Arg arginine 
Asp aspartic acid 
ATP adenosine triphosphate 
A.U. arbitrary units 
BINAP 2,2'-bis( diphenylphosphino)-1,1'-binaphthyl 
bipy 2,2’-bipyridine 
BME β-mercaptoethanol 
Boc tert-butoxycarbonyl 
BPV(pic) dipotassium bisperoxo (picolinato) oxovanadate (V) 
br broad 
BSA bovine serum albumin 
Bu butyl 
C cysteine 
C33A a cervical carcinoma cell line 
Cdc cell division cycle 
CDI 1,1’-carbonyldiimidazole 
CDK cyclin-dependent kinase 
CI chemical ionisation MS 
CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate) 
cLogP calculated logP, where P is the partition coefficient 
cm centimetre(s) 
Cyc cyclin 
Cys cysteine 
d doublet/day(s) 
D aspartic acid 
dba dibenzylideneacetone 
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene 
DDC Imperial College’s Drug Discovery Centre 
dH2O distilled water 
DIAD diisopropyl azodicarboxylate 
DIBAL diisobutylaluminium hydride 
DIPEA N,N-diisopropylethylamine 
DMAP dimethylaminopyridine 
DME dimethoxyethane 
DMEDA N,N’-dimethylethylenediamine 
DMF N,N-dimethylformamide 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dNTP deoxyribonucleotide triphosphate 
dppf 1,1'-bis(diphenylphosphino)ferrocene 
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DTT dithiothreitol 
DUSP dual-specificity phosphatase 
E. Coli Escherichia Coli 
EDTA ethylenediaminetetraacetic acid 
eq. equivalents 
ERK extracellular-signal-regulated kinase 
Et ethyl 
F phenylalanine 
FemX a melanoma cell line 
g gram(s) 
GST glutathione S-transferase 
h hour(s) 
H histidine 
HATU 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate 
Hep3B hepatoma 3B, a liver cancer cell line 
HPLC high-performance liquid chromatography 
HSQC Heteronuclear Single Quantum Coherence 
HT29 heterotransplantable – 29, a colon cancer cell line 
HWE Horner-Wadsworth-Emmons 
Hz Hertz 
IC50 half maximal inhibitory concentration 
IMes 1,3-bis(mesityl)imidazolium 
IPTG isopropyl β-D-thiogalactopyranoside 
IR infra-red 
kbp kilobase pair(s) 
kDa kilo-Daltons 
KOD Thermococcus kodakaraensis 
krpm kilo-revolutions per minute 
kV kilovolt(s) 
LAR leucocyanidin reductase, an oxidoreductase enzyme 
LB Luria Broth 
LHMDS lithium bis(trimethylsilyl)amide 
LE ligand efficiency 
LLE lipophilic ligand efficiency 
LNCaP lymph node carcinoma of the prostate, a prostate cancer cell line 
μg microgram(s) 
μL microlitre(s) 
μm micrometre(s) 
μM micromolar 
m multiplet 
M molar 
mA milliamp(s) 
MAPK mitogen-activated protein (MAP) kinase 
MCF-7 Michigan Cancer Foundation – 7, a breast cancer cell line 
MDA-MB M.D. Anderson – metastatic breast, a breast cancer cell line 
Me methyl 
mg milligram(s) 
MHz megaHertz 
min minute(s) 
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MKP MAPK phosphatase 
mL millilitre(s) 
mM millimolar 
mmol millimole(s) 
mp melting point 
mRNA messenger RNA 
Ms mesyl 
MS mass spectrum/mass spectrometry 
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium 
MVK methylvinylketone 
MW molecular weight 
Myc myelocytomatosis gene product, a transcription factor 
NBS N-bromosuccinimide 
NCI National Cancer Institute 
N.D. not determined 
NETN NP40, EDTA, Tris-HCl, NaCl (see Appendix) 
NHC N-heterocyclic carbene 
NIH-3T3 National Institute of Health – 3T3, a fibroblast cell line 
nm nanometre 
NMR nuclear magnetic resonance 
NP40 octylphenolpoly(ethyleneglycolether) 
OMFP 3-O-methylfluorescein phosphate 
PCR polymerase chain reaction 
petrol petroleum ether (40-60 °C) 
Ph phenyl 
Phe phenylalanine 
pin pinacolate 
ppm parts per million 
PNPP para-nitrophenyl phosphate 
PTP protein tyrosine phosphatase 
R arginine 
Raf rapidly accelerated fibrosarcoma, a family of kinases 
Ras rat sarcoma, a family of GTPase proteins 
Rf retention factor 
RNA ribonucleic acid 
ROS reactive oxygen species 
r.t. room temperature 
s second(s), singlet 
SAR structure-activity relationship(s) 
SDS sodium dodecylsulfate 
SDS-PAGE SDS-polyacrylamide gel electrophoresis 
SEM standard error of the mean 
t triplet 
TAE tris/acetate/EDTA (see Appendix) 
Taq Thermus aquaticus 
TBAB tetra-n-butylammonium bromide 
TCDI 1,1’-thiocarbonyldiimidazole 
Tf triflyl 
TFA trifluoroacetic acid 
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THF tetrahydrofuran 
Thr threonine 
TLC thin layer chromatography 
TMEDA tetramethylethylenediamine 
TMS trimethylsilyl, tetramethylsilane 
tR retention time 
Tris tris(hydroxymethyl)aminomethane 
Tween polysorbate 20 
Tyr tyrosine 
UV ultra-violet 
VHR vaccinia H1-related phosphatase 
W Watt(s) 
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1 Background and Project Aims 
 
 
The eukaryotic cell cycle can be divided into four phases. In the S (synthesis) phase the 
nuclear DNA is replicated, and in the M (mitotic) phase the cell undergoes first nuclear then 
cytoplasmic division. Dividing these key stages are the G1 and G2 (gap) phases, when 
decisions are made about whether to commit to the next stage of division. 
 
The essential processes of the cell cycle are primarily regulated by two key classes of 
interacting protein; cyclins and cyclin-dependent kinases (CDKs). These molecules operate at 
the transitions between the cycle phases, and as such allow environmental signals to regulate 
progression of the cell cycle. Cyclins bind to CDKs and control their ability to phosphorylate 
certain target proteins. This occurs in a cyclical fashion, involving the synthesis and 
degradation of different cyclins at different stages of the cell cycle.
1
  
 
Cell division cycle 25 (cdc25) family proteins are highly conserved dual specificity 
phosphatases that regulate CDK activation by removal of inhibitory phosphate groups from 
both threonine and tyrosine residues.
2,3
 Specifically, dephosphorylation of two CDK residues 
(Thr14 and Tyr15 for CDK1) in the loop involved in positioning the γ-phosphate of ATP 
relieves inhibition of the CDK-cyclin complex, reversing the effect of CDK-inhibitory kinase 
Wee1 and ultimately ensuring irreversible transition to the next stage of the cell cycle (Figure 
1).
4,5,6
 
 
 
Figure 1 – Cdc25 removes inhibitory phosphates from CDK/cyclin complexes 
 
There are three isoforms of cdc25 (A, B and C), which share a highly conserved C-terminal 
catalytic domain that contains the active site and substrate recognition regions. The N-
terminal domain is highly divergent, and this is amplified by alternative splicing that 
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generates at least 12 splice variants.
2
 The N-domain is thought to play a purely regulatory role, 
and it contains common features that serve this purpose; nuclear import-export signals control 
the cellular localisation and phosphorylation, and ubiquitination sites control protein activity, 
degradation and regulatory association.
2
 The catalytic domain contains the key nucleophilic 
cysteine residue that the majority of phosphatases use to displace the phosphate group from 
their substrates, with subsequent hydrolysis of the phospho-cysteine intermediate. 
 
The specific functions of the three cdc25 isoforms are not yet fully understood.
7
 The initial 
models were conceptually simple, with each isoform acting on specific CDK/cyclin substrates 
at well-defined points in the cell cycle (Figure 2).
2
 For example, the role of cdc25A was 
thought to promote transfer to the S phase by dephosphorylation of both the CDK2-cyclin E 
and CDK2-cyclin A complexes,
8,9
 and cdc25B and C were thought to individually play key 
roles in the activation of CDK1-cyclin B at the G2-M transition, irreversibly driving the cell 
into mitosis. 
 
 
Figure 2 – Roles of cdc25 in the cell cycle 2  
 
This relatively simple picture has been significantly complicated by recent studies which have 
revealed conflicting data regarding the roles of the three cdc25 isoforms. Using the RNA 
interference method of targeted inhibition, first cdc25B and then cdc25C were found to affect 
the rate of progression into the S phase, despite the presence of functional cdc25A.
10,11
 
Similar results have been obtained for entry into M phase, with evidence for a key role for 
cdc25C in certain feedback loops for cdc25A activation, demonstrating the cooperative nature 
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of these phosphatases.
12
 Further data were provided by studies in which cdc25B- and C-
knockout mice develop normally in terms of the cell cycle, response to DNA damage and 
regulation of cdc25A.
13
 However, not only has the applicability of this study to human cells 
has been questioned,
14
 other recent studies have also found that cdc25B is essential for 
recovery of cell cycle function following a period of arrest caused by DNA damage.
15
 It is 
likely therefore that the web of interactions is more complex and cooperative than previously 
thought, and that there are subtle functional differences between the isoforms. This evidence 
suggests an overall picture of the cdc25 phosphatases being largely functionally-
interchangeable, with the differing activity observed with different substrates perhaps 
suggesting evolution in progress towards a more narrow range of specialised activity. This is 
supported by the comparison with lower eukaryotic systems that possess a single cdc25 
protein to carry out all the required phosphatase activity, different from the human isoforms 
yet exhibiting structural characteristics of all three.
7
 
 
The role of cdc25 phosphatases in the cellular response to DNA damage is also the subject of 
investigation, as these enzymes are key components in the pathway that leads to cell cycle 
arrest at the G2/M checkpoint. Multiple stress-activated kinases, involved in the response to 
events such as DNA strand breaks, converge to phosphorylate cdc25 and promote its nuclear 
export, thereby separating cdc25 from its nuclear CDK substrates and restraining proliferation 
whilst repair is effected.
14
 
 
 
This project comprises three strands of interlinked research: 
1. the synthesis and testing of novel (and potent) inhibitors of cdc25 
2. the elucidation of novel structural and ligand-binding information 
3. the identification of the precise cellular role of cdc25 isoforms via protein-ligand 
engineering 
In the following sections, the background to each of these aspects will be discussed in detail 
and in context with the proposed goals of the project. 
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1.1  Cdc25 as an Anti-Cancer Target for Medicinal Chemistry 
 
Given the key role of the cdc25 phosphatases in determining whether a cell passes through the 
checkpoints in the cell cycle, it is not surprising that cdc25 has been implicated in tumour 
formation, and there is an extensive body of research to support this hypothesis. Hemizygous 
disruption of cdc25A has been shown to inhibit both cellular transformation and mammary 
tumourigenesis in mice;
16
 this evidence points to the activity of cdc25A alone being a key 
rate-determining factor in some cancers. A wide variety of other studies have classified cdc25 
as a proto-oncogene, exerting a synergistic effect with known oncogenes Myc,
17,18
 Ras
19
 and 
Raf,
17
 and being down-regulated by the tumour suppressor p53.
19
  
 
Studies of various human cancers have revealed that cdc25 is overexpressed in the majority of 
cases, in a manner often specific to the individual isoform (Figure 3).
2,20
 Importantly, it has 
been observed that there is usually a correlation between this overexpression and certain 
clinicopathological features that result in a poor prognosis. The results of these studies are 
clouded by contradictory data regarding mRNA and protein levels, between which there is a 
well-recognised disparity,
21
 and it is clear that factors including the low cellular abundance 
and the many splice variants of cdc25 make this kind of analysis unreliable.
2
  
 
 
Figure 3 – Overexpression of cdc25 in primary tumour samples from patients2 
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However, it is not even necessary to conclusively prove that deregulation of the cdc25 
phosphatases plays a direct and well-defined role in tumour progression when their substrates, 
the CDKs, have generated extensive and long-running research programmes to find 
antiproliferative cancer drugs via direct inhibition of these kinases. The high specificity and 
well-defined mechanism of cdc25 makes its inhibition an obvious candidate for an indirect 
route to the same objective, but this phosphatase has only more recently attracted interest as a 
drug target.
2,20,22
  
 
The key milestone of proof-of-principle use of a selective cdc25 inhibitor to prevent or 
reverse tumour growth had yet to be reached at the outset of this project. Despite the evidence 
above, it was unclear whether the inhibition of cdc25 would only suffice to cause a temporary 
cytostatic effect, although it has been postulated that a consequence of any inhibitor-mediated 
cell-cycle arrest in unstable tumour cells might be the activation of apoptotic pathways.
2
 The 
increasing reports of the effects of selective cdc25 inhibitors in the subsequent years have 
somewhat allayed these concerns (see section 1.1.1), and in any case it has been demonstrated 
that positive cooperative effects are possible using a combination therapy with known drugs, 
such as paclitaxel.
23
  
 
Given their close homology, the issue of isoform selectivity has been considered another 
potential complication of cdc25 as a medicinal chemistry target. This resolves to two potential 
pharmacological strategies. A pan-cdc25 inhibitor should prove most effective in terms of an 
antiproliferative effect, circumventing any loss of efficacy from the putative partial functional 
redundancy of the three isoforms described above. Alternatively a selective inhibitor might 
exploit the observed differences in cdc25 isoform overexpression in specific human tumours 
(Figure 3), selectively causing tumour cell cycle arrest with little effect on normal cells. 
 
Importantly, developing a cell cycle inhibitor targeted at a phosphatase will mitigate the usual 
kinase inhibitor issues of problematic selectivity profiles and relatively poor cellular activity 
due to competition with high intracellular concentrations of ATP.
17
 Even at lower ATP 
concentrations, where an ATP-competitive kinase inhibitor might be more active, inhibition 
of phosphatases is likely more influential than that of kinases from the same signal 
transduction pathway. This is due to the inherent kinetic advantage of a first-order 
dephosphorylation reaction over the competing second-order phosphorylation, potentially 
making phosphatases a much more biochemically-powerful target for inhibition.
24
 The 
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weakness in this argument is the difficulty in finding phosphatase inhibitors with drug-like 
properties due to the inherently charged and hydrophilic active site pockets that have evolved 
to bind phosphate di-anions.
25
 
 
It is worth considering that the best pharmacological approach might prove to be the 
activation of cdc25 phosphatases in combination with the current range of DNA-damaging 
chemo- or radiotherapies, the theory being that this will force the cell past the key repair 
checkpoints and on to apoptosis.
2
 However, in the absence of any known generally-applicable 
strategy for enzyme activation with small molecules, this approach cannot be currently 
investigated. 
 
 
1.1.1 Known Inhibitors of Cdc25  
 
As stated previously, the relatively recent addition of cdc25 to the list of recognised targets 
for medicinal chemistry translates to a relative scarcity of small-molecule inhibitors, 
particularly those with any cell activity (a selection shown in Table 1). The most successful 
class of cdc25 inhibitors are quinonoid compounds, with a range of reported structures 
displaying nanomolar potency, including many with correspondingly good cell activity.
26-42
 
The most advanced cdc25 drug candidate by some margin is Ipsen’s bis-quinone IRC-08364 
(1), recently licensed by Debiopharm although yet to enter clinical trials. IRC-08364 exerts 
low-nanomolar inhibition of all three cdc25 isoforms and a variety of cell lines, and has also 
shown moderate activity against mice bearing human tumour xenografts (Figure 4).
43
 
 
 
Figure 4 – Growth inhibition of xenografted tumours by IRC-083864 (1)43 
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Table 1 – Selected cdc25 inhibitors possessing cell activity 
  
Cmpd 
No. 
Structure 
In vitro IC50 
(cdc25 
isoform) 
Cell IC50  
(cell line) 
Phosphatase 
Selectivity 
Reversibility 
1 
43
 
 
23-53 nM  
(A, B, C) 
7-587 nM 
(panel of cell 
lines)  
8 fold vs. 
VHR, 
PTP1B 
Irreversible 
2 
44
 
 
150-230 nM  
(A, B, C) 
0.1 µM  
(3 cell lines) 
13-fold vs. 
PTP1B; 100-
fold vs. LAR 
N.D. 
3 
45
 
 
<1 µM 
(C) 
<2 µM 
(MiaPaca2,  
DU-145) 
N.D. N.D. 
4 
26
 
 
32-96 nM 
(A, B, C) 
1 µM average 
(NCI 60 
tumour cell 
panel) 
20-fold vs. 
VHR, 
PTP1B 
Irreversible 
5 
46
 
 
0.8-1.0 µM 
(A, B) 
1 µM  
(Hep3B, PLC, 
FemX) 
Selective vs. 
MKP-1, 
PTP1B 
Irreversible 
6 
47
  
 
2.3 µM  
(B) 
10 µM 
(HT-29) 
a
 
N.D. Reversible 
7 
48
 
 
4.5 µM  
(B) 
3.4 µM 
(LNCaP) 
N.D. Reversible 
8 
31
 
 
5-10 µM 
(A, B, C) 
1.2 µM  
(MDA-MB-
435); 6.5 µM 
(PC-3) 
Selective vs. 
VHR, 
PTP1B, PP2 
Reversible 
9 
49
 
 
6.4 µM 
(B) 
7-8 µM  
(MCF-7, HT-
29, A549) 
4-fold vs. 
PTP1B; >20-
fold vs. VHR 
Irreversible 
10 
50
 
 
13.8 µM 
(B) 
20-25 µM  
(PC-3, MDA-
MB-435) 
Selective vs. 
MKP1,3 
Reversible 
 
a – also reported to show “comparable activity to cisplatin in C33A xenograft” 
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Although the data shown in Figure 4 are amongst the first in vivo evidence to support the 
hypothesis of small-molecule cdc25 inhibition for cancer therapy, the use of these simple 
quinone structures for cysteine phosphatase inhibition is likely to cause concern throughout 
the later stages of drug development for the simple reason that this functionality acts as a 
reactive irreversible inhibitor, and the mechanism of inhibition has been shown in nearly all 
cases to be via their oxidative or electrophilic properties. The cdc25 phosphatases are 
extremely sensitive to irreversible modification of the highly nucleophilic active-site cysteine 
by oxidation or covalent attachment, and this susceptibility provides an explanation for the 
high potency and observed selectivity of quinonoid compounds. The concerns over the safety 
of these compounds arise from the likely oxidation or covalent modification of a wide variety 
of other cellular components, the generation of reactive oxygen species (ROS), and the effect 
of the resulting cell damage.
51
 It is clear that in the context of certain chemotherapy, the high 
toxicity of quinone-based drugs is a tolerable side-effect given the lethality of the disease 
itself, as evidenced by the widespread use of the anthracyclines such as daunorubicin. 
However, in these examples the complexity of the surrounding molecular architecture might 
be expected to confer higher selectivity, and in any case a key aim of future cancer medicinal 
chemistry is to find alternatives to reduce the undesirable side-effects that are virtually 
synonymous with current chemotherapy.  
 
This project will therefore focus on reversible cdc25 inhibitors, in which there is growing 
interest but still few reported cell-active compounds (Table 1, compounds 6-8, 10), and none 
with the required potency and pharmacokinetic parameters to be considered a good drug 
candidate. Many of the compounds shown in Table 1 are single screening hits, for which no 
further biological investigations or SAR studies have been attempted. In addition to these cell-
active compounds, there is also a range of natural products and screening hits reported as 
cdc25 inhibitors that fit the conventional model of phosphatase inhibitors, with a vague 
pharmacophore comprising an anionic phosphate mimic and a large hydrophobic region 
(Figure 5).
52-69
 Although this class of compounds likely violates many of the common rules 
that govern desirable pharmacokinetic properties, the relative success of Wyeth’s related 
PTP1B inhibitor Ertiprotafib (18) in reaching phase II clinical trials for the treatment of 
diabetes should allow the similar compounds in Figure 5 to be considered for further inhibitor 
development.
70
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Figure 5 – Selected cdc25 inhibitors containing a conventional anionic phosphate-mimic 
(IC50 against cdc25A or B shown in brackets) 
 
Despite the growing consensus placing it amongst the most interesting and relevant anti-
cancer targets, the lack of success in development of inhibitors of cdc25 is not solely 
attributable to the general issues of targeting phosphatases discussed previously, but also to 
the relative paucity of structural information that might guide rational design or modelling 
studies. This project aimed to try to address this problem, which is discussed in detail in the 
next section. 
 
 
1.2 Structural Aspects of Cdc25 Catalytic Domains 
 
The catalytic domains of each cdc25 isoform have identical phosphatase activity towards their 
appropriate physiological substrate compared to the full-length proteins.
71
 This has allowed 
efforts to understand the structural and mechanistic basis for the activity and selectivity of 
these enzymes to focus purely on the C-terminal catalytic domain.  
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The crystal structures of the catalytic domains of cdc25A and B (Figure 6) revealed an 
unusual topology that is radically different to all other protein tyrosine phosphatases (PTPs), 
the only similarity being the active site loop containing the key sequence of eight residues that 
catalyse dephosphorylation, the HCX5R motif.
72,73
 As in other PTPs, this loop is located at the 
top of a long alpha-helix, the dipole of which lowers the pKa of the active site cysteine from 
ca. 8.0 to ca. 5.9. The effect is to favour the deprotonated thiolate form and thereby increase 
the nucleophilicity of this residue towards the phosphate substrates. A side effect of the 
dramatic increase in acidity of the active site cysteine is the corresponding increase in the rate 
of its oxidation, calculated to be 400-fold faster than that for glutathione, the major cellular 
anti-oxidant.
74
 Under normal circumstances, oxidation of a cysteine residue cannot be used 
for regulatory purposes since any oxidation beyond the initial sulfenic acid is considered 
essentially irreversible. However, the presence of a nearby second cysteine behind the active 
site loop allows the reversible formation under mild oxidative conditions of a disulfide bond, 
which has been resolved in crystal structures. This has led to the proposal that the cdc25 
phosphatases are at least partly regulated by this mechanism.
27,74,75
 
 
          
Figure 6 – Crystal structures of catalytic domains of cdc25A (left) and cdc25B (right) 
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A very rare feature of the cdc25 crystal structures compared to other phosphatases is the 
absence of a residue that could serve as the catalytic acid in the dephosphorylation, normally 
found on an overhanging loop that is absent in the cdc25 active site. This observation 
prompted extensive investigations that identified an ideally placed aspartic acid residue on the 
CDK2 substrate. This catalytic model perhaps explains the high specificity achieved by these 
phosphatases and represents a novel and extremely elegant example of a distinct evolutionary 
solution.
76-79
 This is supported by the absence of any significant substrate recognition pockets 
around the shallow, solvent-exposed active site that would differentiate between 
phosphorylated substrates, which would be insufficient to explain the observed six order of 
magnitude difference in rates between the dephosphorylation of the protein substrate and the 
complementary short peptide sequences.
77
 An additional theory is that of key “hot-spot” 
residues in regions of the large, relatively featureless cdc25-CDK2 interface that are distant 
from the active site yet critical for docking and phosphatase activity. A number of these hot-
spot residues have since been identified by virtual docking and point mutation studies.
6,79-82
 
 
The major differences in the crystal structures of the catalytic domains of cdc25A and B 
suggest that the cdc25A crystal structure does not display the protein in its correctly folded, 
physiologically relevant conformation. Evidence for this conclusion is initially found by close 
comparison of the active site; whereas the conserved HCX5R loop in cdc25B displays an 
almost identical molecular architecture to the vast majority of other phosphatases, the active 
site of cdc25A contains a number of differences.
72
 The most serious consequence of this 
altered folding is that the arginine residue involved in the dephosphorylation mechanism is 
orientated away from the active site. Furthermore, all attempts to crystallise an anionic 
substrate mimic into the active site of cdc25A have been unsuccessful, including with 
phosphate, tungstate and vanadate,
22
 and there are no reports of any difficulty achieving this 
for cdc25B. The most obvious difference between the two crystal structures is the 
conformation and resolution of the C-terminal residues. In cdc25B, an additional α-helix is 
formed adjacent to the active site, with a key H-bond between a glutamic acid in the HCX5R 
loop and a conserved methionine.
73
 This creates a more structured cleft for substrate binding 
compared to the relatively flat surface of the cdc25A crystal structure, in which the C-
terminus extends as a long, unstructured random coil away from the core and is almost 
completely unresolved. Given the similarity between these two isoforms of C-terminal 
primary sequence, substrate specificity and inhibitor potency, it is reasonable to find such a 
significant structural difference as potential evidence that at least one of these crystal 
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structures is not biologically relevant. Although in theory the structure of either isoform could 
be the anomaly, the additional fundamental active site differences explained above point to 
the problem being with cdc25A. This is corroborated by the fact that, whilst cdc25B has been 
crystallised many times in a number of different studies (including as various mutants and in 
different oxidation states), there has only been the one reported crystal of cdc25A. Tellingly, 
the crystal structure of a truncated form of cdc25B, lacking the C-terminal helix, demonstrates 
an arrangement of the active site that appears closer to that of the crystal structure of cdc25A. 
The importance of the extreme C-terminal sequence to substrate binding has been confirmed 
by a variety of deletion and isoform-hybridisation studies.
83
 The additional pocket in cdc25B 
adjacent to the active site, created by the C-terminal helix, has also been proposed as a 
possible small-molecule binding site for a wide range of published inhibitors (see Figure 31). 
This secondary pocket has been dubbed the “swimming pool” due to the large number of 
water molecules found there in the crystal structure.
84
  
 
To summarise, the available structural data for cdc25 are poor, with only cdc25B having been 
reproducibly crystallised. In addition, the active-site features of this protein – specifically the 
lack of many significant structural features – further increases the difficulty of a modelling-
based approach to new cdc25 inhibitors. The final missing piece of data is the lack of any 
crystal structures with bound small molecule inhibitors; this is generally considered a pre-
requisite for both rational design of better inhibitors in the same class and also the validation 
of any docking technique prior to virtual screening for novel inhibitor classes. Section 5 
further discusses these issues and details attempts to provide some of this missing information. 
 
 
1.3 Protein-Ligand Engineering for Chemical Genetics 
 
The third aim of this project is to attempt to elucidate the precise function of each cdc25; this 
is a challenging goal that would undoubtedly further the understanding of cell cycle 
regulation and may ultimately lead to novel therapeutic targets or the discovery of new 
biochemical pathways. The highly conserved nature of the active sites of the cdc25 isoforms 
will likely necessitate an approach to their differentiation that transcends the conceptually 
simple search for a specific chemical inhibitor. Protein-ligand engineering involves site-
specific mutation of the target enzyme, usually creating an enlarged active site pocket (or 
“hole”). The inhibitor is then chemically modified, usually by addition of a sterically 
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demanding group (or “bump”), in an attempt to exploit the additional binding region now 
available (Figure 7A).
85
 The modified inhibitor should exhibit a larger binding affinity for the 
mutant enzyme than for all three wild-type cdc25 isoforms, allowing specific inhibition of the 
target enzyme. Alternative methods of protein-ligand engineering involve interfering with the 
inhibitor binding interactions by altering the direction of H-bonding and ion pairs (Figure 7B).  
 
 
Figure 7 – Approaches for chemical genetics85 
 
There are numerous benefits of the selective inhibitor approach to altering the function of 
cdc25 (chemical genetics) over using directed genetic mutations (classical genetics).
86,87
 The 
most obvious is the conditional nature of the inhibition, which not only allows study of the 
effect of removing the target enzyme activity at different stages of the cell life-cycle 
(especially vital in this case), but during in vivo studies also allows selection of a target 
enzyme (such as cdc25A) that is required for foetal development. Chemical genetics also 
allows careful tuning of the experiment by using different inhibitor concentrations, as 
opposed to the all-or-nothing result of a classical genetic mutation. 
 
Success in this approach will likely require the crystal structure of a bound small-molecule 
inhibitor to allow selection of the appropriate positions for the respective bump and hole 
modifications, which is the combined goal of the first two aims of this research discussed 
above. This technique has found most success in the kinase field, where highly conserved 
ATP-binding sites make protein-ligand-engineering both important and widely applicable,
88
 
but has been extended to phosphatases in a recent study on the prototypical members of the 
protein tyrosine phosphatase (PTP) family.
89
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2 Analogue Synthesis – Dysidiolide Analogues 
 
At the outset of the project, very few of the more drug-like inhibitors shown in Table 1 had 
been reported. Additionally, it was thought that choosing approaches less likely to be pursued 
in the pharmaceutical industry might result in a greater overall contribution to the field. The 
structurally complex phosphate mimic dysidiolide (Figure 5) was chosen with the aim of 
synthesising structural analogues to probe the SAR and ultimately find more potent inhibitors. 
Dysidiolide (11) was isolated in 1996 from a marine sponge and was the first reported natural 
product inhibitor of cdc25, with low micromolar activity against both the purified enzyme and 
two cell lines, and good selectivity against a small panel of related phosphatases.
90
  
 
A survey of the literature had revealed 
that the vitamin D3 steroid rings 
provide an alternative hydrophobic 
region to the complex decalin core of 
dysidiolide (Figure 8).
61,91
 Given the 
undoubtedly imprecise binding mode 
for the large alkyl sections of this 
class of inhibitors, it was thought 
possible in this research to investigate the effect of various phosphate mimic functionalities 
without significant alteration of the binding position or orientation. This would allow 
sequential optimisation of the hydrophilic and hydrophobic regions, with the obvious need in 
the second stage to considerably reduce the size and lipophilicity of the latter region. The few 
reported studies of dysidiolide SAR made no attempt to survey the activity of common 
phosphate bioisosteres, and synthetic efforts to investigate the hydrophobic region have 
largely focussed on the possible diastereomers of the key butenolide side chain.
56,59
  
 
Synthesis of carboxylic acid 20 from vitamin D3 began with ozonolysis using a modified 
reduction with thiourea in order to simplify purification of ketone 21 (Scheme 1). The 
subsequent Horner-Wadsworth-Emmons olefination was extremely slow under standard 
conditions, and also resulted in considerable epimerisation of the ring-junction proton to give 
the more stable cis-fused 6,5-system. However, it was found that using a large excess of the 
phosphonate reagent gave virtually quantitative conversion to the desired ethyl ester 22, with 
 
Figure 8 – Comparison of dysidiolide (11) with 
simpler analogues 19 and 20 
61,91
 
 
(IC50 against cdc25A shown in brackets) 
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92:8 E:Z selectivity and no observed epimerisation. Hydrolysis of this ester gave carboxylic 
acid 20, a known potent cdc25A inhibitor used as a reference in the initial assay development. 
 
 
Scheme 1 – Synthesis of carboxylic acid 20 
 
Conversion to the acid chloride under standard conditions allowed acylation of a variety of 
amines, amides and sulfides to give a range of conventional carboxylic acid bioisosteres 24a-e 
(Table 2).
92
 The N-acetyl and N-trifluoroacetyl amides were also prepared but were found to 
be unstable to hydrolysis and could not be isolated. 
 
Table 2 – Synthesis of carboxylic acid bioisosteres 24a-e  
 
 
Product R Conditions 
Yield from 
20 (%) 
24a -NHSO2Me 
H2NSO2Me, DMAP, Et3N, 
CH2Cl2, r.t. 
73 
24b -NHCN NaNHCN, THF, r.t. 84 
24c -SH NaSH, EtOH, -10 °C 81 
24d -NHOH NH2OH, THF/H2O, 5 °C 85 
24e -NHCO2Me H2NCO2Me, PhMe, 80 °C 53 
 
Attempted synthesis of the corresponding vinyl tetrazole, a widely-used bioisostere for the 
carboxylate group,
92
 (Scheme 2) began with HWE-olefination of ketone 21 to give 
unsaturated nitrile 25 in moderate yield using stoichiometric phosphonate. This reaction 
proceeded much more rapidly than for the phosphonoacetate, presumably due to the higher 
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nucleophilicity and smaller size of the α-nitrile anion. The yield could however be increased 
by using an excess of the cyanomethylphosphonate. The subsequent tetrazole synthesis 
proved unsuccessful, as even under forcing conditions the azide cycloaddition proved to be 
extremely slow and only very low conversion was observed after seven days. An alternative 
acidic heterocycle, oxadiazolone 26, was successfully synthesised by hydroxylamine addition 
and acylation using CDI. Attempted acylation of the amidoxime intermediate using TCDI 
also gave 26 after work-up, indicating hydrolytic instability of the thiocarbonyl group. 
 
 
Scheme 2 – Synthesis of oxadiazolone 26 
 
Attempts to utilise a diphosphonate HWE reagent in the synthesis of the corresponding 
vinylphosphonic acid were unsuccessful, reflecting the hindered, stabilised nature of the 
diphosphonate anion. An alternative allylphosphonate, 28, was prepared in good yield by 
DIBAL reduction, bromination and Arbuzov reaction (Scheme 3). It was found that using 
shorter reaction times with higher temperatures resulted in less decomposition of the reactive 
allyl bromide than prolonged heating at lower temperatures. Acid hydrolysis using TMSBr to 
give the free phosphonic acid 29 was successful, but isolation and purification of this highly 
amphiphilic compound proved extremely difficult. This became a recurring problem for 
synthesis of other highly acidic dysidiolide analogues, and was not resolved prior to the initial 
assay results which prompted us to halt any further efforts (see Section 4). The use of the allyl 
phosphonate had allowed the possibility of electrophilic fluorination to give the α-mono- and 
di-fluorophosphonic acids, which possesses very similar pKa values to the phosphate group of 
the cdc25 substrates.
93,94
 However, preliminary investigations into this transformation using 
standard conditions found it to require extensive optimisation, and this was also not achieved 
prior to the initial negative assay results. 
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Scheme 3 – Attempted synthesis of phosphonic acid 29 
 
The direct synthesis of sulfonic acid analogue 31 from the allylic bromide intermediate 
previously prepared was unsuccessful due to the instability of the bromide to various standard 
nucleophilic sulfonation conditions. An alternative route from allylic alcohol 27 involved 
successful Mitsunobu displacement by thiolacetic acid and subsequent hydrolysis-oxidation 
of thioacetate 30 (Scheme 4). Various oxidation conditions were attempted to give clean 
conversion to sulfonic acid 31, but as with the phosphonic acid it did not prove possible to 
fully purify the highly amphiphilic product prior to the initial assays. 
  
 
Scheme 4 – Attempted synthesis of sulfonic acid 31 
 
Attempted synthesis of malonic acid derivative 34 (Scheme 5) began with reductive 
ozonolysis of vitamin D3, to give only one diastereomer of alcohol 32 in accordance with the 
literature precedent.
60
 Carbenoid insertion into alcohols 27 and 32 using dimethyl 
diazomalonate proceeded in good yield to give diesters 33 and 35. Predictably, the malonic 
acid derivatives resulting from the subsequent hydrolysis caused similar difficulties in 
purification to the phosphonic and sulfonic acids, and once again these compounds were not 
satisfactorily purified prior to the initial assays. 
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Scheme 5 – Attempted synthesis of dicarboxylic acids 34 and 36 
 
Synthesis of α-hydroxy carboxylic acid 39 was attempted via hydrolysis of cyanohydrin 38, 
prepared from alcohol 27 in 2 steps (Scheme 6). It was found that immediate reaction of the 
crude aldehyde gave higher yields, and rapid reaction under solvent-free conditions proved 
most successful.
95
 However, attempted acid hydrolysis of nitrile 38 resulted in rapid 
decomposition under a variety of conditions. 
 
 
Scheme 6 – Attempted synthesis of α-hydroxy carboxylic acid 39 
 
A simple route to the synthesis of a variety of alternative inhibitors can be clearly envisaged 
by acylation reactions of carboxylic acid 20 or alcohol 27. Coupling of acid 20 with various 
alcohols and amines under common coupling conditions proved to be unexpectedly difficult, 
particularly with heterocyclic and aromatic amines. As a result, only the esters of maltol (40) 
and mandelic acid (41) were successfully synthesised in good yield and tested in the 
phosphatase assay (Figure 9). These compounds were designed to hopefully mimic the 
binding modes of known quinone and α-aryl carboxylate inhibitors respectively (see Figure 
5).
5
 Alternative aryl carboxylic acid 42 was also prepared from alcohol 27 using phthalic 
anhydride. 
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Figure 9 – Other inhibitors synthesised by acylation reactions 
 
A further strategy considered for analogue synthesis was the introduction of various α-
substituents to carboxylic acid inhibitor 20. Ynolate chemistry was chosen as the best method 
for olefination of the unreactive ketone 21 to give tetra-substituted alkenes (Scheme 7).
96
 A 
selection of dibromoester substrates were prepared from the corresponding acids by a three 
step esterification and bromination sequence, with optimisation required to overcome the 
significant purification problems that resulted from incomplete conversion in the bromination 
reactions. However, optimisation of the ynolate olefination reaction was also not completed 
before the results of the initial assays terminated this line of investigation. A further proposed 
strategy that could not be completed was the synthesis of tetronic acid phosphate mimics 
based on the potent cdc25 inhibitors inspired by natural product RK-682 (12, see Figure 5).
57
 
 
 
 
Scheme 7 – Proposed synthesis of α-substituted analogues of carboxylic acid inhibitor 20 by 
ynolate olefination of ketone 21 
 
To summarise, the first library of novel compounds was based on known inhibitor 20, 
focussing on alternative phosphate mimics. Low reactivity and difficult purification were 
found to be common problems with this class of compound, and the original goal of a two-
stage optimisation of dysidiolide analogues towards more drug-like compounds was at this 
stage considered too ambitious to warrant further investigation. The next sections detail the 
development of the cdc25 phosphatase assay used above and subsequent attempts to use the 
literature quinonoid inhibitors as starting points for the development of novel, reversible 
inhibitors.  
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3 Assay Development 
 
A validated cdc25 phosphatase activity assay was required for the testing of the synthesised 
compounds. In order to obtain significant quantities of purified cdc25A, a construct had 
previously been prepared by co-workers for bacterial expression of GST-fused cdc25A using 
a pGEX vector. This fusion to GST (glutathione S-transferase), a high-affinity glutathione-
binding enzyme, allows simple purification by selective immobilisation on glutathione-
functionalised beads. pGEX vectors place expression of the gene of interest under control of 
the powerful tac promoter; this is then activated by the addition of IPTG (a non-hydrolysable 
mimic of a lactose metabolite), triggering high levels of transcription of the associated gene. 
 
Initial expression and purification using standard conditions gave moderate levels of both 
yield and purity (assessed by SDS-PAGE analysis). The yield of protein expression is 
dependent on the length of time and the temperature following induction with IPTG, and is 
affected by unknown factors such as protein solubility, toxicity and degradation. The 
expression of GST-fused cdc25A was therefore optimised for incubation temperatures and 
time; SDS-PAGE analysis of the cell lysates suggested that lower temperatures and longer 
induction times resulted in optimal yields of GST-cdc25A. 
 
In accordance with many of the published protocols, the phosphatase activity assay 
development initially used para-nitrophenyl phosphate (PNPP, Figure 10A) as a small 
molecule substrate. PNPP assays measure the absorbance of the para-nitrophenol product 
using a photometer, and are commonly chosen due to the simplicity and low cost. The assay 
was designed to confirm the linear dependence of the end-point absorbance measurement on 
the concentration of solid-supported GST-cdc25A, using a standard buffer composition and 
assay conditions. Addition of NaOH stops the reaction and ensures that all the phenol product 
is in the deprotonated, chromogenic form prior to measurement of the absorbance. An 
approximate linear correlation between enzyme concentration and absorbance was observed, 
but these assays suffered from a very low signal to noise ratio and were also poorly 
reproducible. Attempts to intensify the measured absorbance signal by increasing reaction 
times and PNPP concentration did not achieve a significant improvement. 
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Figure 10 – Artificial substrates for phosphatases 
 
It has been reported that an alternative artificial substrate, 3-O-methylfluorescein phosphate 
(OMFP, Figure 10B) is a much better substrate for cdc25, with a thousand-fold improvement 
in the reaction rate.
97
 Furthermore, the dephosphorylated product is fluorescent, inherently 
increasing the sensitivity of the measurements. A further practical advantage of using a 
continuous (as opposed to end-point) assay was the ability to obtain a full kinetic profile for 
each individual assay well, eliminating the error caused by reliance on a single end-point 
reading. Linear regression of the obtained data points thus allows direct measurement of the 
reaction rate. A potential disadvantage with this alternative assay was the reportedly high 
background rate of OMFP hydrolysis at the alkaline pH required for the assay, with a half-life 
of one hour.
97
 Originally, it was hoped that the use of a very short reaction time would 
circumvent this issue, but fortunately it became clear that the rate of background hydrolysis in 
the buffer used was negligible. 
 
The initial OMFP assay results demonstrated a much improved signal to noise ratio over the 
colourimetric method. Screening of conditions around those reported for literature inhibitor 
assays found suitable conditions using the minimum quantities of the solid-supported protein 
and OMFP that still produced a strong fluorescence signal.
52
 The recorded fluorescence was 
linear throughout the assay and independent of minor changes in the substrate concentration. 
It was next confirmed that relatively high concentrations of DMSO (10-20%) had little effect 
on the phosphatase activity or OMFP hydrolysis. 
 
The accuracy and reliability of the optimised assay was confirmed by measurement of the 
IC50 value of a reference inhibitor, dysidiolide analogue 20. Inhibitor assays were performed 
in triplicate, with 8-10 concentrations for a full IC50 measurement, the reaction rates then 
data-fitted to a standard sigmoid curve using SigmaPlot.
98
 It was discovered during these 
initial attempts that the reproducibility of the data was much lower than anticipated, a possible 
result of the inherent difficulties in using small amounts of solid-supported enzyme in a 
reaction setup that did not allow for mixing during the experiment. It was not known whether 
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the variation in results was due to unpredictable settling of the beads in the assay wells or a 
result of inconsistent transfer of the stock enzyme suspension leading to differences in the 
number of beads in each well. To address this issue, the enzyme was eluted from the beads 
using reduced glutathione to interfere with the binding interactions, this free glutathione then 
being removed from the GST-cdc25A stock solution by dialysis.  
 
The subsequent assays proved to be much more reproducible, and the literature IC50 value for 
reference inhibitor 20 was reproducibly achieved within experimental error. This result 
validated the accuracy and reliability of the OMFP assay, and allowed testing of the novel 
inhibitors synthesised previously. Unfortunately, the results obtained for the initial 
compounds tested were disappointing. Many of the less-polar compounds showed no 
inhibition at all, possibly suggesting problems of solubility or the likely absolute requirement 
for this class of compounds to have an anionic phosphate mimic in order to bind to the active 
site. The remainder of the compounds exhibited poor inhibition, with projected IC50 values > 
50 μM. The only exception was ketosulfonamide 24a (cdc25A IC50 9.3 μM), with potency 
comparable to the reference carboxylic acid. It was clear, therefore, that no conclusions could 
be drawn from the results regarding the phosphate-mimic preference of cdc25A and, as 
discussed in the previous section, the synthetic efforts towards similar compounds that had yet 
to be completed were halted. 
 
The successful development and validation of the cdc25A fluorimetric phosphatase assay 
provided a good basis for the synthesis of the next class of literature inhibitor analogues, 
discussed in Section 4.  
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4 Analogue Synthesis – Quinone Analogues 
 
Having been unsuccessful in our attempts to find novel dysidiolide analogues with improved 
potency (and ultimately improved pharmacokinetic properties), we next reconsidered the 
reported quinonoid cdc25 inhibitors as a possible starting point for further development. 
Whilst the reasons outlined above for the initial rejection of this class remained valid, chiefly 
their irreversible mechanism of inhibition, an alternative strategy was proposed based on 
consideration of the proposed binding affinity of these structures for the cdc25 active site 
prior to the alkylation/oxidation event, with conventional binding models put forward in the 
literature based on molecular modelling for a range of quinone inhibitors.
26,30,42,99,100
 Our 
concept was to mimic these proposed binding interactions of the quinone carbonyl oxygens 
by synthesising analogues of similar molecular shape and size, containing the requisite 
carbonyl groups but lacking the ability to irreversibly alkylate or oxidise the key cdc25 active-
site cysteine. Two classes of simple heterocycle matching these criteria were investigated; 
phthalazinediones and diketopiperazines. 
 
It was noted at this stage that the proposed modifications of the existing literature inhibitors 
were of a highly speculative nature, and that the long-term success of the project likely 
resided with the implementation of a more rational approach to inhibitor design. 
Contemporaneously with the synthesis of quinone analogues described in this section, it was 
therefore decided to attempt to obtain novel structural and ligand-binding information for 
cdc25 (see Section 5). 
 
 
4.1 Phthalazinediones 
 
Direct isosteric replacement of two adjacent carbon atoms from the literature naphthoquinone 
core results in the cyclic hydrazide phthalazinedione. This was identified as the simplest and 
most direct modification that would result in rapidly synthetically-accessible non-quinonoid 
analogues. An isostere of a potent literature quinone (an analogue of 4) was therefore 
synthesised in 3 steps by reaction of phthaloyl dichloride with methylhydrazine to give the 
intermediate mono-alkyl phthalazinedione 43, alkylation with TBS-protected 3-
bromopropanol and deprotection, giving target alcohol 45 in good overall yield (Scheme 8). 
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Scheme 8 – Synthesis of phthalazinedione 45 
 
Two further analogues were prepared from the corresponding alkyl chlorides, including the 
methyl ether analogue of alcohol 45 (Scheme 9). 
 
 
Scheme 9 – Synthesis of phthalazinedione analogues 46 and 47 
 
These three phthalazinediones were subsequently assayed against cdc25A, and were found to 
show no inhibition up to 100 μM. The most likely reason for the failure of this approach is 
that the reported specific initial binding of the quinone inhibitors is very weak, with the 
reported IC50 value deriving almost exclusively from the effect of the ensuing covalent 
attachment, despite the various literature docking studies and SAR interpretation. 
Alternatively, the isosteric replacement in the phthalazinedione series may have a larger effect 
on the binding than originally considered. 
 
Despite the inapplicability to the cdc25 project, in order for phthalazinediones to be integrated 
into the array of heterocycles that are routinely explored in the course of other medicinal 
chemistry investigations it is necessary that they can be synthesised in a regioselective 
manner with respect to the substituents on the phenyl ring and the amide nitrogens. Current 
methods of phthalazinedione synthesis almost invariably proceed (as above) from a benzoic 
di-acid precursor and a hydrazine, with one of the components symmetrically substituted to 
avoid the inevitable and likely inseparable mixture of regioisomers that would result (Scheme 
10, Route A). An alternative method was proposed that would allow for simple and flexible 
synthesis of any regioisomer by directed C-H activation and carbonylative cyclisation of a 
benzoic hydrazide under Pd catalysis (Scheme 10, Route B).  
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Scheme 10 – Conventional and proposed syntheses of substituted phthalazinediones 
 
The regiochemical outcome would be controlled by the simple choice of either ortho- or 
para-substituted benzoyl chlorides, and by using orthogonal strategies for regioselective 
synthesis of mono-substituted hydrazides; acylation of a substituted hydrazine under mild 
conditions usually results in selective reaction of the secondary amine, whereas alkylation or 
reductive amination of an unsubstituted hydrazide will likely occur on the terminal amine-like 
nitrogen.  
 
The proposed synthesis has strong precedent in Orito’s synthesis of benzolactams by a similar 
mechanism (Scheme 11).
101
 It was noted, however, that the increased electron-deficiency of 
the aryl ring of the benzoic hydrazides would likely result in a greatly reduced rate of reaction.  
. 
 
Scheme 11 – Orito’s benzolactam synthesis by directed C-H carbonylation 
 
Slow addition of p-toluoyl chloride to a large excess of methylhydrazine resulted in 
quantitative, regioselective mono-acylation, but the hydrazide product 48 did not undergo the 
desired carbonylative ring-closure under Orito’s conditions, using a full equivalent of the 
Cu(OAc)2 oxidant at this stage (Scheme 12). Repeat attempts were unsuccessful and the 
methodology was not pursued further due to the lack of inhibition observed for this class of 
compound in the enzyme assays.  
  
 
Scheme 12 – Attempted phthalazinedione synthesis by directed C-H carbonylation 
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4.2 Diketopiperazines 
 
The diketopiperazine (DKP) strategy, the more speculative of the two approaches, was based 
on the convergence of two observations; the comparatively flat conformation of the DKP ring 
should place the amide carbonyl groups in similar orientations to that in quinones,
102
 and 
alkenyl DKPs might display a qualitatively similar binding mode to the analogous 
thiazolidinedione cdc25 inhibitors reported by Kim
47
 (Figure 11).  
 
 
Figure 11 – Comparison of proposed DKP structures with literature inhibitors 
 
An initial test of a direct DKP synthesis was attempted by a reported amino acid dimerisation 
with no purification of the intermediates, but gave a very low overall yield (Scheme 13). A 
similar 3-step DKP synthesis was attempted using alternative, more-functionalised amino acid 
derivatives, with characterisation of crude intermediates to identify the problematic step. Once 
again a very low yield of crude DKP product 51 was obtained, with the final cyclisation 
proving most difficult (Scheme 13).  
 
 
Scheme 13 – Attempted rapid synthesis of DKPs by amino acid dimerisation 
 
Modified conditions for the DKP ring closure reaction allowed efficient synthesis of non-
aromatic naphthoquinone mimic 54 from proline and sarcosine in good overall yield (Scheme 
14). 
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Scheme 14 – Synthesis of DKP 54 by amino acid dimerisation 
 
These initial attempts prompted the proposal of a novel strategy to access a library of 3-
alkenyl, 6-alkyl DKPs by derivatisation of an appropriately functionalised common 
intermediate (Scheme 15). This would circumvent carrying out the problematic ring-closure 
reaction for each target compound. DKP 55, formed from the coupling and cyclisation of 
serine and α-phosphonoglycine ester 56, was identified as an appropriate core molecule, 
allowing olefination and O-alkylation as the last steps in the synthesis of a potentially diverse 
library of compounds. The use of a phosphonate intermediate for the synthesis of alkenyl 
DKPs has been shown to be an efficient strategy,
103,104
 with the considerable advantage of 
avoiding the coupling of unreactive dehydro amino acids.
105
  
 
 
Scheme 15 – Proposed synthesis of a DKP library via phosphonate intermediate 55 
 
This choice of substitution pattern for the proposed DKP library was based on a qualitative 
comparison with the literature quinone inhibitors and Kim’s thiazolidinedione 6 (Figure 11). 
Introducing conjugated aryl groups to one position of the DKP would mimic both the 
diarylpyrazole of 6 and the benzene ring of the naphthoquinone inhibitors. This would also 
have the effect of increasing the planarity of the DKP ring. The introduction of small alkyl 
groups to the remaining unsubstituted position would mimic the range of known quinone 
inhibitor substituents, such as the thioethanol chains in quinone 4. 
 
The shortest route to racemic phosphonoglycine 56 was proposed to be via direct amination of 
a phosphonoacetate anion, and the required aminating reagent DPPONH2 (57) was 
synthesised according to the literature procedure in moderate yield (Scheme 16). In order to 
increase the efficiency of the synthetic route, the simultaneous deprotection of both the 
carboxylic acid and the amine required for the final cyclisation was made possible by the use 
of tert-butyl phosphonoacetate in conjunction with N-Boc serine. Amination of tert-butyl 
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diethylphosphonoacetate was carried out in good yield, and the product (56) coupled with N-
Boc serine 58 under standard conditions to give phosphono-dipeptide 59, although this 
compound was not fully purified prior to the attempted cyclisation reactions. 
 
 
Scheme 16 – Synthesis of protected dipeptide 59 
 
Attempted removal of both the Boc group and the tert-butyl ester under standard TFA 
conditions proved to be a very slow reaction, with long reaction times leading to 
decomposition. Addition of triethylsilane as a cation scavenger appeared to prevent the side-
reactions, but did not improve the low conversion. Full deprotection was finally achieved 
using sulfuric acid in CH2Cl2 (Scheme 17). However, cyclisation of resulting crude amino acid 
60 proved equally problematic. A variety of reported conditions for DKP synthesis were 
attempted, including both carbodiimide and HCl activation of the carboxylic acid. In all cases, 
very low conversion was observed, even when using more forcing conditions. 
 
 
Scheme 17 – Attempted synthesis of phosphono-diketopiperazine 55 
 
Although cyclisation conditions for DKPs in the literature are quite varied and substrate-
dependent, the most general method is microwave heating of the methyl amino-ester in water. 
Cyclisation precursor 63 was synthesised in three steps and in comparable yields to the tert-
butyl series, although coupling product 62 proved similarly difficult to fully purify (Scheme 
18). However, the cyclisation reaction was again unsuccessful and resulted in a large number 
of products by 
31
P-NMR and TLC analysis of the crude reaction mixture. The difficulties 
encountered in ring-closure of these phosphono-dipeptides appear to be specific to these 
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substrates, and could stem from issues with steric hindrance, conformational preferences or 
problems of chemoselectivity around this highly-functionalised core.  
 
 
Scheme 18 – Attempted synthesis of phosphono-diketopiperazine 55 via amino-ester 63 
 
A proposed alternative route to these structures was based on a known aldol condensation that 
has not yet been fully explored in the synthesis of a diverse library of DKPs (Scheme 19).
106
 
This route has the obvious advantage of avoiding the cyclisation step that had previously 
proved difficult. Other additional changes of strategy were introduced at this stage; N-
methylation of the intermediate alkenyl DKPs should increase solubility of the products and 
also allows direct electrophilic alkylation of the unsubstituted DKP ring carbon in the final 
step. 
 
 
Scheme 19 – Proposed synthesis of diketopiperazines from glycine anhydride (66) 
 
The initial acetylation step proceeded smoothly to give diimide 67, and the subsequent aldol 
condensation was carried out in CH2Cl2 rather than the more common DMF solvent in order 
to allow precipitation of the product, greatly increasing the yield of the desired mono-
alkenylated DKP product 68 (Scheme 20).
107
 A range of aromatic and heteroaromatic 
aldehydes were used successfully in this reaction, and although unbranched aliphatic 
aldehydes were predicted to be too susceptible to self-condensation, good yields of the desired 
aldol product were obtained in two examples (68m and 68s). 
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Scheme 20 – Synthesis of a DKP library by aldol condensation 
 
The regioselective deacetylation has been proposed to occur via intramolecular acyl transfer 
to the alkoxide intermediate formed following the initial aldol reaction.
106
 The resulting 
acetate then undergoes elimination in a stereoselective manner to give the Z-alkene with high 
selectivity, purportedly resulting from the minimisation of the steric interaction between the 
aryl group and the DKP carbonyl.
106
 
 
In order to directly compare the alkenyl DKPs with analogous literature alkenyl 
thiazolidinedione inhibitor 6, diarylpyrazole aldehyde 70 was prepared from hydrazone 69 in 
good yield using the Vilsmeier-Haack reagent (Scheme 21). 
 
 
Scheme 21 – Synthesis of diarylpyrazole DKP 68w 
 
Following minor modifications to the literature procedure, the subsequent deacetylation gave 
the highly insoluble alkenyl DKPs with good overall mass recovery, although general 
recrystallisation conditions proved elusive. Under standard conditions of sodium hydride and 
iodomethane, the attempted di-methylation of the parent benzylidene DKP proved 
problematic, resulting in a mixture of desired di-methylated product 71a and tri-methylated 
compound 72, which were inseparable by column chromatography (Table 3, Entry 1). 
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Variation of temperature, equivalents of MeI and order of addition did not improve the ratio 
of products (Entry 2). A screen of weaker bases incapable of generating significant 
concentrations of the amide enolates gave better results; Ba(OH)2 initially gave only a trace of 
tri-methylated compound 72 but this ratio worsened on scale-up, whilst K2CO3 was found to 
give complete selectivity regardless of scale (Entries 3-5).  
 
Table 3 – Optimisation of dimethylation of alkenyl-DKP 65a  
 
 
Entry Base (eq.) 
Eq. 
MeI 
Conditions Result 
1 NaH (2.1) 5 DMF, r.t. 71a and 72 
2 NaH (2) 5 DMF, 0 °C 71a and 72 
3 Ag2O (3) 4 DMF, r.t. 
Complex 
mixture 
4 Ba(OH)2 (10) 10 
3:1 DMF/H2O, 
r.t. 
71a and 72 
(trace) 
5 K2CO3 (10) 10 DMF, r.t. 71a 
 
 
Despite this success, purification of the target compounds at this final stage proved 
particularly lengthy. Furthermore, the optimised conditions for methylation were deemed 
incompatible with any nucleophilic functionality on the aryl and heteroaryl groups, such as 
pyridines. At this stage, the first 7 final compounds were screened against cdc25A, B and C 
(Table 4), and only the analogue of thiazolidinedione 6, diarylpyrazole 71w, showed any 
activity (IC50 ca. 100 μM). These disappointing initial results, combined with the speculative 
nature of the approach, led us to terminate this line of investigation without completion of the 
synthesis of the remaining dimethyl alkenyl DKPs, and we next investigated possible methods 
of virtual screening for discovery of novel inhibitor classes (see Section 6). 
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Table 4 – DKPs tested in initial assay 
 
 Structure 
Overal 
Yield (%) 
71a 
 
52 
71g 
 
29 
71h 
 
54 
 
 Structure 
Overall 
Yield (%) 
71q 
 
28 
71v 
 
24 
71w 
 
40 
 
 
 
The considered advantages of the above synthetic route to the DKP targets, in particular the 
mild thermodynamic aldol condensation using the di-imide, were eventually largely 
outweighed by the difficulties in subsequently switching the groups on the amide nitrogens. A 
possible alternative would be a direct 2-step aldol condensation approach using sarcosine 
anhydride, 73 (Scheme 22).  
 
 
Scheme 22 – Proposed synthesis of alkenyl DKPs from sarcosine anhydride, 73 
 
In summary, small libraries of phthalazinediones and DKPs were prepared as possible 
naphthoquinone analogues with a reversible mode of cdc25 inhibition. These compounds 
were not found to show any significant inhibition in in vitro assays, and this approach was 
halted in favour of ligand-based virtual screening as discussed in Section 6. 
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5 Structural Biology 
 
5.1 NMR Studies 
5.1.1 Protein Preparation 
 
It had been recognised, following the failure of the optimisation of dysidiolide-analogue 20, 
that an approach containing a larger rational design element arising from molecular modelling 
techniques would likely prove more effective. However, as discussed previously, the crystal 
structure of cdc25A is unsuitable for this purpose, there is no reported structure for cdc25C, 
and there is no validated ligand binding information for any of the isoforms. Efforts were 
therefore made to obtain detailed, physiologically relevant structures of the cdc25 isoforms 
with associated ligand binding information. This information would be of great value to the 
field, and would lay a strong foundation from which to achieve the aims of the project, in 
terms of finding novel inhibitors and also the chemical genetics approach to dissect the 
precise cellular roles of the isoforms.  
 
Protein structure determination by NMR is a technique that has been rapidly growing in scope 
and influence due to the ongoing development and implementation of new methods and 
technologies, allied with the exponential increase in available computing power.
108
 It is now 
almost considered straightforward to determine the structure of small proteins (<25 kDa). One 
of the chief advantages of protein NMR over X-ray crystallography is obtaining the solution 
conformation, which could be especially relevant for this project given the uncertainty 
discussed previously about the validity of the crystal structure of cdc25A.  
 
Collaboration with Imperial College’s Cross-Faculty NMR Centre allowed access to an 800 
MHz cryoprobe NMR machine, sufficient to provide high resolution protein structures. The 
untagged catalytic domains of the cdc25 isoforms are within the size limit of 25 kDa, and 
therefore should be suitable for NMR structure determination. The start of the catalytic 
domain is defined as the highly conserved LIGD sequence, highlighted in blue in Figure 12. 
The HCX5R active site loop is highlighted in yellow. This sequence alignment demonstrates 
the difference in the levels of conservation in the two domains between the isoforms. 
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cdc25a   MELG-PEPPHRRRLLFA--C--SPPPASQP----VVKALFGASA-AGGLSPVTNLTVTMDQLQGLGSDYEQP--- 
cdc25b   MEVPQPEPAPGSALSPAGVCGGAQRPGHLPGLLLGSHGLLGSPVRAAASSPVTTLTQTMHDLAGLGSRSRLTHLS 
cdc25c   MSTELFSSTREEGSSGSGPSFRSNQRKMLN—LLLERDTSFTVCPDVPRTPVGKFLGDSANLSILSGGTPKRCLD 
 
cdc25a   LEVKNNSNLQRMGSSESTDSGFCLDSPGPLD---SKENLEN--------------PMRRIHSLPQKLLGCSPALK 
cdc25b   LSRRASESSLSSESSESSDAGLCMDSPSPMDPHMAEQTFEQAIQAASRIIRNEQFAIRRFQSMPVRLLGHSPVLR 
cdc25c   LSNLSSGEITATQLTTSAD----LDETGHLDSSGLQEVHLAG------------------MNHDQHLMKCSPAQL 
 
cdc25a   R-SHSDSLDHDIFQLIDP------DENKENEAFEFKKPVRPVSRGCLHSHGLQEGKDLFTQRQNSAPARMLSSNE 
cdc25b   NITNSQAPDGRRKSEAGSGAASSSGEDKENDGFVFKMPWKPTHPSSTHALAEWASRREAFAQRPSSAPDLMCLSP 
cdc25c   LCSTPNGLDR--------------GHRKRD--------------------------------------AMCSSSA 
 
cdc25a   RDSSEPGNFIPLFTPQSPVTATLSD--EDDGFVDLLDGENLKNEEETPSCMASLWTAPLVMRTTN-------LDN 
cdc25b   DRKMEVEELSPLALGRFSLTPAEGDTEEDDGFVDILES-DLKDDDAVPPGMESLISAPLVKTLEKEEEKDLVMYS 
cdc25c   NKENDNGNLVDSEMKYLGSPITT---------VPKLDKNPNLGEDQAEEISDELMEFSLKDQEAK--------VS 
 
cdc25a   RCK-LFDSPSLCSSSTRSVLKRPERSQEESPPGSTKRRKSMSGASPKESTNPEKAHETLHQSLSLASSPKGTIEN 
cdc25b   KCQRLFRSPSMPCSVIRPILKRLERPQDRDTPVQNKRRRSVT--PPEEQQEAEEPKARVLRSKSLCHD---EIEN 
cdc25c   RSG-LYRSPSMPENLNRPRLKQVEKFKDNTIPDKVKKKYFSGQGKLRKG-------LCLKKTVSLCDI---TITQ 
 
cdc25a   ILDNDPRD--LIGDFSKGYLFHTVAGKHQDLKYISPEIMASVLNGKFANLIKEFVIIDCRYPYEYEGGHIKGAVN 
cdc25b   LLDSDHRE--LIGDYSKAFLLQTVDGKHQDLKYISPETMVALLTGKFSNIVDKFVIVDCRYPYEYEGGHIKTAVN 
cdc25c   MLEEDSNQGHLIGDFSKVCALPTVSGKHQDLKYVNPETVAALLSGKFQGLIEKFYVIDCRYPYEYLGGHIQGALN 
 
cdc25a   LHMEEEVEDFLLKKPIVPTD-GKRVIVVFHCEFSSERGPRMCRYVRERDRLGNEYPKLHYPELYVLKGGYKEFFM 
cdc25b   LPLERDAESFLLKSPIAPCSLDKRVILIFHCEFSSERGPRMCRFIRERDRAVNDYPSLYYPEMYILKGGYKEFFP 
cdc25c   LYSQEELFNFFLKKPIVPLDTQKRIIIVFHCEFSSERGPRMCRCLREEDRSLNQYPALYYPELYILKGGYRDFFP 
 
cdc25a   KCQSYCEPPSYRPMHHEDFKEDLKKFRTKSRTWAGEKSKREMYSRLKKL--- 
cdc25b   QHPNFCEPQDYRPMNHEAFKDELKTFRLKTRSWAGERSRRELCSRLQDQ--- 
cdc25c   EYMELCEPQSYCPMHHQDHKTELLRCRSQSKVQEGERQLREQIALLVKDMSP 
 
Figure 12 – Amino acid sequence alignment of cdc25 isoforms 
Blue– start of the catalytic domain; Yellow– conserved active site loop;  
Red – hydrophobic; Blue – acidic; Pink – basic; Green – other hydrophilic 
 
A construct containing the catalytic domain of cdc25A was available and the initial strategy 
necessitated the addition of a GST-tag in order to allow simple purification of large quantities 
of protein. This was achieved by sub-cloning the insert coding for cdc25A(cat.) into the 
pGEX-KG vector used previously for the full-length cdc25A. The resulting construct also 
contained a thrombin cleavage site between the GST tag and the cdc25A domain, which 
would subsequently allow the large GST tag to be removed, leaving the purified, untagged 
catalytic domain for use in the NMR studies. However, only very low expression of GST-
cdc25A(cat.) was observed, and attempts to optimise the induction conditions for time and 
temperature had little effect.  
 
As an alternative strategy, the cdc25A(cat.) insert was sub-cloned into the pET21a vector to 
parallel the literature crystallisation attempts. This vector places the transcription under the 
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control of the T7 promoter, adding an additional amplification step to the induction of protein 
expression. Specifically, IPTG now induces the compatible host cell line (BL21) to express 
the T7 RNA polymerase, which then proceeds to start rapid and extensive transcription of the 
desired gene in the pET21a plasmid. The disadvantage of using this vector is the absence of 
the GST fusion system, necessitating an alternative purification strategy, but during the initial 
expression experiments it became apparent that the pET21a/BL21 expression system was 
generating extremely high levels of cdc25A(cat.), with yields of up to 25 mg/L. 
 
In accordance with literature protocols, the untagged cdc25A(cat.) was purified by an ion-
exchange strategy, starting with extraction from the cell lysate using negatively-charged 
sulfopropyl-sepharose beads. The protein was eluted from the beads using a linear gradient of 
NaCl to disrupt the electrostatic interactions.
72
 Fractions found to contain high levels of 
cdc25A(cat.) by OMFP fluorescence assay were concentrated using a 10 kDa centrifugal filter 
and the retentate then passed through a gel filtration column. This technique retains molecules 
smaller than the bead pore sizes (chosen to be ca. 20 kDa) by effectively presenting a much 
larger column volume than for the larger protein molecules, which elute very quickly. 
Analysis of the fractions and concentration as before resulted in overall high yields of 
cdc25A(cat.) with acceptable purity by SDS-PAGE analysis. 
 
The catalytic domains of cdc25B and C were prepared from the full length versions using 
polymerase chain reaction (PCR). A primer was designed such that the polymerase activity 
started at the LIGD site, amplifying only the C-terminal domain. The polynucleotide products 
were then purified and ligated into the pGEM-T vector, and the insert genes were then each 
sub-cloned into the pET21a vector to give good expression as for cdc25A(cat.). Purification 
by the optimised conditions gave the expected high-concentration solution of active 
phosphatase. 
 
Initial 1D 
1
H-NMR experiments indicated that the recombinant cdc25A(cat.) contained an 
encouraging level of secondary structure, as evidenced by the complexity of the spectrum and 
the appearance of peaks at higher and lower chemical shift values than those expected for 
amino acids in solution. However, in order to obtain data of the quality necessary for protein 
structure determination, millimolar sample concentrations of isotopically labelled protein 
were required, that furthermore were stable and soluble at around 30 ºC for long periods, the 
increased temperature an important part of achieving a good signal-to-noise ratio. Finding 
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buffer conditions that fulfil these requirements is considered the most laborious and difficult 
part of the protein NMR process, and is often the limiting factor. As these initial NMR 
experiments had resulted in extensive precipitation at the moderate protein concentrations 
used, various buffers were screened to give better solubility and stability.  
 
 
5.1.2 1D 1H-NMR: Buffer Optimisation and Confirmation of Protein Folding 
 
Screening for optimal buffer conditions for cdc25A began with the variation of pH and the 
salt composition of the buffer: Adjusting the pH away from the protein pI (estimated to be 6.3 
for cdc25A) usually increases the solubility due to the additional net charge. It is also 
preferable to use as low a pH as the protein can tolerate due to the subsequent reduction in 
base-catalysed amide proton exchange in the NMR spectrum. The nature and concentration of 
the buffer salt can also play an important role. Chaotropic salts (e.g. LiCl, KSCN) prevent 
aggregation by interfering with protein-protein interactions, but can destabilise the protein. 
Kosmotropic salts (e.g. Na2SO4) provide structure to the bulk solvent, raising the energetic 
cost of hydrating partially unfolded protein and thus providing stability.
109
 The Hofmeister 
series ranks ions according to these properties, allowing the choice of a small sample of salts 
that should be representative of the entire range.
110,111
 Various additives can also be included 
to provide extra stability and solubility, the most common class being non-denaturing 
detergents.  
 
In order to maximise the number of different buffer conditions included in the screen, 30 μL 
protein samples were added to a 96-well plate, humidified and subsequently sealed to prevent 
evaporation. The initial screen covered 7 pH values in the range 4.5-7.5, three salts (KSCN, 
NaCl and Na2SO4) and three salt concentrations (0 mM, 50 mM and 150 mM), each with 10 
mg/mL cdc25A(cat.). Incubation of the plate at 37 ºC for 24 h was followed by visual 
inspection of the level of precipitation. All wells contained some precipitate, with ten of the 
buffers giving noticeably less precipitation. Small aliquots of each of these ten solutions were 
tested in the OMFP assay, the assumption being that if the remaining soluble protein were 
correctly folded then significant phosphatase activity (and thus fluorescence) would be 
observed (Table 5). The results displayed clear trends; the chaotropic salt KSCN was 
detrimental to solubility, cdc25A(cat.) is less soluble in the pH range 5.5-6.5 (although it 
cannot be ruled out that this is an unexplained effect of the citrate buffer rather than the pH), 
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and soluble protein at pH < 5.5 is essentially inactive. The best conditions used either NaCl or 
Na2SO4 at variable concentration in higher pH buffer, but significant precipitation was 
observed in all cases. 
 
pH 
Salt  
(mM) 
Fluorescence 
(A.U.) 
4.5 - 0.7 
4.5 NaCl (50) 1.6 
5.0 - 1.1 
5.0 NaCl (50) 1.6 
7.0 NaCl (150) 33.9 
7.0 Na2SO4 (150) 33.1 
7.5 NaCl (50) 37.7 
7.5 NaCl (150) 31.4 
7.5 Na2SO4 (50) 34.2 
7.5 Na2SO4 (150) 33.0 
 
Table 5 – Buffer optimisation assay results for selected wells 
 
A selection of the buffer conditions that contained active soluble protein were then used for a 
small set of 1D 
1
H-NMR experiments. An observation from the initial scan was that the peak 
corresponding to methyl group protons at their standard chemical shift (i.e. not shifted by 
secondary structure effects) was larger than expected for a fully folded protein. It was thought 
that a possible reason for an increased level of disorder could be the lack of regular structure 
in the cdc25A C-terminal region as demonstrated by the unresolved nature of this region in 
the literature crystal structure, although it had been hoped that the solution structure of 
cdc25A(cat.) would display the additional helical fold found in cdc25B. Only full NMR 
structure determination would reveal whether this helix does exist in solution for cdc25A, but 
at this stage it was hypothesised that the binding of an anionic substrate mimic might assist in 
the correct folding of the positively charged C-terminal region. If this were the case, 
comparison of the disorder (i.e. the relative size of the unstructured methyl group peak) in the 
presence and absence of substrate mimics might reveal a change that would provide evidence 
for this hypothesis. A 1D 
1
H-NMR spectrum was therefore run on four samples, all at pH 7.5, 
with the following buffer salts: Na2SO4, Na3PO4 and reported potent vanadate inhibitor 
BPV(Pic) (dipotassium bisperoxo (picolinato) oxovanadate (V))
112
 with NaCl. It was 
predicted that sulfate and phosphate anions might mimic the active site interactions of the 
substrate phosphate group, with BPV(Pic) likely to have a similar mode of action. 
Unfortunately, whilst various significant peak shifts suggested some kind of binding event, 
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the spectra obtained did not show any significant reduction in the relative size of the 
unstructured peak.  
 
A second round of solubility screening was therefore attempted using commonly-used 
additives with a NaCl buffer: glycerol, various detergents (CHAPS, Triton X-100 and 
octylglucoside) and a combination of arginine and glutamic acid (Arg+Glu), based on a report 
suggesting that these amino acids provide stability and prevent aggregation for a variety of 
unrelated proteins.
113
 Additionally, the concentration of cdc25A(cat.) was varied to 
investigate the solubility limit. After 24 h incubation, precipitation was again observed in all 
the wells and the remaining solutions were sampled for the OMFP activity assay (Figure 13).  
 
 
Figure 13 – Assay results for additive screen 
 
It was immediately clear that all the wells containing the detergents contained either 
completely precipitated or inactivated enzyme. Whilst the amino-acid combination proved no 
better than the control buffer containing no additive, glycerol notably improved both 
solubility and activity. However, this additive was subsequently excluded on the basis that 
any increased viscosity of the solution cannot be tolerated when trying to determine the 
structure of a relatively large protein, due to the increased tumbling times and hence lower 
resolution. The higher activity of the wells with lower enzyme concentrations also suggested 
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that the effect of aggregation and precipitation was greater than just to return the levels of 
soluble active protein to a threshold concentration. A follow-up screen investigated the 
reported beneficial effect of introducing the Arg+Glu additive prior to the concentration of the 
protein solution, preventing aggregation during this process and significantly helping 
subsequent stability,
113
 but no difference was observed for a variety of cdc25A concentrations. 
 
The effect of using glycine instead of ionic buffer salts was also investigated. Although this 
additive was not expected to assist the solubility, it is known to have a significant positive 
effect on the thermal stability of protein solutions.
114
 Furthermore, the use of a neutral 
zwitterionic species does not contribute to the conductance of the solution. Electrically 
conductive samples have increased resistance and thus thermal noise,
115
 which can have a 
significant detrimental effect on the sensitivity, especially for cryogenic NMR probes. The 
replacement of buffer salt with 0.5 M glycine was demonstrated not to affect the solubility, 
and this was identified as a possible solution to any later issues with signal sensitivity.  
 
As none of the buffer or additive screens had discovered conditions that improved the 
solubility beyond that of the final storage buffer following the gel filtration column (Tris-HCl, 
200 mM NaCl, 1 mM DTT, 1 mM EDTA, pH 7.5), a screen of cdc25A concentrations was 
carried out to identify the maximum concentration at which precipitation did not occur in this 
buffer. Samples with concentrations ranging from 100-450 μM (in 50 μM increments) were 
incubated at either 20 °C or 30 °C for three days. The lower temperature appeared to be much 
more suitable, with all samples below 300 μM containing no visible precipitate; for the 30 °C 
samples, the limit was 150 μM. Surprisingly, 1H-NMR scans showed that the partially-
precipitated samples that had high initial concentrations had a higher final solution 
concentration of correctly folded protein than the non-precipitated samples, in almost the ratio 
that would be predicted from the starting concentrations (this was subsequently verified by 
Bradford assay). This result contradicted the previous findings regarding the lower final 
enzymatic activity of highly concentrated samples. Importantly, the higher concentration 
samples were found to be stable at 30 °C following the removal of the precipitate, also 
contradicting earlier observations. The reason for this unexpected attainment of sample 
stability was unclear and was attributed to continual small improvements to the experimental 
procedure, which ultimately produced purer, less-aggregated protein.  
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A subsequent screen looking at higher 
concentrations (300-1000 μM in 50 μM 
increments) under the same buffer conditions 
with incubation at 30 °C found that the 
maximum correctly-folded protein solution 
concentration by 
1
H-NMR stabilised at 
roughly 450 μM, with a corresponding 
increase in signal intensity (example shown in 
Figure 14). This screen also directly 
compared the effect of exchanging NaCl for 
glycine for each sample. The results 
confirmed earlier observations that high 
concentrations of glycine provide comparable 
solubility and stability to moderate salt 
concentrations. 
 
The solubility screens therefore identified the optimal pH, ruled out the use of common 
additives, established the maximum solution concentration and confirmed the suitability of 
glycine as a salt equivalent. Overall, the optimal buffer conditions allowed the generation of 
stable, saturated protein solutions that maintained correct folding even when incubated at 
30 °C for up to 1 week. 
  
 
5.1.3 2D NMR: Isotopic Labelling and HSQC Results 
 
Advanced protein NMR techniques require isotopic labelling in order to resolve structural 
data. For preliminary studies, 
15
N-labelled proteins are used to generate simple HSQC spectra 
that provide information using the amide N-H coupling. Further experiments require 
13
C- and 
occasionally 
2
H-labelling. This isotopic labelling is achieved by growing the bacteria in a 
medium that contains these specific elements only as the desired isotope. A common 
additional strategy to assist with the peak assignment is the use of specific labelled amino 
acids in an unlabelled medium. 
 
 
Figure 14 – Concentration dependence 
of 
1
H-NMR peak intensity 
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The most common method of generating isotopically labelled protein in E. coli is using M9 
minimal growth media, which has been designed to allow the bacteria to grow in a solution 
containing a small number of specified ingredients with a single source of carbon and 
nitrogen (glucose and ammonium chloride respectively) that can be easily obtained in the 
desired isotopically pure form.
116
 For the expression of cdc25A, this method produced very 
poor yields of active protein. Attempted optimisation of the expression conditions did not 
improve the yield, and therefore this method was not considered practical or economical. It 
was clear that the low protein yield was primarily due to very poor bacterial growth, and the 
minimal medium was therefore modified by the addition of vitamin and micronutrient 
solutions. However, as before the resulting yield of protein was low, even following 
attempted optimisation. 
 
As an alternative approach, “rich” media contain the cell lysate of algae grown in minimal 
media, and thus contain isotopically-labelled cell components such as amino acids. Bacteria 
generally grow much more efficiently in these media, and the increase in yield can justify the 
significantly increased cost. However, although the expression levels using the Spectra-9 rich 
medium were relatively high, the first 
15
N-NMR scan of isotopically-enriched protein 
unexpectedly showed a high ratio of unfolded protein. Since it is known that bacteria can need 
time to adapt to new media before induction of protein expression,
117
 it was theorised that the 
abrupt switch from the normal LB medium to the rich medium during the final scale-up may 
have been the cause. The expression was repeated using the rich medium for the smaller 
initial cultures, but the same poor folding was observed. An alternative theory was considered, 
where Spectra-9 is deficient in a nutrient or cell component that the bacteria require to 
successfully produce high levels of folded protein. This theory was supported by the 
observation that using a final culture medium containing 10% LB / 90% Spectra-9 produced 
high yields of correctly folded protein by 
15
N-NMR, although the corresponding 10% drop in 
NMR signal would negatively impact on the quality of structural information obtainable from 
later studies. 
 
The 
15
N-
1
H HSQC scans using the labelled, correctly-folded protein produced another 
unexpected result, with a significant proportion of the peaks (corresponding to each amino-
acid) being unresolved, likely resulting from the effect of conformational lability on the NMR 
timescale, perhaps due to the unstructured C-terminal domain. This continual change in 
chemical environment for the affected N-Hs averages the (already weak) observed signals 
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until they can no longer be resolved from the background noise. No improvement was 
observed on binding of the vanadate inhibitor BPV(pic). Although a number of possible NMR 
studies might allow confirmation of this theory, such as synthesis of a truncated form of 
cdc25A, or selective labelling of certain methyl groups to study solution dynamics, the 
priority was to obtain alternative structural data to aid the medicinal chemistry investigations.  
 
A preliminary 1D 
1
H-NMR scan of cdc25B promisingly showed a high degree of folding 
(more so than for cdc25A). 
15
N labelled cdc25B was therefore prepared, but the 
15
N-
1
H 
HSQC spectrum was again found to lack a large number of amino acid peaks, suggesting that 
on the NMR timescale cdc25B displays analogous conformational flexibility to cdc25A. For 
cdc25C, preliminary 
1
H-NMR scans showed a greater degree of disorder than for cdc25B, and 
the labelling studies were therefore not attempted. 
 
A recent literature computational study of the molecular dynamics of cdc25A and B supports 
these conclusions regarding the conformational flexibility of the C-terminus, which in 
solution is predicted to be either unfolded or in an equilibrium between a partially-folded and 
disordered state.
100
 The same result is found for large sections of the N-terminal domain, 
providing an explanation for the difficulty in obtaining crystals of the full-length cdc25 
proteins. Additionally, this study strongly advises against structure-based virtual screening 
using even the fully-folded published crystal structure of cdc25B, as the exposed nature and 
high flexibility of the active site region result in a large diversity of possible binding modes 
for reported inhibitors under dynamic conformational conditions, with transient exposure of 
hydrophobic cavities and clefts that might provide the majority of any real binding interaction. 
 
 
5.2 Crystallisation Studies 
 
Following our failure to obtain novel NMR-derived structures for the cdc25 isoforms, it was 
considered that switching to X-ray crystallography might prove more successful. As stated 
previously, there are effectively no reported viable structures for cdc25A or cdc25C, 
presumably despite considerable effort following the initial discovery and characterisation of 
these important enzymes, yet it was hoped that a fresh approach to this challenge might prove 
more successful. This reasoning was predominantly based on the rapid improvement of 
crystallisation technologies in recent years, with the advent of large libraries of commercial 
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crystallisation buffers that have made the technique almost routine. Furthermore, the 
optimisation of the buffer conditions already carried out to obtain high solution concentrations 
of large quantities of pure protein for 
1
H-NMR was directly applicable to the preparation of 
samples for crystallisation.  
 
Collaboration with Prof Paul Freemont and Imperial College’s Centre for Structural Biology 
crystallisation facility allowed access to high throughput crystallisation screen technology,
118
 
using the sitting-drop crystallisation technique. Specifically, the protein of interest is added 
using a Mosquito liquid dispensing robot to a range of commercially available pre-dispensed 
96-well plate crystallisation screens (i.e. with a wide variety of buffers and additives) and 
incubated. A sub-μL droplet of the buffer is placed by the robot into a small, shallow sub-well 
adjacent to the larger well of the buffer reservoir. A sub-μL droplet of the high-concentration 
protein solution is precisely added to the same location and the plate incubated for several 
weeks. Once the plate is sealed, the headspace above each sub-well is shared with that of the 
adjacent large buffer reservoir, ensuring no changes in solution constitution by evaporation 
processes. 
 
Large cultures of all three cdc25 isoforms were prepared and purified by the standard method, 
before a further automated gel filtration step in order to achieve the rigorous purity required to 
grow high-quality crystals, as analysed by SDS-PAGE. The samples were then concentrated 
to high levels (15-20 mg/mL) and immediately added to nine commercially available 
crystallisation screen plates (a total of 864 buffer conditions per isoform). The plates were 
incubated at 22 °C and each well was visually inspected by microscope at intervals rising 
from approximately one day to one week over a several week period.  
 
Despite the breadth of the initial screen, no definitively positive results were observed. For 
each isoform, a repeat screen was therefore performed. Due to protein degradation, a new 
large batch of each protein was required to be expressed and purified by both ion exchange 
and gel filtration for each new screen. The plates were again monitored for several weeks, and 
at this stage it was decided that a different approach should be taken for each of the three 
isoforms: 
 For cdc25A, due to the lack of any positive results in the screen, combined with the 
known difficulties in producing a relevant crystal for this isoform, further efforts 
towards crystallisation were discontinued. 
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 Since similarly-negative results were observed for cdc25B, a larger-scale screen 
comprising three 24-well plates was carried out based on the published literature 
crystallisation conditions.
73
 Unfortunately, no positive results were obtained at two 
cdc25B concentrations tested.  
 The second 9 × 96-well plate buffer screen carried out with cdc25C also varied the 
buffer:protein ratio, using 1:1 and 1:2 for each buffer condition. This screen showed 
some positive results for the precipitant MPD (2-methyl-2,4-pentanediol) and the co-
solvent PEG (various sizes from 200 to 3350). A follow-up screen was carried out 
with four 24-well plates at the 2 μL scale (rather than 100 nL), varying precipitant 
concentrations and pH. This screen was monitored for two weeks, at which point a 
smaller subset of conditions was identified as potentially promising. A further two 
plate follow-up screen was similarly performed but proved ultimately inconclusive.  
 
At this stage, the failure of the two structural biology approaches had focussed our attention 
instead on using ligand-based virtual screening, thus circumventing the need for any 
additional structural information for the generation of new inhibitor classes for cdc25 (See 
Section 6). An alternative strategy towards crystallisation was implemented by co-workers, 
focussed on generating the reported crystal of cdc25B(cat.) by exact replication of the 
literature conditions; this time generating and using an identical construct.
119
 Success was 
eventually achieved using a specially-created construct missing the short sequence of C-
terminal residues that are not resolved in the literature structure. The crystals obtained are 
currently being used by co-workers in the Mann and Freemont groups for soaking and co-
crystallisation experiments with the best novel inhibitors discussed in later sections. Further 
cloning efforts are also underway by these co-workers to increase the protein stability. 
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6  Ligand-Based Virtual Screening 
 
As discussed previously, the lack of structural information for cdc25 (particularly in the form 
of a bound small molecule crystal structure), combined with the relatively featureless active 
site surface, makes the discovery of new classes of inhibitor extremely difficult. Despite this, 
during the course of this project two studies were reported that described the structure-based 
virtual screening of the reported cdc25B(cat.) crystal structure to identify novel, reversible 
cdc25 inhibitors with micromolar potency.
120,121
 It was still felt, however, that this approach 
could not be sufficiently validated to ensure that the docking scores would translate into real 
inhibition.  
 
The disappointing results of our attempts to both synthesise analogues of literature 
compounds and obtain new structural information led to collaboration with Dr Caroline Low 
of Imperial College’s Drug Discovery Centre to carry out ligand-based virtual screening. This 
technique involves the computational analysis of literature inhibitors to provide a 
pharmacophore template which can be compared against libraries of commercial compounds 
in order to find new inhibitor structural classes. The software of choice, FieldScreen,
122
 uses 
molecular field-based similarity
123
 as the basis for these structural comparisons, and has 
proven successful in finding novel inhibitors of p38 MAP kinase,
124
 the corticotrophin 
releasing factor 1 receptor,
125
 as well as a highly ligand-efficient antagonist of the oxytocin 
receptor.
126
 In this technique, the key electrostatic and van der Waals properties that control 
the binding interactions of molecules are calculated and considered in terms of four types of 
3D molecular field descriptors, or “field points”. Compounds with similar field point patterns 
are assumed to bind in similar manners, regardless of their underlying structure. 
 
 
6.1 Template Selection and Screening Results 
 
Selection of the correct training set for the creation of the template is critical, and this 
immediately proved a problem for our application of this technique to cdc25. The reported 
potencies of all irreversible inhibitors (when reported as a binding constant e.g. IC50) are 
essentially meaningless as descriptors of the strength of the binding interactions, since in 
theory only a stoichiometric quantity of the inhibitor could completely inactivate the enzyme, 
given sufficient time. The scarcity of the remaining reported reversible inhibitors, particularly 
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at this stage of the project, meant that even fairly large, weakly-binding structures had to be 
considered. A further concern was that the lack of structural information or kinetic data for 
these reported inhibitors meant that it could not assumed these compounds were necessarily 
all binding at the active site, a factor which could seriously interfere with the creation of a 
relevant template. 
 
Given these factors, the inclusion in one of the contemporaneously-published structure-based 
virtual screening studies of a crystal structure of cdc25B containing a bound synthetic peptide 
in the active site prompted us to investigate the potential use of this structure as the basis for 
the template.
121
 In particular, knowing the precise 3D conformation of an active inhibitor 
removes a large part of the uncertainty in ligand-based screening. The peptide structure and 
surrounding protein surface were reconstructed from the coordinate tables in the original 
BASF patent,
127
 and analysis showed that although a number of atoms were unresolved, they 
were not in direct contact with the protein (Figure 15).  
 
   
Figure 15 – Crystal structure of BASF synthetic peptide 
 
Unfortunately, no useful information could be gained from further analysis of the bound 
structure, as the only functionality fully in contact with the protein surface proved to be the 
benzylsulfonate anion and parts of the two naphthyl groups. This peptide clearly therefore 
exhibits a binding mode that had been predicted for a large class of cdc25 inhibitors; an 
anionic phosphate mimic bound in the catalytic loop and a large hydrophobic region bound in 
an adjacent cleft.  
 
After surveying a range of combinations of literature inhibitors, the training set that proved 
optimal with respect to finding a common pharmacophore consisted of pyrazole 6
47
, 
thiazolopyrimidine 7
121
 and naphthofurandione 8
31
 (Figure 16 and Table 1). Despite its ortho-
quinone motif, naphthofurandione 8 is reported to be a reversible inhibitor. No similar studies 
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had been performed for thiazolopyrimidine 7, and it was recognised that there was potential 
for irreversible cdc25 cysteine alkylation by conjugate addition to the α,β-unsaturated amide 
functionality, which therefore prompted investigation using a reversibility assay. Prolonged 
incubation of cdc25A(cat.) with thiazolopyrimidine 7, followed by subsequent dilution to a 
concentration at which the inhibitor is inactive, resulted in similar phosphatase activity to 
control experiments, proving this compound does not irreversibly inactivate cdc25. Further 
evidence is provided by the published observation of a reversible kinetic profile for the 
inhibition of the closely related PTP1B by analogous thioxothiazolidinone inhibitors.
128
  
 
 
Figure 16 – Optimal training set for preparation of field point template 
 
The templates were created using the FieldTemplater software package,
129
 which was used to 
determine a consensus view of the most similar conformations of each set of three 
compounds. A set of conformations was generated for each molecule, using an upper 
threshold of 6 kcal/mol above the calculated global energy minimum, which covers all 
conformations likely to be readily accessible at 37 °C. In the optimal set, this gave 200 
conformations of pyrazole 6, 111 conformations of thiazolopyrimidine 7 and 18 
conformations of naphthofurandione 8. The field point pattern surrounding each conformation 
was then calculated and exhaustive cross-correlation of the overlay score for every single pair 
of field point patterns resulted in the highest-scoring pattern of fields common to all three 
molecules. Three templates were identified, all containing the same conformation of pyrazole 
6 (Table 6). These results strongly suggested that conformation 81 (Figure 17) was the 
bioactive conformation of 6, and on this basis the field point pattern associated with this 
structure was used as the input for the virtual screen of commercial compounds. 
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Table 6 – Conformations of the training set with a high overlap score 
 
Template 
Conformation identified 
a
 
6 7 8 
A 81 5 2 
B 81 8 4 
C 81 8 16 
 
a – Conformations numbered from lowest to highest calculated energy 
 
 
Figure 17 – Field point template B (left) and conformation 81 of diarylpyrazole 6 (right) 
Negatively charged field points shown in cyan, positively charged fields in red, surface hydrophobic 
points in yellow and centres of hydrophobic mass in orange. Underlying structures are coloured as 
follows; 6 is pink, 7 is green and 8 is cyan. 
 
 
A library of two million commercial compounds was screened using FieldScreen
122,130
 and a 
list was compiled of 200 compounds found to have the highest overlay score with the field 
point pattern of conformation 81 of pyrazole 6. The vast majority (95%) of these compounds 
were found to contain the same diarylpyrazole motif as the input structure. Resubmission of 
the screen filtering out this structural class resulted in a second list of 200 non-diarylpyrazole 
compounds from which candidates were selected for testing. 
 
 
6.2 Assay Results 
 
6.2.1 Initial Cdc25 Activity Assays 
 
Fluorimetric in vitro cdc25 activity assays were carried out as described in Section 4, and 
further validated by the repetition of the literature IC50 measurement for template 
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thiazolopyrimidine 7 (14.4 μM against cdc25B(cat.), lit.121 13.0 μM). An initial screen of six 
commercial compounds from the FieldScreen list identified simple diarylthiazole T5308252 
(83) as a micromolar inhibitor of all three cdc25 isoforms. Testing of an additional 28 
commercially-sourced thiazoles identified eight further good hits (Table 7).  
 
Table 7 – Virtual screen hits active in Cdc25 activity assay 
   IC50 ± SEM (μM) 
Cmpd 
No. 
Cmpd 
Name 
Structure Cdc25A Cdc25B Cdc25C 
76 T5896241 
 
2.36  
± 0.27 
8.93  
± 0.54 
10.2  
± 0.3 
77 T5959818 
 
4.02  
± 0.46 
10.1  
± 1.2 
14.2  
± 1.8 
78 T5982914 
 
5.62  
± 0.99 
19.0  
± 2.9 
24.3  
± 3.4 
79 T5765678 
 
6.36  
± 1.02 
12.1  
± 2.2 
24.7  
± 8.2 
80 T5846763 
 
6.49  
± 1.15 
17.5  
± 3.2 
18.0  
± 2.0 
81 T5705971 
 
10.2  
± 1.2 
14.9  
± 2.5 
16.8  
± 3.1 
82 T5871826 
 
9.54  
± 1.91 
22.7  
± 1.5 
> 100 
83 T5308252 
 
13.0  
± 4.0 
13.6  
± 2.3 
31.5  
± 12.6 
84 C7991374 
 
17.8  
± 6.9 
> 50 
a
 > 50 
b
 
 
a – 78% inhibition at 100 µM. b – 82% inhibition at 100 µM. 
 
This represents a hit rate for the virtual screening of 26%, obtained from testing a very small 
number of compounds. For this and all subsequent inhibitor data, IC50 values shown represent 
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the mean of at least 3 experiments using 6-10 compound concentrations. The IC50 and SEM 
values were calculated using SigmaPlot data-fitting software. 
 
These compounds all share a common 2,4-diarylthiazole core apart from thiazole 79, which 
has a 3-pyrrole attached at the thiazole 4-position. Many of the aryl rings attached at this 4-
position share a similar feature; benzo-fused 5-membered nitrogen-containing heterocycles 
attached via the 5-position (5-benzimidazolone for compound 76, 5-dihydroindole for 
compounds 77, 78 and 80, 5-oxindole for compound 82). Compounds 81 and 84 both contain 
simple amides of a 3-aniline, but attached to different positions of the thiazole ring. The 
possibility that the 2- and 4-substituents of the thiazole are interchangeable suggested that 
position of the heteroatoms in the thiazole core might not significantly affect the binding 
interaction.  
 
At this stage, the compounds identified were amongst the most potent reversible cdc25 
inhibitors reported. Crucially, they also fulfilled the majority of the criteria used to select 
promising hit compounds for further development: they are relatively small, stable, easily 
synthesised, sufficiently water-soluble and have an appropriately “drug-like” structure. 
Additionally, no diarylthiazoles have been previously reported to inhibit any dual-specificity 
phosphatase. In order to confirm these inhibitors as acting by reversible binding to the active 
site, a reversibility assay was carried out on a selection of these compounds as described for 
thiazolopyrimidine 7, with no inhibition of cdc25A observed following the dilution step.  
 
The original intention was then to compare the field points of those compounds that were 
active with those that were inactive, to try to gain additional SAR information. Unfortunately, 
it became clear that the active compounds were not predicted to bind in a consistent 
orientation due to the inherent symmetry of their field point patterns (and structures). When 
the conformations and field points of four of the top five inhibitors are displayed as aligned to 
the template (not shown), the first and last compounds bind in one orientation with the 
sulfonamide/urea functionality at the top, and the middle two compounds bind in the other 
orientation with the sulfonamide functionality at the bottom (Figure 18). The existence of two 
similar low-energy conformations makes any computational analysis of SAR difficult. This 
finding further supports the suggestion that the positioning of the heteroatoms in the thiazole 
core may have little overall effect on the binding. 
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Figure 18 – Conformations and Field Points of diarylthiazoles 76, 77, 78 and 80 oriented as 
aligned to template pyrazole 6 (not shown) 
 
 
6.2.2 Phosphatase Selectivity Assays 
 
The choice of phosphatases for a relevant selectivity panel was determined by consideration 
of two factors: structural relationship to cdc25 and relevance as a therapeutic target. For the 
former criterion, it is necessary to balance the use of highly related phosphatases as a stringent 
test of inhibitor selectivity with the sampling of phosphatases from a wide range of structural 
classes to give confidence in the breadth and range of any observed selectivity. It was further 
hoped that the use of phosphatases whose inhibition may result in a potential clinical benefit 
would provide the advantage of serendipitous discovery of inhibitors with interesting 
biological activity against pathways and diseases not directly the focus of this project. 
 
Alkaline phosphatase (AP) was selected as a ubiquitous, generic phosphatase with little 
substrate specificity.
131
 The remaining phosphatases were all chosen from the large protein 
tyrosine phosphatase super-family, containing the majority of phosphatases critical to signal 
transduction.
24
 Based on structure and substrate preference, this family can be further divided 
as shown in Figure 19. Protein tyrosine phosphatase 1B (PTP1B) is commonly used as a 
control for conventional PTPs and is a comparatively well-validated and investigated drug 
target for the treatment of a range of diseases such as diabetes.
132
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Figure 19 – Sub-classification of the PTP superfamily of phosphatases24 
 
The selectivity panel was completed by 3 dual-specificity phosphatases (DUSPs) from the 
MAPK-phosphatase (MKP) class that, alongside cdc25, are also emerging drug targets with 
close links to human cancers and chronic inflammatory diseases.
24
 MKP-1 and MKP-3 are 
typical members of this family that have well-characterised influences over the activities of 
the MAP kinases (yet quite different substrate preferences) and are overexpressed in various 
human tumour types.
24,133
 VHR (vaccinia virus phosphatase VH1-related) is a poorly-studied 
DUSP that is believed to be involved in regulation of the MAP kinases, although data 
regarding its cellular substrates are conflicting.
24,25,134
 Cells lacking VHR undergo cell cycle 
arrest, suggesting that VHR inhibition may work synergistically with cdc25 inhibition.
135
 
Although evidence for VHR as a valid drug discovery target is comparatively weak, recent 
reports have strongly linked VHR up-regulation to cancer progression.
136,137
 The overall 
medicinal chemistry profiles for the MKPs and VHR were similar at this stage of the project, 
with few reported reversible inhibitors of moderate potency (MKP-1
138-141
, VHR
57,142-145
) and 
no crystallographic inhibitor-binding information on which to base a rational design approach. 
A more-recent reported crystal structure of VHR bound to a small-molecule inhibitor provides 
very little useful information for rational design, with only the interactions of an anionic 
phosphate mimic and non-specific hydrophobic regions in a similar manner to that of the 
BASF peptide discussed previously bound to cdc25B (see Figure 15).
146
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Optimisation of enzyme concentration and buffer pH was performed for AP, PTP1B and 
VHR, establishing validated and reproducible fluorescence assay conditions using the OMFP 
artificial substrate, with sodium orthovanadate as a positive control for inhibition. Following 
poor results obtained with commercial MKP-1 and -3, discussion with Prof Steve Keyse 
(Dundee) highlighted the requirement for the use of both large quantities of enzyme and 
complexation to the appropriate MAPK to result in a level of phosphatase activity suitable for 
in vitro assays.  
 
Expression of significant quantities of His-tagged MKP-3 from a donated construct was found 
to be problematic; His-purification was successful following the prescribed denaturing 
conditions (8 M urea), but the subsequent renaturing by dialysis proved sensitive and 
capricious. A donated sample of purified MKP-3 and its associated kinase ERK-1 was found 
to show reproducible activity in the colourimetric PNPP assay initially tried for cdc25. The 
expression and in vitro assay of MKP-1 was expected to be similarly difficult, and MKP-5 
was chosen as an alternative. This phosphatase is uniquely characterised by high activity that 
is independent of substrate binding, and has been linked to demyelinating diseases such as 
multiple sclerosis.
147
 Optimisation of the OMFP assay conditions as above proved successful. 
After the completion of these assays, it was noted that the University of Pittsburgh groups 
responsible for most of the medicinal chemistry investigations into MKP-1 and MKP-3 had 
reported reservations over the biological relevancy of their in vitro assays, and as such had 
developed a complex cell-based assay for MKP-3.
148
 
 
The nine thiazole inhibitors found by the virtual screening were assayed against the 
phosphatase selectivity panel, showing no inhibition of AP, PTP1B, MKP-3 or MKP-5, but 
uniformly strong inhibition of VHR, with IC50 values comparable to that for cdc25A and no 
significant selectivity (Table 8). 
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Table 8 – Phosphatase selectivity screen of cdc25-active compounds from Table 7 
   IC50 ± SEM (μM) 
Cmpd 
No. 
Cmpd 
Name 
Structure VHR PTP1B MKP-3 MKP-5 AP 
76 
T589- 
6241 
 
1.92  
± 0.30 
>100 >100 >100 >100 
77 
T595- 
9818 
 
2.68  
± 0.78 
>100 >100 >100 >100 
78 
T598- 
2914 
 
8.04  
± 0.65 
>100 >100 >100 >100 
79 
T576- 
5678 
 
8.29  
± 1.39 
>100 >100 >100 >100 
80 
T584- 
6763 
 
8.10  
± 0.57 
>100 >100 >100 >100 
81 
T570- 
5971 
 
8.89  
± 1.26 
>100 >100 >100 >100 
82 
T587- 
1826 
 
10.6  
± 1.2 
>100 >100 >100 >100 
83 
T530- 
8252 
 
4.44  
± 0.57 
>100 >100 >100 >100 
84 
C799- 
1374 
 
26.1  
± 4.6 
>100 >100 >100 >100 
 
Following this discovery that the diarylthiazoles active against cdc25 were also similarly 
active against VHR, we next tested against VHR the compounds in the initial set that were 
inactive against cdc25, and found four VHR-selective inhibitors (Table 9, compounds 89-92). 
Two of the four VHR-selective inhibitors found in this screen were diarylaminothiazoles. 
Based on a simple hypothesis that this alternative core structure might show a general 
selectivity for VHR against cdc25, 19 further aminothiazoles from the virtual screening 
results were purchased and assayed, resulting in four further VHR-selective 
diarylaminothiazole inhibitors (compounds 85-88), supporting this structural hypothesis for 
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selectivity. The VHR selectivity ranged from >15-fold for aminothiazole 85 to approximately 
3-fold against cdc25B for aminothiazole 92. Whilst the diarylaminothiazole compounds 
identified mostly contain simple aryl substituents, there are no general structural features or 
SAR trends observed, excluding compounds 87 and 88 that are differentiated by a single 
methyl group. The selectivity of diarylthiazoles 90 and 91 for VHR over cdc25 provides 
interesting SAR data; for 90, replacement of the 2-chlorobenzene with furan (compound 84) 
results in increased cdc25 inhibition, and for 91 the analogous dihydroindole sulfonamide 80 
exhibits potent cdc25 inhibition. 
 
Table 9 – VHR-selective inhibitors 
   IC50 ± SEM (μM) 
Cmpd 
No. 
Cmpd 
Name 
Structure Cdc25A Cdc25B Cdc25C VHR  
PTP1B/MKP-
3/MKP-5/AP 
85 
C565 
-3548 
 
>100 >100 >100 
6.72  
± 1.67 
>100 
86 
C785 
-3655 
 
>100 >100 >100 
8.15  
± 2.17 
>100 
87 
C609 
-9253 
 
>100 >100 >100 
8.41  
± 1.11 
>100 
88 
C718 
-8297 
 
>50 
a >50 b >100 
11.5  
± 2.9 
>100 
89 
C593 
-5510 
 
>100 >50 c >100 
20.7  
± 2.9 
>100 
90 
C616 
-2452 
 
>100 >100 >100 
23.8  
± 8.3 
>100 
91 
T559 
-8472 
 
>100 >100 >100 
24.3  
± 3.0 
>100 
92 
T0511 
-8034 
 
>100 >50 d >100 
31.9  
± 5.9 
>100 
 
Compounds with IC50 >50 µM: inhibition at 100 µM: a – 67%, b – 67%, c – 60%, d – 52%. 
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6.2.3 Cell-Based Assays: MTS Assays, Flow Cytometry and Phosphorylation Status 
 
In order to test the potential cellular effects of these cdc25/VHR inhibitors, the MTS assay 
was chosen to provide quantitative data about growth inhibition (the expected phenotype of 
the enzyme inhibition). This assay quantitatively measures mitochondrial activity via bio-
reduction of an arylated tetrazole derivative to give a coloured formazan product (Figure 20), 
and can be performed in a high-throughput 96-well format.  
 
 
Figure 20 – Molecular mechanism of colourimetric MTS assay 
 
The assay, carried out by co-workers in the Mann group, was optimised for cell number and 
incubation time.
119
 The compounds active in the in vitro enzyme assays were then screened 
against various cell lines, with IC50 values subsequently measured for active compounds. Four 
compounds were found to have a concentration-dependent anti-proliferative effect at 
concentrations below 40 µM against at least one cell line, with IC50 values comparable to the 
in vitro inhibition of cdc25A and/or VHR (Table 10). Furanamide 84 was found to inhibit 
proliferation in all cell lines tested with IC50 values at or slightly below those found in vitro 
against cdc25/VHR. At this stage, the poor solubility of this class of compounds proved a 
persistent problem, limiting testing at any higher concentrations. 
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Table 10 – MTS assay results for cell-active compounds 
   MTS Cell Assay IC50 ± SEM (μM) 
Cmpd 
No. 
Cmpd 
Name 
Structure 293T MCF7 HeLa 3T3 
79 
T576- 
5678 
 
6.92 
± 3.46 
41% 
inhibition 
at 40 µM 
>40 N.D. 
81 
T570- 
5971 
 
5.76 
± 0.88 
49% 
inhibition 
at 40 µM 
55% 
inhibition 
at 40 µM 
N.D. 
84 
C799- 
1374 
 
7.95 
± 0.95 
5.28 
± 1.76 
9.64 
± 1.33 
14.89 
± 3.07 
87 
C609 
-9253 
 
8.96 
± 2.25 
50% 
inhibition 
at 40 µM 
23.61 
± 1.79 
27% 
inhibition 
at 40 µM 
 
 
This growth inhibition was further investigated by biochemistry collaborators using flow 
cytometry.
119
 Selected active compounds were added at 40 μM to cultures of NIH-3T3 cells 
(mouse fibroblasts) that were chosen as a representative example of cells with a normal cell 
cycle, and following incubation the cells were harvested and analysed by quantification of 
DNA synthesis. Although no difference in cell cycle profile was observed between the control 
and treated cells, it was proposed that non-specific cell cycle checkpoint inhibition would not 
cause accumulation of cell population in any particular phase. Encouragingly, the cells 
showed no sign of increased apoptosis (sub-G1 population), demonstrating that these 
compounds are not inherently toxic. 
 
NIH-3T3 cells were therefore synchronised, starting with an initial quiescence by removal of 
the growth serum so that all entered the G0 phase. Addition of growth serum then re-started 
cell growth, synchronised at the G1 phase. Flow cytometry indicated that a selection of the 
compounds inhibited S phase entry to some degree by their action at the G1/S phase transition 
following the release from quiescence (Figure 21), although the effect was not pronounced for 
compounds 76, 77 and 84. 
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Figure 21 – Quantification of DNA synthesis in NIH-3T3 cells 
Quiescent cells (-) were stimulated with 10% serum (NCS) without addition (control), vector control only 
(DMSO) or in the presence of cdc25/VHR inhibitors (40 µM). Inhibitors were added concurrently with the 
serum and incubated for 17 h before harvesting and staining with propidium iodide. Data is expressed as the % 
of the given population in G1 (quiescence), S (synthesis) or G2 (mitotic) phase of the cell cycle. 
 
To test more directly the cellular targets of these active compounds, collaborators in the Mann 
group then assessed the phosphorylation status of CDK2 and MAPK, the reported targets of 
cdc25 and VHR respectively.
119
 NIH-3T3 cells were synchronized via quiescence as before, 
and treated with the compounds following resumption of the cell cycle. Immunoblotting of 
the treated cells revealed that for compound 79, an increase in the level of phosphorylated 
CDK2 was observed, consistent with cdc25 inhibition (Figure 22). However, no similar 
results were obtained in this initial study for the other cell-active compounds. No increase in 
phosphorylated MAPK was observed with any of the compounds tested, suggesting that none 
of these compounds acts as an inhibitor of a MAPK phosphatase in vivo. These 
phosphorylation status results suggest that furanamide inhibitor 84 might produce its cellular 
anti-proliferative effect by inhibition of a target not tested in this study. This is supported by 
the observation that some of the MTS assay IC50 values for furanamide 84 were slightly lower 
than those from the in vitro enzyme assays. Furthermore, the absence of any effect on the 
phosphorylation status of a physiologically relevant MAPK by VHR inhibitor 87 suggests that 
either this compound also exerts an anti-proliferative effect via inhibition of an unknown 
target, or inhibition of VHR causes G1 arrest by an undiscovered pathway that does not 
include MAPK.  
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Figure 22 – Analysis of CDK2 and MAPK phosphorylation status in treated cells 
NIH 3T3 cells were rendered quiescent by culture in 0.5% serum for 72 h. Cells were then stimulated with 10% 
normal calf serum for 1 h. Compounds (40 µM) or vehicle (DMSO) were then added and the cells incubated for 
a further 7 h followed by immunoblotting for the indicated form of each protein. Samples were also harvested 
immediately prior to serum addition (0) and immediately prior to compound/DMSO addition (1). 
 
 
To summarise, nine diarylthiazoles were discovered to have good potency against the cdc25 
isoforms and VHR, and a further eight compounds were identified with selectivity for VHR. 
Four compounds were then shown to exert an anti-proliferative effect against various cell 
lines with low micromolar potency comparable to the measured in vitro values, suggesting 
good cell membrane permeability. These compounds showed no cytotoxicity, demonstrating 
only the expected cell cycle arrest, and showed selectivity against related targets. The next 
section describes the synthesis and testing of compound libraries based around these hits. 
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7 Analogue Synthesis Part 3 – Analogues of Screening Hits 
 
7.1 Parallel Synthesis by a Divergent Coupling Approach 
 
Following the successful virtual screening, it was decided that an appropriate medicinal 
chemistry strategy would be not to immediately begin the process of systematically 
optimising the most potent compounds, but to instead attempt to further explore the broader 
SAR in the hope of perhaps discovering novel and more potent structural classes not likely to 
be accessible by an optimisation strategy. The rationalisation for this diversity-oriented 
approach was based on the relatively wide range of structural classes found in the virtual 
screen that exhibited similar inhibitory potency, suggesting potential tolerance of a variety of 
functionality, specifically at the C4-position (Figure 23). 
 
 
Figure 23 – Selected inhibitors with diverse C4 substituents, yet similar potency 
 
In order to prepare diverse libraries of analogues in a rapid and divergent manner, the 
conventional Hantzsch approach to diarylthiazoles was rejected in favour of a more modern 
approach based on Pd-catalysed cross-coupling of bromide 93, itself potentially derived from 
a regioselective Suzuki coupling of 2,4-dibromothiazole 94 (Scheme 23). This regioselective 
coupling had little precedent at this stage of the project, although a comprehensive 
investigation into this reaction and that of similar heterocycles has subsequently been 
reported.
149
  
 
 
Scheme 23 – Proposed synthesis of diarylthiazoles by regioselective Suzuki coupling 
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7.1.1 Optimisation of Regioselective Suzuki Coupling 
 
Although 2,4-dibromothiazole is commercially available, we anticipated requiring a 
significant quantity of this key core unit for the synthesis of inhibitor libraries, and therefore 
attempted synthesis via bromination of 2,4-thiazolidinedione (95). Literature conditions using 
POBr3 proved highly variable, and the high cost of the bromination reagent made it unsuitable 
for gram-scale reactions when used in the large excess required. A small set of reaction 
conditions and work-up procedures were explored in order to optimise this reaction, and in 
situ preparation of POBr3
150
 allowed reproducible isolation of large quantities of 2,4-
dibromothiazole (> 15 g) in good purity and moderate yield (Scheme 24). 
 
 
Scheme 24 –Synthesis of 2,4-dibromothiazole, 94 
 
Following a brief screen of conditions, successful regioselective Suzuki coupling of 2,4-
dibromothiazole was achieved using a small excess of the boronic acid to achieve full 
conversion (Scheme 25). Similarly good yields were obtained with the less-reactive 
phenylboronic acid, and an identical result was observed for the analogous coupling of the 
corresponding 2.5-dibromothiazole (97), allowing the exploration of the influence of the 
thiazole substitution pattern. 
 
 
Scheme 25 – Synthesis of bromothiazoles 93, 96 and 98 by regioselective Suzuki coupling 
 
Collaboration with Cancer Research Technology (CRT) allowed access to a range of parallel 
synthesis equipment, including a semi-automated microwave reactor. The conditions for the 
regioselective Suzuki coupling were therefore adapted for microwave heating to allow rapid 
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synthesis of compound libraries. The initial conditions chosen for the model reaction of the 
dibromide with p-methoxyphenylboronic acid were successful, with mono-coupled product 
isolated in 68% yield (Table 11, Entry 1). Lowering the excess of boronic acid to 1.05 eq. led 
to incomplete conversion (Entries 2 and 3). Intermediate levels of boronic acid excess gave 
correspondingly intermediate conversion values (Entries 4 and 5), suggesting that 1.2 eq. is 
the optimal value. On scaling up, the reaction time had to be extended from 20 to 30 minutes 
to achieve full conversion (Entries 6 and 7). Further scale up again caused lower conversion 
and similarly lower yield (Entry 8). At this stage, various non-chromatographic methods were 
attempted to remove the excess boronic acid that proved the major impurity in the crude 
reaction mixture, including using a basic carbonate resin and a PhMe/NaHCO3(aq.) work-up. 
Although these were moderately successful, further purification was still necessary, so for 
later reactions only column chromatography was used. 
 
Table 11 – Optimisation of regioselective Suzuki coupling under microwave heating 
 
 
 
Entry 
Scale  
/ mmol 
Time  
/ min 
Eq. boronic 
acid 
Conversion 
(Yield) / % 
a
 
1 0.5 20 1.2 100 (68) 
2 0.2 20 1.05 66 
3 0.2 20 1.05  61 
b
 
4 0.2 20 1.1 84 
5 0.2 20 1.15 97 
6 2.0 20 1.2 89 (81) 
7 2.0 30 1.2 100 (74) 
8 4.0 30 1.2 83 (54) 
 
a – Conversion calculated from HPLC UV trace. b – Using p-cyanophenylboronic acid 
 
Following the success of the initial regioselective Suzuki coupling and large scale synthesis of 
bromide 93 as a common intermediate, attempts were made to optimise the second coupling 
under microwave conditions as before. Four boronic acids with varying electronic character 
and sensitivity to protodeboronation were then used, with a slightly higher reaction 
temperature of 160 °C. Whilst 4-pyridyl and 4-acetamidophenyl boronic acids (Entries 1 and 
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2) gave full conversion, 2-thiophene boronic acid was unreactive under these conditions 
(Entry 3) and 4-(1H)-pyrazole boronic acid gave a low conversion (Entry 4). A second 
coupling was attempted on the crude mixture of this latter reaction, increasing the SM/product 
ratio to 1:1. The moderate success of these test coupling reactions was considered sufficient to 
proceed with the library synthesis.  
 
Table 12 – Optimisation of Suzuki coupling of 4-bromothiazole 93 under microwave heating 
 
 
 
Entry 
Boronic acid 
 (1.2 eq.) 
Conversion 
/ % 
a 
 
1 4-pyridine 100 
2 4-AcNHPh 100 
3 2-thiophene 19 
4 4-(1H)-pyrazole 29, 50 
b
 
 
a – Conversion calculated from HPLC UV trace. b – Initial conversion of 29%; further 
reaction with additional 1.2 eq. boronic acid and 3 mol% catalyst gave 50% conversion. 
 
 
7.1.2 Library 1 – Suzuki Coupling 
 
Choice of a subset of boronic acids and esters for the Suzuki coupling from the full range of 
245 available for use
151
 began by generation of a virtual library of all possible Suzuki 
products and calculation of the properties of these compounds using StarDrop software.
152
 
Compounds with high lipophilicity (cLogP > 6) or high MW (> 500) were discarded, along 
with those derived from simple alkylboronic acids. The remaining 188 compounds were 
subjected to an optimisation algorithm to determine a selection of 75 that would be both 
maximally diverse (based on Tanimoto coefficients
153
) and give products compliant with the 
Lipinski rules,
154
 with a weighting of 90:10 in favour of diversity.  
 
 
Scheme 26 – Suzuki coupling of 4-bromothiazole 93 
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Of the 77 library reactions, 44 proved successful (99-142), with pyridyl, indolyl and amine-
containing boronic acids disproportionately represented amongst those that failed. This high 
level of attrition was not unexpected given the known difficulties in the unoptimised coupling 
of heterocyclic boronic acids, particularly those with coordinating functionality that can 
deactivate the catalyst. As for all subsequent libraries, a sample of each product was purified 
by preparative mass-directed reverse-phase HPLC. For each library, a list of all the reactions 
attempted is included in the appendix. 
 
At this stage, the resynthesis of potent inhibitors 76 and 80 (Table 7) and their analogues was 
attempted by an alternative Suzuki coupling strategy using the thiazole boronate ester. 
Optimisation of this route would greatly expand the range of potential substituents that could 
be introduced at the C4 position. Bromides 143 and 145 were prepared by Curtius 
rearrangement and reduction/mesylation respectively, with both obtained in high yield 
(Scheme 27). 
 
 
Scheme 27 –Synthesis of aryl bromide coupling partners 143 and 145 
 
Attempted Miyaura borylation of 4-bromothiazole 93 resulted in decomposition under both 
standard Pd-
155
 and recently-reported Cu-catalysis
156
 (Scheme 28). No further attempt was 
made to optimise this reaction at this stage, but a subsequent literature study has successfully 
developed conditions for the preparation of thiazole boronate esters and the difficult 
subsequent Suzuki coupling.
157
  
 
 
Scheme 28 – Attempted borylation of bromothiazole 93 
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An analogous synthesis of C4-alkyl substituted thiazoles was investigated using the Negishi 
coupling of alkyl zinc halides (Scheme 29), but under standard conditions
158
 low conversions 
were obtained. Given the limited selection of alkyl zinc reagents available in the CRT 
compound collection and the high calculated lipophilicity of the resulting products, this 
reaction was not optimised further. An alternative regioselective Negishi coupling of 2,4-
dibromothiazole was however subsequently optimised (see Section 7.3). 
 
 
Scheme 29 – Negishi coupling of 4-bromothiazole 93 
  
 
7.1.3 Library 2 – Aminocarbonylation 
 
An alternative method for rapidly achieving high structural diversity at the thiazole 4-position 
was by aminocarbonylation of bromothiazole 93 with a library of amines. The ability to 
simply switch between the synthesis of C4-aryl compounds and C4-amide compounds from a 
common intermediate demonstrates the power of the Pd-coupling approach to synthesis of 
diverse analogue libraries. The reported microwave conditions for a similar transformation 
used trans-di(μ-acetato)bis[o-(di-o-tolyl-phosphino)benzyl] dipalladium(II) as the preferred 
catalyst due to its high thermal stability, acting to slowly release active Pd species and prevent 
any aggregation
159
. A range of amines of varying reactivity was tested under literature 
conditions (Scheme 30),
160
 with high to moderate conversions following the trend of amine 
nucleophilicity as expected.  
 
 
Scheme 30 – Aminocarbonylation of bromothiazole 93 
 
In the preparation of a library of aminocarbonylation reactions, the choice of amines was 
computationally optimised as above based on size and diversity. Of the 33 reactions attempted, 
17 resulted in isolation of the desired product (149-165). The unsuccessful reactions used 
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almost exclusively the least reactive (usually electron-deficient heteroaromatic) amines, 
suggesting that, under these conditions, the aminocarbonylation reaction requires a certain 
level of amine nucleophilicity to overcome competing pathways. 
 
 
7.1.4 Library 3 – Amide, Sulfonamide and Urea Analogues of Furanamide 84 
 
Given the relative prevalence of 3-aminophenyl amides in the virtual screening hits, and the 
broad antiproliferative activity of furanamide 84 (Table 7), a library of amides and amide 
analogues was considered as a simple and efficient way to explore SAR in this region. Aniline 
precursor 166 was prepared by Suzuki coupling under the standard microwave conditions in 
good yield and the reaction could be scaled up successfully (Scheme 31), despite the concern 
that the unprotected amine might cause problems by coordination to the simple catalyst. 
 
 
Scheme 31 – Synthesis of library precursor 166 
 
A selection of acid chlorides (×32), sulfonyl chlorides (×23) and isocyanates (×13) were 
reacted in parallel with aniline 166 at room temperature under standard conditions, following 
computational selection of an optimal set according to size and diversity (Scheme 32). Eleven 
reactions were unsuccessful, in this case most likely reflecting the quality of the starting 
material, leaving 27 amides (167-193), 18 sulfonamides (194-211) and 12 ureas (212-223). In 
order to further probe the SAR in this region, a further library of 60 amides selected by the 
same criteria was prepared from a selection of carboxylic acids using the coupling reagent 
HATU under standard conditions, with 44 reactions successful (224-267). 
 
 
Scheme 32 – Synthesis of amide, sulfonamide and urea libraries from aniline 166 
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7.1.5 Library 4 – Buchwald-Hartwig Coupling 
 
A further strategy for investigation of the SAR around the furoyl aniline of cell-active 
inhibitor 84 was the attachment of various aromatic and heteroaromatic groups directly to the 
aniline intermediate 166 in place of the furoyl group. A small screen of standard conditions 
for Buchwald-Hartwig coupling found XantPhos
161
 to be the best ligand for this 
transformation (Scheme 33). This reaction possesses a higher degree of difficulty than many 
standard aminations due to the preferred use of stoichiometric aniline rather than the usual 
excess of amine nucleophile. 
  
  
Scheme 33 – Buchwald-Hartwig coupling of aniline 166 
 
These conditions were used in the synthesis of a small library of arylated anilines, with only 8 
of the 17 reactions successful (268-275). Coupling partners bearing the most activated halides 
(such as 2-pyridyl and 2-pyrimidyl) gave the best results; this seemed to be a bigger factor 
than whether the halide in question was bromide or chloride.  
 
The same screen of standard Buchwald-Hartwig conditions was then used for the amination 
of bromothiazole 93, with XantPhos again proving slightly superior (Scheme 34). These 
compounds would be, in effect, “reverse” aminothiazoles which may have very similar 
properties to the conventional 2-aminothiazoles, but are much less common on account of the 
inapplicability of the Hantzsch condensation approach to this substitution pattern. This 
strategy was conceived as a method to prepare regioisomeric analogues of the cell-active 2-
aminothiazole 87 (see Table 9), which contains a p-methoxyphenyl group at the C4-position, 
since the 2-aminothiazole core structure is both extensively covered in the patent literature 
and also has been identified as a potent toxicological liability (see Section 7.3.1). 
 
 
Scheme 34 – Buchwald-Hartwig coupling of 4-bromothiazole 93 
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A selection of amines was introduced at this position, attempting to achieve both diversity 
(using StarDrop optimisation) and also the introduction of groups similar to those found in the 
identified aminothiazole inhibitors. As with the aminocarbonylation reactions, the most 
nucleophilic amines gave superior results, with 18 out of 39 reactions successful (276-293). 
For more direct SAR, and in order to discover novel 2-aminothiazole inhibitors for a patent 
application, a small panel of five 2-aminothiazoles were prepared by Hantzsch synthesis (294-
298), the products closely related to the cell-active inhibitor 87. 
 
 
7.1.6 Library 5 – Consecutive One-pot Suzuki Coupling for Variation of Thiazole 2-Position 
 
In order to vary the simple phenyl substituent of cell-active furanamide 84 (Table 7), a one-
pot consecutive Suzuki coupling procedure was envisaged to allow quick access to a library 
of diarylthiazoles with a common 4-substituent and a diverse range of aryl and heteroaryl 
groups at the 2-position. The required boronic acid for the installation of the furanamide 
group was initially prepared by simple acylation of 3-aminobenzeneboronic acid. However, 
the difficulties encountered during the purification of this compound led to a change in 
strategy, with protection as the pinacol ester and subsequent acylation in quantitative yield to 
give boronate 300 (Scheme 35). 
 
 
Scheme 35 –Synthesis of boronate ester 300 
  
Initial attempts at a one-pot two-step reaction sequence using the standard microwave Suzuki 
coupling conditions optimised previously with three heteroaryl boronic acids resulted in a 
successful reaction but a large number of by-products, making purification difficult. A silica 
pad filtration between the two couplings did not improve the results, nor did switching to 
conventional heating at a lower temperature. Three alternative aryl boronic acids were chosen, 
and these gave good results for the double coupling sequence (Scheme 36), likely due to the 
greater stability and lower propensity for side reactions of aryl boronic acids compared to 
their heteroaryl analogues. Concurrent exploration of room temperature Suzuki reactions 
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based on reports by Fu
162
 and Buchwald
163
 ultimately proved unnecessary, but in any case did 
not result in the clean primary coupling that this one-pot procedure requires. 
 
 
Scheme 36 – Consecutive one-pot Suzuki couplings of 2,4-dibromothiazole 
 
A library of compounds was synthesised by this route, investigating simple alterations to the 
phenyl ring in a comprehensive approach, as well as attempting to introduce some diversity of 
size and functionality at this position (using StarDrop optimisation). Overall, 34 out of 46 
reactions were successful (301-334), although often with poor purity. As expected, the 
difficulties observed during the reaction optimisation when using heteroaryl boronic acids 
were also found during the library synthesis, and even for the aryl boronic acids the purity of 
the final compound was not high enough in many cases. A better approach would have been 
to clarify the importance of the thiazole core orientation prior to this library synthesis, 
potentially allowing the use of a common mono-coupled intermediate as for Library 1. 
 
 
7.1.7 Assay Results 
 
All the compounds successfully synthesised and purified from the above small libraries were 
then tested in the OMFP phosphatase assay against cdc25A and VHR. It was considered that 
the greater potency observed for this class of inhibitor against cdc25A in the virtual screening 
results would likely translate to these analogues, thus allowing testing against cdc25B and C 
of only those compounds found to be potent against cdc25A. The screening results for all 
synthesised compounds are given in an abbreviated form in the appendix. 
 
The results of the C4-variation from libraries 1 and 2 (Suzuki coupling and 
aminocarbonylation) proved disappointing, and largely contradicted the hypothesis from the 
virtual screening results that a wide exploration of structural diversity at this position would 
result in potentially much more potent inhibitors (see Figure 23). Inhibition of cdc25A was 
particularly poor, with all of the synthesised compounds at least 5-fold worse than the best 
compounds from the virtual screen (Table 13). The two most potent compounds (134 and 118) 
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are however promising hits, being both small and less lipophilic, but give contradictory SAR 
information regarding the preferred electronic character at this position. Amide-linked 
pyridone 157, synthesised by aminocarbonylation, definitively justified this speculative 
synthetic effort by demonstrating the possibility of removing a lipophilic aryl unit whilst 
maintaining good potency. This pyridone was the most potent of the compounds from 
libraries 1 and 2 against VHR (Table 14). A greater number of inhibitors were discovered 
against VHR than for cdc25A, although again without much interpretable SAR. Overall, these 
libraries were not successful at improving the potency of the virtual screening hits. 
 
Table 13 – Libraries 1 and 2: selected cdc25A-active compounds 
   IC50 ± SEM (μM) 
Cmpd 
No. 
Cmpd 
Name 
Structure Cdc25A VHR  
134 
CRT-
99 
 
14.5  
± 0.9 
>50 
118 
CRT-
59 
 
16.7  
± 1.5 
>50 
157 
CRT-
129 
 
18.1  
± 2.0 
5.29  
± 0.63 
 
Table 14 – Libraries 1 and 2: selected VHR-active compounds 
   IC50 ± SEM (μM) 
Cmpd 
No. 
Cmpd 
Name 
Structure Cdc25A VHR  
157 
CRT-
129 
 
18.1  
± 2.0 
5.29  
± 0.63 
141 
CRT-
113 
 
48.0  
± 8.9 
8.85  
± 1.47 
117 
CRT-
57 
 
54% 
inhibition  
at 50 μM 
9.65  
± 1.46 
139 
CRT-
106 
 
54% 
inhibition  
at 50 μM 
10.7  
± 2.0 
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More success was found in the variation of the amide region of cell-active furoyl aniline 84, 
with pyridone 238 exhibiting very low micromolar activity against cdc25A (Table 15). 
Unfortunately, there again were not any simple SAR trends that could be elucidated from the 
data, but in general alternative small heterocycles gave similar potency to the furan of 84.  
 
Table 15 – Library 3 amides: selected cdc25A-active compounds 
   IC50 ± SEM (μM) 
Cmpd 
No. 
Cmpd 
Name 
Structure Cdc25A VHR  
238 
CRT-
284 
 
1.17  
± 0.40 
2.60  
± 0.20 
254 
CRT-
280 
 
9.44  
± 1.08 
>50 
173 
CRT-
180 
 
10.8  
± 3.0 
16.2  
± 1.1 
169 
CRT-
167 
 
11.0  
± 2.0 
10.5  
± 1.2 
237 
CRT-
260 
 
12.4  
± 1.4 
16.1  
± 3.5 
 
 
Similar results were found for VHR, although for this enzyme a further pyridone, 240, proved 
potent and selective (Table 16). This compound is both an isomer of 238 and a direct 
analogue of aminocarbonylation product 157, which has the alternatively-oriented amide 
linker and is missing the central phenyl ring. The similarity in potency of these compounds 
suggested a possible SAR trend that was supported by further data, specifically that the 
phenyl-thiazole-phenyl motif of these inhibitors likely represents a non-specific hydrophobic 
interaction. In this example, removal of the central phenyl group could theoretically shift the 
placement of the remaining thiazole-phenyl motif such that the pyridones of 157 and 240 
overlay. The virtually-identical VHR potency for these two pyridones further suggests that the 
additional size and lipophilicity of the extra phenyl ring contributes little to the binding 
interaction, allowing a possible switch to a more lead-like core structure – see Figure 26 for a 
computational assessment of this theory.  
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Table 16 – Library 3 amides: selected VHR-active compounds 
   IC50 ± SEM (μM) 
Cmpd 
No. 
Cmpd 
Name 
Structure Cdc25A VHR  
238 
CRT-
284 
 
1.17  
± 0.40 
2.60  
± 0.20 
240 
CRT-
233 
 
>50 
5.26  
± 0.41 
257 
CRT-
248 
 
30.3  
± 7.2 
10.3  
± 0.8 
169 
CRT-
167 
 
11.0  
± 2.0 
10.5  
± 1.2 
 
The sulfonamide analogues showed similar levels of mid-micromolar activity to many of the 
amides, again providing no clear SAR (Table 17). Direct comparison of cell-active 
furanamide 84 with its sulfonamide analogue 204 found a two-fold increase in potency for 
VHR with the sulfonamide, and a two-fold drop in potency for cdc25. Benzoxazolone 201 
was found as a promising low micromolar cdc25 hit perhaps comparable to the 
benzimidazolone virtual screening hit 76, with no similar compounds tested.  
 
Table 17 – Library 3 sulfonamides: selected compounds ranked by VHR activity  
   IC50 ± SEM (μM) 
Cmpd 
No. 
Cmpd 
Name 
Structure Cdc25A VHR  
198 
CRT-
193 
 
>50 
9.29  
± 0.85 
201 
CRT-
197 
 
3.21  
± 0.30 
11.7  
± 1.6 
204 
CRT-
201 
 
>50 
13.1  
± 0.8 
200 
CRT-
195 
 
47.2  
± 5.4 
13.3  
± 1.1 
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The compounds in the small urea library all proved broadly active with moderate potency 
(Table 18), pointing to a concerning lack of structure-dependency in the binding of these 
compounds. The high lipophilicity and low solubility of these ureas additionally discouraged 
any further investigation into this class of compounds. 
 
Table 18 – Library 3 ureas: selected compounds ranked by cdc25A activity  
   IC50 ± SEM (μM) 
Cmpd 
No. 
Cmpd 
Name 
Structure Cdc25A VHR  
214 
CRT-
208 
 
14.9  
± 1.0 
8.50  
± 0.34 
222 
CRT-
218 
 
18.2  
± 1.9 
5.59  
± 0.56 
213 
CRT-
207 
 
20.0  
± 2.8 
12.6  
± 0.8 
 
As expected, some of the 4-aminothiazoles showed similar levels of VHR selectivity to the 2-
aminothiazoles found in the virtual screening, with aminopyridine 277 having promisingly 
good potency for its size and lipophilicity (Table 19). However, the direct 4-aminothiazole 
analogue of cell-active 2-aminothiazole screening hit 87 proved inactive, suggesting that the 
binding may not be as insensitive to the thiazole orientation as predicted. The library of N-
arylated derivatives of aniline 166 also prepared by Buchwald-Hartwig coupling proved 
mostly inactive. 
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Table 19 – Library 4: selected compounds ranked by VHR activity 
   IC50 ± SEM (μM)  
Cmpd 
No. 
Cmpd 
Name 
Structure Cdc25A VHR  
277 
CRT-
351 
 
33.4  
± 3.4 
7.13  
± 0.50 
283 
CRT-
370 
 
>50 
13.3  
± 1.0 
271 
CRT-
334 
 
29.7  
± 4.1 
20.6  
± 1.5 
268 
CRT-
324 
 
>50 
25.8  
± 1.7 
 
 
Although it had been hoped that the variation of the 2-phenyl group of furanamide 84 would 
provide broad scope for optimisation, almost every compound tested proved inactive against 
cdc25A (Table 20). By contrast, a wide variety of functionality was tolerated by VHR, with a 
maximum two-fold increase in potency over the parent phenyl compound. This data displays 
perhaps the only clear SAR trend found across the parallel synthesis libraries, and might be 
applicable as method of introducing VHR selectivity and some additional potency to many of 
the successful compounds from the other small libraries above.  
 
Table 20 – Library 5: selected compounds ranked by VHR activity 
   IC50 ± SEM (μM) 
Cmpd 
No. 
Cmpd 
Name 
Structure Cdc25A VHR  
307 
CRT-
408 
 
>50 
12.6  
± 1.2 
319 
CRT-
430 
 
>50 
13.8  
± 1.8 
305 
CRT-
406 
 
>50 
16.2  
± 1.0 
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As discussed previously, identification of the most-promising lead compounds from these 
diverse libraries required consideration not only of overall potency and selectivity, but also 
compound size and lipophilicity. This analysis was based on two observations: during the lead 
optimisation, process compounds become larger and more lipophilic, and also drug candidates 
that are lipophilic tend to have poor pharmacokinetic parameters and increased binding 
promiscuity.
164,165
 In order for this to be a quantitative analysis, applicable across any 
structural class, various binding efficiency metrics have recently been developed. Ligand 
efficiency (LE) determines which compounds make the most effective use of their size, 
calculating the average free-energy change of binding attributed to each heavy atom in the 
molecule.
164
 Lipophilic ligand efficiency (LLE) determines the relationship between the 
potency and lipophilicity (as the calculated partition coefficient cLogP),
165
 in theory 
identifying compounds that deliver a high contribution of their affinity from the specific 
electronic interactions of polar hydrophilic functionality, as opposed to the non-specific 
hydrophobic interactions of lipophilic compounds.  
 
In this project, the narrow spread of observed potencies limits the utility of the ligand 
efficiency metric, as the value is predominantly determined by the much-greater spread of 
compound size, ultimately resulting largely in the elevation of the smallest compounds to the 
highest rankings. As such, pyrrole 105 ranks highest for both cdc25A (Table 21) and VHR 
(Table 22). The Suzuki coupling products 118 and 134 also score highly for cdc25A, ahead of 
the potent pyridone 238. For VHR, this latter compound ranks lower than the smaller amide-
linked pyridone 157. 
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Table 21 – Top compounds ranked by cdc25A LE 
Cmpd 
No. 
Cmpd 
Name 
Structure 
Cdc25A 
IC50 (μM) 
LE 
a
 
105 
CRT-
24 
 
25.6  
± 1.7 
0.35 
118 
CRT-
59 
 
16.7  
± 1.5 
0.33 
277 
CRT-
351 
 
33.4  
± 3.4 
0.31 
134 
CRT-
99 
 
14.5  
± 0.9 
0.30 
238 
CRT-
284 
 
1.17  
± 0.40 
0.30 
 
a – LE = ΔG / no. of heavy atoms 
 
Table 22 – Top compounds ranked by VHR LE 
Cmpd 
No. 
Cmpd 
Name 
Structure 
VHR 
 IC50 (μM) 
LE 
a
 
105 
CRT-
24 
 
12.6  
± 1.7 
0.37 
277 
CRT-
351 
 
7.13  
± 0.50 
0.35 
276 
CRT-
346 
 
26.8  
± 3.5 
0.33 
141 
CRT-
113 
 
8.85  
± 1.47 
0.31 
157 
CRT-
129 
 
5.29  
± 0.63 
0.31 
 
a – LE = ΔG / no. of heavy atoms 
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In contrast to the LE tables, the LLE measurement provides more novel insight into which 
compounds qualify as good leads, with the inclusion of the previously-unconsidered cLogP 
values. For both cdc25A (Table 23) and VHR (Table 24), the highly polar pyridones 
compounds rank highly, with aminocarbonylation product 157 generating particularly high 
efficiency scores for both enzymes. 
 
Table 23 – Top compounds ranked by cdc25A LLE 
Cmpd 
No. 
Cmpd 
Name 
Structure 
Cdc25A 
IC50 (μM) 
cLogP LLE 
a
 
157 
CRT-
129 
 
18.1  
± 2.0 
1.0 3.8 
238 
CRT-
284 
 
1.17  
± 0.40 
3.0 2.9 
118 
CRT-
59 
 
16.7  
± 1.5 
2.1 2.6 
227 
CRT-
235 
 
21.0  
± 1.6 
2.7 1.9 
 
a – LLE = pIC50 - cLogP 
 
Table 24 – Top compounds ranked by VHR LLE 
Cmpd 
No. 
Cmpd 
Name 
Structure 
VHR 
 IC50 (μM) 
cLogP LLE 
a
 
157 
CRT-
129 
 
5.29  
± 0.63 
1.0 4.3 
238 
CRT-
284 
 
2.60  
± 0.20 
3.0 2.6 
240 
CRT-
233 
 
5.26  
± 0.41 
2.8 2.5 
277 
CRT-
351 
 
7.13  
± 0.50 
3.1 2.0 
 
a – LLE = pIC50 - cLogP 
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In order to rapidly confirm that the cell-activity from the virtual screening hits had been 
maintained in the synthesis of these compound libraries, and also to identify novel cell-active 
compounds for a patent application, several close analogues of furanamide 84 found to be 
cdc25A inhibitors were tested against a panel of cell lines by co-workers in the Mann group. 
Pyrazoles 169 and 232 proved active at similar low micromolar concentrations to their in vitro 
IC50 values (Table 25).  
 
Table 25 – MTS assay results; proof of retention of cell-activity 
   
MTS Cell Assay IC50 ± SEM 
(μM) 
Cmpd 
No. 
Cmpd 
Name 
Structure 293T HeLa 3T3 
169 
CRT-
167 
 
6.64  
± 1.00 
17.2  
± 2.0 
16.5  
± 1.8 
232 
CRT-
251 
 
7.39  
± 0.37 
10.4 
± 0.4 
9.51 
± 0.48 
 
 
In summary, parallel synthesis, purification and testing of a wide range of compound 
structures based around the virtual screening hits was only moderately successful; although no 
significant increase in potency was observed, many of the synthesised compounds possessed 
better physical properties as quantified by binding efficiency metrics. During the parallel 
synthesis effort carried out on placement at CRT, we were also granted access to small 
samples of any commercial compounds contained in the company library, and the next section 
describes the subsequent compound selection and phosphatase assays. 
 
 
7.2 Screening of CRT Compounds 
7.2.1 Compound Selection 
 
In order to rapidly expand the SAR of the virtual screening hits, three substructure-based 
searches were performed on the CRT database of 90,000 compounds. As before, all the 
compound properties were calculated using StarDrop and compounds with undesired features 
or properties were discarded (including high complexity, similarity to compounds in active 
CRT research programs and compounds where the desired substructure formed only part of 
the side-chain of a large alternative core structure). As in the virtual screening, 
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diarylpyrazoles were also excluded to attempt to move further from the initial literature 
template inhibitor. The chosen compounds comprised: 
 399 commercially available 2,4-disubstituted thiazoles  
 979 commercially available N-,C4-disubstituted 2-aminothiazoles  
 564 commercially available 5-membered aromatic heterocycles (containing at least 
one nitrogen atom) with a 1,3-substitution pattern containing at least one 
(hetero)aromatic ring 
 
Of this selection, a subset of 983 compounds was retrieved (based on a minimum number per 
CRT storage plate to reduce robot usage). Each compound was tested in triplicate at 20 μM 
against cdc25A and VHR using the fluorescence assays developed previously. Those 
showing >50% inhibition were purchased (if available) and full 10-concentration IC50 values 
were measured. 
 
Prior to these assays, a pET21a construct expressing untagged VHR (previously obtained 
commercially) had been prepared by co-workers in the Mann group, but this was found to not 
express efficiently, perhaps due to poor solubility of the resulting protein.
119
 A construct for 
GST-tagged VHR was prepared by co-workers as an alternative, and in our hands this gave 
high yields of protein, readily purified using the GST tag. 
 
 
7.2.2 Assay Results 
 
The assay results for selected compounds from the CRT library are shown in Table 26 and 
Table 27. The data showed that this screen was successful in finding a variety of low-
micromolar hit compounds for both cdc25A and VHR. Pyrazinoyl aminothiazole 335 
represented the most promising of a range of acylaminothiazoles identified as good cdc25A 
hits, with quinazolinone 341 highly potent and VHR selective. Various non-thiazole core 
structures were identified including oxadiazoles 353-356 that represented a novel alternative 
series with likely lower lipophilicity than the corresponding thiazoles. Compounds 363-368 
possess one alkyl substituent on the arylthiazole core, and as such were thought likely to 
deviate from the highly planar conformation and poor solubility of the virtual screening hits. 
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Table 26 – Selected active compounds from CRT library grouped by structural class, ranked by cdc25A activity 
Cmpd 
No. 
Cmpd 
Name 
Structure 
Cdc25A 
 IC50 (μM) 
VHR 
 IC50 (μM) 
 Cmpd 
No. 
Cmpd 
Name 
Structure 
Cdc25A 
 IC50 (μM) 
VHR 
 IC50 (μM) 
335 
C726-
4901 
 
3.3  
± 0.3 
3.1  
± 0.1 
 
344 
C742-
6778 
 
5.3  
± 0.5 
2.07  
± 0.34 
336 
CD 
0663- 
0359  
5.1  
± 1.1 
21.2  
± 2.7 
 
345 
C741-
1786 
 
7.9  
± 0.7 
9.1  
± 0.5 
337 
C727-
0205 
 
6.7  
± 0.7 
3.1  
± 0.4 
 
346 
C593- 
5313 
 
20.3  
± 4.0 
28.8  
± 11.3 
338 
C728-
2381 
 
9.5  
± 1.2 
14.1  
± 2.2 
 
347 
ASN 
0488- 
0636  
N.D. 
13.9  
± 0.9 
339 
C725-
5305 
 
13.4  
± 2.4 
12.5  
± 1.8 
 
348 
CD 
8009- 
2477 
 
4% 
inhibition  
at 20 μM 
21.4  
± 2.7 
340 
C593- 
2609 
 
14.5  
± 13.5 
24.2  
± 2.6 
 
349 
ASN 
1214- 
3136  
27% 
inhibition  
at 20 μM 
17.8  
± 6.6 
341 
C749- 
5697 
 
7% 
inhibition  
at 20 μM  
1.64  
± 0.55 
 
350 
C785- 
7802 
 
20.5  
± 5.3 
8.3  
± 1.0 
342 
C728- 
9542 
 
1% 
inhibition  
at 20 μM 
11.0  
± 0.9 
 
351 
C785-
1425 
 
~75 
17.2  
± 4.4 
343 
ASN 
0658-
8123  
0% 
inhibition 
at 20 μM 
41.1  
± 9.0 
 
352 
C656-
9389 
 
~100 
31.2  
± 10.6 
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Table 27 – Selected active compounds from CRT library grouped by structural class, ranked by cdc25A activity 
Cmpd 
No. 
Cmpd 
Name 
Structure 
Cdc25A 
 IC50 (μM) 
VHR 
 IC50 (μM) 
 Cmpd 
No. 
Cmpd 
Name 
Structure 
Cdc25A 
 IC50 (μM) 
VHR 
 IC50 (μM) 
353 
C888-
5549 
 
12.2  
± 1.4 
9.4  
± 1.2 
 
362 
SP-
00521 
 
~50 
25.6  
± 7.3 
354 
SEW- 
03756 
 
18%  
inhibition  
at 20 μM 
19.8  
± 2.7 
 
363 
CD 
G569-
0282  
7.2  
± 0.4 
10.6  
± 1.1 
355 
CD 
E595-
0578  
7.1  
± 1.4 
14.5  
± 1.0 
 
364 
CD 
G856-
2968  
11.4  
± 0.8 
11.2  
± 1.1 
356 
CD 
E595-
0205  
7.8  
± 1.6 
18.1  
± 1.6 
 
365 
CD 
G571-
0233  
18.6  
± 1.4 
33.6  
± 8.8 
357 
KO 3T-
0868 
 
20.5  
± 4.8 
~50 
 
366 
CD 
G571- 
0231  
20.5  
± 1.7 
18.4  
± 1.4 
358 
KO 5F-
909 
 
14.9  
± 3.3 
36.2  
± 5.7 
 
367 
CD 
G856-
2962  
31.6  
± 4.2 
~50 
359 
SP-
00519 
 
6.3  
± 0.8 
3.3  
± 0.4 
 
368 
KM-
03222 
 
4.0  
± 0.6 
2.47  
± 0.33 
360 
SP-
00707 
 
14.8  
± 2.2 
34.0  
± 5.4 
 
369 
SP-
00559 
 
26.4  
± 3.6 
~50 
361 
SPB-
05833 
 
32.5  
± 4.8 
20.4  
± 1.7 
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7.3 Target-Oriented Synthesis 
 
At this stage of the project, a variety of structural classes had been discovered as new and 
promising leads for cdc25 inhibition, but with no outstanding candidate for further 
development; Figure 24 illustrates some of the different groups of substructures obtained. In 
order to maximise the value of the single analogues synthesised and purified by non-parallel 
methods, it was decided to attempt to delineate the key structural classes further by the 
preparation of hybrid structures in order to challenge specific hypotheses. 
 
 
Figure 24 – Summary of key compound classes 
 
A computational analysis of the potential binding modes of a selection of the novel inhibitors 
was attempted using the FieldTemplater and FieldAlign software. Although various 
combinations of compounds were tested, very little consensus was obtained with respect to a 
possible binding conformation, both in terms of the ranked overlap scores within a sample of 
compounds and especially in terms of comparing the results of templating the same 
compound against different sets of similar inhibitors. Similarly, the broadest and most 
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information-rich template, generated from templating all the low energy conformations 
(approximately 100) of each of the 7 compounds with potencies of less than 5 µM against 
every conformation of the other 6 compounds, was only able to find a common overlay for 5 
of the 7 compounds, this overlay also suffering from the same inconsistencies as described 
above. Attempted analysis of inactive compounds also gave no viable information, probably 
due to the relatively small difference between nominally active and inactive compounds in the 
current data.  
 
A necessary alternative was therefore to adopt a more qualitative approach in assessing the 
potential similarities between inhibitor binding modes, using the modelling software to assess 
the feasibility of any hypotheses. The first hypothesis derived from the possible similar 
binding modes for pyridones 157 (Table 14) and 240 (Table 16) discussed previously, which 
pointed towards groups 2 and 3 (Figure 24) potentially overlaying the key functionality. It 
was proposed that the group 5 acylaminothiazoles such as 335, to some extent isomeric with 
the group 3 amidothiazoles, might also bind in a similar fashion; in each case the additional 
non-amide-containing thiazole substituent is usually a small, relatively lipophilic aryl group 
(Figure 25). 
 
 
Figure 25 – Inhibitors proposed to share a similar binding mode 
 
The optimal overlaid conformations of pyridones 157 and 240 (generated from the larger 
template containing 7 compounds with diverse structures) appeared to support the above 
hypothesis (Figure 26), with the pyridone amides superimposed at the expense of the 
lipophilic thiazole rings, each of which is instead aligned with an aryl group. However, the 
validity of this overlay is questioned by the preference for the orientation of the pyridones; in 
one example, the carbonyl groups are placed on the same side of the planar molecule, and in 
the other the amide and pyridone N-Hs are similarly aligned. This has the effect of enhancing 
the field point pattern for the central linking amide in both cases, with these presumably high 
energy conformations scoring much higher with respect to field point overlap due to this 
exaggerated electronic character. On the other hand, all the conformations used are accessible 
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at room-temperature energy, so perhaps the perceived repulsion in these displayed 
conformations is not as high as it might seem. 
 
 
Figure 26 – FieldTemplater overlay of pyridones 240 and 157 
 
A similar overlay between groups 3 and 5 identified the same conformation of 4-
amidothiazole pyridone 157, this time aligning well with acylaminothiazole 335 despite the 
reversal of both the amide orientation and that of the thiazole ring (Figure 27). As before, the 
highly-convincing overlay of steric and electronic fields are put in doubt by the questionable 
conformations, with acylpyrimidine 335 aligning the lone pairs of the carbonyl and azine 
nitrogen to match the large negative field point found in the matching conformation of 
pyridone 157.  
 
 
Figure 27 – FieldTemplater overlay of pyridone 157 and pyrazinoyl aminothiazole 335 
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It was also theorised that the alkyl-linked amides of group 4 might represent more flexible 
versions of the acylanilinothiazoles of group 2, with the central phenyl ring of the latter 
replaced by the alkyl linker. FieldTemplater analysis demonstrated that the flexible ethyl-
linked oxamide compounds such as 365 can adopt very similar conformations to the more 
rigid pyridone aniline 238 (Figure 28). 
 
 
Figure 28 – FieldTemplater overlay of pyridone 238 and bis-oxamide 365 
 
It was therefore proposed that replacement of the central phenyl ring of furanamide 84 (Table 
7) with an allyl analogue should provide a smaller, more flexible and less lipophilic variant 
(cLogP 3.65 vs. 4.58), and prove a test of the necessity of an aromatic group at this position. 
Synthesis of required vinylboronate coupling partner 371 was achieved by acylation of 
propargylamine with 2-furoyl chloride in high yield and use of the resulting propargyl amide 
(370) in the standard hydroboration/oxidation/esterification sequence (Scheme 37), although 
purification of boronate product 371 proved difficult. At this stage, the choice was made to 
attempt the subsequent coupling reaction with bromothiazole 96 under the standard Suzuki 
conditions used previously, and this reaction was successful, giving vinylthiazole 372 in a 
good overall yield. Further problems with complete purification were to be addressed pending 
the outcome of an initial enzyme assay. Many of the purification issues with this reaction 
sequence might have been avoided by diverting the boronate ester synthesis to give the 
corresponding trifluoroborate, which in addition to other practical advantages are generally 
readily recrystallised to high purity. 
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Scheme 37 – Synthesis of allyl furanamide 372 
 
 
A further test of the influence of both the amide functionality and the conformational rigidity 
of furanamide 84 was envisaged by the synthesis of the corresponding α-aminoketone 375, 
with the inclusion of a methylene spacer (Scheme 38). Complete conversion of 2-furoyl 
chloride to diazoketone 373 using TMSCHN2 required minor optimisation of the literature 
conditions; additional equivalents of the diazomethane reagent did not increase the rate 
enough to prevent the competing decomposition of the product, and it was found that 
inclusion of a base (Et3N) and a change in solvent (Et2O to CH2Cl2) gave complete 
conversion and a good isolated yield of the desired product. Rhodium-catalysed insertion of 
this diazoketone into the N-H bond of aniline 166 was attempted as a direct route to target α-
aminoketone 375, but this reaction was unsuccessful, producing a complex mixture of 
products. An alternative route to α-aminoketone 375 was successfully carried out via 
synthesis of the intermediate α-bromoketone (374) in high yield, and standard nucleophilic 
substitution. 
 
 
Scheme 38 – Synthesis of α-anilino ketone 375 
 
 
A further test of the potential similarity between groups 2 and 4 shown in Figure 28 was 
proposed as the synthesis of 2-aminoethyl-substitued thiazole 376 that would allow for both 
the generation of flexible and smaller analogues of the active furan and pyridone amides 84 
and 238, and also synthesis of a small library of bis-oxamide inhibitors (Scheme 39).  
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Scheme 39 – Proposed synthesis of amide and bis-oxamide libraries from amine 376 
 
The synthetic strategy involved synthesis of 4-(2-aminoethyl)-thiazole precursor 376 by a 
literature condensation route
166
 in order to straightforwardly generate a large quantity of this 
common intermediate (Scheme 40). Thiobenzamide (378) was prepared in two steps in good 
yield by benzoylation of ammonia and subsequent thionation using Lawesson’s reagent. 
Required β-amino ketone 379 was prepared in protected form and high yield by the conjugate 
addition of phthalimide to MVK with catalytic ethoxide base. Regioselective bromination of 
the less-hindered α-position of ketone 379 was carried out as described in the literature,166 but 
the 
1
H-NMR data for the major product of the mixture obtained from this reaction did not 
match that reported. However, use of this crude bromide in the subsequent condensation with 
thiobenzamide gave the expected 4-(2-aminoethyl)-thiazole 380 in moderate yield over the 
two steps. None of the thiazole product that would have resulted from bromination on the 
more-substituted position of ketone 379 was detected, but it is possible that the fairly mild 
condensation reaction conditions were selective for thioamide S-alkylation with only the 
primary bromide. Removal of the phthalimide group and subsequent amine acylation gave 
target furanamide 381 in good yield over the two steps. The initial plan to optimise and scale-
up this route in preparation for bis-oxamide library synthesis was not completed due to the 
reassessment of the assay results (see Section 9). 
 
 
 
Scheme 40 – Synthesis of ethylene-linked thiazole furanamide 381 
 
 
To complete the investigation of smaller, alkyl-linked furanamide thiazoles, methylene-linked 
analogue 383 was prepared from bromothiazole 96 (Scheme 41). The initial test of Pd-
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catalysed cyanation under microwave conditions was successful, albeit giving nitrile 382 in 
low yield. It was considered that lower temperature might have provided a cleaner reaction 
and higher yield, as much decomposition was observed. Nitrile 382 was then reduced and 
acylated in quantitative yield to give target furanamide 383. 
  
 
Scheme 41 – Synthesis of methylene-linked thiazole furanamide 383 
 
 
As part of the exploration of chemistry likely to be relevant for future inhibitor synthesis, the 
SAR for the thiazole 2-position of analogues of furanamide 84 discussed previously had 
suggested that small alkyl substituents might prove optimal. In keeping with the divergent 
coupling-based strategy employed in this research, a regioselective Negishi coupling of 2,4-
dibromothiazole was used employing readily-accessible alkylzinc chlorides (Scheme 42). 
 
 
Scheme 42 – Proposed synthesis of 2-alkyl analogues of furanamide 84 
 
The literature conditions reported
167
 for this reaction were reproducibly found to give a low 
conversion (Table 28, Entry 1), with the product inseparable from the starting dibromide. A 
parallel series of small-scale test reactions were carried out to determine the cause of the poor 
conversion (Entries 2-7). The initial theory of poor catalyst activation was challenged by the 
similarly-poor conversion obtained from Pd(dppf) prepared from alternative precursors, and 
also when using PPh3 or S-Phos as ligands. The highest conversions obtained in these test 
reactions resulted from increasing the reaction temperature (Entry 4) and using alternative 
bidentate phosphine bis(2-diphenylphosphinophenyl)ether (DPE-Phos) (Entry 7). A 
combination of these improved conditions on a larger scale (Entry 8) gave almost complete 
conversion of the starting dibromide, with a small quantity of the di-coupled product observed 
by 
1
H-NMR. 
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Table 28 – Optimisation of regioselective Negishi coupling of dibromothiazole 94 
 
 
 
Entry Catalyst Conditions 
Scale 
(mmol) 
Conversion 
(%) 
a
 
1 Pd2(dba)3, dppf r.t., 16 h 1.0 21 
2 Pd(MeCN)2Cl2, dppf r.t., 16 h 0.2 4 
3 Pd(dppf)Cl2 r.t., 16 h 0.2 6 
4 Pd2(dba)3, dppf 70 °C, 16 h 0.2 15 
5 Pd(PPh3)2Cl2 r.t., 16 h 0.2 1 
6 Pd(MeCN)2Cl2, S-Phos r.t., 16 h 0.2 2 
7 Pd(MeCN)2Cl2, DPE-Phos r.t., 16 h 0.2 29 
8 Pd(MeCN)2Cl2, DPE-Phos 70 °C, 60 h 1.0 97 
 
a – Conversion calculated by ratio of integrals of thiazole 5-H peaks in 1H-NMR 
 
The somewhat unusual 4,5,6,7-tetrahydrobenzothiazole structure found in screening hit 336 
(see Section 7.2.2) was considered as a possible alternative to 2-alkylthiazoles for design of a 
small hydrophobic region. The positioning of the thiazole substituents (alternatively construed 
as the position of the sulfur atom in the ring) has been proposed to be potentially insignificant, 
allowing the small hydrophobic region to be installed at the C4- and C5-positions instead. 
According to this strategy, a fused cycloalkyl analogue of furanamide 84 was synthesised 
(Scheme 43). The route required the synthesis of chloride 389 as an intermediate for a final-
step Buchwald amidation that could be used for simple late-stage diversification. 
Monobromination of cyclohexanone was initially attempted using two sets of conditions 
recently reported as being especially suited to this transformation; NBS in DMSO (purported 
to weaken the N-Br bond by coordination) gave rapid conversion but a complex mixture, and 
NBS in Et2O catalysed by NH4OAc gave a low conversion. Using the more conventional 
conditions of Br2 in MeOH gave a good yield of desired bromide 385. 3-Chlorobenzamide 
(387) was prepared and thionated in high yield, and condensed with bromide 385 to give key 
intermediate chloride 389. Amidation with furanamide 386 using a recently-reported 
Buchwald ligand
168
 proceeded in excellent yield to give target compound 390. 
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Scheme 43 – Synthesis of 4,5-fused cycloalkyl thiazole 390 
 
 
As further exploration of thiazole coupling chemistry, a key experiment proposed following 
the virtual screening was to directly compare the novel diarylthiazole hits to diarylpyrazole 
template 6 (see Figure 16) by the addition of the extra C-5 substituent removed in the 
screening process, the thiazolidine-2,4-dione. A direct and divergent synthesis was planned 
via dibromothiazole 391, which contained an additional hydroxymethyl substituent that could 
be transformed into a variety of 5-substituents (Scheme 44). This in turn could be prepared 
from a known double bromination/formylation of thiazolidine-2,4-dione,
169
 similar to the 
conditions used for the synthesis of 2,4-dibromothiazole but including an equivalent of DMF 
to perform a further Vilsmeier-Haack formylation at the free C5-position.  
  
 
Scheme 44 – Retrosynthetic analysis for divergent coupling-based approach to  
5-substituted 2,4-diarylthiazoles 
 
Unfortunately, initial attempts at this literature transformation with POBr3/DMF gave a low 
mass recovery. Previous experience with POBr3 suggested this reagent can give inconsistent 
results, and an alternative strategy was to substitute bromine for chlorine using POCl3, likely 
giving a cleaner halogenation reaction in addition to the lower cost and easier handling of the 
reagent. A further advantage would be the exploration of the Suzuki coupling of the 2,4-
dichlorothiazole for possible use in place of the dibromothiazole for other syntheses. The 
desired alcohol was obtained in moderate yield over 2 steps following NaBH4 reduction 
(Scheme 45). This reduction gave several advantages: the aldehyde intermediate proved 
difficult to purify and somewhat unstable to long-term storage. Furthermore, use of this 
aldehyde in the key Suzuki coupling as a more direct synthetic strategy was likely to give 
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poorer regioselectivity due to the additional conjugative electron-withdrawal from the 4-
chloride. 
 
 
Scheme 45 – Synthesis of 5-substituted 2,4-dichlorothiazole 392 
 
At this stage of the project, no examples of regioselective Suzuki coupling of a 2,4-
dichlorothiazole without a conjugated electron-withdrawing substituent at the 5-position had 
been reported. An initial test reaction using the unsubstituted 2,4-dichlorothiazole under the 
optimised microwave Suzuki conditions gave an encouraging 81% conversion to the 2-
phenyl-4-chlorothiazole. However, attempted regioselective Suzuki coupling of the 5-
hydroxymethyl dichlorothiazole instead gave 5-formylthiazole 393 in good yield (Scheme 46), 
possibly by intramolecular transfer of a hydride to the adjacent Pd centre in oxidative adduct 
394, simultaneously oxidising the alcohol and reducing the C4-position. Further experiments 
are necessary to investigate the generality of this reaction, and to test the proposed reaction 
sequence and intramolecular hydride delivery. Interception of the initially-formed 2-phenyl 
intermediate and resubmission to the reaction conditions would confirm the order of events, 
and synthesis of the deuterated hydroxymethyl analogue would test the proposed 
intramolecular nature of the reduction.  
  
 
Scheme 46 – Synthesis of 5-formyl-2-phenylthiazole 393 and proposed mechanism 
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7.3.1 Analogues of C7264901 (335) with Decreased Toxicological Liability 
 
Although the combination of high potency, small size and low cLogP seemed to make 
pyrazinoyl aminothiazole 335 an attractive target for future development, 2-aminothiazoles 
are not generally considered as viable hit structures by medicinal chemists due to concerns 
about a metabolically-induced toxic effect in vivo. This has been discovered to result from 
ring-opening of the thiazole ring following epoxidation of the C4 and C5 positions, and 
depends critically on the 5-position being both electron-rich and unsubstituted.
170
 
Consequently, simple aminothiazole analogues with an additional methyl or fluoro substituent, 
or with the C5 carbon replaced by a nitrogen, have been found to exhibit greatly-reduced 
toxicity.
170,171
 The synthesis of similar analogues of aminothiazole 335 that retained good 
potency would therefore allow this compound to be considered for further development 
(Figure 29). 
 
 
Figure 29 – Pyrazinoyl aminothiazole 335 and proposed reduced-toxicity analogues 396-398 
 
The 5-methyl analogue 396 was prepared using a classic heterocyclic synthesis route, with 
Friedel-Crafts acylation of fluorobenzene, subsequent condensation with thiourea to give the 
aminothiazole, and acylation to give the desired amide (Scheme 47). Whilst the initial two 
steps proceeded in excellent yield, the amide bond formation proved much more challenging. 
Pyrazinoyl chloride 399 was found to be difficult to prepare with good purity, susceptible to 
decomposition, and poorly soluble. A variety of conditions were used for the acylation of 
aminothiazole 401 with different batches of the acid chloride prepared and purified by 
different methods, and the best conditions were found to be the use of oxalyl chloride for the 
initial chlorination, and immediate reaction with the aminothiazole using a full equivalent of 
DMAP.  
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Scheme 47 – Synthesis of 5-methyl aminothiazole analogue 396 
 
The synthesis of the 5-fluoro analogue was initially planned by this successful route used for 
the 5-methyl analogue, which required the synthesis of chlorofluoroacetyl chloride 402 
(Scheme 48). Hydrolysis of the commercially available ester and standard work-up gave the 
carboxylic acid, but this was found to be both highly volatile and water-soluble. As an 
alternative, the sodium salt was prepared in good yield, but attempts at chlorination of this 
compound were stopped due to the extremely high volatility of the acid chloride product.  
 
 
Scheme 48 – Attempted synthesis of chlorofluoroketone 403 
 
An alternative strategy was carried out using electrophilic fluorination of the unsubstituted 
aminothiazole ring (Scheme 49). The Friedel-Crafts acylation and thiourea condensation 
again proceeded in excellent yield to give unsubstituted aminothiazole 405. The fluorination 
reaction gave good conversion to the product by 
1
H-NMR, but no separation of starting 
aminothiazole and product was observed by TLC analysis. Although increasing the 
equivalents of SelectFluor
®
 gave a mixture of products, the use of a new batch of the 
fluorination reagent gave full conversion and a moderate yield of the 5-fluoro target 
compound 406. Unfortunately, at this stage all attempts at acylation with the pyrazinoyl 
chloride were unsuccessful.  
 
 
Scheme 49 – Synthesis of 5-fluoro aminothiazole analogue 406  
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Thiadiazole analogue 398 was envisaged to be prepared according to an adapted literature 
route from 3-bromo-5-chloro-1,2,4-thiadiazole (409) by regioselective amination, acylation 
with pyrazinoyl chloride and Suzuki coupling to install the 3-aryl group (Scheme 50).
172
 
Whereas the literature synthesis of similar compounds requires intermediate Boc-protection 
for the 5-amino group in order to obtain good yields in the Suzuki coupling, it was hoped that 
in this case a more efficient synthesis would be to first introduce the desired pyrazinoyl group 
in order to deactivate this amine.  
 
 
Scheme 50 – Proposed synthesis of thiadiazole analogue 398  
 
The initial chloride displacement was successful, and the yield of amine 408 was improved by 
changing the work-up procedure (Scheme 51). However, as for the 5-methyl aminothiazole, 
the initial acylation attempts with the pyrazinoyl chloride were unsuccessful. As observed 
with the 5-fluoro analogue, the conditions that eventually proved reactive with the 5-methyl 
compound gave a very low conversion with the more electron-poor thiadiazole amine, and 
more forcing conditions resulted in decomposition (it had been noted by the group developing 
the subsequent Suzuki coupling that bromide 408 was unstable to basic conditions and 
elevated temperatures).  
 
 
Scheme 51 – Unsuccessful synthesis of pyrazinoyl aminothiadiazole 407  
 
It was hoped that the corresponding 3-aryl-5-aminothiadiazole might prove a more stable 
coupling partner for the unreactive pyrazinoyl chloride, and the literature route to this 
compound proved successful, giving the desired amine 412 in high yield (Scheme 52).  
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Scheme 52 – Synthesis of 3-aryl-5-aminothiadiazole 412 
 
All further attempts to acylate the amine of both the 5-fluoro and the thiadiazole analogues, 
including HATU coupling, were unsuccessful, and the reassessment of the original assay 
results (see Section 9) lowered the priority of this strand of research. 
 
 
In summary, a range of chemistry was explored towards the synthesis of individual target 
compounds that attempted to provide information about binding modes or structural 
alternatives, rather than simply to further increase the potency of the best inhibitors. At this 
stage of the project, it became clear that much of the original assay data on which these 
hypotheses were based was not reliable, and a full reassessment was carried out (see Section 
9). During this period, novel and relevant methodology towards aminothiazole synthesis was 
investigated which could be performed independently of the results of the original assays, and 
this research is discussed in the next section. 
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8 Development of a Divergent Synthesis of 2-(Hetero)aryl Aminothiazoles 
 
8.1 Initial Approaches to the Synthesis of Diarylaminothiazole 87 
 
Immediately following the successful virtual screening, the synthesis of a further quantity of 
aminothiazole 87 (see Table 9) was required for biological testing. However, the divergent 
Suzuki coupling strategy used above for the synthesis of diarylthiazoles was not immediately 
applicable to this class of compound, as it had been reported that 2-halothiazoles are poor 
substrates for Pd-catalysed aminations with aniline nucleophiles (see Section 8.3 for further 
discussion).
173
 Simple direct nucleophilic substitutions also do not work well for these 
substrates. It was proposed that the recently reported copper-catalysed arylation of 2-
aminothiazoles
174
 could be used in combination with a Suzuki coupling of 4-bromo-2-
aminothiazole in a divergent coupling strategy that mirrors that proposed for the 
diarylthiazoles (Scheme 53). 
 
 
Scheme 53 – Proposed synthesis of diarylaminothiazoles by a sequential coupling strategy 
 
Synthesis of aminothiazole 413 has not been reported, and attempts to access this compound 
from 2,4-dibromothiazole were unsuccessful; direct amination with ammonia in a sealed tube 
gave very low conversion, as did Pd-catalysed coupling with LHMDS
175
 (Scheme 54). 
 
 
Scheme 54 – Attempted synthesis of 4-bromo-2-aminothiazole, 413 
 
Prior to any further attempts at the synthesis of this bromide coupling precursor, the 
aminothiazole N-arylation step was tested using 2-aminothiazole and the trifluoromethyl 
iodobenzene necessary for the synthesis of VHR inhibitor 87 (see Table 9). Unfortunately, a 
complex mixture of products was repeatedly obtained using the standard literature conditions 
(Scheme 55),
174
 and it was decided that the low yields and difficult purifications resulting 
from this chemistry were not appropriate for parallel synthesis of compound libraries. 
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Scheme 55 – Attempted copper-catalysed N-arylation of 2-aminothiazole 
 
At this stage, in order to prepare target diarylaminothiazole 87, a compromise strategy was 
devised, incorporating a final coupling step on a halo-aminothiazole synthesised via a 
conventional condensation/halogenation route (Scheme 56).  
 
 
Scheme 56 – Proposed synthesis of diarylaminothiazoles by a divergent coupling strategy 
 
The synthesis of thiourea 415 was achieved by a reported two-step procedure involving 
formation of benzoyl thiocyanate, immediate reaction with the trifluoromethyl aniline, 
isolation of the benzoyl thiourea and then subsequent hydrolysis (Scheme 57).
176
 The crude 
thiourea obtained was condensed with ethyl bromoacetate to give aminothiazolone 416 in 
moderate yield over the three steps. The subsequent chlorination was carried out using 
unusual conditions reported in the literature to give a low (but comparative) yield of 4-chloro-
2-aminothiazole 417.
177
 Unfortunately, attempted Suzuki coupling under a variety of standard 
conditions with Pd(PPh3)4 repeatedly gave low conversion, and it is likely that a more 
electron-rich catalyst would have proved more successful for the difficult oxidative addition 
into the very electron-rich heteroaryl chloride. 
 
 
Scheme 57 – Attempted synthesis of diarylaminothiazole 87 by Suzuki coupling 
 
At this stage, attempts at developing novel coupling routes towards diarylaminothiazoles were 
postponed due to the immediate requirement for preparation of VHR inhibitor 87 for 
biological testing, but this Suzuki coupling approach was subsequently further investigated 
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(see Section 8.4.3). Hantzsch synthesis of aminothiazole 87 was successfully carried out by 
condensation of thiourea 415 and the appropriate bromoketone in good overall yield (Scheme 
58). 
 
 
Scheme 58 – Hantzsch synthesis of diarylaminothiazole 87 
 
 
8.2 Oxidative C-H Amination of 4-Substituted Thiazoles 
 
Prior to any further investigations into the Suzuki coupling of chlorothiazole 417, a direct C-
H amination of thiazole was reported by Mori using various amine nucleophiles under 
oxidative Cu catalysis, although with a fairly narrow substrate scope.
178
 This suggested an 
alternative rapid and flexible route to diarylthiazoles by Suzuki coupling of commercially 
available 4-bromothiazole prior to direct amination at the 2-position (Scheme 59). These 
reactions could also potentially be performed sequentially in a one-pot process.  
 
 
Scheme 59 – Proposed synthesis of aminothiazoles by sequential Pd- and Cu-catalysis 
 
A screen of ten solvents was performed using Mori’s conditions to try to find an alternative to 
the microwave-inert xylene, in preparation for application to rapid library synthesis. However, 
this reaction proved highly sensitive to small variations in substrate and conditions, with only 
trace amounts of product obtained in all cases, and thus was not suitable to analogue synthesis. 
Instead, we sought to find new, more broadly applicable conditions for this transformation by 
analogy with existing Cu-catalysed reactions. In theory, the proposed reaction is a 
mechanistic combination of the direct arylation of acidic heterocyclic protons pioneered by 
Daugulis
179
 (which is purported to proceed via copper-assisted deprotonation) and Ullmann 
coupling
180
 (which aminates aryl-copper intermediates). 
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Scheme 60 – Proposed synthesis of aminothiazoles by direct amination 
 
A screen of conditions common to these two coupling reactions was performed using 4-
methylthiazole and aniline, with all combinations of selected ligands, bases and solvents 
(Scheme 61). 
 
 
Scheme 61 – Attempted direct amination of 4-methylthiazole 
 
No definitively positive results were obtained by LCMS analysis, and a wider screen of 
conditions was explored that alternately varied the base, ligand, solvent, temperature and 
copper source from Daugulis’ optimised conditions. As before, no successful conditions were 
observed, with widespread decomposition presumably resulting from oxidation of the aniline.  
 
An even closer literature analogy was made to Stahl’s recently-reported direct amidation of 
alkynes,
181
 which similarly involves the desired copper-assisted deprotonation and oxidative 
amination of a relatively acidic position (Scheme 62). The similarity in pKa between terminal 
alkyne protons (29)
182
 and the acidic C-2 position of 5-membered azoles (25-29)
183
 provides a 
firm mechanistic basis for the desired thiazole amination. Further support is given by recent 
development of the analogous direct thiolation of benzoxazole under CuI catalysis, which 
proceeds via a similar mechanism.
184
 Two further screens of conditions were carried out to 
broadly cover and merge the reaction conditions used by Mori and Stahl, but as before only 
small amounts of the desired products were obtained.  
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Scheme 62 – Stahl’s direct amidation of terminal alkynes 
 
At this stage, the lack of success achieved in the optimisation of a general oxidative Cu-
catalysed approach led to reconsideration of the Pd-catalysed amination of 2,4-
dibromothiazole. 
 
 
8.3 Regioselective Buchwald-Hartwig Amination of Dibromothiazole 
 
As an alternative strategy, it was proposed that a regioselective Buchwald-Hartwig amination 
of 2,4-dibromothiazole could be followed by a Suzuki coupling at the 4-position to access 
diarylaminothiazoles in a rapid and divergent manner (Scheme 63).  
 
 
Scheme 63 – Proposed synthesis of aminothiazoles from 2,4-dibromothiazole  
by sequential Pd-catalysis 
 
For this reaction pathway, an excess of amine cannot be used in the Buchwald-Hartwig 
coupling in order to prevent a second amination occurring. However, Hartwig has shown that 
the thiazole 2-position is a very difficult substrate for amination, with a low yield being 
obtained for the amination of 2-bromothiazole with a 4-fold excess of methylaniline under 
highly-optimised conditions that differed from the general conditions used for other substrates 
(Scheme 64).
173
  
 
 
Scheme 64 – Hartwig’s Pd-catalysed amination of 2-bromothiazole 
 
It was hoped that the recent advances in phosphine ligand design, including the availability of 
the competing Buchwald ligands, would allow us to improve on Hartwig’s results and also to 
demonstrate the first regioselective amination of thiazoles. A 26-member ligand set was tested 
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with 2,4-dibromothiazole and p-anisidine (1 eq.) on small scale under high-temperature 
microwave conditions. Follow up screens using conventional heating on those reactions found 
to give traces of product by LCMS analysis gave very low conversion, as expected from 
Hartwig’s result above. Following this initial failure of the more advanced ligands to provide 
any greater success in this reaction, the Pd-catalysed approach was not further investigated. 
At this stage, the difficulties encountered with the various thiazole amination reactions in the 
previous two sections prompted reconsideration of the aminothiazole arylation strategy found 
to give poor results using recently-reported Cu-catalysis (see Scheme 55). 
 
 
8.4 Consecutive Suzuki and Buchwald-Hartwig Coupling Approach 
 
The latest generation of Buchwald’s biarylphosphine catalysts have been shown to rapidly 
arylate hindered and poorly-nucleophilic amides with aryl chlorides under mild conditions,
168
 
and it was proposed that this reaction might be applicable to the analogous arylation of 2-
aminothiazoles. Reported methods for Pd-catalysed aminothiazole arylation require the use of 
highly-activated halides
185
 or strong bases incompatible with a range of functional groups.
186
 
The sequential coupling approach would therefore require an initial Suzuki reaction at the C4-
position of a 4-halo-2-aminothiazole precursor (Scheme 65). 
 
 
Scheme 65 – Proposed synthesis of diarylaminothiazoles from functionalised  
2-aminothiazoles by sequential Pd-catalysis 
 
 
8.4.1 Synthesis of Diarylaminothiazole Precursor 4-Halo-2-aminothiazole 
 
The most direct method for the synthesis of 4-halo-2-aminothiazole was proposed to be the 
functional group interconversion of the carbonyl moiety of pseudothiohydantoin (419) 
(Scheme 66). Deprotonation and reaction with electrophiles was however found to occur 
preferentially on the 2-amino group. A reported literature preparation of 4-chloro-2-
aminothiazole from pseudothiohydantoin (without yield or experimental) suggested simple 
treatment with POCl3 would work,
187
 but multiple attempts resulted in a complex mixture and 
very poor mass recovery. 
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Scheme 66 – Attempted activation of the 4-position of  
pseudothiohydantoin for cross-coupling 
 
An alternative three-step route was then attempted, the first two steps having been previously 
reported (Scheme 67).
188
 Pseudothiohydantoin was acetylated and then chlorinated in good 
overall yield and purity. However, deacetylation proved more difficult than anticipated as the 
acidic conditions commonly used for close analogues repeatedly resulted in comprehensive 
decomposition. Attempts under basic conditions or with amine nucleophiles (such as 
ammonia and hydrazine) gave very low conversion, and ultimately this route was not further 
pursued. 
 
 
Scheme 67 – Attempted synthesis of 4-chloro-2-aminothiazole (422) 
 
As an alternative, N-Boc aminothiazolone 423 was prepared (Scheme 68). Although only a 
moderate yield was obtained using reported conditions,
189
 logical adaptations such as addition 
of catalytic DMAP or switching to DMF solvent (pseudothiohydantoin is poorly soluble in 
THF) resulted in a mixture of products that proved difficult to separate. N-Boc 
aminothiazolone 423 did not prove stable to the POCl3 chlorination conditions, so a 
sulfonation was used as a mild alternative. The nonaflate derivative was initially targeted due 
to its greater stability,
190
 but the nonaflyl fluoride electrophile proved highly unreactive, a 
finding mirrored in an analogous literature sulfonation of a pyrazolidone, where the nonaflyl 
anhydride was used instead.
191
 Triflate 424 was instead prepared according to a literature 
method in excellent yield, which dropped slightly on scale-up.  
 
 
Scheme 68 –Synthesis of N-protected triflate 424 
 
Removal of the Boc group using standard TFA conditions gave a clean reaction but poor yield 
of 30%. Optimisation of reagents and work-up procedures gave an maximum yield of 72% of 
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the crude 4-triflyl-2-aminothiazole, but it became clear that this compound suffered from poor 
stability (in a seemingly analogous fashion to the 4-chloro analogue that proved difficult to 
isolate) and it was therefore decided that the deprotected triflate did not represent a viable 
common intermediate for a divergent coupling strategy. Although deprotection following the 
coupling reaction was thought likely to result in improved yield and ease of synthesis, this 
alternative strategy somewhat compromised the initial ideal of a rapid, divergent approach. 
 
 
8.4.2 Buchwald-Hartwig Coupling of 4-Aryl-2-aminothiazoles 
 
The key novel reaction of the proposed new strategy towards aminothiazoles was the N-
(hetero)arylation of the free 2-amino group using Buchwald’s conditions for Pd-catalysed 
arylation of amides.
168
 This approach is valuable and highly relevant as a method for final-
stage diversification from 4-substituted 2-aminothiazoles, which can be synthesised on large 
scale by conventional condensation chemistry. 4-Aryl-2-aminothiazole 425 was prepared by 
Hantzsch condensation from the acetophenone in moderate yield on large scale (Scheme 69). 
The attempted synthesis of the α-halo-acetophenone by the Friedel-Crafts route previously 
successful for fluorobenzene derivatives gave a poor yield using the more reactive anisole. 
 
 
Scheme 69 –Synthesis of 4-aryl-2-aminothiazole 425 
 
The key biarylphosphine ligand used for Buchwald’s arylation of primary amides is 
t
BuBrettPhos (429). Using the published route,
192
 biaryl iodide precursor 427 was obtained on 
gram-scale in comparable yield by addition of hindered aryl Grignard 426 across an in situ-
prepared benzyne intermediate (Scheme 70). Attempted reaction of iodide 427 with di-tert-
butyl chlorophosphine under the reported conditions gave a very low conversion, and as an 
alternative the analogous dicyclohexylphosphine, BrettPhos (428), shown to be similarly 
competent in the amidation reactions, was prepared in good yield. 
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Scheme 70 – Synthesis of Buchwald ligand BrettPhos, 428 
 
In the initial test reaction, a solution of Pd catalyst and ligand was pre-activated
193
 and added 
to two reactions: amination of 4-chlorotoluene with benzamide and with 4-aryl aminothiazole 
425 (Scheme 71). A good 
1
H-NMR yield of tolylamide 430 was obtained, in line with 
Buchwald’s results,168 but no conversion of aminothiazole 425 was observed. 
  
 
Scheme 71 – Attempted Buchwald arylation of benzamide and aminothiazole 425 
 
A screen of stronger bases was carried out, giving only moderate conversion even under harsh 
conditions (Table 29). With the proposed advantage of mild conditions and wide substrate 
scope now not applicable, no advantage could be foreseen in further optimisation of this 
methodology. Additionally, the low purity of these reactions proffered no practical advantage. 
Although N-arylation of aminothiazoles with aryl chlorides has yet to be demonstrated, it was 
felt that if successful this would only represent an incremental increase over the known 
methods.  
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Table 29 – Attempted N-arylation of aminothiazole 425 using stronger bases 
 
Entry Base (eq.) Solvent Conditions Conversion 
a
 (%) 
1 K2CO3 (2.4) 
t
BuOH 100 °C, 15 h 0 
2 NaO
t
Bu (2.4) dioxane 110 °C, 15 h 13 
3 NaO
t
Bu (2.4) PhMe 110 °C, 15 h 51 
4 LHMDS (2.4) THF 100 °C, 15 h 42 
 
a – Conversion calculated by ratio of integrals in 1H-NMR 
 
In an extensive study published immediately following these results, Buchwald also 
demonstrated that 2-aminothiazoles are abnormally poor nucleophiles for N-arylation 
reactions (Scheme 72).
194
 In attempting to exemplify virtually every conceivable class of 
amine arylation reaction, with particular emphasis on the use of heterocycles, the sole use of 
2-aminothiazole in coupling with a bromopyrimidine gave only a moderate yield, despite an 
extended reaction time and extremely high catalyst loading. Although this result attracted no 
special comment, comparison of the arylation of the similarly electron-deficient 2-
aminopyrimidine suggests that the poor results found for 2-aminothiazoles may stem from an 
effect specific to this compound class, with unexpectedly strong catalyst chelation from the 
sulfur and exocyclic nitrogen perhaps the most likely possibility. 
 
 
Scheme 72 – Selected examples of amino-heterocycle arylation reported by Buchwald194 
 
 
8.4.3 Suzuki Coupling of 4-Triflyl-2-aminothiazoles 
 
A Suzuki coupling approach to the divergent synthesis of 4-aryl-2-aminothiazoles from a 4-
halo precursor, as briefly explored previously (Scheme 57), would still represent valuable 
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methodology for analogue synthesis. Practically, the most efficient route would be large-scale 
synthesis of a thiazolone using a classical condensation approach, followed by activation of 
the C-4 position towards Pd-insertion. This general strategy has been reported once in the 
literature,
177
 using unusual optimised chlorination conditions to give generally poor to 
moderate yields of the 4-chloro-2-aminothiazole, although these were then used in 
nucleophilic substitution reactions rather than Pd coupling. For our initial investigations, the 
known N-phenyl aminothiazolone 432 was prepared in high yield (Scheme 73). 
 
  
Scheme 73 – Synthesis of N-phenyl-2-aminothiazolone, 432 
 
N-Phenyl aminothiazolone 432 was then subjected to the triflation conditions previously 
successful for N-Boc analogue 424 (Table 30, Entry 1). The initial attempt used a reduced 
number of equivalents of Tf2O compared to the N-Boc example due to concerns about 
possible N-triflation, and gave a 44% isolated yield of the product 433 without full conversion 
of the starting material. Increasing the equivalents of Tf2O gave only a small increase in the 
observed 
1
H-NMR yield (Entries 2-3), and lowering the temperature showed no improvement 
(Entry 4). At this stage, the thiazolone starting material was further purified by 
recrystallisation as a precaution against any residual impurities not visible by NMR analysis. 
The conditions for Entry 3 were repeated, without any improvement in yield (Entry 5). 
Increasing the equivalents of Tf2O (Entry 6) decreased the yield, as did conducting the 
reaction at a higher temperature for less time (Entry 7). Changing the Tf2O addition protocol 
worked well when a 30 minute gap was introduced (Entry 8). Slow addition was less effective 
(Entry 9), but the small volumes being used limit any differences in addition speed. A further 
increase in yield was seen when switching to Et3N (Entry 10), and combining this base with 
the modified addition led to a 
1
H-NMR yield of 72% (Entry 11). Alternative addition 
protocols did not improve this result (Entries 12-13). A scaled-up repeat of Entry 11, where 
the slow addition of the Tf2O was clearly more effective at keeping the concentration low, 
gave an isolated yield of 85%, double that of the initial attempt (Entry 14). 
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Table 30 – Optimisation of triflation of 2-aminothiazolone 432  
 
 
Entry 
Eq. 
Tf2O 
Changes to procedure Base (eq.) 
NMR yield 
a
  
(Isolated yield) / % 
1 1.2 - 2,6-lutidine (2) N.D. (44) 
2 1.5 - 2,6-lutidine (3) 33 
3 2.0 - 2,6-lutidine (3) 54 
4 2.0 -78 °C, 1.5 h 2,6-lutidine (3) 38 
5 2.0 - 2,6-lutidine (3) 48 
6 3.0 - 2,6-lutidine (3) 41 
7 3.0 0 °C to r.t., 15 min 2,6-lutidine (3) 40 
8 2.5 
1.5 eq. added, stirred 30 
min, 1.0 eq. added 
2,6-lutidine (3) 64 
9 2.0 Slower addition 2,6-lutidine (3) 48 
10 2.0 - Et3N (3) 60 
11 2.5 
1.5 eq. added, stirred 30 
min, 1.0 eq. added 
Et3N (3) 72 
12 2.0 
1.0 eq. added, stirred 30 
min, 1.0 eq. added 
Et3N (3) 68 
13 2.0 
4 aliquots of 0.5 eq. added 
in 10 min intervals 
Et3N (3) 63 
14 
b
 2.0 
1.5 eq. added, stirred 30 
min, 0.5 eq. added 
Et3N (3) N.D. (85) 
 
a – Yield determined by ratio of integrals in 1H-NMR compared to internal standard (1,3,5-
trimethoxybenzene). b – 10 mmol scale (all other reactions performed at 1 mmol scale) 
 
Literature precedent for the conversion of a pyrazolone to the corresponding pyrazole triflate 
suggested that using the more mild PhNTf2 triflating agent might give better yields than 
Tf2O,
195
 but this reagent gave no conversion with aminothiazolone 432 (Scheme 74). 
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Scheme 74 – Attempted triflation of aminothiazolone 432 with PhNTf2 
 
 
Following the successful synthesis of aminothiazole triflates 424 and 433, the Suzuki 
coupling reactions were then investigated. N-Boc triflate 424 was chosen for the initial 
reactions due to its simpler synthesis and purification. The Suzuki coupling conditions first 
attempted were a range of common literature conditions, which uniformly gave fairly clean 
reactions but incomplete conversion by 
1
H-NMR (Table 31, Entries 1-6). After switching to 
the p-tolyl boronic acid to aid crude NMR interpretation, microwave heating conditions were 
found to result in decomposition of the starting material (Entries 7-8).  
 
Table 31 – Optimisation of Suzuki coupling of triflate 424  
 
 
Entry 
ArB(OH)2 
(eq.) 
Catalyst 
(mol%) 
Base  
(eq.) 
Solvent Conditions 
Conversion 
a
 
(%) 
1 Ph (1.5) Pd(PPh3)4 (2) K2CO3 (2) PhMe 85 °C, 16 h 46 
2 Ph (1.5) Pd(PPh3)4 (2) K2CO3 (2) 
DME/H2O 
(4:1) 
85 °C, 16 h 65 
3 Ph (1.5) Pd(PPh3)4 (2) KF (2) 
DME/H2O 
(4:1) 
85 °C, 16 h 50 
4 Ph (1.5) Pd(PPh3)4 (2) LiOH (2) 
DME/H2O 
(4:1) 
85 °C, 16 h 83 
5 Ph (1.5) Pd(dppf)Cl2 (2) K3PO4 (2) dioxane 85 °C, 16 h 84 
6 Ph (1.5) Pd(dppf)Cl2 (2) K2CO3 (2) 
dioxane/H2O 
(4:1) 
85 °C, 16 h 85 
7 p-Tolyl (1.5) Pd(dppf)Cl2 (5) K2CO3 (3) 
dioxane/H2O 
(4:1) 
150 °C, 15 
min 
decomposition 
8 p-Tolyl (1.5) Pd(PPh3)2Cl2 (5) K2CO3 (3) 
dioxane/H2O 
(4:1) 
150 °C, 15 
min 
decomposition 
 
a – Conversion determined by ratio of integrals in 1H-NMR compared to internal standard (1,3,5-
trimethoxybenzene) 
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In order to improve the conversion, a screen of more-active catalysts was carried out, using 
four different Buchwald biaryl ligands, a Nolan NHC complex
196
 and an air-stable electron-
rich catalyst reported by Amgen (PdCl2[P(
t
Bu)2(4-Me2NPh)]2)
197
 (Table 32, Entries 1-6). All 
gave complete conversion, but the 
1
H-NMR yield was fairly low in every case. 
 
Table 32 – Optimisation of Suzuki coupling of triflate 424 
 
 
Entry Catalyst (mol%) Base (3 eq.) Solvent 
NMR Yield 
a
 
(%) 
1 Pd(OAc)2 (4), S-Phos (8) K3PO4 
t
AmOH 21 
2 Pd(OAc)2 (4), RuPhos (8) K3PO4 
t
AmOH 35 
3 Pd(OAc)2 (4), X-Phos (8) K3PO4 
t
AmOH 23 
4 Pd(OAc)2 (4), (2-Ph)PhPCy2 (8) K3PO4 
t
AmOH 14 
5 Pd(OAc)2 (4), IMes (8) Cs2CO3 dioxane 15 
6 PdCl2[P(
t
Bu)2(4-Me2NPh)]2 (4) K2CO3 
/H2O 
(10:1) 
N.D. 
7 
b
 Pd(OAc)2 (4), RuPhos (8) K3PO4 
t
AmOH 87 
c
 
 
a – Yield determined by ratio of integrals in 1H-NMR compared to internal standard (1,3,5-
trimethoxybenzene). b – 20 h, 0.5 mmol scale. c – Deprotected 4-arylaminothiazole product 
obtained. 
 
Repeating the best of these conditions on a larger scale gave a good yield of the coupled, but 
also deprotected, aminothiazole (Entry 7), which was encouraging given that the envisaged 
next step in this methodology would be this deprotection. However, all attempts to repeat this 
result were unsuccessful, with mixtures of protected and deprotected aminothiazoles being 
obtained in moderate yields. Two screens of conditions slightly varying the coupling 
conditions and the catalyst loadings gave similar results (example shown in Scheme 75). 
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Scheme 75 – Attempted one-pot Suzuki coupling/deprotection of triflate 424 
 
It was hoped that milder conditions could be found that would give reproducible yields of the 
protected compound, and a screen around some of the more successful conditions from the 
first screen was carried out (Table 33). The best result (Entry 1) gave a clean, full conversion 
to a good 
1
H-NMR yield of the coupled, protected aminothiazole 435 using Suzuki and 
Miyaura’s originally-reported conditions.198 The use of KBr to stabilise the Pd catalyst was 
not successful (Entry 2),
199
 and alternative catalyst systems gave lower yields (Entry 3) or low 
conversion (Entry 4). 
 
Table 33 – Optimisation of Suzuki coupling of triflate 424  
 
 
Entry Catalyst (mol%) Base (eq.) Solvent Conditions NMR Yield 
a
 / % 
1 Pd(PPh3)4 (3) K3PO4 (1.5) dioxane 85 °C, 15 h 79 
2 Pd(PPh3)4 (3), KBr (1.5 eq.) K3PO4 (1.5) dioxane 85 °C, 15 h 36 
3 Pd(dppf)Cl2 (3) K3PO4 (1.5) THF 60 °C, 15 h 58 
4 Pd2(dba)3 (3), 
t
Bu3PHBF4 (6) KF (3.3) THF 60 °C, 15 h N.D. 
 
a – Yield determined by ratio of integrals in 1H-NMR compared to internal standard (1,3,5-trimethoxybenzene) 
 
With optimised conditions for coupling of N-Boc triflate 424, a range of aminothiazolones 
were synthesised with the aim of exploring the scope of the substituents that could be used 
(Table 34). In addition to N-phenyl thiazolone 432 prepared previously, three 5-substituted N-
phenyl thiazolones were also prepared (437-440). The methyl and fluoro analogues (Entries 2 
and 4) would ultimately generate 2-aminothiazole analogues with small substituents at the 
C5-position to block in vivo metabolism, as discussed in Section 7.3.1. The use of ethyl 
chlorofluoroacetate was unsuccessful for the fluoro compound, so the corresponding bromide 
was used instead. Synthesis of a 2-allyl aminothiazolone was also successful (Entry 5).  
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Table 34 – Synthesis of 2-aminothiazolones 
 
 
 
Entry 
Cmpd 
No. 
R′ R″ Yield (%) 
1 432 H Ph 99 
2 437 Me Ph 88 
3 438 Ph Ph 85 
4 439 F Ph 52 
5 440 H Allyl 60 
 
 
Suzuki coupling of N-phenyl triflate 433 was initially attempted using the Pd(OAc)2/RuPhos 
system since there was no longer an issue of Boc deprotection, but triflate hydrolysis was the 
major reaction in the 
t
AmOH solvent used (Scheme 76). A small screen of electron-rich 
catalysts under anhydrous conditions (dioxane) resulted in a complex mixture, again with 
some hydrolysis observed. The conditions successful for the N-Boc triflate 424 resulted in 
low conversion. The rate of reaction was increased substantially using CsOAc,
200
 but the 
major product was again from triflate hydrolysis. A screen of very mild conditions was 
carried out, using common catalysts and Fu’s Pd(OAc)2/PCy3 system
162
 in THF at r.t. and 
60 °C. Low conversions were obtained for the room temperature reactions, and again mostly 
hydrolysis was observed at 60 °C, confirmed by repeat reactions. No further optimisation was 
attempted, and it is likely that for the N-phenyl series the triflate is too unstable, suggesting 
the use of a halide or perhaps a nonaflate alternative.  
 
  
Scheme 76 – Attempted Suzuki coupling of triflate 433 
 
To summarise, attempted development of novel methodology towards the divergent synthesis 
of aminothiazoles proved ultimately unsuccessful. However, simple conditions were found for 
the synthesis and Suzuki coupling of a highly electron-rich aminothiazole C4-triflate. 
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9 Reassessment of Assay Results 
 
Collaboration with Imperial’s Drug Discovery Centre (DDC) led to the biochemical assays 
being re-established at this late stage in the DDC labs to provide continuity following 
completion of this project and greater assay throughput. The resulting assay optimisation by 
DDC co-workers found a high detergent dependence for many of the novel inhibitors reported 
above, with a corresponding drop in potency in a detergent-controlled assay (Table 35).  
 
Table 35 – Comparison of cdc25-active virtual screening hits: detergent effect 
 
   
IC50 (μM)  
- no detergent 
IC50 (μM) 
- with detergent 
Cmpd 
No. 
Cmpd 
Name 
Structure Cdc25A  VHR Cdc25A  VHR 
76 T5896241 
 
2.36  1.92  23.4 20.0 
77 T5959818 
 
4.02  2.68  41.7 39.8 
78 T5982914 
 
5.62  8.04  31.6 39.8 
79 T5765678 
 
6.36  8.29  30.9 33.1 
80 T5846763 
 
6.49  8.10  42.7 45.7 
81 T5705971 
 
10.2  8.89  > 100 > 100 
82 T5871826 
 
9.54  10.6  33.9 64.6 
83 T5308252 
 
13.0  4.44  30.2 60.3 
84 C7991374 
 
17.8  26.1  > 100 > 100 
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Testing of a further selection of active compounds gave more mixed results, with many of the 
more polar compounds retaining their original potency (Table 36). 
 
Table 36 – Selected active detergent-insensitive inhibitors 
   
IC50 (μM)  
- no detergent 
IC50 (μM) 
- with detergent 
Cmpd 
No. 
Cmpd 
Name 
Structure Cdc25A  VHR Cdc25A Cdc25B Cdc25C VHR  
201 
CRT-
197 
 
3.21  11.7  2.14 3.55 44.7 34.7 
238 
CRT-
284 
 
1.17  2.60  6.92 4.17 8.51 >100 
157 
CRT-
129 
 
18.1  5.29  17.4 6.76 N.D. > 100 
118 
CRT-
59 
 
16.7  >50 25.1 19.5 >100 >100 
368 
KM-
03222 
 
4.00  2.47  2.75 1.70 9.55 25.7 
338 
C728-
2381 
 
9.5  14.1  7.41 2.69 11.0 66.1 
356 
CD 
E595-
0205  
7.8  18.1  8.71 5.62 4.47 21.9 
359 
SP-
00519 
 
6.3  3.3  12.3 3.02 8.91 > 100 
345 
C741-
1786 
 
7.9  9.1  12.3 5.89 9.33 25.1 
344 
C742-
6778 
 
5.3  2.07 20.0 0.89 8.32 17.0 
353 
C888-
5549 
 
12.2  9.4  24.0 5.37 4.79 95.5 
358 
KO 
5F-
909 
 
14.9  36.2  27.5 6.46 5.50 44.7 
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This detergent-dependency of some of these inhibitors is a result of compound aggregation 
under the assay conditions. The phenomenon of aggregation has only been relatively recently 
investigated, and displays many counter-intuitive properties.
201
 There is a specific, 
reproducible and reversible Critical Aggregation Concentration (CAC) above which large 
particles suddenly form, often in the mid-micromolar range. These particles strongly bind the 
enzymes to their surface, reducing the solution concentration and hence enzyme activity to 
near zero. A complicating factor for identifying aggregation behaviour is that this CAC results 
in a characteristically steep hill-slope on an IC50 curve; the resulting curve looks very similar 
to that seen under optimal conditions for non-aggregation inhibitors. It has also been reported 
that the aggregation effect can be optimised by conventional medicinal chemistry approaches, 
displaying clear, interpretable SAR within a series.
202
 
 
The original non-detergent assay conditions have been widely used in literature studies of 
cdc25 inhibitors, and the IC50 values for multiple reported inhibitors were successfully 
repeated over the course of this project. Despite these misleading results, the use of detergent 
controls in enzyme assays was known at this early stage to be important for the confirmation 
of the expected mechanism of inhibition. However, these experiments were de-prioritised 
following the initial cell assay results which demonstrated inhibition of proliferation at similar 
IC50 values to the in vitro assays, and the subsequent confirmation of cdc25 as the likely 
target protein. These results cannot be caused by aggregation, which would not occur in the 
highly-concentrated intracellular environment, and as such this was taken as fairly conclusive 
evidence that the discovered class of inhibitors worked by a standard stoichiometric binding 
mode of inhibition. Upon the realisation of the detergent dependency, the obtained cell results 
and their interpretation must be called into question, and further studies are underway. The 
possibility of cell inhibition by an alternative pathway does provide an explanation to the 
incongruities in the original cell data observed at the time, namely why the more potent in 
vitro inhibitors were not cell active, and why the anti-proliferation activity did not correlate 
well with the flow cytometry data. 
 
There are several key conclusions from analysis of the new assay data in Tables 35 and 36: 
 Whilst the compounds identified in the virtual screen are only weak cdc25 and VHR 
inhibitors, the subsequent synthesis and screening efforts have found significantly-
improved hits. 
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 The cell-active furanamide 84, the compound around which much of the parallel 
synthesis and subsequent target-oriented synthesis is based, does not inhibit cdc25 or 
VHR to any significant extent below 100 µM. 
 Of the compounds in Table 36 found to be detergent-insensitive inhibitors for cdc25, 
the majority show greatly reduced VHR inhibition, and no VHR-specific compounds 
have so far been identified under the new assay conditions. There are now a wide 
range of compounds exhibiting moderate to good selectivity for cdc25 over VHR, and 
these results suggest the inhibitory effect of aggregation is proportionally much 
greater for VHR. 
 The majority of the most potent compounds appear to be detergent-insensitive, with 
the converse observation that many compounds thought to be moderate to low potency 
inhibitors have now been excluded. This has the overall effect of dramatically 
sharpening the SAR across the various compound series, making future interpretation 
for lead optimisation much simpler. 
 Due to the inclusion of cdc25B and cdc25C in the re-assaying of compounds in Table 
36, it is now clear that the original assumption from the virtual screening (and the 
majority of the reported literature) that inhibitors would likely show low selectivity is 
incorrect. Various compounds actually show moderate to high selectivity for cdc25B 
(and often C) against cdc25A; for example, bis-amide 344 is the first nM-potency hit 
identified, with 10-fold selectivity over cdc25C and >20-fold over cdc25A and VHR. 
One conclusion from this additional data is that missed active compounds are quite 
probable, and all compounds should be re-screened against cdc25B and C.  
 A higher proportion of non-diarylthiazole analogues proved to be detergent-
independent, perhaps suggesting a particular aggregation problem with the core 
substructures identified in the virtual screen. 
 
Further testing is currently ongoing by DDC co-workers to complete the re-testing of the 
various compound sets against all the required phosphatases, and also to investigate the anti-
proliferative activity against various cell lines in the context of the new IC50 values. Analysis 
of the kinetics of inhibitor binding for selected compounds is also underway. 
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10 Generation of Cdc25 Active Site Mutants 
 
Despite the lack of a reliable crystal structure for cdc25A, or any ligand binding information, 
the homology with the cdc25B active site allows prediction of residues that might be suitable 
for the point mutation necessary for the bump-hole approach to substrate determination. 
Various reports have docked published inhibitors into the active site, and although there are 
often differences in conformation and orientation, there is a general consensus regarding 
which residues are important for the binding interactions (Figure 30).
26,31,42,99
 The generation 
of a panel of active site point mutants would also provide immediate information as to the 
likely binding site for novel inhibitors, prior to any attempted steric complementation. 
 
 
Figure 30 – Selected active site amino acids of cdc25B 
 
The additional binding pocket created by the C-terminal helix (the space denoted as B in 
Figure 30) has been proposed to be similarly important for inhibitor binding to the active site 
loop, and contains two crucial arginine residues, R482 and R544. The latter arginine is 
located at the C-terminal end of this extra helix and thus is not found in this position in the 
crystal structure of cdc25A. These arginine residues are considered by some reports to be 
ideally placed to anchor the carbonyl groups of quinone derivatives via H-bonds (Figure 
31i),
26
 although in other cases it is predicted that small aromatic systems stack between the 
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guanidine side chains (Figure 31ii).
43
 Binding pocket A (Figure 30) is the loop created by the 
HCX5R motif and is the likely binding region for any phosphate-mimic functionality. Many 
of the larger inhibitors have also been proposed to interact with residues lining this pocket, for 
example the proposed T-shaped aromatic interaction with F475 in Figure 31iii.
99
 
 
           
                       i                                             ii                                                       iii 
Figure 31 – Published binding modes derived from molecular modelling  
 
For the initial synthesis of point mutants of cdc25A, the analogous residues to F475 and R482 
(F432 and R439) were chosen as active site residues likely to form part of the binding pockets 
for OMFP-competitive inhibitors. A literature study of active site point mutations for cdc25B 
contains implicit evidence that the targeted mutants are correctly folded, sufficiently active 
phosphatases.
29
 
 
The site-directed mutagenesis technique used is separated into two stages, increasing the 
likelihood of success. Two separate PCR experiments are performed in which an 
oligonucleotide encoding the mutated residue is extended to either the 5’ or 3’ end of the 
template wild-type DMA using a specifically-targeted primer (Figure 32). Following 
purification, the two newly-synthesised sections of the desired mutated DNA, their sequences 
overlapping at the mutated region, are then resubmitted to the same PCR conditions with both 
terminal primers to allow the full strand to be synthesised. Restriction sites are often 
engineered into the two primers that become the termini of the strands to allow for subsequent 
ligation into the desired vector. An additional restriction site can also be engineered into the 
mutation-bearing oligonucleotide to allow for simple digestion analysis as a means of 
checking whether the resulting DNA is the wild-type or mutant version. 
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Figure 32 – Schematic of PCR technique used to generate mutants 
 
For cdc25A, the F432A, R439A and R439D mutants were synthesised by this method and 
ligated into the pET21a vector. The first two correspond to steric alterations of the active site 
by changing to a smaller alanine residue, whereas the latter change of an arginine residue for 
an aspartic acid can be considered a reversal of the electrostatic properties. This allows two 
different methods of inhibitor-mutant complementation to be pursued.  
 
The strategy for further experiments to find a mutant-selective inhibitor will likely be 
determined by the success in ligand-binding experiments following the successful 
crystallisation of cdc25B and the ongoing assay results which have started to uncover 
isoform-selective inhibitors (see Section 9), although the selectivity achievable with a bump-
hole approach is likely to be much greater.  
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11 Summary and Future Work 
 
 
The initial aims of this project encompassed a range of challenging areas regarding the 
discovery of cdc25 inhibitors and the elucidation of novel structural information. The early 
research focussed on analogues of the structurally complex literature inhibitor dysidiolide, 
specifically attempting at this stage to optimise the butenolide phosphate mimic. However, 
these analogues proved difficult to prepare and purify, and the initial cdc25 phosphatase 
assays did not uncover any promising novel inhibitors. A further series of literature analogues 
were subsequently prepared based on the large class of literature quinonoid cdc25 inhibitors, 
with a strategy designed to mimic the reported non-covalent binding interactions of the 
quinone carbonyl groups whilst removing the oxidative and electrophilic properties. This 
approach was also unsuccessful, emphasising the likely dominant influence of the chemical 
modification of the cdc25 active-site cysteine on the observed inhibitor potency. 
 
Attempted structural studies of the cdc25 catalytic domains began with the successful 
optimisation of buffer conditions to give a thermally stable sample with the strongest possible 
NMR signal. However, preliminary structural studies showed a high degree of conformational 
flexibility, suggesting future work in this area may require selective isotopic labelling 
techniques to further understand the solution dynamics of this partially-disordered enzyme. 
Similarly, although extensive screening of crystallisation conditions did not prove successful 
in this project, ongoing work by co-workers is focussed on the expression and crystallisation 
of specially-designed truncated forms of cdc25B with greater stability that might lead to the 
first inhibitor-bound crystal structure for this phosphatase class. Ultimately, isoform-selective 
inhibitors derived from either medicinal chemistry or protein-ligand engineering would allow 
biochemistry collaborators to investigate the precise cellular roles of the cdc25 isoforms. 
 
A ligand-based virtual screening approach was successful in finding diarylthiazoles as novel, 
potent and drug-like inhibitors of cdc25 and the related phosphatase VHR, although it was 
later discovered that a substantial component of the potency of these compounds derived from 
detergent-sensitive aggregation. However, parallel synthesis of a wide range of diarylthiazole 
analogues, and subsequent substructure-based screening of commercial compounds has 
identified a range of extremely promising, detergent-insensitive novel inhibitors. Many of 
these compounds have affinities and physical properties that classify them as excellent leads 
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for further development, and a medicinal chemistry lead optimisation programme will 
hopefully result in potent, reversible and cell-active cdc25 inhibitors for in vivo anti-cancer 
studies. Support from a range of biochemical assays and structural studies has been 
established in this project, and should increase the potential for rapid optimisation of the 
chosen inhibitor class. The selection of a lead structure will depend on the results of ongoing 
phosphatase and cell proliferation assays. 
 
Various approaches to C-N bond formation for the rapid and divergent synthesis of 2-
aminothiazoles proved unsuccessful, although the Suzuki coupling of a highly electron-rich 
aminothiazole C4-triflate was optimised. Further work in this area is likely to re-examine the 
recently-developed oxidative C-H amination reaction, as further publications in this emerging 
area are clarifying important mechanistic aspects and slowly expanding the substrate scope. 
Any further attempts to achieve the N-arylation of 2-aminothiazoles by Pd-catalysis will 
likely need an alternative strategy to prevent the catalyst deactivation that has been proposed 
to impede this reaction.  
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12 Experimental 
 
General methods: All reactions were carried out under an argon atmosphere at r.t. using 
oven-dried glassware, unless otherwise specified. 
 
Solvents: Petrol refers to the fraction of light petroleum-ether boiling between 40-60 °C. THF, 
PhMe, CH2Cl2, MeOH and Et2O were purified by Innovative Technology Inc. PureSolv
TM
 
Solvent Purification System. Other solvents were used as purchased from Sigma-Aldrich or 
BDH, with DME, EtOH, MeCN, dioxane and DMF obtained in Sure-Seal
TM
 bottles. 
 
Reagents: Chemicals were purchased from Acros Organics, Aldrich Chemical Co., Alfa 
Aesar, Apollo Scientific, Avocado Chemical Co., Fisher Scientific, Fluka, Fluorochem, 
Lancaster Synthesis, Maybridge and Sigma Chemical Co. and handled in accordance with 
COSHH regulations. 
n
BuLi was titrated against diphenylacetic acid. 
 
Chromatography: Flash chromatography was performed on silica gel (Merck Kieselgel 60 
F254 230-400 mesh). TLC was performed on glass-backed plates pre-coated with silica (0.2 
mm, 60 F254), which were developed using standard visualising agents: UV fluorescence (254 
and 366 nm) and KMnO4 with appropriate heating. 
 
1
H-NMR spectroscopy: These were recorded on Bruker AV-400 instruments at 400 MHz; 
chemical shifts (δH) are quoted in ppm (to the nearest 0.01 ppm) downfield from TMS by 
referencing to the appropriate residual solvent peak (CHCl3, δ = 7.24 ppm, DMSO-d5, δ = 
2.50 ppm, CD3OD, δ = 3.31 ppm), with coupling constants (J) reported to the nearest 0.1 Hz.  
 
13
C-NMR spectroscopy: These were recorded on Bruker AV-400 instruments at 101 MHz; 
chemical shifts (δC) are quoted in ppm (to the nearest 0.1 ppm) downfield from TMS by 
referencing to the appropriate solvent peak (CDCl3, δ = 77.0 ppm, DMSO-d6, δ = 39.4 ppm, 
CD3OD, δ = 49.2 ppm). 
 
31
P-NMR spectroscopy: These were recorded on Bruker AV-400 instruments at 162 MHz; 
chemical shifts (δP) are quoted in ppm (to the nearest 0.01 ppm) downfield from 85% H3PO4. 
 
19
F-NMR spectroscopy: These were recorded on Bruker AV-400 instruments at 376 MHz; 
chemical shifts (δF) are quoted in ppm (to the nearest 0.01 ppm) downfield from CFCl3. 
 
MS: These were recorded on either VG Platform II or VG AutoSpec spectrometers, with only 
selected major peaks being reported, with intensities quoted as percentages of the base peak.  
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IR spectroscopy: These were recorded as thin films on a Perkin Elmer Spectrum 100 FT-IR 
Spectrometer. Only selected absorbances (νmax) are reported, to the nearest 1 cm
-1
. 
 
Melting Points: Melting points were determined on a Reichert microscope melting point 
apparatus. 
 
Nomenclature: Compounds were named using IUPAC nomenclature. 
 
Compounds prepared by parallel synthesis and HPLC purification:  
 
All parallel microwave reactions were performed using a Biotage Initiator Sixty microwave. 
All compounds were purified by mass-directed preparative HPLC, with the MS of the isolated 
product in every case giving a strong peak for the correct molecular ion. Preparative HPLC-
MS was performed using one of two separate Waters systems and a 50 × 19 mm C18 reverse-
phase column from either SunFire or XBridge. In each case the injection volume was 500 µL 
and the flow rate was 25 mL/min. The mobile phases of water and methanol contained either 
0.1% formic acid (acidic conditions) or 0.03% ammonium hydroxide (basic conditions). For 
the acidic conditions, the elution gradient was water/methanol (75:25 → 15:85), total run time 
5.8 min. For the basic conditions, the elution gradient was water/methanol (85:15 → 15:85), 
total run time 7 min. 
 
 
(1R,3aR,7aR)-1-((R)-1,5-Dimethyl-hexyl)-7a-methyl-octahydro-inden-4-one, 21 
203
 
 
O2 was bubbled through a stirred solution of vitamin D3 (5.00 g, 13.0 mmol) in MeOH (150 
mL) at -78 °C for 10 min. O3 was then bubbled through the solution until a blue colour was 
observed, and for a further 15 min (1.5 h in total), before O2 was bubbled through for 10 min 
to give a colourless solution. Thiourea (6.93 g, 91.2 mmol) was added and the solution stirred 
at -78 °C for 1 h, followed by 17 h at r.t. The solvent was removed in vacuo and the residue 
partitioned between H2O (50 mL) and pentane (50 mL). The aqueous layer was extracted with 
pentane (3 × 30 mL) and the combined organic layers were dried (MgSO4) and the solvent 
removed in vacuo. Column chromatography eluting with Et2O/petrol (0:1 → 1:3) afforded the 
- 132 - 
 
title compound as a colourless oil (3.37 g, 98%), Rf 0.45 (Et2O/petrol 1:19); δH (400 MHz, 
CDCl3) (identifiable peaks) 2.44 (1H, dd, J 11.7, 7.5, COCH), 0.94 (3H, d, J 6.2, CH3), 0.86 
(3H, d, J 6.5, CH3), 0.85 (3H, d, J 6.6, CH3), 0.63 (3H, s, CH3); m/z (CI) 282 (MNH4
+
, 100%), 
265 (MH
+
, 12). Data is in agreement with the literature.
203
 
 
[(1R,3aS,7aR)-1-((R)-1,5-Dimethyl-hexyl)-7a-methyl-octahydro-inden-(4E)-ylidene]-
acetic acid ethyl ester, 22 
204
  
 
Triethyl phosphonoacetate (12.6 mL, 63.8 mmol) was added dropwise to a slurry of NaH 
(2.23 g, 60% dispersion in mineral oil, 55.8 mmol) in THF (35 mL) at 0 °C. The mixture was 
stirred at r.t. for 1 h to give a colourless solution. A solution of ketone 21 (2.09 g, 7.89 mmol) 
in THF (5 mL) was added dropwise at 0 °C and the reaction mixture stirred at r.t. for 20 h. 
The resulting yellow solution was poured into sat. aq. NH4Cl and extracted with Et2O (3 × 60 
mL). The combined organic layers were dried (MgSO4) and the solvent removed in vacuo. 
Column chromatography eluting with Et2O/petrol (0:1 → 1:9) afforded the title compound as 
a colourless oil (2.65 g, 99%), Rf 0.80 (Et2O/petrol 1:3); υmax (CDCl3)/cm
-1 
1712, 1644; δH 
(400 MHz, CDCl3) (identifiable peaks) 5.45 (1H, s, C=CH), 4.19-4.10 (2H, m, OCH2), 3.90-
3.81 (1H, m, C=CCH), 0.92 (3H, d, J 6.1, CH3), 0.87 (3H, d, J 6.6, CH3), 0.86 (3H, d, J 6.7, 
CH3), 0.58 (3H, s, CH3); δC (101 MHz, CDCl3) 167.0, 163.5, 111.9, 59.5, 56.9, 56.8, 47.1, 
40.2, 39.5, 36.1, 36.0, 29.7, 28.0, 27.4, 23.8, 22.8, 22.6, 22.2, 18.8, 15.3, 14.3, 12.1; m/z (CI) 
352 (MNH4
+
, 100%), 335 (MH
+
, 86), 289 (13), 221 (12). Found: MH
+
, 335.2948. C22H39O2 
requires MH
+
, 335.2950. Data is in agreement with the literature.
204
 
 
[(1R,3aS,7aR)-1-((R)-1,5-Dimethyl-hexyl)-7a-methyl-octahydro-inden-(4E)-ylidene]-
acetic acid, 20 
91
  
 
A solution of ester 22 (519 mg, 1.55 mmol) and LiOH.H2O (652 mg, 15.5 mmol) in 
THF/MeOH/H2O (3:1:1) (10 mL) was stirred at reflux for 4.5 h. The reaction mixture was 
then added to aq. NaHCO3 and extracted with petrol (3 × 20 mL). The combined organic 
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layers were washed with brine, and the combined aqueous layers acidified with 1 M HCl and 
extracted with Et2O (3 × 30 mL). The combined organic layers were dried (MgSO4) and the 
solvent removed in vacuo to afford the title compound as a white solid (456 mg, 97%), mp 
117-119 °C; Rf 0.26 (Et2O/petrol 1:3); []
20
D   +129.3 (c. 3.00 in CH2Cl2); υmax (CDCl3)/cm
-1 
3431, 1687, 1638; δH (400 MHz, CDCl3) (identifiable peaks) 5.49 (1H, s, C=CH), 3.90-3.80 
(1H, m, C=CCH), 2.13 (1H, t, J 9.1, C=CCH2), 2.02 (1H, d, J 12.6, C=CCH2), 0.93 (3H, d, J 
5.8, CH3), 0.87 (3H, d, J 6.6, CH3), 0.86 (3H, d, J 6.5, CH3), 0.58 (3H, s, CH3); m/z (CI) 324 
(MNH4
+
, 22%), 263 (18), 120 (57), 61 (100). Found: MNH4
+
, 324.2905. C20H38NO2 requires 
MNH4
+
, 324.2903. Data is in agreement with the literature.
91
 
 
 [(1R,3aS,7aR)-1-((R)-1,5-Dimethyl-hexyl)-7a-methyl-octahydro-inden-(4E)-ylidene]-
acetyl chloride, 23 
 
Oxalyl chloride (65 μL, 0.75 mmol) was added dropwise to a stirred solution of carboxylic 
acid 20 (207 mg, 0.68 mmol) in CH2Cl2 (5 mL) at 0 °C. Following addition of DMF (1 drop), 
the reaction mixture was stirred at 0 °C for 10 min and then at r.t. for 2.5 h. The solvent and 
excess oxalyl chloride were removed in vacuo to give the title compound as a yellow solid, 
which was used without purification in the subsequent reactions. 
 
 
N-[2-[(1R,3aS,7aR)-1-((R)-1,5-Dimethyl-hexyl)-7a-methyl-octahydro-inden-(4E)-
ylidene]-acetyl]-methanesulfonamide, 24a 
 
A solution of acid chloride 23 (110 mg, 0.34 mmol) in CH2Cl2 (2 mL) was added dropwise to 
a solution of MeSO2NH2 (162 mg, 1.70 mmol), DMAP (4 mg, 0.03 mmol) and Et3N (60 μL, 
0.44 mmol) in CH2Cl2 (1 mL) to give an orange solution. The reaction mixture was stirred at 
r.t. for 18 h before being poured into aq. NH4Cl and extracted with Et2O (3 × 10 mL). The 
combined organic layers were dried (MgSO4) and the solvent removed in vacuo. Column 
chromatography eluting with Et2O/petrol (1:3 → 1:0) afforded the title compound as a white 
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solid (95 mg, 73% over 2 steps), mp 125-128 °C; Rf 0.22 (Et2O/petrol 1:1); []
20
D   +65.5 (c. 
3.85 in CH2Cl2); υmax (CHCl3)/cm
-1
 3183, 1667, 1635, 1335, 1131; δH (400 MHz, CDCl3) 
(identifiable peaks) 8.34 (1H, s, NH), 5.38 (1H, s, C=CH), 3.92-3.84 (1H, m, C=CCH), 3.33 
(3H, s, SO2CH3), 2.13 (1H, t, J 9.0, C=CCH2), 2.02 (1H, d, J 12.7, C=CCH2), 0.92 (3H, d, J 
5.7, CH3), 0.86 (3H, d, J 6.7, CH3), 0.86 (3H, d, J 6.7, CH3), 0.57 (3H, s, CH3); δC (101 MHz, 
CDCl3) 168.4, 164.4, 111.4, 57.2, 56.8, 47.7, 41.8, 39.9, 39.5, 36.0, 35.9, 29.8, 28.0, 27.4, 
24.0, 23.8, 22.8, 22.6, 22.1, 18.8, 12.2; m/z (CI) 401 (MNH4
+
, 86%), 323 (66), 306 (67), 91 
(100). Found: MNH4
+
, 401.2843. C21H41N2O3S requires MNH4
+
, 401.2838. 
 
[(1R,3aS,7aR)-1-((R)-1,5-Dimethyl-hexyl)-7a-methyl-octahydro-inden-(4E)-ylidene]-N-
cyano-acetamide, 24b 
 
A solution of acid chloride 23 (111 mg, 0.34 mmol) in THF (1 mL) was added dropwise to a 
solution of NaNHCN (66 mg, 1.03 mmol) in THF (5 mL) and stirred for 18 h. The reaction 
mixture was added to aq. NaHCO3 and extracted with petrol (3  20 mL). The combined 
organic layers were washed with brine, and the combined aqueous layers acidified with 1 M 
HCl and extracted with Et2O (3 × 30 mL). The combined organic layers were dried (MgSO4) 
and removed in vacuo. Column chromatography eluting with Et2O/petrol (1:1 → 1:0) 
afforded the title compound as a white gum (24 mg, 24% over two steps, 84% based on 
recovered carboxylic acid 20), Rf 0.56 (Et2O); []
20
D   +106.7 (c. 1.20 in CH2Cl2); υmax 
(CHCl3)/cm
-1
 3335, 3191, 2162, 1694, 1634; δH (400 MHz, CDCl3) (identifiable peaks) 5.61 
(1H, br s, C=CH), 4.04 (1H, br s, NH), 3.87-3.78 (1H, m, C=CCH), 2.21-2.15 (1H, m, 
C=CCH2), 2.04 (1H, d, J 12.9, C=CCH2), 0.93 (3H, d, J 5.7, CH3), 0.87 (3H, d, J 6.6, CH3), 
0.86 (3H, d, J 6.6, CH3), 0.58 (3H, s, CH3); δC (101 MHz, CDCl3) 183.6, 169.9, 165.0, 108.0, 
57.3, 56.7, 47.9, 39.8, 39.4, 35.9, 30.1, 28.0, 27.3, 24.0, 23.8, 22.8, 22.5, 22.0, 18.7, 12.2; m/z 
(CI) 348 (MNH4
+
, 100%), 306 (48), 289 (67). Found MNH4
+
, 348.3015. C21H38N3O requires 
MNH4
+
, 348.3015. 
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[(1R,3aS,7aR)-1-((R)-1,5-Dimethyl-hexyl)-7a-methyl-octahydro-inden-(4E)-ylidene]-
thioacetic acid, 24c  
 
A solution of acid chloride 23 (111 mg, 0.34 mmol) in THF (1 mL) was added dropwise to a 
solution of NaSH (58 mg, 1.03 mmol) in EtOH (5 mL) at -10 °C and stirred for 4 h. The 
reaction mixture was poured into aq. NaHCO3 and extracted with petrol (3  20 mL). The 
combined organic layers were washed with brine, and the combined aqueous layers acidified 
with 1 M HCl and extracted with Et2O (3 × 30 mL). The combined organic layers were dried 
(MgSO4) and the solvent removed in vacuo. Column chromatography eluting with Et2O/petrol 
(1:1 → 1:0) afforded the title compound as a white solid (71 mg, 81% over two steps), mp 
105-110 °C; []20D   +208.4 (c. 0.95 in CH2Cl2); υmax (CHCl3)/cm
-1
 2360, 1698, 1612, 1265, 
1032; δH (400 MHz, CDCl3) (identifiable peaks) 5.96 (1H, s, C=CH), 3.70 (1H, d, J 13.0, 
C=CCH), 2.15 (1H, m, C=CCH2), 2.01 (1H, d, J 12.3, C=CCH2), 0.87 (6H, d, J 6.1, 2 × CH3), 
0.59 (3H, s, CH3); δC (101 MHz, CDCl3) 165.6, 159.2, 116.3, 57.1, 56.8, 48.0, 41.3, 39.9, 
39.4, 36.0, 31.0, 28.0, 27.4, 24.0, 23.8, 22.8, 22.6, 22.1, 18.7, 12.3; m/z (CI) 340 (MNH4
+
, 
50%), 322 (MH
+
, 18), 289 (100), 261 (26). Found: MNH4
+
, 340.2672. C20H38NOS requires 
MNH4
+
, 340.2674. 
 
2-[(1R,3aS,7aR)-1-((R)-1,5-Dimethyl-hexyl)-7a-methyl-octahydro-inden-(4E)-ylidene]-
N-hydroxy-acetamide, 24d 
 
A solution of acid chloride 23 (115 mg, 0.35 mmol) in THF (1 mL) was added dropwise to a 
solution of NH2OH (50% aq., 140 μL, 2.10 mmol) in THF (1.5 mL) at -15 °C. The reaction 
was slowly warmed to 5 °C and stirred for 1 h. The reaction mixture was added to 1 M HCl 
and extracted with CHCl3 (3  25 mL). The combined organic layers were dried (MgSO4) and 
the solvent removed in vacuo. Column chromatography eluting with AcOH/Et2O/petrol (0:1:1 
→ 1:49:0) afforded the title compound as a pale orange oil (96 mg, 85% over two steps), Rf 
0.50 (Et2O); []
20
D   +105.8 (c. 4.80 in CH2Cl2); υmax (CHCl3)/cm
-1
 3216, 1655, 1265; δH (400 
MHz, CDCl3) (identifiable peaks) 5.27 (1H, br s, C=CH), 3.71 (1H, br s, C=CCH), 0.93 (3H, 
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d, J 5.8, CH3), 0.86 (3H, d, J 6.6, CH3), 0.86 (3H, d, J 6.6, CH3), 0.56 (3H, s, CH3); δC (101 
MHz, CDCl3) 166.7, 160.6, 109.4, 56.7, 54.4, 46.9, 40.0, 39.4, 36.0, 35.9, 28.0, 27.4, 24.0, 
23.8, 22.8, 22.5, 22.2, 18.8, 12.0; m/z (CI) 339 (MNH4
+
, 87%), 322 (MH
+
, 100), 289 (12). 
Found MH
+
, 322.2756. C20H36NO2 requires MH
+
, 322.2746. 
 
 [2-[(1R,3aS,7aR)-1-((R)-1,5-Dimethyl-hexyl)-7a-methyl-octahydro-inden-(4E)-ylidene]-
acetyl]-carbamic acid methyl ester, 24e 
 
To a solution of acid chloride 23 (115 mg, 0.35 mmol) in PhMe (1 mL) was added methyl 
carbamate (79 mg, 1.05 mmol) and the resulting solution was stirred at 80 °C for 2 h. The 
reaction mixture was cooled and purification by column chromatography eluting with 
Et2O/petrol (1:3 → 1:1) afforded the title compound as a colourless oil (69 mg, 53% over two 
steps), Rf 0.30 (Et2O/petrol 1:1); []
20
D   120.0 (c. 2.45 in CHCl3); υmax (CHCl3)/cm
-1
 3216, 
1655, 1265; δH (400 MHz, CDCl3) (identifiable peaks) 7.80 (1H, br s, NH), 6.24 (1H, s, 
C=CH), 3.76 (3H, s, OCH3), 3.28-3.07 (1H, m, C=CCH), 0.86 (3H, d, J 6.6, CH3), 0.85 (3H, 
d, J 6.6, CH3), 0.58 (3H, s, CH3); δC (101 MHz, CDCl3) 166.2, 165.7, 152.5, 112.7, 65.8, 57.2, 
56.8, 52.8, 47.4, 40.1, 39.4, 36.0, 30.3, 28.0, 27.4, 23.8, 22.8, 22.5, 22.2, 18.7, 12.1; m/z (CI) 
381 (MNH4
+
, 100%), 364 (MH
+
, 82), 324 (10). Found MH
+
, 364.2859. C22H38NO3 requires 
MH
+
, 364.2852. 
 
 [(1R,3aS,7aR)-1-((R)-1,5-Dimethyl-hexyl)-7a-methyl-octahydro-inden-(4E)-ylidene]-
acetonitrile, 25 
 
Diisopropyl cyanomethylphosphonate (3.44 mL, 17.0 mmol) was added dropwise to a slurry 
of NaH (610 mg, 60% dispersion in mineral oil, 14.9 mmol) in THF (20 mL) at 0 °C. The 
mixture was stirred at r.t. for 1 h to give a colourless solution. A solution of ketone 21 (1.12 g, 
4.26 mmol) in THF (5 mL) was added dropwise at 0 °C and the reaction mixture stirred at r.t. 
for 15 h. The resulting orange solution was poured into sat. aq. NH4Cl and extracted with 
Et2O (3 × 30 mL). The combined organic layers were dried (MgSO4) and the solvent removed 
- 137 - 
 
in vacuo. Column chromatography eluting with Et2O/petrol (0:1 → 1:9) afforded the title 
compound as a colourless oil (1.14 g, 93%), Rf 0.74 (Et2O/petrol 1:3); []
20
D   +112.0 (c. 2.25 
in CH2Cl2); υmax (CHCl3)/cm
-1
 2218, 1628; δH (400 MHz, CDCl3) (identifiable peaks) 4.89 
(1H, s, C=CH), 2.92 (1H, dd, J 14.0, 4.3, C=CCH), 0.92 (3H, d, J 5.9, CH3), 0.86 (3H, d, J 
6.6, CH3), 0.86 (3H, d, J 6.5, CH3), 0.55 (3H, s, CH3); δC (101 MHz, CDCl3) 168.9, 117.4, 
90.7, 56.5, 56.1, 47.3, 39.5, 39.4, 36.0, 35.9, 33.0, 27.8, 26.9, 24.9, 22.8, 22.6, 21.8, 18.7, 11.9; 
m/z (CI) 305 (MNH4
+
, 100%). Found: MNH4
+
, 305.2962. C20H37N2 requires MNH4
+
, 
305.2957. 
 
3-[(1R,3aS,7aR)-1-((R)-1,5-Dimethyl-hexyl)-7a-methyl-octahydro-inden-(4E)-
ylidenemethyl]-4H-[1,2,4]oxadiazol-5-one, 26  
 
According to the method of Sangshetti,
205
 to a solution of nitrile 25 (515 mg, 1.79 mmol) in 
MeOH (12 mL) was added NH2OH.HCl (249 mg, 3.59 mmol) and NaHCO3 (603 mg, 7.18 
mmol). The reaction mixture was stirred at reflux for 8 h before being cooled to r.t. and 
filtered. The filtrate was concentrated in vacuo, a further 5 mL of MeOH was added and the 
resulting suspension was filtered again. The filtrate was concentrated in vacuo to give the 
intermediate amidoxime as a white semi-solid which was used without further purification in 
the subsequent reaction.  
 
To a solution of the intermediate amidoxime (144 mg, 0.45 mmol) in dioxane (3 mL) was 
added CDI (91 mg, 0.56 mmol). The reaction mixture was stirred at reflux for 45 min to give 
a yellow solution, which was cooled to r.t. The solvent was removed in vacuo, water (5 mL) 
and 2 M HCl (5 mL) were added before extraction with CHCl3 (3  15 mL). The organic 
layers were combined, washed with brine, dried (MgSO4) and concentrated in vacuo. Column 
chromatography eluting with Et2O/petrol (0:1 → 1:9) gave the title compound as a yellow oil 
(91 mg, 59% over 2 steps), Rf 0.69 (Et2O/petrol 1:3); []
20
D   +125.7 (c. 4.25 in CH2Cl2); 
υmax/cm
-1
 3369, 1628, 819; δH (400 MHz, CDCl3) (identifiable peaks) 4.88 (1H, s, C=CH), 
2.91 (1H, dd J 14.0, 4.5, C=CCH), 0.92 (3H, d, J 6.0, CH3), 0.86 (3H, d, J 6.7, CH3), 0.86 (3H, 
d, J 6.6, CH3), 0.55 (3H, s, CH3); δC (101 MHz, CDCl3) 168.8, 165.4, 117.3, 91.6, 90.7, 56.4, 
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56.0, 47.2, 39.5, 39.4, 36.0, 35.8, 33.0, 28.0, 27.3, 23.6, 22.8, 22.5, 21.7, 18.7, 11.9; m/z (CI) 
305 (decarboxylation product, 100%).  
 
2-[(1R,3aS,7aR)-1-((R)-1,5-Dimethyl-hexyl)-7a-methyl-octahydro-inden-(4E)-ylidene]-
ethanol, 27 
 
DIBAL (1.0 M in hexanes, 11.8 mL, 11.8 mmol) was added to a solution of ester 22 (1.60 g, 
3.77 mmol) in PhMe (8 mL) at -78 °C. The reaction mixture was stirred for 1.5 h at this 
temperature before being poured into aq. Na2SO4, filtered through Celite
®
 and extracted with 
Et2O (3 × 25 mL). The combined organic layers were dried (MgSO4) and the solvent removed 
in vacuo. Column chromatography eluting with Et2O/petrol (0:1 → 1:1) afforded the title 
compound as a colourless oil (1.35 g, 96%), Rf 0.23 (Et2O/petrol 1:3); []
20
D   +51.9 (c. 4.20 in 
CH2Cl2); υmax (CHCl3)/cm
-1
 3366, 1667, 2165, 996; δH (400 MHz, CDCl3) (identifiable peaks) 
5.20 (1H, t, J 7.0, C=CH), 4.19 (2H, d, J 7.0, CH2O), 2.62-2.58 (1H, m, C=CCH), 0.91 (3H, d, 
J 6.4, CH3), 0.86 (3H, d, J 6.6, CH3), 0.85 (3H, d, J 6.7, CH3), 0.54 (3H, s, CH3); δC (101 
MHz, CDCl3) 143.7, 119.2, 58.6, 56.6, 55.6, 45.3, 40.3, 39.5, 36.1, 28.7, 28.0, 27.6, 23.8, 
23.5, 22.8, 22.5, 22.1, 18.8, 11.8; m/z (CI) 310 (MNH4
+
, 8%), 292 (MH
+
, 47), 275 (100). 
Found MNH4
+
, 310.3120. C21H38N3O requires MNH4
+
, 310.3110. 
 
 [2-[(1R,3aS,7aR)-1-((R)-1,5-Dimethyl-hexyl)-7a-methyl-octahydro-inden-(4E)-ylidene]-
ethyl]-phosphonic acid diethyl ester, 28 
 
PBr3 (147 μL, 1.56 mmol) was added to a stirred solution of alcohol 27 (912 mg, 3.12 mmol) 
in Et2O (20 mL) at 0 °C. The reaction mixture was stirred for 4 h before being poured into 
ice-water and extracted with Et2O (3 × 25 mL). The combined organic layers were dried 
(MgSO4) and the solvent removed in vacuo to give the crude intermediate bromide, which 
was used without purification in the next reaction. 
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The intermediate bromide was added to P(OEt)3 (5 mL) and heated to reflux at 170 °C for 5 h. 
The reaction mixture was cooled, poured into ice-water, acidified with 1 M HCl and extracted 
with Et2O (3 × 20 mL). The combined organic layers were dried (MgSO4) and the solvent 
removed in vacuo. Column chromatography eluting with Et2O/petrol (1:3 → 1:0) afforded the 
title compound as a colourless oil (1.13 g, 88%), Rf 0.27 (Et2O); []
20
D   + 88.0 (c. 0.75 in 
CH2Cl2); υmax (CHCl3)/cm
-1
 1668, 1254, 1054, 1030; δH (400 MHz, CDCl3) (identifiable 
peaks) 4.90 (1H, m, C=CH), 4.11-3.99 (4H, m OCH2), 2.64-2.48 (3H, m PCH2, C=CCH), 
0.87 (3H, d, J 6.4, CH3), 0.82 (3H, d, J 6.6, CH3), 0.82 (3H, d, J 6.5, CH3), 0.51 (3H, s, CH3); 
δC (101 MHz, CDCl3) 143.8, 107.9, 65.8, 63.6, 61.5, 56.4, 55.7, 45.3, 40.3, 39.4, 36.0, 28.6, 
27.9, 27.5, 23.7, 23.1, 22.7, 22.4, 22.1, 18.7, 11.7; m/z (CI) 430 (48%), 413 (MH
+
, 100). 
Found MH
+
, 413.3196. C24H46O3P requires MH
+
, 413.3185. 
 
Thioacetic acid S-[2-[(1R,3aS,7aR)-1-((R)-1,5-dimethyl-hexyl)-7a-methyl-octahydro-
inden-(4E)-ylidene]-ethyl] ester, 30 
 
Diisopropyl azodicarboxylate (480 μL, 2.42 mmol) was added to a solution of PPh3 (635 mg, 
2.42 mmol) in THF (4 mL) at 0 °C. The resulting white slurry was stirred at this temperature 
for 30 min before a solution of alcohol 27 (353 mg, 1.21 mmol) in THF (1 mL) was added. 
The reaction mixture was stirred for 5 min before the addition of thiolacetic acid (170 μL, 
2.42 mmol) and then for 1 h at 0 °C, followed by a further 1 h at r.t. The reaction mixture was 
then washed with sat. aq. NaHCO3 (4  25 mL) and the solvent removed in vacuo. Hexane 
(25 mL) was added and the solution was filtered through Celite
®
 and then silica. The solvent 
was removed in vacuo to give a yellow oil and purification by column chromatography 
eluting with Et2O/petrol (0:1 → 1:3) afforded the title compound as a pale yellow oil (268 mg, 
63%), Rf 0.68 (Et2O/petrol 1:3); []
20
D   +70.2 (c. 2.45 in CH2Cl2); υmax (CHCl3)/cm
-1
 1693, 
1665, 1135, 1111, 630; δH (400 MHz, CDCl3) (identifiable peaks) 5.00 (1H, t, J 8.0, C=CH), 
3.65-3.49 (2H, m, CH2S), 2.67-2.59 (1H, m, C=CCH), 2.31 (3H, s, COCH3), 0.90 (3H, d, J 
6.5, CH3), 0.86 (3H, d, J 6.7, CH3), 0.85 (3H, d, J 6.7, CH3), 0.51 (3H, s, CH3); δC (101 MHz, 
CDCl3) 169.1, 144.1, 116.8, 109.4, 56.5, 55.6, 45.4, 40.3, 39.5, 36.1, 30.4, 28.6, 28.0, 27.6, 
26.7, 23.8, 23.4, 22.8, 22.5, 22.1, 18.8, 11.7; m/z (CI) 368 (92%), 351 (MH
+
, 100), 309 (27), 
274 (35). Found MH
+
, 351.2724. C22H39SO requires MH
+
, 351.2722. 
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2-[(1R,3aR,4S,7aR)-1-((R)-1,5-Dimethyl-hexyl)-7a-methyl-octahydro-inden-4-yloxy]-
malonic acid dimethyl ester, 33 
 
O2 was bubbled through a stirred solution of vitamin D3 (5.00 g, 13.0 mmol) in MeOH (150 
mL) at -78 °C for 10 min. O3 was then bubbled through the solution until a blue colour was 
observed, and for a further 15 min (1.5 h in total), before O2 was bubbled through for 10 min 
to give a colourless solution. NaBH4 (4.43 g, 117 mmol) was added and the solution stirred at 
-78 °C for 1 h, followed by 1.5 h at r.t. 1 M HCl (50 mL) was added and the MeOH removed 
in vacuo. The aqueous solution was extracted with Et2O (3 × 200 mL) and the combined 
organic layers dried (MgSO4) and the solvent removed in vacuo. Partial purification by 
column chromatography eluting with Et2O/petrol (1:3 → 1:1) afforded alcohol 32 as a 
colourless oil (2.01 g), which was used directly in subsequent reactions. 
 
According to the method of Cox,
206
 Rh2(OAc)4 (5 mg, 0.01 mmol) was added to a stirred 
solution of alcohol 32 (259 mg, 0.97 mmol) and dimethyl diazomalonate (153 mg, 0.97 mmol) 
in CH2Cl2 (3 mL) at r.t. to give a green solution. After stirring for 2.5 h, the solvent was 
removed in vacuo and purification by column chromatography eluting with Et2O/petrol (5:95 
→ 15:85), affording the title compound as a colourless oil (303 mg, 47% over 2 steps), Rf 
0.56 (Et2O/petrol 1:1); []
20
D   +71.3 (c. 1.15 in CH2Cl2); υmax (CHCl3)/cm
-1
 1771, 1749, 1163, 
1128; δH (400 MHz, CDCl3) (identifiable peaks) 4.47 (1H, s, OCH(CO2Me)2), 3.78 (3H, s, 
OCH3), 3.77 (3H, s, OCH3), 3.73 (1H, m, OCH), 2.02-1.95 (1H, m, OCHCH), 0.92 (3H, s, 
CH3), 0.88 (3H, d, J 6.5, CH3), 0.86 (3H, d, J 6.5, CH3), 0.85 (3H, d, J 6.3, CH3); δC (101 
MHz, CDCl3) 167.9, 167.7, 79.0, 78.3, 56.7, 52.7, 52.6, 52.3, 42.0, 40.4, 39.5, 36.0, 35.3, 
29.7, 28.0, 27.2, 23.8, 22.8, 22.5, 22.4, 18.6, 17.7, 13.2; m/z (CI) 414 (MNH4
+
, 100%), 282 (5). 
Found MNH4
+
, 414.3226. C23H44NO5 requires MNH4
+
, 414.3219. 
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2-[2-[(1R,3aS,7aR)-1-((R)-1,5-Dimethyl-hexyl)-7a-methyl-octahydro-inden-(4E)-
ylidene]-ethoxy]-malonic acid dimethyl ester, 35 
 
According to the method of Cox,
206
 Rh2(OAc)4 (4 mg, 0.007 mmol) was added to a stirred 
solution of alcohol 27 (213 mg, 0.73 mmol) and dimethyl diazomalonate (124 mg, 0.78 mmol) 
in CH2Cl2 (2 mL) at r.t. to give a green solution. After stirring for 3 h, the solvent was 
removed in vacuo and purification by column chromatography eluting with Et2O/petrol (1:3 
→ 1:1) afforded the title compound as a colourless oil (245 mg, 80%), Rf 0.50 (Et2O/petrol 
1:1); []20D   +59.1 (c. 1.05 in CH2Cl2); υmax (CHCl3)/cm
-1
 1748, 1667, 1266, 1238, 1166, 1026; 
δH (400 MHz, CDCl3) (identifiable peaks) 5.12 (1H, t, J 7.3, C=CH), 4.57 (1H, s, OCH), 4.30-
4.18 (2H, m, OCH2), 3.79 (6H, s, 2 × OCH3), 2.56-2.50 (1H, m, C=CCH), 0.90 (3H, d, J 6.4, 
CH3), 0.85 (3H, d, J 6.6, CH3), 0.85 (3H, d, J 6.6, CH3), 0.53 (3H, s, CH3); δC (101 MHz, 
CDCl3) 167.3, 167.2, 147.3, 114.6, 66.4, 65.8, 56.5, 55.8, 52.8, 45.4, 40.2, 39.4, 36.0, 28.8, 
28.0, 27.5, 23.8, 23.4, 22.8, 22.5, 22.1, 18.8, 11.9; m/z (CI) 454 (4%), 440 (MH
+
, 100), 275 
(29) Found MH
+
, 440.3377. C25H46NO5 requires MH
+
, 440.3376. 
  
[(1R,3aS,7aR)-1-((R)-1,5-Dimethyl-hexyl)-7a-methyl-octahydro-inden-(4E)-ylidene]-
acetaldehyde, 37 
204
  
 
To a solution of oxalyl chloride (2 M in CH2Cl2, 990 μL, 1.98 mmol) in CH2Cl2 at -60 °C was 
added DMSO (0.28 mL, 3.98 mmol). The reaction mixture was stirred for 5 min before 
dropwise addition of alcohol 27 (482 mg, 1.66 mmol) in CH2Cl2 (3 mL) and further stirring 
for 15 min. Et3N (1.11 mL, 7.97 mmol) was then added dropwise before the reaction mixture 
was stirred for 5 min and then allowed to warm to r.t. The solvent was removed in vacuo and 
purification by column chromatography eluting with Et2O/petrol (1:4) gave the title 
compound as a colourless oil (349 mg, 73%), Rf 0.40 (Et2O/petrol 1:3); δH (400 MHz, CDCl3) 
(identifiable peaks) 10.10 (1H, d, J 8.2, CHO), 5.73 (1H, d, J 8.2, C=CH), 3.39-3.33 (1H, m, 
C=CCH), 0.93 (3H, d, J 5.9, CH3), 0.86 (3H, d, J 6.6, CH3), 0.86 (3H, d, J 6.5, CH3), 0.60 
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(3H, s, CH3); m/z (CI) 308 (100%), 291 (MH
+
, 74), 273 (42). Found MH
+
, 291.2694. C20H35O 
requires MH
+
, 291.2688. Data is in agreement with the literature.
204
 
 
3-[(1R,3aS,7aR)-1-((R)-1,5-Dimethyl-hexyl)-7a-methyl-octahydro-inden-(4E)-ylidene]-2-
hydroxy-propionitrile, 38 
 
To a solution of oxalyl chloride (2 M in CH2Cl2, 0.71 mL, 1.41 mmol) in CH2Cl2 (3 mL) 
at -60 °C was added DMSO (0.20 mL, 2.81 mmol). The reaction mixture was stirred for 5 
min before dropwise addition of alcohol 27 (342 mg, 1.17 mmol) in CH2Cl2 (1 mL) and 
further stirring for 15 min. Et3N (0.79 mL, 5.62 mmol) was then added dropwise before the 
reaction mixture was stirred for 5 min and then allowed to warm to r.t. The solvent was 
removed in vacuo to give crude aldehyde 37, which was used in the next reaction without 
purification. 
 
According to the method of Baeza,
207
 to a mixture of aldehyde 37 (339 mg, 1.17 mmol) and 
Et3N (33 μL, 0.24 mmol) at r.t. was added TMSCN (172 μL, 1.29 mmol) and the reaction 
mixture was stirred for 2 h. The volatile materials were removed in vacuo to give an orange 
oil and purification by column chromatography eluting with Et2O/petrol (1:3) gave the title 
compound as a colourless oil (297 mg, 80% over 2 steps), Rf 0.11 (Et2O/petrol 1:3); []
20
D   
+54.4 (c. 1.25 in CH2Cl2); υmax (CHCl3)/cm
-1
 3420, 2254, 1662, 1028, 909; δH (400 MHz, 
CDCl3) (identifiable peaks) 5.27-5.17 (2H, m, C=CH, CHOH), 2.56 (1H, m, C=CCH), 0.92 
(3H, d, J 6.3, CH3), 0.87 (3H, d, J 6.6, CH3), 0.86 (3H, d, J 6.7, CH3), 0.56 (3H, s, CH3); δC 
(101 MHz, CDCl3) 149.5, 119.7, 115.2, 57.3, 56.5, 55.4, 46.2, 45.8, 39.9, 39.4, 36.0, 29.3, 
28.0, 27.5, 23.8, 23.3, 22.8, 22.5, 21.9, 18.8, 11.8; m/z (CI) 308 (100%), 291 (40), 273 (18). 
Found MH
+
, 317.2720. C20H35O requires MH
+
, 317.2719. 
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[(1R,3aS,7aR)-1-((R)-1,5-Dimethyl-hexyl)-7a-methyl-octahydro-inden-(4E)-ylidene]-
acetic acid 2-methyl-4-oxo-4H-pyran-3-yl ester, 40 
 
To a stirred solution of carboxylic acid 20 (42 mg, 0.14 mmol) in CH2Cl2 (3 mL) at r.t. was 
added DCC (31 mg, 0.15 mmol), 3-hydroxy-2-methylpyrone (19 mg, 0.15 mmol) and DMAP 
(2 mg, 0.02 mmol). The reaction mixture was stirred for 3 d before being filtered to remove 
the white urea precipitate, which was washed with CH2Cl2. Brine (10 mL) was added to the 
filtrate, and the organic layer separated. The aqueous layer was extracted with CH2Cl2 (2  10 
mL). The combined organic layers were dried (Na2SO4) and the solvent removed in vacuo. 
Column chromatography eluting with Et2O/petrol (1:3 → 1:0) afforded the title compound as 
a colourless oil (40 mg, 70%), Rf 0.40 (Et2O); []
20
D   +35.0 (c. 0.40 in CH2Cl2); υmax 
(CHCl3)/cm
-1
 1766, 1664, 1171; δH (400 MHz, CDCl3) (identifiable peaks) 7.65 (1H, d, J 5.8, 
pyrone 6-H), 6.39 (1H, d, J 5.8, pyrone 5-H), 5.72 (1H, br s, O2CCH=C), 2.23 (3H, s, pyrone 
CH3), 0.86 (3H, d, J 6.7, CH3), 0.86 (3H, d, J 6.5, CH3); δC (101 MHz, CDCl3) 172.0, 168.8, 
158.9, 154.0, 138.7, 133.2, 125.6, 116.9, 54.3, 51.5, 41.2, 40.9, 39.5, 35.4, 34.8, 33.6, 29.7, 
29.0, 28.0, 24.4, 22.8, 22.5, 21.4, 19.8, 14.9; m/z (CI) 415 (MH
+
, 98%), 225 (100), 127 (20). 
Found: MH
+
, 415.2853. C26H39O4 requires MH
+
, 415.2848. 
 
(2-[(1R,7aR)-1-((R)-1,5-Dimethyl-hexyl)-7a-methyl-octahydro-inden-(4E)-ylidene]-
acetoxy)-phenyl-acetic acid, 41 
 
To a stirred solution of (+/-)-mandelic acid (96 mg, 0.63 mmol) and DMAP (7 mg, 0.063 
mmol) in CH2Cl2 (0.5 mL) at r.t. was added acid chloride 23 (41 mg, 0.13 mmol) and Et3N 
(90 μL, 0.63 mmol). The reaction mixture was stirred for 14 h before sat. aq. NaHCO3 (10 mL) 
was added. The aqueous layer was extracted with CH2Cl2 (3  20 mL) and then acidified with 
1 M HCl before being extracted with CH2Cl2 (3  20 mL). The combined organic layers were 
dried (MgSO4) and the solvent removed in vacuo. Column chromatography eluting with 
AcOH/Et2O/petrol (2:25:75 → 2:33:67) afforded the title compound as a colourless oil (48 
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mg, 87%), Rf 0.50 (Et2O/petrol 1:5:5); []
20
D   +24.2 (c. 1.73 in CH2Cl2); υmax (CHCl3)/cm
-1
 
1731, 1643, 1143; δH (400 MHz, CDCl3) (identifiable peaks) 7.52-7.45 (2H, m, Ar-H), 7.40-
7.35 (3H, m, Ar-H), 5.91 (1H, s, OCHCO2H), 5.60 (1H, br s, CH=C), 0.91 (3H, d, J 6.5, CH3), 
0.87 (6H, d, J 6.4, 2  CH3), 0.86 (3H, s, CH3); δC (101 MHz, CDCl3) 174.1, 171.6, 133.3, 
133.2, 129.4, 128.8, 127.6, 125.4, 74.0, 54.3, 51.4, 41.4, 40.8, 39.5, 35.4, 34.8, 33.6, 29.6, 
29.0, 28.0, 24.4, 22.8, 22.6, 21.3, 19.8; m/z (CI) 458 (95%), 441 (MH
+
, 29), 289 (30), 272 
(100), 97 (22). Found: MH
+
, 441.3004. C28H41O4 requires MH
+
, 441.3005. 
 
Phthalic acid mono-(2-[(1R,3aS,7aR)-1-((R)-1,5-dimethyl-hexyl)-7a-methyl-octahydro-
inden-(4E)-ylidene]-ethyl) ester, 42  
 
To a stirred solution of phthalic anhydride (51 mg, 0.34 mmol) in THF (2 mL) at r.t. was 
added alcohol 27 (95 mg, 0.33 mmol) and Et3N (142 μL, 1.02 mmol). The reaction mixture 
was stirred for 14 h before sat. aq. NaHCO3 (10 mL) was added. The aqueous layer was 
extracted with Et2O (3  15 mL) and then acidified with 1 M HCl before being extracted with 
Et2O (3  40 mL). The combined organic layers were dried (MgSO4) and the solvent removed 
in vacuo. Column chromatography eluting with Et2O/petrol (1:1 → 3:1) afforded the title 
compound as a white semi-solid (143 mg, 100%), Rf 0.70 (Et2O); []
20
D   +42.0 (c. 1.33 in 
CH2Cl2); υmax (CHCl3)/cm
-1
 1726, 1702, 1285, 1124, 1072; δH (400 MHz, CDCl3) 
(identifiable peaks) 7.93 (1H, dd, J 7.5, 1.3, Ar-H), 7.70 (1H, dd, J 7.4, 1.3, Ar-H), 7.58 (2H, 
m, Ar-H), 5.23 (1H, t, J 7.3, OCH2CH=C), 4.91 (2H, d, J 7.4, OCH2CH=C), 2.70 (1H, m, 
C=CCH), 0.91 (3H, d, J 6.4, CH3), 0.87 (3H, d, J 6.7, CH3), 0.86 (3H, d, J 6.5, CH3), 0.54 
(3H, s, CH3); δC (101 MHz, CDCl3) 171.7, 168.3, 147.2, 133.6, 132.2, 130.7, 130.1, 128.8, 
113.3, 62.3, 56.5, 55.7, 45.5, 40.3, 39.5, 36.0, 28.9, 28.0, 27.5, 23.8, 23.5, 22.8, 22.5, 22.1, 
18.8, 11.8; m/z (CI) 441 (MH
+
, 1%), 292 (24), 275 (100), 184 (45). Found: MH
+
, 441.3009. 
C28H41O4 requires MH
+
, 441.3005. 
 
 
 
 
 
- 145 - 
 
2-Methyl-2,3-dihydro-phthalazine-1,4-dione, 43 
208
 
 
To a stirred solution of phthaloyl dichloride (5.00 mL, 34.7 mmol) and Et3N (14.5 mL, 104 
mmol) in CH2Cl2 (200 mL) at 0 °C was added methylhydrazine (1.85 mL, 34.7 mmol) 
dropwise. The reaction mixture was allowed to warm to r.t. and stirred for 14 h. The solvent 
was removed in vacuo and the residue suspended in Et2O and filtered. Recrystallisation from 
EtOH afforded the title compound as white amorphous crystals (4.55 g, 75%), mp > 250 °C; 
δH (400 MHz, CDCl3) 11.63 (1H, s, NH), 8.23-8.19 (1H, m, Ar-H), 7.98-7.94 (1H, m, Ar-H), 
7.92-7.84 (2H, m, Ar-H), 3.56 (3H, s, CH3); m/z (ES) 294 (26%), 253 (17), 251 (100), 210 
(27), 144 (18). Found: MH
+
, 177.0669. C9H9N2O2 requires MH
+
, 177.0664. Data is in 
agreement with the literature.
208
 
 
2-[3-(tert-Butyl-dimethyl-silanyloxy)-propyl]-3-methyl-2,3-dihydro-phthalazine-1,4-
dione, 44 
 
A suspension of phthalazine dione 43 (50 mg, 0.28 mmol), (3-bromo-propoxy)-tert-butyl-
dimethyl-silane (79 μL, 0.34 mmol), K2CO3 (59 mg, 0.43 mmol) and KI (24 mg, 0.14 mmol) 
in MeCN (4 mL) was stirred at reflux for 24 h. The reaction mixture was cooled, filtered and 
the solvent removed in vacuo. Column chromatography eluting with Et2O/petrol (1:3 → 1:1) 
afforded the title compound as a colourless oil (68 mg, 69%), Rf 0.66 (Et2O/petrol 1:1); υmax 
(CHCl3)/cm
-1
 1649, 1590, 1328, 1258, 1097; δH (400 MHz, CDCl3) 8.40-8.34 (1H, m, Ar-H), 
7.95-7.90 (1H, m, Ar-H), 7.77-7.70 (2H, m, Ar-H), 4.37 (2H, t, J 6.2, CH2O), 3.81 (2H, t, J 
6.2, CH2N), 3.70 (3H, s, NCH3), 2.03 (2H, quin, J 6.2, CH2CH2O), 0.87 (9H, s, C(CH3)3), 
0.03 (6H, s, 2  SiCH3); δC (101 MHz, CDCl3) 158.8, 149.8, 132.5, 131.7, 129.0, 126.9, 124.9, 
123.3, 63.6, 59.7, 38.8, 32.0, 25.9, 18.3, -5.4; m/z (ES) 515 (7%), 351 (4), 350 (26), 349 (MH
+
, 
100), 297 (7). Found: MH
+
, 349.1947. C18H29N2O3Si requires MH
+
, 349.1947. 
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2-(3-Hydroxy-propyl)-3-methyl-2,3-dihydro-phthalazine-1,4-dione, 45 
 
To a stirred solution of TBS-protected alcohol 44 (33 mg, 0.095 mmol) in THF (0.1 mL) at 
0 °C was added TBAF (1 M in THF, 114 μL, 0.11 mmol) dropwise. The reaction mixture was 
stirred for 2 h, the solvent removed in vacuo. Column chromatography eluting with 
MeOH/Et2O (0:1 → 1:9) afforded the title compound as a white semi-solid (22 mg, 100%), Rf 
0.21 (Et2O); υmax (CHCl3)/cm
-1
 1641, 1579, 1332, 1266, 1102; δH (400 MHz, CDCl3) 8.34-
8.28 (1H, m, Ar-H), 7.87-7.82 (1H, m, Ar-H), 7.73-7.65 (2H, m, Ar-H), 4.39 (2H, t, J 6.0, 
CH2O), 3.86 (2H, t, J 6.0, CH2N), 3.64 (3H, s, NCH3), 2.50 (1H, br s, OH), 2.07 (2H, quin, J 
6.0, CH2CH2O); δC (101 MHz, CDCl3) 158.7, 149.9, 132.5, 131.8, 128.8, 126.9, 124.6, 123.3, 
63.9, 59.4, 38.8, 31.9; m/z (ES) 401 (18%), 236 (13), 235 (MH
+
, 100), 211 (4), 177 (4). Found: 
MH
+
, 235.1094. C12H15N2O3 requires MH
+
, 235.1083. 
 
N,N-Dimethyl-2-(3-methyl-1,4-dioxo-3,4-dihydro-1H-phthalazin-2-yl)-acetamide, 46 
 
A suspension of phthalazine dione 43 (75 mg, 0.43 mmol), N,N-dimethyl-2-chloroacetamide 
(53 μL, 0.51 mmol), K2CO3 (147 mg, 1.07 mmol) and KI (71 mg, 0.43 mmol) in MeCN (4 
mL) was stirred at reflux for 40 h. The reaction mixture was cooled, filtered and the solvent 
removed in vacuo. Column chromatography eluting with MeOH/EtOAc (2:98) afforded the 
title compound as a white solid (111 mg, 100%), mp 118-119 °C; Rf 0.56 (EtOAc); υmax 
(neat)/cm
-1
 2943, 1648, 1621, 1586, 1492, 1328; δH (400 MHz, CDCl3) 8.35-8.28 (1H, m, Ar-
H), 8.04-7.98 (1H, m, Ar-H), 7.74-7.67 (2H, m, Ar-H), 4.94 (2H, s, CH2N), 3.63 (3H, s, 
NNCH3), 3.03 (3H, s, NCH3), 2.95 (3H, s, NCH3); δC (101 MHz, CDCl3) 167.1, 158.9, 148.9, 
132.8, 132.1, 129.1, 126.9, 124.4, 123.7, 63.8, 38.9, 36.3, 35.7; m/z (ES) 325 (11%), 263 (15), 
262 (MH
+
, 100). Found: MH
+
, 262.1198. C13H16N3O3 requires MH
+
, 262.1192. 
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2-(3-Methoxy-propyl)-3-methyl-2,3-dihydro-phthalazine-1,4-dione, 47 
 
A suspension of phthalazine dione 43 (75 mg, 0.43 mmol), 1-chloro-3-methoxy-propane (55 
mg, 0.51 mmol), K2CO3 (147 mg, 1.07 mmol) and KI (71 mg, 0.43 mmol) in MeCN (4 mL) 
was stirred at reflux for 40 h. The reaction mixture was cooled, filtered and the solvent 
removed in vacuo. Column chromatography eluting with EtOAc/petrol (1:1 → 4:1) afforded 
the title compound as a white solid (49 mg, 46%), mp 100-102 °C; Rf 0.80 (EtOAc); υmax 
(neat)/cm
-1
 1649, 1621, 1590, 1328; δH (400 MHz, CDCl3) 8.38-8.29 (1H, m, Ar-H), 7.95-
7.87 (1H, m, Ar-H), 7.75-7.66 (2H, m, Ar-H), 4.33 (2H, t, J 6.3, CH2O), 3.68 (3H, s, OCH3), 
3.55 (2H, t, J 6.3, CH2N), 3.33 (3H, s, NCH3), 2.08 (2H, quin, J 6.3, CH2CH2O); δC (101 
MHz, CDCl3) 158.9, 149.8, 132.6, 131.9, 129.1, 127.0, 124.9, 123.5, 69.5, 64.0, 58.9, 38.9, 
29.2; m/z (ES) 415 (4%), 250 (14), 249 (MH
+
, 100). Found: MH
+
, 249.123.4 C13H17N2O3 
requires MH
+
, 249.1239. 
 
4-Methyl-benzoic acid N-methyl-hydrazide, 48 
209
 
 
A solution of p-toluoyl chloride (661 μL, 5.0 mmol) in CH2Cl2 (33 mL) was added to a 
solution of methylhydrazine (2.66 mL, 50 mmol) in CH2Cl2 (33 mL) at 0 °C over 1.5 h, and 
the resulting solution stirred at 0 °C for 30 min and at r.t. for a further 1.5 h. The reaction 
mixture was poured into sat. aq. NaHCO3 (50 mL), and the aqueous layer extracted with 
CH2Cl2 (3 × 50 mL). The combined organic layers were dried (Na2SO4) and the solvent 
removed in vacuo. Column chromatography eluting with MeOH:EtOAc (0:1 → 5:95) 
afforded the title compound as a colourless oil which solidified on storage at -20 °C (824 mg, 
100%), Rf 0.60 (EtOAc); δH (400 MHz, CDCl3) 7.33 (2H, d, J 6.6, Ar 2-H, 6-H), 7.16 (2H, d, 
7.9, Ar 3-H, 5-H), 4.34 (2H, br s, NH2), 3.18 (3H, s, NCH3), 2.33 (3H, s, ArCH3); m/z (ES) 
331 (4%), 228 (4), 166 (6), 165 (MH
+
, 100). Found: MH
+
, 165.1020. C9H13N2O requires MH
+
, 
165.1028. Data is in agreement with the literature.
209
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(S)-Pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester, 52 
210
 
 
To a stirred solution of L-proline (10.0 g, 86.9 mmol) in a mixture of 1 M NaOH (85 mL), 
dioxane (80 mL) and H2O (40 mL) at 0 °C was added di-tert-butyl dicarbonate (19.0 g, 86.9 
mmol). The reaction mixture was stirred for 30 min at 0 °C and 2 h at r.t. before the dioxane 
was removed in vacuo. The remaining aqueous solution was washed with CH2Cl2 (2 × 50 mL), 
acidified to pH 3 with citric acid, and extracted with EtOAc (3 × 100 mL). The combined 
organic layers were dried (MgSO4) and the solvent removed in vacuo to give a white 
crystalline powder. Recrystallised from EtOAc/petrol afforded the title compound as white 
crystals (14.0 g, 75%), mp 129-130 °C; δH (400 MHz, CDCl3) (mixture of rotamers) 8.70 (1H, 
br s, OH), 4.36-4.16 (1H, m, CHCO), 3.69-3.18 (2H, m, CH2N), 2.37-1.74 (4H, m, 
CH2CH2CH), 1.44 (4.7H, s, C(CH3)3), 1.39 (4.3H, s, C(CH3)3); m/z (ES) 510 (85%), 341 (38), 
336 (100), 279 (68), 238 (MNa
+
, 39). Found: MNa
+
, 238.1067. C10H17N2O4Na requires MNa
+
, 
238.1055. Data is in agreement with the literature.
210
 
 
(S)-2-Methyl-hexahydro-pyrrolo[1,2-a]pyrazine-1,4-dione, 54 
211
 
 
To a stirred suspension of N-Boc L-proline 52 (5.00 g, 23.3 mmol), sarcosine methyl ester 
hydrochloride (3.25 g, 23.3 mmol), and NaHCO3 (5.86 g, 69.8 mmol) in CH2Cl2 (60 mL) at 
0 °C was added EDC (4.68 g, 24.4 mmol). The reaction mixture was stirred for 18 h at r.t. 
before the addition of 1 M HCl (30 mL). The aqueous layer was then extracted with 30 mL 
CH2Cl2 before being basified with 30 mL 20% aq. NaHCO3 and extracted with CH2Cl2 (3 × 
30 mL). The combined organic layers were dried (MgSO4) and the solvent removed in vacuo. 
Partial purification by column chromatography eluting with EtOAc afforded crude dipeptide 
53 (4.53 g), which was used directly in the subsequent ring-closure. 
 
According to the method of Nitecki,
212
 dipeptide 53 (4.12 g, 13.8 mmol) was dissolved in 
formic acid (100 mL) and stirred for 4 h at r.t. The solvent was removed in vacuo and the 
residue dissolved in a mixture of isobutanol (75 mL) and PhMe (25 mL). The solution was 
heated to 110 °C in an open flask for 3 h, removing any remaining formic acid and effecting 
cyclisation. The solvent was removed in vacuo and purification by column chromatography 
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eluting with MeOH/EtOAc (0:1 → 1:9) afforded the title compound as a white gum (2.15 g, 
60% over 2 steps), Rf 0.14 (EtOAc); δH (400 MHz, CDCl3) 4.08 (1H, d, J 16.7, CH3NCH2), 
4.04-3.94 (1H, m, NCH), 3.69 (1H, d, J 16.7, CH3NCH2), 3.58-3.47 (1H, m, CH2CH2N), 
3.47-3.38 (1H, m CH2CH2N), 2.89 (3H, s, CH3), 2.34-2.25 (1H, m, proline 3-H or 4-H), 1.99-
1.89 (2H, m, proline 3-H or 4-H), 1.86-1.77 (1H, m, proline 3-H or 4-H); m/z (ES) 335 (54%), 
319 (21), 251 (100), 206 (22), 169 (MH
+
, 57). Found: MH
+
, 169.0973. C8H13N2O2 requires 
MH
+
, 169.0977. Data is in agreement with the literature.
211
 
 
 
O-Diphenylphosphinyl hydroxylamine, 57 
213
 
 
According to the method of Armstrong,
213
 7.1 M NaOH (7.0 mL) was added to a stirred 
solution of hydroxylamine hydrochloride (3.96 g, 57.0 mmol) in H2O (8.5 mL). Dioxane (30 
mL) was added and the solution cooled to 0 °C. Diphenylphosphinyl chloride (5.00 g, 21.1 
mmol) in dioxane (25 mL) was added with vigorous stirring to give a white precipitate. After 
4 min, H2O (30 mL) was added and the slurry was filtered under vacuum, washing with cold 
H2O (30 mL). The white solid was dried in vacuo for 3 h, then purified by stirring as a slurry 
with 0.25 M NaOH (50 mL) at 0 °C for 30 min. The product was filtered under vacuum, 
washing with cold H2O (30 mL), then dried in vacuo for 7 d to give the title compound as a 
white powdery solid (1.90 g, 39%, ca. 90% purity), mp >150 (decomp.); δH (400 MHz, CDCl3) 
7.88-7.81 (4H, m, Ar-H), 7.57-7.53 (2H, m, Ar-H), 7.50-7.44 (4H, m, Ar-H), 1.74 (2H, br s, 
NH2). Data is in agreement with the literature.
213
 
 
N-Boc DL-serine, 58 
214
  
 
Boc2O (2.49 g, 11.4 mmol) was added to a stirred solution of DL-serine (1.00 g, 9.50 mmol) 
in 2:1 1 M NaOH/dioxane (30 mL) at 0 °C and stirred at r.t. overnight. The dioxane was 
removed in vacuo and the resulting aqueous solution was washed with Et2O (2  40 mL). 
EtOAc (40 mL) was added followed by acidification with 1 M HCl to pH 2 whilst stirring. 
NaCl was added to the aqueous layer, which was then extracted with EtOAc (3  40 mL), 
dried (MgSO4), filtered and the solvent removed in vacuo to give the title compound as a 
colourless viscous oil (1.80 g, 92%, ca. 75% purity), δH (400 MHz, CDCl3) 5.86 (1H, br d, J 
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7.5, NH), 4.36 (1H, br s, CHNH), 4.09-4.00 (1H, m, CHHOH), 3.90-3.81 (1H, m, CHHOH), 
1.44 (9H, s, C(CH3)3); m/z (ES
-
) 272 (100%), 204 (M
-
, 94), 174 (20), 130 (38). Found: M
-
, 
204.0865. C8H14NO5 requires M
-
, 204.0872. Data is in agreement with the literature.
214
 
 
tert-Butyl α-amino(diethylphosphono)acetate, 56 215 
 
tert-Butyl diethyethylphosphonoacetate (260 μL, 1.12 mmol) was added dropwise to a stirred 
suspension of NaH (48 mg, 60% dispersion in mineral oil, 1.24 mmol) in THF (5 mL) at 0 °C 
and stirred for 30 min to give a clear solution. The solution was transferred by cannula to a 
stirred suspension of DPPONH2 (57) (220 mg, 90% purity, 0.85 mmol) in THF (5 mL) at -
78 °C. The reaction mixture was stirred for 2 h at -78 °C and 16 h at r.t. CH2Cl2 (25 mL) was 
added and the solution was extracted with 20% aq. p-TsOH (3  20 mL). The combined 
aqueous extracts were basified with NaHCO3, extracted with CH2Cl2 (3  50 mL), dried 
(MgSO4) and the solvent removed in vacuo to give the title compound as a colourless oil (160 
mg, 70%), δH (400 MHz, CDCl3) 4.21-4.12 (4H, m, 2  OCH2), 3.81 (1H, d, J 19.9, CHNH2), 
1.84 (2H, br s, NH2), 1.48 (9H, s, C(CH3)3), 1.36-1.30 (6H, m, CH2CH3); δP[
1
H] (162 MHz, 
CDCl3) 20.48; m/z (ES) 557 (100%), 268 (MH
+
, 27). Found: MH
+
, 268.1325. C10H23NO5P 
requires MH
+
, 268.1314. Data is in agreement with the literature.
215
 
 
tert-Butyl (2-tert-butoxycarbonylamino-3-hydroxy-propionylamino)-(diethoxy-
phosphoryl)-acetate, 59 
 
To a solution of amine 56 (64 mg, 0.24 mmol) and carboxylic acid 58 (60 mg, 0.29 mmol) in 
3:1 CH2Cl2/DMF (4 mL) at 0 °C was added NaHCO3 (24 mg, 0.29 mmol), HOBt (46 mg, 
0.34 mmol) and EDC (65 mg, 0.34 mmol). The reaction mixture was stirred for 16 h at r.t., 
whereupon H2O (5 mL) was added. The aqueous layer was extracted with EtOAc (3  10 mL). 
The organic extracts were extracted with H2O (20 mL) and brine (20 mL), dried (Na2SO4) and 
the solvent removed in vacuo to give a colourless oil. Partial purification by column 
chromatography eluting with MeOH/EtOAc (0:1 → 5:95) afforded the title compound as a 
colourless oil (90 mg, 83%, ca. 90% purity), Rf 0.35 (EtOAc); δH (400 MHz, CDCl3) 7.22-
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7.03 (1H, m, NH), 5.61-5.47 (1H, m, NH), 5.05 (1H, dd, J 21.1, 9.0, PCH), 4.30-3.98 (6H, m, 
2  CH2O, CH2OH), 3.70-3.62 (1H, m, CHCH2OH), 1.49 (9H, s, C(CH3)3), 1.45 (9H, d, J 4.7, 
C(CH3)3), 1.38-1.30 (6H, m, 2  CH2CH3); δP (162 MHz, CDCl3) 17.2; m/z (ES) 539 (9%), 
477 (MNa
+
, 100), 455 (MH
+
, 8), 343 (9). Found: MH
+
, 455.2152. C18H36N2O9P requires MH
+
, 
455.2158.  
 
Methyl (2-tert-butoxycarbonylamino-3-hydroxy-propionylamino)-(diethoxy-
phosphoryl)-acetate, 62 
 
Methyl diethylphosphonoacetate (220 μL, 1.20 mmol) was added dropwise to a stirred 
suspension of NaH (52 mg, 60% dispersion in mineral oil, 1.30 mmol) in THF (5 mL) at 0 °C 
and stirred for 30 min to give a clear solution. The solution was transferred by cannula to a 
stirred suspension of DPPONH2 (230 mg, 90% purity, 0.90 mmol) in THF (5 mL) at -78 °C. 
The reaction mixture was stirred for 2 h at -78 °C and 16 h at r.t. CH2Cl2 (25 mL) was added 
and the solution was extracted with sat. aq. p-TsOH (3  20 mL). The combined aqueous 
extracts were basified with NaHCO3, extracted with CH2Cl2 (3  50 mL), dried (MgSO4) and 
the solvent removed in vacuo to give amine 61 which was used directly without further 
purification. 
 
To a solution of amine 61 (130 mg, 0.59 mmol) and carboxylic acid 58 (150 mg, 0.71 mmol) 
in 3:1 CH2Cl2/DMF (9 mL) at 0 °C was added NaHCO3 (70 mg, 0.83 mmol), HOBt (0.11 g, 
0.83 mmol) and EDC (160 mg, 0.83 mmol). The reaction mixture was stirred for 16 h at r.t., 
whereupon H2O (15 mL) was added. The aqueous layer was extracted with EtOAc (3  20 
mL), the organic extracts were extracted with H2O (40 mL) and brine (40 mL), dried (Na2SO4) 
and the solvent removed in vacuo to give a colourless oil. Partial purification by column 
chromatography eluting with MeOH/EtOAc (0:1 to 5:95) afforded the title compound as a 
colourless oil (150 mg, ca. 95% purity, 40% over 2 steps), Rf 0.20 (EtOAc); δH (400 MHz, 
CDCl3) 7.34 (1H, br s, NH), 5.57 (1H, br s, NH), 5.16 (1H, dd, J 21.7, 8.9, PCH), 4.30-4.00 
(6H, m, 2  CH2O, CH2OH), 3.81 (3H, s, OCH3), 3.71-3.65 (1H, m, CHCH2OH), 1.46 (4.5H, 
s, C(CH3)3), 1.45 (4.5H, s, C(CH3)3), 1.38-1.29 (6H, m, 2  CH2CH3). 
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1,4-Diacetyl-piperazine-2,5-dione, 67 
216
  
 
According to the method of Shawe,
216
 a stirred suspension of glycine anhydride (25.0 g, 0.22 
mol) in Ac2O (130 mL) was heated to reflux for 7 h. The solvent from the resulting brown 
solution was removed in vacuo and recrystallisation twice from EtOAc/hexane afforded the 
title compound as off-white amorphous crystals (37.5 g, 86%), mp 100-102 °C; δH (400 MHz, 
CDCl3) 4.61 (4H, s, 2  NCH2), 2.60 (6H, s, 2  CH3); δC (101 MHz, CDCl3) 170.8, 165.9, 
47.2, 26.8; m/z (CI) 217 (12%), 216 (MNH4
+
, 100), 174 (5), 77 (4), 52 (96). Found: MNH4
+
, 
216.0988. C8H14N3O4 requires MNH4
+
, 216.0984. Data is in agreement with the literature.
216
 
 
General procedure for synthesis of 1-acetyl-3-arylidene-piperazine-2,5-diones 
 
According to the method of Gallina,
106
 to a stirred solution of diacetyl-piperazine-2,5-dione 
67 (1 eq.) and aldehyde (2 eq.) in CH2Cl2 at 0 °C was added a solution of KO
t
Bu (1 eq.) in 
t
BuOH. The reaction mixture was stirred at r.t. for 16 h and the resulting precipitate was 
isolated by filtration and washed with cold EtOAc. 
 
N-Phenyl-N'-[1-phenyl-eth-(E)-ylidene]-hydrazine, 69 
217
 
 
According to the method of Rathelot,
217
 a solution of phenylhydrazine (550 μL, 5.59 mmol), 
acetophenone (711 μL, 6.10 mmol) and glacial acetic acid (0.25 mL) in EtOH (25 mL) was 
stirred at reflux for 6 h. The solvent was removed in vacuo and the resulting residue was 
triturated with petrol to give the title compound as a white powder (1.17 g, 99%), mp 102-
103 °C; δH (400 MHz, CDCl3) 7.93-7.86 (2H, m, Ar-H), 7.52-7.44 (2H, m, Ar-H), 7.44-7.36 
(3H, m, Ar-H), 7.32-7.26 (2H, m, Ar-H), 7.03-6.95 (1H, m, Ar-H), 2.27 (3H, s, CH3); m/z (ES) 
313 (5%), 212 (16), 211 (MH
+
, 100), 209 (3), 133 (2). Found: MH
+
, 211.1241. C14H15N2 
requires MH
+
, 211.1235. Data is in agreement with the literature.
217
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1,3-Diphenyl-1H-pyrazole-4-carbaldehyde, 70 
218
 
 
According to the method of Rathelot,
217
 POCl3 (666 μL, 7.14 mmol) was added dropwise to 
DMF (553 μL, 7.14 mmol) at 0 °C. The reaction mixture was stirred for 20 min to give a 
white solid. A solution of hydrazone 69 (500 mg, 2.38 mmol) in DMF (3 mL) was added 
dropwise at 0 °C and the reaction mixture was stirred at r.t. for 30 min to give a clear solution. 
The reaction was then heated to reflux for 5 h before being cooled to r.t. Sat. aq. K2CO3 (8 mL) 
was added to give a suspension which was isolated by filtration, washing with cold H2O. The 
crude product was then dissolved in CH2Cl2, filtered to remove impurities and the solvent was 
removed in vacuo. Recrystallisation of the resulting solid from EtOH afforded the title 
compound as off-white amorphous crystals (427 mg, 72%), mp 146-147 °C; δH (400 MHz, 
CDCl3) 10.07 (1H, s, CHO), 8.58 (1H, s, pyrazole-H), 7.90-7.80 (4H, m, Ar-H), 7.59-7.50 
(5H, m, Ar-H), 7.46-7.40 (1H, m, Ar-H); m/z (ES) 250 (16%), 249 (MH
+
, 100), 227 (4), 218 
(4), 206 (3). Found: MH
+
, 249.1031. C16H13N2O requires MH
+
, 249.1028. Data is in 
agreement with the literature.
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General procedure for synthesis of 3-arylidene-piperazine-2,5-diones 
 
To a stirred suspension of 1-acetyl-3-arylidene-piperazine-2,5-dione 68 in DMF (ca. 0.5 M) at 
r.t. was added dropwise hydrazine hydrate (4 eq.). The reaction mixture was stirred for 2.5 h 
before being poured onto an amount of ice approximately twice the volume of the reaction 
solvent. The precipitate was isolated by filtration and washed with cold H2O and EtOAc.  
 
General procedure for synthesis of 1,4-dimethyl 3-arylidene piperazine-2,5-diones  
 
To a stirred suspension of 3-arylidene-piperazine-2,5-dione (1 eq.) and K2CO3 (4 eq.) in DMF 
(ca. 0.1 M) at r.t. was added dropwise MeI (4 eq.). The reaction mixture was stirred for 16 h 
- 154 - 
 
before being partitioned between EtOAc and 20% brine/H2O. The organic layer was 
extensively extracted with 20% brine/H2O to remove the DMF. The combined aqueous layers 
were then re-extracted with a small volume of EtOAc. The combined organic layers were 
dried (MgSO4) and the solvent removed in vacuo. The crude product was purified by column 
chromatography.  
 
1,4-Dimethyl-3-[1-phenyl-meth-(Z)-ylidene]-piperazine-2,5-dione, 71a 
219
 
 
Colourless oil (500 mg, 52% over 3 steps), Rf 0.56 (EtOAc); δH (400 MHz, CDCl3) 7.45-7.18 
(6H, m, 5  Ar-H, C=CH), 4.12 (2H, s, CH2CO), 3.10 (3H, s, CH3), 2.89 (3H, s, CH3); m/z 
(ES) 308 (52%), 231 (MH
+
, 100), 217 (30), 208 (18), 197 (20). Found: MH
+
, 231.1138. 
C13H15N2O2 requires MH
+
, 231.1134. Data is in agreement with the literature.
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3-[1-(4-Methoxy-phenyl)-meth-(Z)-ylidene]-1,4-dimethyl-piperazine-2,5-dione, 71g 
 
White semi-solid (190 mg, 29% over 3 steps), Rf 0.25 (CH2Cl2); υmax (CHCl3)/cm
-1
 1680, 
1624, 1607, 1513, 1370, 1248, 1165, 911, 723; δH (400 MHz, CDCl3) 7.16 (2H, d, J 8.6, Ar-
H), 7.10 (1H, s, C=CH), 6.85-6.80 (2H, d, J 8.6, Ar-H), 4.02 (2H, s, CH2CO), 3.75 (3H, s, 
OCH3), 2.99 (3H, s, NCH3), 2.84 (3H, s, NCH3); δC (101 MHz, CDCl3) 165.0, 162.8, 159.8, 
131.0, 130.2, 125.8, 121.7, 113.8, 55.3, 52.4, 34.8, 34.0; m/z (ES) 427 (35%), 262 (15), 261 
(MH
+
, 100), 232 (35), 211 (19). Found: MH
+
, 261.1248. C14H17N2O3 requires MH
+
, 261.1239. 
 
1,4-Dimethyl-3-[1-naphthalen-2-yl-meth-(Z)-ylidene]-piperazine-2,5-dione, 71h  
 
Pale orange gum (282 mg, 54% over 3 steps), Rf 0.42 (MeOH/CH2Cl2 5:95); υmax 
(CHCl3)/cm
-1
 1683, 1621, 1370, 1339, 1266, 733; δH (400 MHz, CDCl3) 7.78-7.73 (3H, m, 
Ar-H), 7.67 (1H, s, C=CH), 7.47-7.40 (2H, m, Ar-H), 7.37 (2H, m, Ar-H), 4.07 (2H, s, 
CH2CO), 3.03 (3H, s, CH3), 2.84 (3H, s, CH3); δC (101 MHz, CDCl3) 164.8, 162.4, 133.0, 
132.9, 131.8, 131.2, 129.1, 128.1, 128.1, 127.7, 126.9, 126.8, 126.6, 121.8, 52.4, 35.2, 34.2; 
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m/z (ES) 447 (22%), 282 (20), 281 (MH
+
, 100), 242 (33), 222 (21). Found: MH
+
, 281.1298. 
C17H17N2O2 requires MH
+
, 281.1290. 
 
3-[1-(2-Methoxy-phenyl)-meth-(Z)-ylidene]-1,4-dimethyl-piperazine-2,5-dione, 71q 
 
Colourless oil (187 mg, 28% over 3 steps), Rf 0.53 (MeOH/EtOAc 5:95); υmax (CHCl3)/cm
-1
 
1680, 1624, 1596, 1485, 1426, 1370, 1245, 1026, 727; δH (400 MHz, CDCl3) 7.34-7.28 (2H, 
m, Ar-H), 7.16 (1H, d, J 7.8, C=CH), 6.97-6.87 (2H, m, Ar-H), 4.10 (2H, s, CH2CO), 3.84 
(3H, s, OCH3), 3.08 (3H, s, NCH3), 2.82 (3H, s, NCH3); δC (101 MHz, CDCl3) 164.5, 162.4, 
157.3, 131.9, 130.4, 130.1, 122.9, 120.2, 117.7, 110.5, 55.5, 52.3, 34.2, 34.0; m/z (ES) 386 
(50%), 262 (8), 261 (MH
+
, 100), 247 (24), 232 (42). Found: MH
+
, 261.1237. C14H17N2O3 
requires MH
+
, 261.1239. 
 
3-[1-Cyclohexyl-meth-(Z)-ylidene]-1,4-dimethyl-piperazine-2,5-dione, 71v 
 
White gum (141 mg, 24% over 3 steps), Rf 0.53 (EtOAc); υmax (CHCl3)/cm
-1
 2929, 2852, 
1687, 1631, 1426, 1384, 1314, 991; δH (400 MHz, CDCl3) 6.04 (1H, d, J 6.0, C=CH), 3.95 
(2H, s, CH2CO), 3.25 (3H, s, NCH3), 2.99 (3H, s, NCH3), 2.46-2.34 (1H, m, C=CCH), 1.80-
1.73 (2H, m, Cy-H), 1.73-1.65 (3H, m, Cy-H), 1.34-1.16 (5H, m, Cy-H); δC (101 MHz, 
CDCl3) 164.5, 163.0, 131.1, 130.5, 52.3, 37.0, 35.0, 33.9, 32.8, 25.7, 25.5; m/z (ES) 403 
(50%), 314 (72), 240 (42), 237 (MH
+
, 100), 220 (51). Found: MH
+
, 237.1611. C13H21N2O2 
requires MH
+
, 237.1603. 
 
3-[1-(1,3-Diphenyl-1H-pyrazol-4-yl)-meth-(Z)-ylidene]-1,4-dimethyl-piperazine-2,5-
dione, 71w 
 
White gum (120 mg, 40% over 3 steps), Rf 0.33 (MeOH/CH2Cl2 2:98); υmax (CHCl3)/cm
-1
 
1684, 1632, 1598, 1502, 1370, 1268, 758, 695; δH (400 MHz, CDCl3) 7.90 (1H, s, pyrazole-
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H), 7.76-7.71 (4H, m, Ar-H), 7.49-7.37 (5H, m, Ar-H), 7.31 (1H, t, J 7.4, Ar-H), 7.20 (1H, s, 
C=CH), 3.96 (2H, s, CH2CO), 3.03 (3H, s, NCH3), 2.95 (3H, s, CH3N); δC (101 MHz, CDCl3) 
164.5, 162.4, 152.6, 139.4, 132.3, 131.7, 129.6, 128.7, 128.6, 127.9, 127.8, 127.1, 119.1, 
114.4, 112.7, 52.3, 34.2, 34.0; m/z (ES) 498 (6%), 389 (5), 374 (22), 373 (MH
+
, 100), 309 (6). 
Found: MH
+
, 373.1668. C22H21N4O2 requires MH
+
, 373.1665. 
 
2,4-Dibromo-thiazole, 94 
220
 
 
Adapted from the method of Amb,
150
 bromine (18.9 mL, 369 mmol) was added slowly to 
stirred PBr3 (34.7 mL, 369 mmol) cooled in a water bath to give a yellow solid. P2O5 (17.5 g, 
123 mmol) was added and the solids thoroughly mixed with a spatula under N2. The reaction 
was then heated to 100 °C for 3 h to give a black oil, before being cooled to r.t. to give a black 
solid. Thiazolidine-2,4-dione (17.9 g, 154 mmol) was added, and the solids mixed thoroughly 
with a spatula under N2. The reaction mixture was then heated to 170 °C for 2.5 h before 
being cooled to r.t. and placed in a water bath. MeOH (200 mL) was then added very slowly 
down the condenser, resulting in a large volume of HBr gas, which was piped through a 
Dreschel bottle into a large container of sat. aq. Na2CO3. After 15 min stirring, the suspension 
was decanted into a large conical flask and neutralised by the addition of solid Na2CO3. The 
resulting suspension was partitioned between H2O (200 mL) and Et2O (200 mL), and the 
aqueous layer extracted with Et2O (4  200 mL). The combined organic layers were dried 
(MgSO4) and the solvent removed in vacuo. Recrystallisation from hexane afforded the title 
compound as pale brown crystals (11.3 g). The remaining oil was purified by column 
chromatography eluting with Et2O/petrol (0:1 → 5:95) to give the title compound as white 
rods (6.57 g, total yield 17.9 g, 48%), mp 78-81 °C; Rf 0.30 (Et2O/petrol 5:95); δH (400 MHz, 
CDCl3) 7.19 (1H, s, thiazole-H); δC (101 MHz, CDCl3) 136.5, 124.4, 121.0; m/z (CI) 407 
(15%), 405 (14), 246 (MH
+
, 51), 244 (MH
+
, 100), 242 (MH
+
, 49). Found MH
+
, 241.8276. 
C3H2NBr2S requires 241.8275. Data is in agreement with the literature.
220
 
 
4-Bromo-2-(4-methoxy-phenyl)-thiazole, 93 
221
  
 
A suspension of dibromothiazole 94 (122 mg, 0.50 mmol), 4-methoxyphenylboronic acid (91 
mg, 0.60 mmol), K2CO3 (173 mg, 1.25 mmol) and Pd(PPh3)4 (17 mg, 0.015 mmol) in 
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DME/H2O (4:1, 3 mL) was stirred at reflux for 72 h. The reaction was then partitioned 
between H2O (20 mL) and EtOAc (20 mL), the aqueous layer was extracted with EtOAc (3 × 
20 mL) and the combined organic layers washed with brine (50 mL) and dried (Na2SO4). The 
solvent was removed in vacuo and purification by column chromatography eluting with 
Et2O/petrol (1:9 → 1:3) afforded the title compound as off-white rods (114 mg, 84%), mp 70-
73 °C; Rf 0.68 (Et2O/petrol 1:1); υmax (neat)/cm
-1
 3116, 1600, 1520, 1464, 1259; δH (400 MHz, 
CDCl3) 7.87-7.80 (2H, m, Ar-H), 7.10 (1H, s, thiazole-H), 6.94-9.88 (2H, m, Ar-H), 3.82 (3H, 
s, CH3); δC (101 MHz, CDCl3) 169.1, 161.8, 128.1, 125.8, 125.6, 115.6, 114.5, 55.6; m/z (CI) 
295 (49%), 272 (MH
+
, 98), 271 (35), 270 (MH
+
, 100), 192 (26). Found MH
+
, 269.9588. 
C10H9NOBrS requires 269.9588. Data is in agreement with the literature.
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4-Bromo-2-phenyl-thiazole, 96 
149
  
 
A suspension of dibromothiazole 94 (500 mg, 2.1 mmol), phenylboronic acid (276 mg, 2.3 
mmol), K2CO3 (710 mg, 5.1 mmol) and Pd(PPh3)4 (71 mg, 0.06 mmol) in DME/H2O (4:1, 15 
mL) was stirred at reflux for 15 h. The reaction was then partitioned between H2O (30 mL) 
and EtOAc (30 mL). The aqueous layer was extracted with EtOAc (3 × 30 mL) and the 
combined organic layers washed with brine (60 mL) and dried (Na2SO4). The solvent was 
removed in vacuo and purification by column chromatography eluting with Et2O/petrol (1:4) 
afforded the title compound as an off-white solid (355 mg, 72%), mp 73-75 °C; Rf 0.63 
(EtOAc/petrol 1:4); δH (400 MHz, CDCl3) 7.99-7.95 (2H, m, Ar-H), 7.50-7.46 (3H, m, Ar-H), 
7.25 (1H, s, thiazole-H); m/z (CI) 243 (22%), 242 (MH
+
, 100), 241 (34), 240 (MH
+
, 98). 
Found MH
+
, 239.9477. C9H7NBrS requires 239.9483. Data is in agreement with the 
literature.
149
 
 
5-Bromo-2-phenyl-thiazole, 98 
149
 
 
A suspension of 2,5-dibromothiazole (485 mg, 1.9 mmol), phenylboronic acid (276 mg, 2.3 
mmol), K2CO3 (710 mg, 5.1 mmol) and Pd(PPh3)4 (71 mg, 0.06 mmol) in DME/H2O (4:1, 15 
mL) was stirred at reflux for 15 h. The reaction was then partitioned between H2O (30 mL) 
and EtOAc (30 mL). The aqueous layer was extracted with EtOAc (3 × 30 mL) and the 
combined organic layers washed with brine (60 mL) and dried (Na2SO4). The solvent was 
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removed in vacuo and purification by column chromatography eluting with Et2O/petrol (1:6) 
afforded the title compound as a white solid (347 mg, 70%), mp 79-81 °C; Rf 0.67 
(EtOAc/petrol 1:4); δH (400 MHz, CDCl3) 7.87-7.82 (2H, m, Ar-H), 7.72 (1H, s, thiazole-H), 
7.45-7.40 (3H, m, Ar-H); m/z (CI) 244 (51%), 242 (MH
+
, 100), 241 (32), 240 (MH
+
, 96). 
Found MH
+
, 239.9479. C9H7NBrS requires 239.9483. Data is in agreement with the 
literature.
149
 
 
Parallel Synthesis: General Procedure for Suzuki Couplings 
 
 
A solution of bromide 93 (27 mg, 100 μmol), boronic acid (120 μmol), K2CO3 (35 mg, 250 
μmol) and Pd(PPh3)4 (3.5 mg, 3 μmol) in DME/H2O (4:1, 0.5 mL) was heated (MW, 160 °C, 
20 min). Upon cooling, the reaction mixture was partitioned between H2O (5 mL) and CH2Cl2 
(10 mL), the organic layer separated, the solvent removed in vacuo and the product purified 
by HPLC under acidic conditions. 
 
4-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-pyridine, 99 (JCC-CRT-10) 
 
Light brown powder (2.0 mg, 7% yield, ca. 60% purity by 
1
H-NMR), δH (400 MHz, DMSO-
d6) 8.68-8.65 (2H, m, pyridine 2-H, 6-H), 8.45 (1H, s, thiazole-H), 8.02-7.97 (4H, m, pyridine 
3-H, 5-H, Ar 3-H, 5-H), 7.12-7.08 (2H, m, Ar 2-H, 6-H), 3.84 (3H, s, CH3). tR (HPLC) 2.60 
min. 
 
N-(4-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-phenyl)-acetamide, 100 
222
 (JCC-CRT-13) 
 
Light brown powder (2.0 mg, 6% yield, ca. 60% purity by 
1
H-NMR), δH (400 MHz, DMSO-
d6) 10.07 (1H, s, NH), 7.98-7.93 (5H, m, Ar-H, thiazole-H), 7.67 (2H, d, J 8.8, Ar-H), 7.08 
(2H, d, J 8.8, Ar-H), 3.84 (3H, s, OCH3), 2.06 (3H, s, COCH3). tR (HPLC) 3.65 min. 
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2-(4-Methoxy-phenyl)-4-(2-trifluoromethyl-phenyl)-thiazole, 101 (JCC-CRT-16) 
 
Orange gum (1.2 mg, 34% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
7.95-7.84 (3H, m, 2 × Ar-H, thiazole-H), 7.82-7.71 (3H, m, Ar-H), 7.66 (1H, br. t, J 7.4, Ar-
H), 7.10-7.04 (2H, m, Ar-H), 3.83 (3H, s, CH3). tR (HPLC) 4.13 min. 
 
N-(4-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-phenyl)-4-methyl-benzenesulfonamide, 102 
222
 
(JCC-CRT-17) 
 
Light brown gum (0.9 mg, 22% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.36 (1H, s, NH), 7.95-7.90 (3H, m, Ar-H, thiazole-H), 7.87 (2H, d, J 8.6, Ar-H), 7.67 (2H, 
d, J 8.3, Ar-H), 7.34 (2H, d, J 8.3, Ar-H), 7.17 (2H, d, J 8.6, Ar-H), 7.09-7.04 (2H, m, Ar-H), 
3.83 (3H, s, OCH3), 2.32 (3H, s, ArCH3). tR (HPLC) 4.05 min. 
 
6-Chloro-2-methoxy-3-[2-(4-methoxy-phenyl)-thiazol-4-yl]-phenol, 103 (JCC-CRT-22) 
 
Dark brown solid (1.0 mg, 29% yield, ca. 80% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
9.65 (1H, s, OH), 8.04 (1H, s, thiazole-H), 8.01-7.92 (2H, m, Ar-H), 7.65 (1H, d, J 1.9, Ar-H), 
7.57 (1H, d, J 1.9, Ar-H), 7.11-7.03 (2H, m, Ar-H), 3.93 (3H, s, CH3), 3.83 (3H, s, CH3). tR 
(HPLC) 4.05 min. 
 
2-(4-Methoxy-phenyl)-4-(4-pyrazol-1-ylmethyl-phenyl)-thiazole, 104 (JCC-CRT-23) 
 
Light brown gum (0.6 mg, 18% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
8.29 (1H, s, pyrazole-H), 7.95 (1H, s, thiazole-H), 7.93-7.89 (2H, m, Ar-H), 7.66 (1H, s, 
pyrazole-H), 7.39-7.25 (5H, m, pyrazole-H, 4 × Ar-H), 7.09-7.03 (2H, m, Ar-H), 5.38 (2H, s, 
CH2), 3.82 (3H, s, CH3). tR (HPLC) 3.85 min. 
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2-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-pyrrole-1-carboxylic acid tert-butyl ester, 105 
(JCC-CRT-24) 
 
Brown solid (1.4 mg, 5% yield, ca. 80% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 11.33 
(1H, s, NH), 7.98-7.91 (2H, m, Ar-H), 7.54 (1H, s, thiazole-H), 7.10-7.05 (2H, m, Ar-H), 6.83 
(1H, d, J 1.9, pyrrole-H), 6.56 (1H, m, pyrrole-H), 6.11 (1H, dd, J 5.7, 1.9, pyrrole-H), 3.83 
(3H, s, CH3). tR (HPLC) 4.14 min. 
 
N-(3-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-phenyl)-acetamide, 106 (JCC-CRT-27) 
 
Light brown gum (2.7 mg, 8% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.08 (1H, s, NH), 8.21 (1H, s, thiazole-H), 7.99 (1H, s, Ar-H), 7.98-7.94 (2H, m, Ar-H), 7.66 
(2H, dd, J 8.0, 1.8, Ar-H), 7.37 (1H, t, J 7.9, Ar-H), 7.10 (2H, d, J 8.9, Ar-H), 3.84 (3H, s, 
OCH3), 2.07 (3H, s, COCH3). tR (HPLC) 3.64 min. 
 
N-Ethyl-4-[2-(4-methoxy-phenyl)-thiazol-4-yl]-benzenesulfonamide, 107 (JCC-CRT-29) 
 
Off-white powder (6.0 mg, 16% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
8.30 (1H, s, thiazole-H), 8.24 (2H, d, J 8.5, Ar-H), 7.99 (2H, d, J 8.5, Ar-H), 7.87 (2H, d, J 
8.5, Ar-H), 7.61 (1H, t, J 5.7, NH), 7.10 (2H, d, J 8.5, Ar-H), 3.84 (3H, s, OCH3), 2.86-2.76 
(2H, m, CH2), 0.98 (3H, t, J 7.3, CH2CH3). tR (HPLC) 3.69 min. 
 
3-Fluoro-4-[2-(4-methoxy-phenyl)-thiazol-4-yl]-phenylamine, 108 (JCC-CRT-30) 
 
Light brown powder (9.9 mg, 33% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-
d6) 7.96-7.91 (2H, m, Ar-H), 7.79 (1H, d, J 2.4, thiazole-H), 7.65 (1H, dd, J 12.9, 1.7, Ar-H), 
7.58 (1H, dd, J 8.3, 1.8, Ar-H), 7.09-7.03 (2H, m, Ar-H), 6.82 (1H, dd, J 9.2, 8.5, Ar-H), 5.38 
(2H, s, NH2), 3.83 (3H, s, CH3). tR (HPLC) 3.72 min. 
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4-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-pyridine, 109 (JCC-CRT-31) 
 
Off-white solid (2.3 mg, 8% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
8.52 (1H, d, J 5.2, pyridine-H), 8.40 (1H, s, thiazole-H), 8.02-7.95 (2H, m, Ar-H), 7.88 (1H, s, 
pyridine-H), 7.78 (1H, d, J 5.2, pyridine-H), 7.12-7.06 (2H, m, Ar-H), 3.84 (3H, s, OCH3), 
2.55 (3H, s, ArCH3). tR (HPLC) 4.05 min. 
 
N-(2-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-phenyl)-methanesulfonamide, 110 (JCC-CRT-
32) 
 
Light brown solid (1.6 mg, 4% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
8.29 (1H, s, NH), 8.00-7.94 (3H, m, thiazole-H, 2 × Ar-H), 7.56 (2H, d, J 7.5, Ar-H), 7.42 
(1H, t, J 7.1, Ar-H), 7.23 (1H, t, J 7.5, Ar-H), 7.12 (2H, d, J 8.8, Ar-H), 3.85 (3H, s, OCH3), 
3.06 (3H, s, SO2CH3). tR (HPLC) 3.74 min. 
 
3-Fluoro-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-pyridine, 111 (JCC-CRT-34) 
 
Light brown powder (0.9 mg, 3% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-
d6) 9.15 (1H, s, pyridine-H), 8.58 (1H, d, J 2.7, pyridine-H), 8.38 (1H, s, thiazole-H), 8.33-
8.28 (1H, m, pyridine-H), 8.04-7.98 (2H, m, Ar-H), 7.10 (2H, d, J 8.9, Ar-H), 3.84 (3H, s, 
CH3). tR (HPLC) 3.87 min. 
 
4-(2-Methanesulfonyl-phenyl)-2-(4-methoxy-phenyl)-thiazole, 112 (JCC-CRT-35) 
 
Light brown powder (2.1 mg, 6% yield, ca. 60% purity by 
1
H-NMR), δH (400 MHz, DMSO-
d6) 8.11 (1H, d, J 6.8, Ar-H), 7.89 (2H, d, J 8.8, Ar-H), 7.76-7.72 (1H, m, Ar-H), 7.70 (1H, d, 
J 7.4, Ar-H), 7.11-7.06 (2H, m, Ar-H), 3.83 (3H, s, OCH3), 3.52 (3H, s, SO2CH3). tR (HPLC) 
3.30 min. 
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4-(3-Methanesulfonyl-phenyl)-2-(4-methoxy-phenyl)-thiazole, 113 (JCC-CRT-51) 
 
Off-white powder (14.4 mg, 42% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-
d6) 8.55 (1H, t, J 1.6, Ar-H), 8.38 (1H, dt, J 8.1, 1.1, Ar-H), 8.34 (1H, s, thiazole-H), 7.99 (2H, 
d, J 8.8, Ar-H), 7.92 (1H, dt, J 8.0, 1.1, Ar-H), 7.76 (1H, t, J 7.8, Ar-H), 7.10 (2H, d, J 8.8, 
Ar-H), 3.84 (3H, d, J 3.3, OCH3), 3.30 (3H, s, SO2CH3). tR (HPLC) 3.59 min. 
 
1-(3-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-benzyl)-piperidine, 114 (JCC-CRT-54) 
 
Light brown gum (16.0 mg, 44% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
8.19 (1H, s, thiazole-H), 8.06 (1H, s, Ar-H), 7.98-7.95 (2H, m, Ar-H), 7.91 (1H, d, J 7.8, Ar-
H), 7.42 (1H, t, J 7.6, Ar-H), 7.30 (1H, d, J 7.6, Ar-H), 7.12-7.05 (2H, m, Ar-H), 3.84 (3H, s, 
CH3), 3.55 (2H, s, NCH2Ar), 2.45-2.37 (4H, m, 2 × NCH2CH2), 1.57-1.48 (4H, m, 2 × 
NCH2CH2), 1.44-1.36 (2H, m, NCH2CH2CH2). tR (HPLC) 2.25 min. 
 
4-(3-Isopropoxy-4-methoxy-phenyl)-2-(4-methoxy-phenyl)-thiazole, 115 (JCC-CRT-55) 
 
Brown oil (8.0 mg, 22% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 7.97-
7.92 (3H, m, thiazole-H, Ar-H), 7.62-7.57 (2H, m, Ar-H), 7.10-7.02 (3H, m, Ar-H), 4.66 (1H, 
hept, J 6.0, CH(CH3)2), 3.83 (3H, s, OCH3), 3.80 (3H, s, OCH3), 1.29 (6H, d, J 6.1, 
CH(CH3)2). tR (HPLC) 4.51 min. 
 
5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-1H-indole, 116 (JCC-CRT-56) 
 
Light brown powder (14.7 mg, 48% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, 
DMSO-d6) 11.18 (1H, s, NH), 8.26 (1H, s, thiazole-H), 8.01-7.95 (2H, m, Ar-H), 7.87 (1H, s, 
Ar-H), 7.78 (1H, dd, J 8.5, 1.6, Ar-H), 7.46 (1H, d, J 8.4, Ar-H), 7.40-7.36 (1H, m, Ar-H), 
7.12-7.06 (2H, m, Ar-H), 6.51 (1H, d, J 2.0, Ar-H), 3.84 (3H, s, CH3). tR (HPLC) 3.99 min. 
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N-Cyclopropyl-4-[2-(4-methoxy-phenyl)-thiazol-4-yl]-benzenesulfonamide, 117 (JCC-
CRT-57) 
 
Light brown powder (15.2 mg, 39% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, 
DMSO-d6) 8.30 (1H, s, thiazole-H), 8.29-8.24 (2H, m, Ar-H), 8.01-7.96 (2H, m, Ar-H), 7.94 
(1H, d, J 2.7, NH), 7.92-7.87 (2H, m, Ar-H), 7.12-7.07 (2H, m, Ar-H), 3.84 (3H, s, CH3), 
2.19-2.11 (1H, m, NCH), 0.52-0.46 (2H, m, CH2), 0.42-0.36 (2H, m, CH2). tR (HPLC) 3.82 
min. 
 
5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-pyrimidin-2-ylamine, 118 (JCC-CRT-59) 
 
White powder (7.1 mg, 25% yield, ca. 80% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
8.86 (2H, s, NH2), 7.97-7.93 (2H, m, Ar-H), 7.92 (1H, s, thiazole-H), 7.10-7.04 (2H, m, Ar-H), 
6.89 (2H, s, pyrimidine-H), 3.83 (3H, s, CH3). tR (HPLC) 3.30 min. 
 
4-(3-Fluoro-4-methyl-phenyl)-2-(4-methoxy-phenyl)-thiazole, 119 (JCC-CRT-60) 
 
Light brown powder (3.2 mg, 11% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-
d6) 8.13 (1H, s, thiazole-H), 8.01-7.94 (2H, m, Ar-H), 7.80 (1H, d, J 1.3, Ar-H), 7.78 (1H, s, 
Ar-H), 7.38 (1H, t, J 8.0, Ar-H), 7.11-7.05 (2H, m, Ar-H), 3.84 (3H, s, OCH3), 2.28 (3H, d, J 
1.3, ArCH3). tR (HPLC) 5.23 min. 
 
N-Benzyl-4-[2-(4-methoxy-phenyl)-thiazol-4-yl]-benzenesulfonamide, 120 (JCC-CRT-62) 
 
Off-white powder (6.8 mg, 16% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
8.30 (1H, s, thiazole-H), 8.25-8.17 (3H, m, NH, 2 × Ar-H), 8.02-7.97 (2H, m, Ar-H), 7.92-
7.87 (2H, m, Ar-H), 7.32-7.18 (5H, m, Ar-H), 7.14-7.06 (2H, m, Ar-H), 4.02 (2H, d, J 5.8, 
CH2), 3.85 (3H, s, CH3). tR (HPLC) 4.10 min. 
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 (5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-pyridin-2-yl)-dimethyl-amine, 121 (JCC-CRT-63) 
 
Yellow powder (6.5 mg, 21% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
8.76 (1H, d, J 2.4, pyridine-H), 8.09 (1H, dd, J 8.9, 2.4, pyridine-H), 7.98-7.92 (2H, m, Ar-H), 
7.83 (1H, s, thiazole-H), 7.12-7.04 (2H, m, Ar-H), 6.72 (1H, d, J 8.9, pyridine-H), 3.83 (3H, s, 
OCH3), 3.08 (6H, s, N(CH3)2). tR (HPLC) 2.44 min. 
 
2-(4-Methoxy-phenyl)-4-(1-phenyl-1H-pyrazol-3-yl)-thiazole, 122 (JCC-CRT-65) 
 
Light brown powder (12.0 mg, 36% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, 
DMSO-d6) 8.62 (1H, d, J 2.4, pyrazole-H), 8.49 (1H, t, J 1.8, ArH), 8.24 (1H, s, thiazole-H), 
8.04-7.94 (3H, m, Ar-H), 7.88-7.81 (1H, m, Ar-H), 7.80 (1H, d, J 1.6, Ar-H), 7.59 (1H, t, J 
7.9, Ar-H), 7.14-7.06 (2H, m, Ar-H), 6.59 (1H, dd, J 2.4, 1.7, pyrazole-H), 3.84 (3H, s, CH3). 
tR (HPLC) 4.23 min. 
 
3-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-benzoic acid ethyl ester, 123 (JCC-CRT-67) 
 
Off-white powder (5.8 mg, 17% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
8.60 (1H, t, J 1.6, Ar-H), 8.32-8.27 (1H, m, Ar-H), 8.24 (1H, s, thiazole-H), 8.02-7.93 (3H, m, 
Ar-H), 7.63 (1H, t, J 7.8, Ar-H), 7.15-7.05 (2H, m, Ar-H), 4.37 (2H, q, J 7.2, CH2), 3.84 (3H, 
s, OCH3), 1.36 (3H, t, J 7.1, CH2CH3). tR (HPLC) 4.86 min. 
 
4-(3-Fluoro-5-methoxy-phenyl)-2-(4-methoxy-phenyl)-thiazole, 124 (JCC-CRT-68) 
 
Off-white powder (8.7 mg, 28% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
8.22 (1H, s, thiazole-H), 8.01-7.94 (2H, m, Ar-H), 7.48-7.42 (2H, m, Ar-H), 7.12-7.04 (2H, m, 
Ar-H), 6.84 (1H, dt, J 10.8, 2.3, Ar-H), 3.85 (3H, s, CH3), 3.84 (3H, s, CH3). tR (HPLC) 4.83 
min. 
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(2-(4-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-phenoxy)-ethyl)-dimethyl-amine, 125 (JCC-
CRT-71) 
 
Off-white solid (7.4 mg, 21% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
8.18 (1H, s, thiazole-H), 7.99-7.92 (4H, m, Ar-H), 7.11-7.00 (4H, m, Ar-H), 4.12 (2H, t, J 5.7, 
OCH2), 3.83 (3H, s, OCH3), 2.71 (2H, t, J 5.8, NCH2), 2.28 (6H, s, N(CH3)2). tR (HPLC) 2.21 
min. 
 
4-(3-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-phenyl)-morpholine, 126 (JCC-CRT-72) 
 
Light brown powder (11.4 mg, 32% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, 
DMSO-d6) 8.07 (1H, s, thiazole-H), 8.01-7.93 (2H, m, Ar-H), 7.63-7.57 (1H, m, Ar-H), 7.48 
(1H, d, J 7.8. Ar-H), 7.31 (1H, t, J 8.0, Ar-H), 7.11-7.05 (2H, m, Ar-H), 6.95 (1H, dd, J 8.1, 
2.1, Ar-H), 3.83 (3H, s, CH3), 3.81-3.73 (4H, m, 2 × OCH2), 3.22-3.16 (4H, m, 2 × NCH2). tR 
(HPLC) 4.27 min. 
 
2-(4-Methoxy-phenyl)-4-[3-(2H-pyrazol-3-yl)-phenyl]-thiazole, 127 (JCC-CRT-73) 
 
Brown gum (11.3 mg, 34% yield, ca. 80% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
8.47 (1H, s, Ar-H), 8.16 (1H, s, thiazole-H), 8.04-7.93 (3H, m, Ar-H), 7.80 (2H, m, Ar-H), 
7.51 (1H, t, J 7.7, Ar-H), 7.16-7.07 (2H, m, Ar-H), 6.82 (1H, d, J 2.1, Ar-H), 3.84 (3H, s, 
CH3). tR (HPLC) 4.04 min. 
 
2-Chloro-3-[2-(4-methoxy-phenyl)-thiazol-4-yl]-4-methyl-pyridine, 128 (JCC-CRT-74) 
 
Off-white solid (14.1 mg, 44%, ca. 3:1 starting material/product), δH (400 MHz, DMSO-d6) 
8.34 (1H, d, J 5.0, pyridine-H), 7.91 (2H, d, J 8.8, Ar-H), 7.79 (1H, s, thiazole-H), 7.43 (1H, d, 
J 4.9, pyridine-H), 7.06 (2H, d, J 8.8, Ar-H), 3.83 (3H, s, OCH3), 2.20 (3H, s, ArCH3).  
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4-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-1H-indazole, 129 (JCC-CRT-75) 
 
Off-white solid (12.8 mg, 42% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
13.25 (1H, s, NH), 8.71 (1H, s, indazole 3-H), 8.27 (1H, s, thiazole-H), 8.08-8.00 (2H, m, Ar-
H), 7.80 (1H, d, J 6.8, Ar-H), 7.57 (1H, d, J 8.3, Ar-H), 7.48-7.41 (1H, m, Ar-H), 7.16-7.09 
(2H, m, Ar-H), 3.85 (3H, s, CH3). tR (HPLC) 3.88 min. 
 
5-Fluoro-2-[2-(4-methoxy-phenyl)-thiazol-4-yl]-phenol, 130 (JCC-CRT-77) 
 
Light brown solid (11.2 mg, 37% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-
d6) 11.27 (1H, s, OH), 8.20-8.12 (1H, m, Ar-H), 8.10 (1H, s, thiazole-H), 7.98-7.90 (2H, m, 
Ar-H), 7.13-7.05 (2H, m, Ar-H), 6.81-6.73 (2H, m, Ar-H), 3.84 (3H, s, CH3). tR (HPLC) 4.85 
min. 
 
N-(4-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-phenyl)-methanesulfonamide, 131 (JCC-CRT-
92) 
 
Very light brown powder (13.9 mg, 39% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, 
DMSO-d6) 9.93 (1H, s, NH), 8.04-7.93 (5H, m, 4 × Ar-H, thiazole-H), 7.29 (2H, d, J 8.6, Ar-
H), 7.08 (2H, d, J 8.6, Ar-H), 3.83 (3H, s, OCH3), 3.03 (3H, s, SO2CH3). tR (HPLC) 3.61 min. 
 
2-Methoxy-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-pyrimidine, 132 (JCC-CRT-95) 
 
Light brown solid (5.6 mg, 19%, ca. 1.25:1 starting material/product), δH (400 MHz, DMSO-
d6) 9.21 (2H, s, pyrimidine-H), 8.20 (1H, s, thiazole-H), 8.02-7.96 (2H, m, Ar-H), 7.09 (2H, 
m, Ar-H), 3.98 (3H, s, CH3), 3.84 (3H, s, CH3).  
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4-Furan-2-yl-2-(4-methoxy-phenyl)-thiazole, 133
223
 (JCC-CRT-97) 
 
Off-white powder (3.0 mg, 12% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
7.97-7.91 (2H, m, Ar-H), 7.78-7.76 (2H, m, thiazole-H, furan-H), 7.10-7.06 (2H, m, Ar-H), 
6.88 (1H, d, J 3.2, furan-H), 6.63 (1H, dd, J 3.3, 1.8, furan-H), 3.83 (3H, s, CH3). tR (HPLC) 
3.97 min. 
 
2-(4-Methoxy-phenyl)-4-(3-nitro-phenyl)-thiazole, 134 (JCC-CRT-99) 
 
Light brown solid (3.6 mg, 12% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6 
DMSO-d6) 8.85-8.81 (1H, m, Ar-H), 8.51-8.46 (1H, m, Ar-H), 8.42 (1H, s, thiazole-H), 8.26-
8.19 (1H, m, Ar-H), 8.04-7.95 (2H, m, Ar-H), 7.78 (1H, t, J 8.0, Ar-H), 7.15-7.06 (2H, m, Ar-
H), 3.84 (3H, s, CH3). tR (HPLC) 4.73 min. 
 
3-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-benzoic acid, 135 (JCC-CRT-100) 
 
Light brown solid (6.1 mg, 20% yield, ca. 80% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
13.17 (1H, br s, OH), 8.60 (1H, s, Ar-H), 8.27 (1H, d, J 7.8, Ar-H), 8.23 (1H, s, thiazole-H), 
7.98 (2H, d, J 8.8, Ar-H), 7.94 (1H, d, J 7.7, Ar-H), 7.60 (1H, t, J 7.7, Ar-H), 7.10 (2H, d, J 
8.8, Ar-H), 3.84 (3H, s, CH3). tR (HPLC) 3.90 min. 
 
4-(2-(4-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-pyrazol-1-yl)-ethyl)-morpholine, 136 (JCC-
CRT-101) 
 
Light brown gum (16.6 mg, 45% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
8.20 (1H, s, thiazole-H), 7.91-7.87 (3H, m, 2 × Ar-H, pyrazole-H), 7.63 (1H, s, pyrazole-H), 
7.07 (2H, d, J 8.9, Ar-H), 4.27 (2H, t, J 6.6, NNCH2), 3.83 (3H, s, CH3), 3.59-3.52 (4H, m, 2 
× OCH2), 2.74 (2H, t, J 6.6, NNCH2CH2N), 2.44-2.39 (4H, m, 2 × NCH2CH2O). tR (HPLC) 
2.21 min. 
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4-(1-Isobutyl-1H-pyrazol-4-yl)-2-(4-methoxy-phenyl)-thiazole, 137 (JCC-CRT-102) 
 
Light brown gum (18.2 mg, 58% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
8.16 (1H, s, thiazole-H), 7.97-7.86 (3H, m, 2 × Ar-H, pyrazole-H), 7.63 (1H, s, pyrazole-H), 
7.13-7.01 (2H, m, Ar-H), 3.95 (2H, d, J 7.2, CH2), 3.82 (3H, s, OCH3), 2.20-2.09 (1H, m, 
CH(CH3)2), 0.86 (6H, d, J 6.7, CH(CH3)2). tR (HPLC) 3.89 min. 
 
2-Methoxy-4-[2-(4-methoxy-phenyl)-thiazol-4-yl]-phenylamine, 138 (JCC-CRT-103) 
 
Brown solid (8.9 mg, 28% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
7.98-7.91 (2H, m, Ar-H), 7.74 (1H, s, thiazole-H), 7.46-7.43 (1H, m, Ar-H), 7.40 (1H, dd, J 
8.1, 1.7, Ar-H), 7.12-7.03 (2H, m, Ar-H), 6.68 (1H, d, J 8.0, Ar-H), 4.96 (2H, s, NH2), 3.86 
(3H, s, CH3), 3.83 (3H, s, CH3). tR (HPLC) 3.50 min. 
 
2-(4-Methoxy-phenyl)-4-(1-thiophen-2-ylmethyl-1H-pyrazol-4-yl)-thiazole, 139 (JCC-
CRT-106) 
 
Light brown solid (10.5 mg, 30% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-
d6) 8.26 (1H, s, thiazole-H), 7.97-7.88 (3H, m, Ar-H), 7.66 (1H, s, Ar-H), 7.49 (1H, dd, J 5.1, 
1.2, Ar-H), 7.21-7.13 (1H, m, Ar-H), 7.11-7.05 (2H, m, Ar-H), 7.05-6.98 (1H, m, Ar-H), 5.57 
(2H, s, CH2), 3.83 (3H, s, CH3). tR (HPLC) 3.80 min. 
 
4-(1-Benzyl-1H-pyrazol-4-yl)-2-(4-methoxy-phenyl)-thiazole, 140 (JCC-CRT-109) 
 
Brown gum (17.4 mg, 50% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
8.28 (1H, s, thiazole-H), 7.95 (1H, s, pyrazole-H), 7.94-7.88 (2H, m, Ar-H), 7.65 (1H, s, 
pyrazole-H), 7.41-7.33 (2H, m, Ar-H), 7.33-7.25 (3H, m, Ar-H), 7.10-7.03 (2H, m, Ar-H), 
5.38 (2H, s, CH2), 3.83 (3H, s, CH3). tR (HPLC) 3.90 min. 
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5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-1H-indazole, 141 (JCC-CRT-113) 
 
Off-white solid (9.1 mg, 30%, ca. 1:2 starting material/product), δH (400 MHz, DMSO-d6) 
13.15 (1H, s, NH), 8.46 (1H, s, indazole-H), 8.16 (1H, s, thiazole-H), 8.06-7.95 (4H, m, Ar-
H), 7.61 (1H, d, J 8.7, Ar-H), 7.12-7.08 (2H, m, Ar-H), 3.84 (3H, s, CH3). tR (HPLC) 3.70 
min. 
 
One further compound was successfully synthesised, but the purification was not sufficient 
for assignment of the 
1
H-NMR data. This compound was tested in the enzyme assays. 
– 4-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-quinoline, 142 (JCC-CRT-69) 
 
 
 
5-Bromo-1,3-dihydro-benzoimidazol-2-one, 143 
224
  
 
According to the method of Vernier,
225
 Et3N (1.55 mL, 11.1 mmol) was added to a stirred 
suspension of 5-bromoanthranilic acid (2.00 g, 9.26 mmol) in PhMe (50 mL) to give a dark 
red solution. DPPA (2.00 mL, 9.26 mmol) was then added and the reaction mixture heated to 
90 °C for 3 h before cooling to r.t. The reaction mixture was then partitioned between 1 M 
NaOH (50 mL) and EtOAc (100 mL). The aqueous layer was extracted with EtOAc (2 × 100 
mL) and the combined organic layers washed with brine (100 mL), dried (MgSO4) and the 
solvent removed in vacuo. Recrystallisation from EtOAc afforded the title compound as a 
white powder (1.58 g, 80%), mp >250 °C; δH (400 MHz, DMSO-d6) 10.80 (2H, br s, 2 × NH), 
7.14-7.00 (2H, m, Ar-H), 6.87 (1H, d, J 7.9, Ar-H); m/z (ES) 256 (78%), 254 (100), 229 (11), 
227 (11), 215 (MH
+
, 10), 213 (MH
+
, 10). Found MH
+
, 212.9673. C7H6N2OBr requires 
212.9663. Data is in agreement with the literature.
224
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5-Bromo-2,3-dihydro-1H-indole, 144 
226
  
 
According to the method of Chandra,
226
 5-bromoindole (2.00 g, 10 mmol) was added to 
AcOH (20 mL). After stirring for 10 min, NaBH3CN (2.56 g, 41 mmol) was added in portions. 
The reaction was stirred for a further 1 h before slow addition to a solution of NaOH (14.0 g) 
in H2O (100 mL). This was extracted with Et2O (4 × 75 mL), the combined organic layers 
dried (MgSO4) and the solvent removed in vacuo. Column chromatography eluting with 
Et2O/petrol (1:3 → 3:2) afforded the title compound as a colourless oil that became a white 
semi-solid on storage at -20 °C (1.62 g, 80%), Rf 0.20 (Et2O/petrol 1:3); δH (400 MHz, CDCl3) 
7.20-7.15 (1H, m, Ar-H), 7.07 (1H, dd, J 8.3, 1.9, Ar-H), 6.48 (1H, d, J 8.2, Ar-H), 3.60 (1H, 
br s, NH), 3.54 (2H, t, J 8.4, NCH2), 3.00 (2H, t, J, 8.4, ArCH2); m/z (CI) 217 (24%), 215 (25), 
200 (MH
+
, 97) 199 (33), 198 (MH
+
, 100). Found MH
+
, 197.9915. C8H9NBr requires 197.9918. 
Data is in agreement with the literature.
226
 
 
5-Bromo-1-methanesulfonyl-2,3-dihydro-1H-indole, 145 
 
MsCl (470 μL, 6.1 mmol) was added dropwise to a stirred solution of Et3N (1.06 mL, 7.6 
mmol) and dihydroindole 144 (1.00 g, 5.1 mmol) in CH2Cl2 at 0 °C. The reaction was stirred 
at r.t. for 48 h before the addition of H2O (30 mL). The aqueous layer was extracted with 
CH2Cl2 (3 × 25 mL) and the combined organic layers were washed with 1 M HCl (50 mL) 
and brine (50 mL) and dried (MgSO4). The solvent was removed in vacuo and purification by 
column chromatography eluting with Et2O/petrol (1:2 → 1:0) afforded the title compound as 
off-white rods (1.37 g, 99%), mp 139-140.5 °C; Rf 0.14 (Et2O/petrol 1:1); υmax (neat)/cm
-1
 
1467, 1321, 1146, 1104, 1031; δH (400 MHz, CDCl3) 7.36-7.25 (3H, m, Ar-H), 3.97 (2H, t, J 
8.5, NCH2), 3.14 (2H, t, J 8.5, ArCH2), 2.86 (3H, s, CH3); δC (101 MHz, CDCl3) 141.3, 133.7, 
131.0, 128.7, 116.5, 115.2, 50.7, 34.7, 27.8; m/z (CI) 296 (21%), 295 (MNH4
+
, 100), 294 (20), 
293 (MNH4
+
, 98). Found MNH4
+
, 292.9958. C9H14N2O2BrS requires 292.9959.  
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Parallel Synthesis: General Procedure for Negishi Couplings 
 
 
A solution of bromide 93 (27 mg, 100 μmol), alkyl zinc chloride (120 μmol) and Pd(PPh3)4 
(5.8 mg, 5 μmol) in THF (0.4 mL) was heated (70 °C, 16 h). Upon cooling, the reaction 
mixture was partitioned between H2O (5 mL) and CH2Cl2 (10 mL), the organic layer 
separated, the solvent removed in vacuo and the product purified by HPLC under acidic 
conditions. 
 
4-Cyclopropyl-2-(4-methoxy-phenyl)-thiazole, 147 (JCC-CRT-80) 
 
Brown gum (3.1 mg, 13% yield, ca. 75% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 7.83-
7.78 (2H, m, Ar-H), 7.20 (1H, s, thiazole-H), 7.04-7.00 (2H, m, Ar-H), 3.81 (3H, s, OCH3), 
2.16-2.04 (1H, m, CH), 0.96-0.83 (4H, m, 2 × CH2). tR (HPLC) 3.68 min. 
 
2-(4-Methoxy-phenyl)-4-(2-methyl-benzyl)-thiazole, 148 (JCC-CRT-81) 
 
Light brown gum (1.5 mg, 5% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
7.85-7.80 (2H, m, Ar-H), 7.21-7.11 (4H, m, Ar-H), 7.07 (1H, s, thiazole-H), 7.05-7.01 (2H, m, 
Ar-H), 4.08 (2H, s, CH2), 3.81 (3H, s, OCH3), 2.33 (3H, s, ArCH3). tR (HPLC) 3.72 min. 
 
 
Parallel Synthesis: General Procedure for Aminocarbonylation Reactions 
 
 
A solution of bromide 93 (27 mg, 100 μmol), amine (200 μmol), DBU (45 μL, 300 μmol), 
t
Bu3PHBF4 (2.9 mg, 10 μmol), trans-di(μ-acetato)bis[o-(di-o-tolyl-phosphino)benzyl] 
dipalladium(II) (4.8 mg, 5 μmol), DMAP (24.4 mg, 200 μmol) and Mo(CO)6 (26.4 mg, 100 
μmol) in dioxane (1 mL) was heated (MW, 140 °C, 20 min). Upon cooling, the reaction 
mixture was partitioned between H2O (5 mL) and CH2Cl2 (10 mL), the organic layer 
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separated, the solvent removed in vacuo and the product purified by HPLC under acidic 
conditions. 
 
 [2-(4-Methoxy-phenyl)-thiazol-4-yl]-morpholin-4-yl-methanone, 149 (JCC-CRT-83) 
 
Off-white solid (8.6 mg, 28% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
8.09 (1H, s, thiazole-H), 7.97-7.84 (2H, m, Ar-H), 7.14-7.01 (2H, m, Ar-H), 3.83 (3H, s, CH3), 
3.85-3.60 (6H, m, 3 × CH2), 3.28 (2H, d, J 12.2, CH2). tR (HPLC) 2.97 min. 
 
2-(4-Methoxy-phenyl)-thiazole-4-carboxylic acid (pyridin-4-ylmethyl)-amide, 150 (JCC-
CRT-84) 
 
Off-white solid (8.7 mg, 27% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
9.18 (1H, t, J 6.2, NH), 8.50 (2H, d, J 5.4, pyridine-H), 8.25 (1H, s, thiazole-H), 8.06-7.96 
(2H, m, Ar-H), 7.32 (2H, d, J 5.7, pyridine-H), 7.15-7.04 (2H, m, Ar-H), 4.52 (2H, d, J 6.3, 
CH2), 3.84 (3H, s, CH3). tR (HPLC) 2.10 min. 
  
2-(4-Methoxy-phenyl)-thiazole-4-carboxylic acid (4-methoxy-phenyl)-amide, 151 (JCC-
CRT-85) 
 
Dark brown gum (2.7 mg, 8% yield, ca. 1:1 starting material/product), δH (400 MHz, DMSO-
d6) 10.10 (1H, s, NH), 8.33 (1H, s, thiazole-H), 8.13-8.05 (2H, m, Ar-H), 7.79-7.72 (2H, m, 
Ar-H), 7.12-7.08 (2H, m, Ar-H), 6.97-6.91 (2H, m, Ar-H), 3.85 (3H, s, CH3), 3.76 (3H, s, 
CH3). tR (HPLC) 3.41 min. 
 
2-(4-Methoxy-phenyl)-thiazole-4-carboxylic acid (5-ethyl-[1,3,4]thiadiazol-2-yl)-amide, 
152 (JCC-CRT-114) 
 
Light brown solid (8.2 mg, 24% yield, ca. 50% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
12.69 (1H, s, NH), 8.60 (1H, s, thiazole-H), 8.13 (2H, d, J 8.8, Ar-H), 7.09 (2H, d, J 8.8, Ar-
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H), 3.85 (3H, s, OCH3), 3.04 (2H, q, J 7.5, CH2), 1.33 (3H, t, J 7.5, CH2CH3). tR (HPLC) 3.76 
min. 
 
2-(4-Methoxy-phenyl)-thiazole-4-carboxylic acid isopropylamide, 153 (JCC-CRT-115) 
 
Brown solid (8.2 mg, 30% yield, ca. 80% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 8.17 
(1H, d, J 2.4, thiazole-H), 8.07-7.97 (2H, m, Ar-H), 7.15-7.04 (2H, m, Ar-H), 4.20-4.07 (1H, 
m, NCH), 3.84 (3H, s, OCH3), 1.21 (6H, d, J 6.7, 2 × C(CH3)2). tR (HPLC) 3.49 min. 
 
2-(4-Methoxy-phenyl)-thiazole-4-carboxylic acid (3-morpholin-4-yl-propyl)-amide, 154 
(JCC-CRT-117) 
 
Light brown gum (15.4 mg, 43% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
8.56 (1H, s, NH), 8.17 (1H, s, thiazole-H), 7.98 (2H, d, J 8.9, Ar-H), 7.08 (2H, d, J 8.9, Ar-H), 
3.84 (3H, s, CH3), 3.60-3.56 (4H, m, 2 × OCH2), 3.34 (2H, dd, J 13.1, 6.7, NHCH2), 2.41-
2.32 (6H, m, N(CH2)3), 1.76-1.66 (2H, m, NHCH2CH2). tR (HPLC) 1.59 min. 
 
2-(4-Methoxy-phenyl)-thiazole-4-carboxylic acid (3-imidazol-1-yl-propyl)-amide, 155 
(JCC-CRT-118) 
 
Light yellow solid (6.4 mg, 19% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
8.58 (1H, s, NH), 8.19 (1H, s, thiazole-H), 8.04-7.95 (2H, m, Ar-H), 7.68 (1H, s, imidazole-
H), 7.23 (1H, s, imidazole-H), 7.08 (2H, d, J 8.9, Ar-H), 6.89 (1H, s, imidazole-H), 4.02 (2H, 
t, J 6.9, imidazole-CH2), 3.84 (3H, s, CH3), 3.28 (2H, dd, J 13.1, 6.7, NHCH2), 2.04-1.93 (2H, 
m, NHCH2CH2). tR (HPLC) 1.60 min. 
 
2-(4-Methoxy-phenyl)-thiazole-4-carboxylic acid cyclohexylamide, 156 (JCC-CRT-119) 
 
Pale orange solid (6.9 mg, 22% yield, ca. 80% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
8.17 (1H, s, thiazole-H), 8.00 (2H, d, J 8.9, Ar-H), 7.07 (2H, d, J 8.9, Ar-H), 3.84 (3H, s, 
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CH3), 3.81-3.72 (1H, m, NCH), 1.81 (2H, d, J 12.0, NHCHCH2), 1.73 (2H, d, J 12.7, 
NHCHCH2), 1.65-1.27 (6H, m, 3 × CH2). tR (HPLC) 4.05 min. 
 
2-(4-Methoxy-phenyl)-thiazole-4-carboxylic acid (2-oxo-1,2-dihydro-pyridin-3-yl)-amide, 
157 (JCC-CRT-129) 
 
Pale brown solid (3.5 mg, 11% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
12.17 (1H, s, NH), 10.09 (1H, s, NH), 8.44 (1H, s, thiazole-H), 8.39 (1H, dd, J 7.2, 1.7, 
pyridone-H), 7.99-7.91 (2H, m, Ar-H), 7.20-7.11 (3H, m, 2 × Ar-H, pyridone-H), 6.31 (1H, t, 
J 6.9, pyridone-H), 3.85 (3H, s, CH3). tR (HPLC) 3.49 min. 
 
2-(4-Methoxy-phenyl)-thiazole-4-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide, 
158 (JCC-CRT-130) 
 
Orange solid (8.3 mg, 26% yield, ca. 80% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 8.39 
(1H, t, J 6.0, NH), 8.20 (1H, s, thiazole-H), 8.01-7.95 (2H, m, Ar-H), 7.11-7.06 (2H, m, Ar-H), 
4.06-3.96 (1H, m, OCH), 3.84 (3H, s, CH3), 3.81-3.75 (1H, m, OCHH), 3.64 (1H, dd, J 14.5, 
7.3, OCHH), 1.96-1.74 (3H, m, NCH2, OCHCH2), 1.67-1.54 (1H, m, OCHCH2), 1.28 (2H, m, 
OCH2CH2). tR (HPLC) 3.36 min. 
 
2-(4-Methoxy-phenyl)-thiazole-4-carboxylic acid (2-methoxy-ethyl)-amide, 159 (JCC-
CRT-131) 
 
Orange solid (11.2 mg, 38% yield, ca. 70% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
8.44 (1H, s, NH), 8.20 (1H, s, thiazole-H), 8.02-7.95 (2H, m, Ar-H), 7.12-7.06 (2H, m, Ar-H), 
3.84 (3H, s, CH3), 3.53-3.39 (4H, m, CH2), 3.27 (3H, s, CH3). tR (HPLC) 3.21 min. 
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2-(4-Methoxy-phenyl)-thiazole-4-carboxylic acid [1-(4-fluoro-phenyl)-ethyl]-amide, 160 
(JCC-CRT-136) 
 
Orange gum (5.0 mg, 14% yield, ca. 60% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 8.80 
(1H, d, J 8.5, NH), 8.21 (1H, s, thiazole-H), 8.07-7.99 (2H, m, Ar-H), 7.41-7.22 (4H, m, Ar-
H), 7.11-7.07 (2H, m, Ar-H), 5.21 (1H, p, J 7.1, NCH), 3.84 (3H, s, OCH3), 1.54 (3H, d, J 7.0, 
CHCH3). tR (HPLC) 3.92 min. 
 
2-(4-Methoxy-phenyl)-thiazole-4-carboxylic acid (2-hydroxy-indan-1-yl)-amide, 161 
(JCC-CRT-140) 
 
Brown solid (1.4 mg, 4% yield, ca. 65% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 8.80 
(1H, d, J 9.1, NH), 8.28 (1H, s, thiazole-H), 8.02 (2H, d, J 8.9, Ar-H), 7.24-7.08 (4H, m, Ar-
H), 7.07-7.03 (2H, m, Ar-H), 5.40 (1H, d, J 6.0, OH), 5.30 (1H, t, J 8.0, OCH), 4.62-4.50 (1H, 
m, NCH), 3.82 (3H, s, CH3), 3.18 (1H, dd, J 15.4, 7.3, CHH), 2.76 (1H, dd, J 15.4, 8.0, CHH). 
tR (HPLC) 3.60 min. 
 
4-(([2-(4-Methoxy-phenyl)-thiazole-4-carbonyl]-amino)-methyl)-benzoic acid methyl 
ester, 162 (JCC-CRT-142) 
 
Brown gum (4.9 mg, 13% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 9.20 
(1H, t, J 6.3, NH), 8.24 (1H, s, thiazole-H), 8.04-7.98 (2H, d, J 8.9, Ar-H), 7.93 (2H, d, J 8.3, 
Ar-H), 7.47 (2H, d, J 8.3, Ar-H), 7.08 (2H, d, J 8.9, Ar-H), 4.57 (2H, d, J 6.3, CH2), 3.84 (6H, 
s, 2 × CH3). tR (HPLC) 3.60 min. 
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2-(4-Methoxy-phenyl)-thiazole-4-carboxylic acid (2-methanesulfonyl-ethyl)-amide, 163 
(JCC-CRT-143) 
 
White solid (5.9 mg, 17% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 8.73 
(1H, t, J 5.9, NH), 8.24 (1H, s, thiazole-H), 8.05-7.91 (2H, m, Ar-H), 7.17-7.01 (2H, m, Ar-H), 
3.84 (3H, s, OCH3), 3.73 (2H, dd, J 13.1, 6.6, NCH2), 3.40 (2H, dd, J 16.3, 9.5, SO2CH2), 
3.06 (3H, s, SO2CH3). tR (HPLC) 2.85 min. 
 
Two further compounds were successfully synthesised, but the purification was not sufficient 
for assignment of the 
1
H-NMR data. These compounds were tested in the enzyme assays. 
– 2-(4-Methoxy-phenyl)-thiazole-4-carboxylic acid (5-thiophen-2-yl-2H-pyrazol-3-yl)-
amide, 164 (JCC-CRT-132) 
 
– 2-(4-Methoxy-phenyl)-thiazole-4-carboxylic acid (2-chloro-pyridin-4-yl)-amide, 165 
(JCC-CRT-139) 
 
 
 
3-(2-Phenyl-thiazol-4-yl)-phenylamine, 166 
227
 
 
A solution of bromide 96 (240 mg, 1.00 mmol), 3-aminophenylboronic acid (164 mg, 1.20 
mmol), K2CO3 (346 mg, 2.50 mmol) and Pd(PPh3)4 (35 mg, 0.030 mmol) in DME/H2O (4:1, 
7.5 mL) was stirred at reflux for 14 h. The reaction mixture was partitioned between H2O (20 
mL) and EtOAc (20 mL), the aqueous layer extracted with EtOAc (3 × 20 mL), the combined 
organic layers dried (MgSO4) and the solvent removed in vacuo. Column chromatography 
eluting with EtOAc/hexane (1:3 → 1:2) afforded the title compound as white rods (204 mg, 
81%), mp 96-99 °C; Rf 0.20 (EtOAc/hexane 1:3); υmax (neat)/cm
-1
 3332, 1606, 1585, 1471, 
1458; δH (400 MHz, CDCl3) 8.06-8.01 (2H, m, Ar-H), 7.48-7.41 (3H, m, Ar-H), 7.40 (1H, s, 
thiazole-H), 7.39-7.38 (1H, m, Ar-H), 7.36-7.32 (1H, m, Ar-H), 7.22 (1H, t, J 7.8, Ar-H), 6.67 
(1H, ddd, J 7.8, 2.3, 0.7, Ar-H), 3.75 (2H, br s, NH2); δC (101 MHz, CDCl3) 167.8, 156.5, 
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147.0, 135.6, 133.9, 130.1, 129.8, 129.1, 126.7, 116.9, 115.2, 113.4, 112.9; m/z (ES) 295 (7%), 
294 (32), 254 (18), 253 (MH
+
, 100). Found MH
+
, 253.0804. C15H13N2S requires 253.0799. 
Data is in agreement with the literature.
227
 
 
Parallel Synthesis: General Procedure for Aniline Acylations 
 
 
A solution of aniline 166 (20 mg, 80 μmol), acid chloride (100 μmol) and DIPEA (35 μL, 200 
μmol) in CH2Cl2 (0.5 mL) was shaken (24 h). The solvent was removed under a stream of N2 
and the product purified by HPLC under acidic conditions. 
 
4-Methyl-oxazole-5-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 167 (JCC-
CRT-161) 
 
Pale orange solid (13.9 mg, 48% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.41 (1H, s, NH), 8.56 (1H, s, oxazole-H), 8.48-8.45 (1H, m, Ar-H), 8.13 (1H, s, thiazole-H), 
8.04 (2H, dd, J 7.8, 1.7, Ar-H), 7.82-7.76 (2H, m, Ar-H), 7.58-7.49 (3H, m, Ar-H), 7.45 (1H, t, 
J 7.9, Ar-H), 2.46 (3H, s, CH3). tR (HPLC) 3.93 min. 
 
Furan-2-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 168 (JCC-CRT-166) 
 
Off-white solid (7.0 mg, 25% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.33 (1H, s, NH), 8.45 (1H, t, J 1.7, Ar-H), 8.13 (1H, s, thiazole-H), 8.07-8.02 (2H, m, Ar-H, 
furan-H), 7.97-7.95 (1H, m, Ar-H), 7.84-7.80 (1H, m, Ar-H), 7.78-7.74 (1H, m, Ar-H), 7.58-
7.50 (3H, m, Ar-H), 7.45 (1H, t, J 7.9, Ar-H), 7.39 (1H, d, J 3.3, furan-H), 6.73 (1H, dd, J 3.5, 
1.7, furan-H). tR (HPLC) 3.88 min. 
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1,5-Dimethyl-1H-pyrazole-3-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 
169 (JCC-CRT-167) 
 
Pale yellow solid (5.9 mg, 20% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.03 (1H, s, NH), 8.53 (1H, t, J 1.7, Ar-H), 8.11 (1H, s, thiazole-H), 8.05 (2H, dd, J 7.7, 1.6, 
Ar-H), 7.87-7.83 (1H, m, Ar-H), 7.75-7.71 (1H, m, Ar-H), 7.58-7.50 (3H, m, Ar-H), 7.41 (1H, 
t, J 7.9, Ar-H), 6.59 (1H, s, pyrazole-H), 3.86 (3H, s, NCH3), 2.32 (3H, s, pyrazole-CH3). tR 
(HPLC) 3.99 min. 
 
3-Methyl-isoxazole-5-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 170 
(JCC-CRT-168) 
 
Pale yellow solid (15.6 mg, 54% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.83 (1H, s, NH), 8.48 (1H, t, J 1.6, Ar-H), 8.15 (1H, s, thiazole-H), 8.04 (2H, dd, J 7.7, 1.7, 
Ar-H), 7.84-7.79 (2H, m, Ar-H), 7.58-7.50 (3H, m, Ar-H), 7.48 (1H, t, J 8.0, Ar-H), 7.16 (1H, 
s, isoxazole-H), 2.36 (3H, s, CH3). tR (HPLC) 4.01 min. 
 
2-Methyl-2H-pyrazole-3-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 171 
(JCC-CRT-172) 
 
White solid (8.9 mg, 31% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 10.35 
(1H, s, NH), 8.40 (1H, t, J 1.7, Ar-H), 8.15 (1H, s, thiazole-H), 8.04 (2H, dd, J 7.7, 1.6, Ar-H), 
7.82-7.77 (2H, m, Ar-H), 7.58-7.50 (4H, m, 3 × Ar-H, pyrazole-H), 7.47 (1H, t, J 7.9, Ar-H), 
7.13 (1H, d, J 2.1, pyrazole-H), 4.12 (3H, s, CH3). tR (HPLC) 3.97 min. 
 
 
 
 
- 179 - 
 
3,5-Dimethyl-isoxazole-4-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 172 
(JCC-CRT-179) 
 
Off-white solid (18.7 mg, 62% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.19 (1H, s, NH), 8.37 (1H, t, J 1.6, Ar-H), 8.14 (1H, s, thiazole-H), 8.03 (2H, dd, J 7.8, 1.6, 
Ar-H), 7.79-7.75 (1H, m, J 7.8, Ar-H), 7.72-7.69 (1H, m, Ar-H), 7.58-7.50 (3H, m, Ar-H), 
7.46 (1H, t, J 7.9, Ar-H), 2.58 (3H, s, CH3), 2.36 (3H, s, CH3). tR (HPLC) 3.94 min. 
 
5-Methyl-isoxazole-4-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 173 
(JCC-CRT-180) 
 
Pale orange solid (5.5 mg, 19% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.20 (1H, s, NH), 9.13 (1H, s, isoxazole-H), 8.35 (1H, t, J 1.7, Ar-H), 8.16 (1H, s, thiazole-
H), 8.04 (2H, dd, J 7.9, 1.6, Ar-H), 7.81-7.75 (2H, m, Ar-H), 7.59-7.50 (4H, m, Ar-H), 7.49-
7.44 (1H, m, Ar-H), 2.71 (3H, s, CH3). tR (HPLC) 3.98 min. 
 
5-Methyl-isoxazole-3-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 174 
(JCC-CRT-181) 
 
White solid (16.1 mg, 56% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.76 (1H, s, NH), 8.52 (1H, d, J 1.7, Ar-H), 8.14 (1H, s, thiazole-H), 8.06-8.02 (2H, m, Ar-
H), 7.81 (2H, dt, J 6.8, 1.6, Ar-H), 7.58-7.50 (3H, m, Ar-H), 7.47 (1H, t, J 7.9, Ar-H), 6.71 
(1H, s, isoxazole-H), 2.52 (3H, s, CH3). tR (HPLC) 4.13 min. 
 
2-Methoxy-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-benzamide, 175 (JCC-CRT-151) 
 
Orange solid (9.7 mg, 31% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.26 (1H, s, NH), 8.46 (1H, s, Ar-H), 8.13 (1H, s, thiazole-H), 8.04 (2H, dd, J 7.6, 1.7, Ar-
H), 7.80-7.73 (2H, m, Ar-H), 7.66 (1H, dd, J 7.6, 1.6, Ar-H), 7.60-7.48 (4H, m, Ar-H), 7.44 
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(1H, t, J 7.9, Ar-H), 7.20 (1H, d, J 8.3, Ar-H), 7.08 (1H, t, J 7.6, Ar-H), 3.92 (3H, s, CH3). tR 
(HPLC) 4.67 min. 
 
N-[3-(2-Phenyl-thiazol-4-yl)-phenyl]-benzamide, 176 (JCC-CRT-152) 
 
Pale orange solid (5.1 mg, 18% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.41 (1H, s, NH), 8.55-8.44 (1H, m, Ar-H), 8.14 (1H, s, thiazole-H), 8.08-7.97 (4H, m, Ar-
H), 7.88-7.73 (2H, m, Ar-H), 7.67-7.51 (6H, m, Ar-H), 7.46 (1H, t, J 7.9, Ar-H). tR (HPLC) 
4.21 min. 
 
2,2-Dimethyl-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-propionamide, 177 (JCC-CRT-153) 
 
White solid (5.5 mg, 21% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 9.36 
(1H, s, NH), 8.31 (1H, t, J 1.8, Ar-H), 8.10 (1H, s, thiazole-H), 8.06-8.01 (2H, m, Ar-H), 
7.75-7.67 (2H, m, Ar-H), 7.59-7.51 (3H, m, Ar-H), 7.39 (1H, t, J 7.9, Ar-H), 1.26 (9H, s, 
C(CH3)3). tR (HPLC) 4.07 min. 
 
N-[3-(2-Phenyl-thiazol-4-yl)-phenyl]-acetamide, 178 (JCC-CRT-154) 
 
Off-white solid (9.2 mg, 39% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.09 (1H, s, NH), 8.24 (1H, s, Ar-H), 8.10 (1H, s, thiazole-H), 8.06-7.99 (2H, m, Ar-H), 
7.71-7.63 (2H, m, Ar-H), 7.59-7.50 (3H, m, Ar-H), 7.39 (1H, t, J 7.9, Ar-H), 2.08 (3H, s, 
CH3). tR (HPLC) 3.72 min. 
 
2-Methyl-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-benzamide, 179 (JCC-CRT-155) 
 
White solid (8.9 mg, 30% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 10.45 
(1H, s, NH), 8.48 (1H, s, Ar-H), 8.11 (1H, s, thiazole-H), 8.03 (2H, dd, J 7.6, 1.7, Ar-H), 7.77 
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(2H, dd, J 15.0, 8.1, Ar-H), 7.58-7.48 (4H, m, Ar-H), 7.48-7.36 (2H, m, Ar-H), 7.32 (2H, d, J 
7.4, Ar-H), 2.42 (3H, s, CH3). tR (HPLC) 4.22 min. 
 
N-[3-(2-Phenyl-thiazol-4-yl)-phenyl]-propionamide, 180
228
 (JCC-CRT-156) 
 
Off-white solid (9.2 mg, 37% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.02 (1H, s, NH), 8.28 (1H, s, Ar-H), 8.10 (1H, s, thiazole-H), 8.04-8.00 (2H, m, Ar-H), 7.67 
(2H, dd, J 7.9, 1.6, Ar-H), 7.59-7.49 (3H, m, Ar-H), 7.39 (1H, t, J 7.9, Ar-H), 2.36 (2H, q, J 
7.6, CH2), 1.11 (3H, t, J 7.5, CH3). tR (HPLC) 3.87 min. 
 
N-[3-(2-Phenyl-thiazol-4-yl)-phenyl]-isobutyramide, 181
228
 (JCC-CRT-157) 
 
Off-white solid (6.6 mg, 25% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
9.99 (1H, s, NH), 8.31 (1H, t, J 1.6, Ar-H), 8.10 (1H, s, thiazole-H), 8.03 (2H, dd, J 7.7, 1.6, 
Ar-H), 7.72-7.65 (2H, m, Ar-H), 7.59-7.50 (3H, m, Ar-H), 7.39 (1H, t, J 7.9, Ar-H), 2.63 (1H, 
hept, J 6.9, COCH), 1.13 (6H, d, J 6.8, C(CH3)2). tR (HPLC) 3.94 min. 
 
Cyclopropanecarboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 182 (JCC-CRT-
158) 
 
Pale orange solid (7.5 mg, 29% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.34 (1H, s, NH), 8.29 (1H, t, J 1.7, Ar-H), 8.09 (1H, s, thiazole-H), 8.06-7.99 (2H, m, Ar-
H), 7.71-7.63 (2H, m, Ar-H), 7.59-7.49 (3H, m, Ar-H), 7.39 (1H, t, J 7.9, Ar-H), 1.92-1.74 
(1H, m, COCH), 0.93-0.70 (4H, m, 2 × CH2). tR (HPLC) 3.94 min. 
 
3-Methyl-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-butyramide, 183
228
 (JCC-CRT-159) 
 
Off-white solid (8.1 mg, 30% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.00 (1H, s, NH), 8.27 (1H, t, J 1.6, Ar-H), 8.09 (1H, s, thiazole-H), 8.05-7.98 (2H, m, Ar-
H), 7.72-7.64 (2H, m, Ar-H), 7.59-7.49 (3H, m, Ar-H), 7.38 (1H, t, J 7.9, Ar-H), 2.22 (2H, d, 
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J 7.0, CH2), 2.16-2.05 (1H, m, CH(CH3)2), 0.96 (6H, d, J 6.7, CH(CH3)2). tR (HPLC) 4.17 
min. 
 
Cyclopentanecarboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 184 (JCC-CRT-
160) 
 
Off-white needles (11.4 mg, 41% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-
d6) 10.00 (1H, s, NH), 8.31 (1H, t, J 1.7, Ar-H), 8.09 (1H, s, thiazole-H), 8.06-8.00 (2H, m, 
Ar-H), 7.68 (2H, dd, J 7.9, 1.8, Ar-H), 7.58-7.48 (3H, m, Ar-H), 7.38 (1H, t, J 7.9, Ar-H), 
2.82 (1H, p, J 7.9, COCH), 1.99-1.82 (2H, m, CH2), 1.82-1.65 (4H, m, 2 × CH2), 1.65-1.50 
(2H, m, CH2). tR (HPLC) 4.38 min. 
 
N-[3-(2-Phenyl-thiazol-4-yl)-phenyl]-nicotinamide, 185 (JCC-CRT-162) 
 
Off-white product (7.8 mg, 27% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.59 (1H, s, NH), 9.17-9.14 (1H, m, pyridine-H), 8.78 (1H, dd, J 4.8, 1.6, pyridine-H), 8.48 
(1H, t, J 1.8, Ar-H), 8.38-8.31 (1H, m, pyridine-H), 8.15 (1H, s, thiazole-H), 8.08-8.01 (2H, m, 
Ar-H), 7.88-7.76 (2H, m, Ar-H, pyridine-H), 7.62-7.44 (5H, m, Ar-H). tR (HPLC) 3.84 min. 
 
N-[3-(2-Phenyl-thiazol-4-yl)-phenyl]-isonicotinamide, 186 (JCC-CRT-163) 
 
White solid (8.0 mg, 28% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 10.64 
(1H, s, NH), 8.81 (2H, dd, J 4.4, 1.7, pyridine-H), 8.48 (1H, t, J 1.7, Ar-H), 8.16 (1H, s, 
thiazole-H), 8.07-8.01 (2H, m, Ar-H), 7.92 (2H, dd, J 4.4, 1.7, pyridine-H), 7.88-7.78 (2H, m, 
Ar-H), 7.58-7.52 (3H, m, Ar-H), 7.49 (1H, t, J 7.9, Ar-H). tR (HPLC) 3.92 min. 
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2-Phenyl-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-acetamide, 187 (JCC-CRT-164) 
 
White solid (9.2 mg, 31% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 10.32 
(1H, s, NH), 8.30 (1H, t, J 1.7, Ar-H), 8.10 (1H, s, thiazole-H), 8.06-7.98 (2H, m, Ar-H), 
7.73-7.65 (2H, m, Ar-H), 7.61-7.48 (3H, m, Ar-H), 7.44-7.29 (5H, m, Ar-H), 7.29-7.20 (1H, 
m, Ar-H), 3.68 (2H, s, CH2). tR (HPLC) 4.21 min. 
 
Thiophene-2-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 188
228
 (JCC-CRT-
165) 
 
White solid (7.5 mg, 56% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 10.38 
(1H, s, NH), 8.42 (1H, t, J 1.8, Ar-H), 8.15 (1H, s, thiazole-H), 8.09 (1H, dd, J 3.7, 1.0, 
thiophene-H), 8.07-8.01 (2H, m, Ar-H), 7.88 (1H, dd, J 5.0, 1.0, thiophene-H), 7.83-7.74 (2H, 
m, Ar-H), 7.60-7.51 (3H, m, Ar-H), 7.46 (1H, t, J 7.9, Ar-H), 7.25 (1H, dd, J 5.0, 3.7, 
thiophene-H). tR (HPLC) 4.18 min. 
 
3-Chloro-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-benzamide, 189 (JCC-CRT-169) 
 
White solid (9.2 mg, 30% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 10.49 
(1H, s, NH), 8.47 (1H, t, J 1.8, Ar-H), 8.14 (1H, s, thiazole-H), 8.09-8.01 (3H, m, Ar-H), 
8.00-7.94 (1H, m, Ar-H), 7.89-7.82 (1H, m, Ar-H), 7.81-7.76 (1H, m, Ar-H), 7.68 (1H, ddd, J 
7.9, 2.0, 0.9, Ar-H), 7.62-7.50 (4H, m, Ar-H), 7.47 (1H, t, J 7.9, Ar-H). tR (HPLC) 4.95 min. 
 
3,4,5-Trimethoxy-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-benzamide, 190 (JCC-CRT-171) 
 
White needles (9.9 mg, 28% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.28 (1H, s, NH), 8.42 (1H, t, J 1.8, Ar-H), 8.15 (1H, s, thiazole-H), 8.07-8.02 (2H, m, Ar-
H), 7.84-7.75 (2H, m, Ar-H), 7.59-7.50 (3H, m, Ar-H), 7.47 (1H, t, J 7.9, Ar-H), 7.34 (2H, s, 
Ar-H), 3.89 (6H, s, 2 × CH3), 3.75 (3H, s, CH3). tR (HPLC) 4.29 min. 
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4-Chloro-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-benzamide, 191 (JCC-CRT-173) 
 
White solid (2.3 mg, 7% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 10.46 
(1H, s, NH), 8.46 (1H, t, J 1.8, Ar-H), 8.14 (1H, s, thiazole-H), 8.09-8.01 (4H, m, Ar-H), 
7.88-7.80 (1H, m, Ar-H), 7.80-7.74 (1H, m, Ar-H), 7.66-7.61 (2H, m, Ar-H), 7.59-7.52 (3H, 
m, Ar-H), 7.47 (1H, t, J 7.9, Ar-H). tR (HPLC) 4.70 min. 
 
4-Methyl-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-benzamide, 192 (JCC-CRT-174) 
 
White solid (6.9 mg, 23% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 10.30 
(1H, s, NH), 8.48 (1H, t, J 1.8, Ar-H), 8.13 (1H, s, thiazole-H), 8.09-8.02 (2H, m, Ar-H), 7.93 
(2H, d, J 8.2, Ar-H), 7.89-7.82 (1H, m, Ar-H), 7.79-7.73 (1H, m, Ar-H), 7.59-7.49 (3H, m, 
Ar-H), 7.45 (1H, t, J 7.9, Ar-H), 7.36 (2H, d, J 8.2, Ar-H), 2.40 (3H, s, CH3). tR (HPLC) 4.47 
min. 
 
One further compound was successfully synthesised, but the purification was not sufficient 
for assignment of the 
1
H-NMR data. This compound was tested in the enzyme assays. 
–  4-Isopropoxy-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-benzamide, 193 (JCC-CRT-175) 
 
 
Parallel Synthesis: General Procedure for Sulfonamide Synthesis 
 
 
A solution of aniline 166 (20 mg, 80 μmol), sulfonyl chloride (100 μmol) and DIPEA (35 μL, 
200 μmol) in CH2Cl2 (0.5 mL) was shaken (24 h). The solvent was removed under a stream of 
N2 and the product purified by HPLC under acidic conditions. 
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4-Methoxy-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-benzenesulfonamide, 194 (JCC-CRT-184) 
 
Pale orange solid (14.1 mg, 33% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.29 (1H, s, NH), 8.08 (1H, s, thiazole-H), 8.03-7.97 (2H, m, Ar-H), 7.82 (1H, s, Ar-H), 7.75 
(2H, d, J 8.9, Ar-H), 7.65 (1H, d, J 7.8, Ar-H), 7.59-7.52 (3H, m, Ar-H), 7.32 (1H, t, J 7.9, 
Ar-H), 7.12-7.04 (3H, m, Ar-H), 3.77 (3H, s, CH3). tR (HPLC) 3.46 min. 
 
Butane-1-sulfonic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 195 (JCC-CRT-185) 
 
Pale orange solid (3.9 mg, 10% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
9.90 (1H, s, NH), 8.14 (1H, s, thiazole-H), 8.02 (2H, dd, J 7.6, 1.7, Ar-H), 7.94 (1H, s, Ar-H), 
7.74 (1H, d, J 7.9, Ar-H), 7.58-7.51 (3H, m, Ar-H), 7.42 (1H, t, J 7.9, Ar-H), 7.23 (1H, d, J 
7.9, Ar-H), 3.17-3.08 (2H, m, SO2CH2), 1.73-1.61 (2H, m, SO2CH2CH2), 1.42-1.30 (2H, m, 
CH3CH2), 0.83 (3H, t, J 7.3, CH3). tR (HPLC) 3.51 min. 
 
C-Phenyl-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-methanesulfonamide, 196 (JCC-CRT-190) 
 
Pale orange solid (9.0 mg, 22% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
9.97 (1H, s, NH), 8.13 (1H, s, thiazole-H), 8.03 (2H, dd, J 7.7, 1.6, Ar-H), 7.94-7.89 (1H, m, 
Ar-H), 7.74 (1H, d, J 7.9, Ar-H), 7.59-7.52 (3H, m, Ar-H), 7.43 (1H, t, J 7.9, Ar-H), 7.38-
7.29 (5H, m, Ar-H), 7.21 (1H, dd, J 8.1, 1.5, Ar-H), 4.51 (2H, s, CH2). tR (HPLC) 3.51 min. 
 
4-[3-(2-Phenyl-thiazol-4-yl)-phenylsulfamoyl]-benzoic acid, 197 (JCC-CRT-191) 
 
White solid (34.3 mg, 79% yield, ca. 75% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.44 (1H, s, NH), 8.49 (1H, t, J 1.6, Ar-H), 8.15 (1H, s, thiazole-H), 8.05 (2H, dd, J 7.9, 1.6, 
Ar-H), 7.99 (2H, d, J 8.3, Ar-H), 7.91-7.84 (1H, m, Ar-H), 7.81-7.73 (3H, m, Ar-H), 7.60-
7.49 (3H, m, Ar-H), 7.46 (1H, t, J 7.9, Ar-H). tR (HPLC) 2.68 min. 
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2,3-Dihydro-benzo[1,4]dioxine-6-sulfonic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 
198 (JCC-CRT-193) 
 
White solid (9.9 mg, 22% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 10.33 
(1H, s, NH), 8.09 (1H, s, thiazole-H), 8.01 (2H, dd, J 7.7, 1.6, Ar-H), 7.84 (1H, t, J 1.8, Ar-H), 
7.66 (1H, d, J 7.9, Ar-H), 7.59-7.51 (3H, m, Ar-H), 7.34 (1H, t, J 7.9, Ar-H), 7.31-7.26 (2H, 
m, Ar-H), 7.13-7.09 (1H, m, Ar-H), 7.00 (1H, d, J 8.8, Ar-H), 4.29-4.22 (4H, m, J 4.7, 2 × 
CH2). tR (HPLC) 3.39 min. 
 
1,1-Dioxo-tetrahydro-1λ6-thiophene-3-sulfonic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-
amide, 199 (JCC-CRT-194) 
 
Off-white solid (8.4 mg, 19% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.28 (1H, s, NH), 8.18 (1H, s, thiazole-H), 8.02 (2H, dd, J 7.8, 1.7, Ar-H), 7.93 (1H, t, J 1.7, 
Ar-H), 7.81 (1H, d, J 7.9, Ar-H), 7.58-7.51 (3H, m, Ar-H), 7.46 (1H, t, J 7.9, Ar-H), 7.26 (1H, 
dd, J 7.8, 1.5, Ar-H), 4.28-4.16 (1H, m, SO2CH), 4.11 (2H, d, J 4.8, SO2CH2), 3.53 (2H, dd, J 
13.9, 9.4, SO2CH2), 1.14 (2H, d, J 6.6, SO2CH2CH2). tR (HPLC) 2.58 min. 
 
Thiophene-2-sulfonic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 200 (JCC-CRT-195) 
 
Orange gum (2.7 mg, 7% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 8.09 
(1H, s, thiazole-H), 8.01 (2H, dd, J 7.8, 1.5, Ar-H), 7.90-7.85 (2H, m, Ar-H), 7.69 (1H, d, J 
7.8, thiophene-H), 7.59-7.51 (4H, m, Ar-H), 7.35 (1H, t, J 7.9, Ar-H), 7.15-7.10 (2H, m, 
thiophene-H). tR (HPLC) 2.83 min. 
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2-Oxo-2,3-dihydro-benzooxazole-5-sulfonic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-
amide, 201 (JCC-CRT-197) 
 
Light brown solid (1.5 mg, 3% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.36 (1H, br s, NH), 8.08 (1H, s, thiazole-H), 7.99 (2H, dd, J 7.9, 1.4, Ar-H), 7.82 (1H, t, J 
1.7, Ar-H), 7.64 (1H, d, J 7.9, Ar-H), 7.59-7.49 (5H, m, Ar-H), 7.32 (1H, t, J 7.9, Ar-H), 
7.13-7.05 (2H, m, Ar-H). tR (HPLC) 3.24 min. 
 
1-Methyl-1H-pyrazole-3-sulfonic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 202 
(JCC-CRT-199) 
 
Off-white solid (4.8 mg, 12% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.50 (1H, s, NH), 8.08 (1H, s, thiazole-H), 8.01 (2H, dd, J 7.8, 1.5, Ar-H), 7.89 (1H, t, J 1.8, 
Ar-H), 7.85 (1H, d, J 2.3, Ar-H), 7.67 (1H, d, J 7.9, Ar-H), 7.59-7.50 (3H, m, Ar-H), 7.34 (1H, 
t, J 7.9, Ar-H), 7.15 (1H, m, pyrazole-H), 6.67 (1H, d, J 2.3, pyrazole-H), 3.88 (3H, s, CH3). 
tR (HPLC) 2.69 min. 
 
Furan-3-sulfonic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 203 (JCC-CRT-200) 
 
Orange gum (4.6 mg, 12% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.34 (1H, s, NH), 8.37-8.34 (1H, m, furan-H), 8.13 (1H, s, thiazole-H), 8.02 (2H, dd, J 7.7, 
1.6, Ar-H), 7.88 (1H, t, J 1.8, Ar-H), 7.84 (1H, t, J 1.8, Ar-H), 7.73 (1H, d, J 7.8, Ar-H), 7.58-
7.52 (3H, m, Ar-H), 7.39 (1H, t, J 7.9, Ar-H), 7.17 (1H, dd, J 8.0, 1.3, furan-H), 6.74-6.66 
(1H, m, furan-H). tR (HPLC) 2.86 min. 
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Furan-2-sulfonic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 204 (JCC-CRT-201) 
 
Pale orange solid (2.8 mg, 7% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
8.10 (1H, s, thiazole-H), 8.01 (2H, dd, J 7.9, 1.6, Ar-H), 7.95 (1H, s, Ar-H), 7.83 (1H, s, Ar-
H), 7.69 (1H, d, J 7.8, Ar-H), 7.59-7.52 (4H, m, Ar-H, furan-H), 7.35 (1H, t, J 7.9, Ar-H), 
7.17 (1H, d, J 3.4, Ar-H), 7.11 (1H, dd, J 7.9, 1.6, furan-H), 6.63 (1H, dd, J 3.5, 1.6, furan-H). 
tR (HPLC) 2.63 min. 
 
1,5-Dimethyl-1H-pyrazole-4-sulfonic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 205 
(JCC-CRT-203) 
 
Pale orange gum (14.5 mg, 35% yield, ca. 75% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.27 (1H, s, NH), 8.10 (1H, s, thiazole-H), 8.01 (2H, dd, J 7.8, 1.6, Ar-H), 7.86 (1H, t, J 1.8, 
Ar-H), 7.72 (1H, s, pyrazole-H), 7.67 (1H, d, J 7.8, Ar-H), 7.58-7.50 (4H, m, Ar-H), 7.34 (1H, 
t, J 7.9, Ar-H), 7.10 (1H, dd, J 8.0, 1.4, Ar-H), 3.69 (3H, s, NCH3), 2.35 (3H, s, pyrazole-
CH3). tR (HPLC) 3.24 min. 
 
1-Methyl-1H-imidazole-4-sulfonic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 206 
(JCC-CRT-204) 
 
Off-white solid (7.2 mg, 18% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.33 (1H, s, NH), 8.06 (1H, s, thiazole-H), 8.02 (2H, dd, J 7.9, 1.6, Ar-H), 7.88 (1H, d, J 1.0, 
imidazole-H), 7.86 (1H, t, J 1.8, Ar-H), 7.75 (1H, d, J 1.0, imidazole-H), 7.63 (1H, d, J 7.8, 
Ar-H), 7.58-7.51 (3H, m, Ar-H), 7.31 (1H, t, J 7.9, Ar-H), 7.16 (1H, dd, J 8.1, 1.4, Ar-H), 
3.64 (3H, s, CH3). tR (HPLC) 2.99 min. 
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2H-[1,2,4]Triazole-3-sulfonic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 207 (JCC-
CRT-205) 
 
White solid (12.1 mg, 32% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 8.69 
(1H, s, triazole-H), 8.06 (1H, s, thiazole-H), 8.01 (2H, dd, J 7.7, 1.7, Ar-H), 7.90 (1H, t, J 1.8, 
Ar-H), 7.68 (1H, d, J 7.9, Ar-H), 7.58-7.52 (3H, m, Ar-H), 7.34 (1H, t, J 7.9, Ar-H), 7.21-
7.16 (1H, m, Ar-H). tR (HPLC) 2.48 min. 
 
Four further compounds were successfully synthesised, but the purification was not sufficient 
for assignment of the 
1
H-NMR data. These compounds were tested in the enzyme assays. 
–  N-[3-(2-Phenyl-thiazol-4-yl)-phenyl]-methanesulfonamide, 208 (JCC-CRT-183) 
 
– 2-Fluoro-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-benzenesulfonamide, 209 (JCC-CRT-
186) 
 
– 3,5-Dimethyl-isoxazole-4-sulfonic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 210 
(JCC-CRT-189) 
 
– 2-Phenyl-ethanesulfonic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 211 (JCC-
CRT-192) 
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Parallel Synthesis: General Procedure for Urea Synthesis 
 
 
A solution of aniline 166 (20 mg, 80 μmol) and isocyanate (100 μmol) in CH2Cl2 (0.5 mL) 
was shaken (24 h). The solvent was removed under a stream of N2 and the product purified by 
HPLC under acidic conditions. 
 
1-Phenyl-3-[3-(2-phenyl-thiazol-4-yl)-phenyl]-urea, 212 (JCC-CRT-206) 
 
White solid (1.2 mg, 4% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 8.87 
(1H, s, NH), 8.71 (1H, s, NH), 8.14 (1H, t, J 1.7, Ar-H), 8.12 (1H, s, thiazole-H), 8.03 (2H, dd, 
J 7.8, 1.6, Ar-H), 7.65-7.61 (1H, m, Ar-H), 7.58-7.46 (6H, m, Ar-H), 7.38 (1H, t, J 7.9, Ar-H), 
7.31-7.27 (2H, m, Ar-H), 6.98 (1H, t, J 7.4, Ar-H). tR (HPLC) 4.26 min. 
 
1-Ethyl-3-[3-(2-phenyl-thiazol-4-yl)-phenyl]-urea, 213 (JCC-CRT-207) 
 
White solid (2.7 mg, 10% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 8.58 
(1H, s, NH), 8.08-8.05 (2H, m, thiazole-H, Ar-H), 8.04-8.01 (2H, m, Ar-H), 7.57-7.51 (4H, m, 
Ar-H), 7.46-7.43 (1H, m, Ar-H), 7.31 (1H, t, J 7.9, Ar-H), 6.11 (1H, t, J 5.6, NH), 3.17-3.06 
(2H, m, CH2), 1.07 (3H, t, J 7.1, CH3). tR (HPLC) 3.73 min. 
 
1-Benzyl-3-[3-(2-phenyl-thiazol-4-yl)-phenyl]-urea, 214 (JCC-CRT-208) 
 
White solid (0.5 mg, 1.5% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 8.76 
(1H, s, NH), 8.09 (1H, t, J 1.8, Ar-H), 8.07 (1H, s, thiazole-H), 8.04-7.99 (2H, m, Ar-H), 
7.58-7.50 (4H, m, Ar-H), 7.49-7.43 (1H, m, Ar-H), 7.37-7.30 (5H, m, Ar-H), 7.28-7.23 (1H, 
m, Ar-H), 6.66 (1H, t, J 5.9, NH), 4.33 (2H, d, J 6.0, CH2). tR (HPLC) 4.05 min. 
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1-Cyclohexyl-3-[3-(2-phenyl-thiazol-4-yl)-phenyl]-urea, 215 (JCC-CRT-209) 
 
White solid (1.3 mg, 4% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 8.47 
(1H, s, NH), 8.08-8.06 (2H, m, Ar-H, thiazole-H), 8.05-7.99 (2H, m, Ar-H), 7.58-7.49 (4H, m, 
Ar-H), 7.45-7.37 (1H, m, Ar-H), 7.31 (1H, t, J 7.9, Ar-H), 6.09 (1H, d, J 7.8, NH), 3.56-3.43 
(1H, m, NCH), 1.82 (2H, d, J 12.2, CH2), 1.71-1.62 (2H, m, CH2), 1.60-1.51 (1H, m, CHH), 
1.39-1.26 (2H, m, CH2), 1.26-1.11 (3H, m, CHH, CH2). tR (HPLC) 4.36 min. 
 
1-tert-Butyl-3-[3-(2-phenyl-thiazol-4-yl)-phenyl]-urea, 216 (JCC-CRT-210) 
 
White solid (4.4 mg, 15% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 8.41 
(1H, s, NH), 8.07 (1H, s, thiazole-H), 8.04-7.99 (3H, m, Ar-H), 7.57-7.49 (4H, m, Ar-H), 
7.43-7.38 (1H, m, Ar-H), 7.30 (1H, t, J 7.9, Ar-H), 6.01 (1H, s, NH), 1.31 (9H, s, C(CH3)3). tR 
(HPLC) 4.08 min. 
 
1-(3-Chloro-phenyl)-3-[3-(2-phenyl-thiazol-4-yl)-phenyl]-urea, 217 (JCC-CRT-211) 
 
White solid (1.2 mg, 4% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 8.97 
(2H, m, NH), 8.15 (1H, t, J 1.8, Ar-H), 8.13 (1H, s, thiazole-H), 8.03 (2H, dd, J 7.8, 1.6, Ar-
H), 7.75-7.73 (1H, m, Ar-H), 7.68-7.63 (1H, m, Ar-H), 7.58-7.52 (3H, m, Ar-H), 7.52-7.48 
(1H, m, Ar-H), 7.39 (1H, t, J 7.9, Ar-H), 7.32-7.28 (2H, m, Ar-H), 7.03 (1H, dt, J 6.6, 2.3, Ar-
H). tR (HPLC) 4.93 min. 
 
1-(2-Chloro-phenyl)-3-[3-(2-phenyl-thiazol-4-yl)-phenyl]-urea, 218 (JCC-CRT-212) 
 
White solid (1.7 mg, 5% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 9.61 
(1H, s, NH), 8.35 (1H, s, NH), 8.20 (1H, dd, J 8.3, 1.5, Ar-H), 8.14 (2H, m, thiazole-H, Ar-H), 
8.06-8.00 (2H, m, Ar-H), 7.67-7.63 (1H, m, Ar-H), 7.59-7.52 (4H, m, Ar-H), 7.47 (1H, dd, J 
8.0, 1.4, Ar-H), 7.41 (1H, t, J 7.9, Ar-H), 7.36-7.28 (1H, m, Ar-H), 7.09-7.00 (1H, m, Ar-H). 
tR (HPLC) 4.78 min. 
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1-(3-Methoxy-phenyl)-3-[3-(2-phenyl-thiazol-4-yl)-phenyl]-urea, 219 (JCC-CRT-214) 
 
White solid (1.3 mg, 4% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 8.86 
(1H, s, NH), 8.73 (1H, s, NH), 8.12 (2H, m, thiazole-H, Ar-H), 8.03 (2H, dd, J 7.9, 1.7, Ar-H), 
7.66-7.61 (1H, m, Ar-H), 7.58-7.52 (4H, m, Ar-H), 7.52-7.48 (1H, m, Ar-H), 7.38 (1H, t, J 
7.9, Ar-H), 7.22-7.16 (2H, m, Ar-H), 6.96 (1H, dd, J 7.9, 1.2, Ar-H), 6.56 (1H, dd, J 8.3, 2.2, 
Ar-H), 3.82 (3H, s, CH3). tR (HPLC) 4.20 min. 
 
1-(4-Methoxy-phenyl)-3-[3-(2-phenyl-thiazol-4-yl)-phenyl]-urea, 220 (JCC-CRT-215) 
 
White solid (0.7 mg, 2% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 8.80 
(1H, s, NH), 8.53 (1H, s, NH), 8.15-8.12 (1H, m, Ar-H), 8.11 (1H, s, thiazole-H), 8.03 (2H, 
dd, J 7.8, 1.6, Ar-H), 7.62 (1H, d, J 7.8, Ar-H), 7.58-7.51 (3H, m, Ar-H), 7.51-7.47 (1H, m, 
Ar-H), 7.40-7.34 (3H, m, Ar-H), 6.88 (2H, d, J 9.1, Ar-H), 3.72 (3H, s, CH3). tR (HPLC) 4.14 
min. 
 
1-(2-Methoxy-phenyl)-3-[3-(2-phenyl-thiazol-4-yl)-phenyl]-urea, 221 (JCC-CRT-216) 
 
White solid (5.2 mg, 16% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 9.50 
(1H, s, NH), 8.28 (1H, s, NH), 8.17 (1H, dd, J 7.8, 1.8, Ar-H), 8.13 (2H, m, thiazole-H, Ar-H), 
8.03 (2H, dd, J 7.7, 1.6, Ar-H), 7.63 (1H, d, J 7.7, Ar-H), 7.59-7.49 (4H, m, Ar-H), 7.38 (1H, 
t, J 7.9, Ar-H), 7.03 (1H, dd, J 8.0, 1.5, Ar-H), 6.96 (1H, td, J 7.7, 1.8, Ar-H), 6.91 (1H, td, J 
7.6, 1.5, Ar-H), 3.89 (3H, s, CH3). tR (HPLC) 4.46 min. 
 
1-(3-Cyano-phenyl)-3-[3-(2-phenyl-thiazol-4-yl)-phenyl]-urea, 222 (JCC-CRT-218) 
 
White solid (1.4 mg, 5% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 9.10 
(2H, m, NH), 8.16 (1H, t, J 1.7, Ar-H), 8.14 (1H, s, thiazole-H), 8.03 (2H, dd, J 7.8, 1.5, Ar-
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H), 8.02-7.99 (1H, m, Ar-H), 7.73-7.69 (1H, m, Ar-H), 7.69-7.64 (1H, m, Ar-H), 7.59-7.48 
(5H, m, Ar-H), 7.46-7.37 (2H, m, Ar-H). tR (HPLC) 4.17 min. 
 
One further compound was successfully synthesised, but the purification was not sufficient 
for assignment of the 
1
H-NMR data. This compound was tested in the enzyme assays. 
–  [3-(2-Phenyl-thiazol-4-yl)-phenyl]-urea, 223 (JCC-CRT-217) 
 
 
Parallel Synthesis: General Procedure for HATU Amide Couplings 
 
 
A solution of aniline 166 (20 mg, 80 μmol), carboxylic acid (88 μmol), DIPEA (35 μL, 200 
μmol) and HATU (34 mg, 88 μmol) in CH2Cl2 (0.5 mL) was shaken (72 h). The solvent was 
removed under a stream of N2 and the product purified by HPLC under acidic conditions. 
 
5-Oxo-pyrrolidine-2-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 224 (JCC-
CRT-231) 
 
Pale orange solid (16.6 mg, 57% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.21 (1H, s, NH), 8.32 (1H, t, J 1.6, Ar-H), 8.13 (1H, s, thiazole-H), 8.03 (2H, dd, J 7.8, 1.5, 
Ar-H), 7.93 (1H, s, NH), 7.75-7.68 (2H, m, Ar-H), 7.59-7.50 (3H, m, Ar-H), 7.42 (1H, t, J 7.9, 
Ar-H), 4.23 (1H, dd, J 8.6, 4.3, NCH), 2.41-1.99 (4H, m, 2 × CH2). tR (HPLC) 4.17 min. 
 
Pyridine-2-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 225 (JCC-CRT-232) 
 
Pale orange solid (14.9 mg, 52% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.76 (1H, s, NH), 8.77 (1H, d, J 4.4, pyridine-H), 8.63 (1H, t, J 1.7, Ar-H), 8.21 (1H, d, J 7.8, 
pyridine-H), 8.15 (1H, s, thiazole-H), 8.11 (1H, dd, J 7.7, 1.7, Ar-H), 8.09-8.04 (2H, m, Ar-H, 
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pyridine-H), 7.96 (1H, dd, J 8.0, 1.2, pyridine-H), 7.82-7.79 (1H, m, Ar-H), 7.70 (1H, ddd, J 
7.6, 4.8, 1.2, Ar-H), 7.59-7.52 (3H, m, Ar-H), 7.48 (1H, t, J 7.9, Ar-H). tR (HPLC) 4.61 min. 
 
Pyrazine-2-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 226 (JCC-CRT-234) 
 
Off-white solid (11.9 mg, 41% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.86 (1H, s, NH), 9.34 (1H, d, J 1.5, pyrazine-H), 8.96 (1H, d, J 2.4, pyrazine-H), 8.84 (1H, 
dd, J 2.4, 1.5, pyrazine-H), 8.64 (1H, t, J 1.7, Ar-H), 8.15 (1H, s, thiazole-H), 8.07-8.04 (2H, 
m, Ar-H), 7.94 (1H, dd, J 8.0, 1.3, Ar-H), 7.84-7.80 (1H, m, Ar-H), 7.59-7.51 (3H, m, Ar-H), 
7.49 (1H, t, J 7.9, Ar-H). tR (HPLC) 4.11 min. 
 
6-Hydroxy-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-nicotinamide, 227 (JCC-CRT-235) 
 
Orange solid (13.0 mg, 43% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
12.14 (1H, s, pyridone-NH), 10.12 (1H, s, NH), 8.38 (1H, t, J 1.7, Ar-H), 8.26 (1H, d, J 2.6, 
pyridone-H), 8.13 (1H, s, thiazole-H), 8.05-7.99 (3H, m, Ar-H, pyridone-H), 7.79 (1H, dd, J 
8.1, 1.2, Ar-H), 7.75-7.71 (1H, m, Ar-H), 7.58-7.51 (3H, m, Ar-H), 7.44 (1H, t, J 7.9, Ar-H), 
6.43 (1H, d, J 9.6, pyridone-H). tR (HPLC) 3.69 min. 
 
Pyridazine-4-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 228 (JCC-CRT-
237) 
 
Pale orange solid (14.4 mg, 50% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.87 (1H, s, NH), 9.70 (1H, dd, J 2.1, 1.1, pyridazine-H), 9.52 (1H, dd, J 5.3, 1.1), 8.48 (1H, 
s, Ar-H), 8.19-8.16 (2H, m, pyridazine-H, thiazole-H), 8.04 (2H, dd, J 7.7, 1.7, Ar-H), 7.87-
7.81 (2H, m, Ar-H), 7.58-7.48 (4H, m, Ar-H). tR (HPLC) 3.74 min. 
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5-Methyl-2H-pyrazole-3-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 229 
(JCC-CRT-245) 
 
Off-white solid (12.3 mg, 43% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
13.12 (1H, s, pyrazole-NH), 10.05 (1H, s, CONH), 8.54 (1H, s, Ar-H), 8.10 (1H, s, thiazole-
H), 8.05 (2H, dd, J 7.7, 1.6, Ar-H), 7.85 (1H, d, J 8.5, Ar-H), 7.74 (1H, d, J 7.7, Ar-H), 7.58-
7.52 (3H, m, Ar-H), 7.42 (1H, t, J 7.9, Ar-H), 6.54 (1H, s, pyrazole-H), 2.31 (3H, s, CH3). tR 
(HPLC) 3.90 min. 
 
4-Methyl-thiazole-5-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 230 (JCC-
CRT-249) 
 
Off-white solid (18.5 mg, 61% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.38 (1H, s, NH), 9.15 (1H, s, thiazole 2-H), 8.38 (1H, t, J 1.6, Ar-H), 8.14 (1H, s, thiazole 
5-H), 8.04 (2H, dd, J 7.8, 1.7, Ar-H), 7.80-7.77 (1H, m, Ar-H), 7.73 (1H, dd, J 8.0, 1.2, Ar-H), 
7.58-7.51 (3H, m, Ar-H), 7.46 (1H, t, J 7.9, Ar-H), 2.65 (3H, s, CH3). tR (HPLC) 3.93 min. 
 
2,4-Dimethyl-thiazole-5-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 231 
(JCC-CRT-250) 
 
Off-white solid (13.0 mg, 41% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.23 (1H, s, NH), 8.36 (1H, t, J 1.7, Ar-H), 8.14 (1H, s, thiazole-H), 8.03 (2H, dd, J 7.7, 1.7, 
Ar-H), 7.79-7.76 (1H, m, Ar-H), 7.71 (1H, dd, J 8.2, 1.1, Ar-H), 7.58-7.51 (3H, m, Ar-H), 
7.45 (1H, t, J 7.9, Ar-H), 2.67 (3H, s, CH3), 2.57 (3H, s, CH3). tR (HPLC) 4.07 min. 
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5-Methyl-1H-pyrazole-3-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 232 
(JCC-CRT-251) 
 
Off-white solid (8.8 mg, 31% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
13.12 (1H, s, pyrazole-NH), 10.05 (1H, s, CONH), 8.54 (1H, s, Ar-H), 8.10 (1H, s, thiazole-
H), 8.05 (2H, dd, J 7.7, 1.6, Ar-H), 7.85 (1H, d, J 8.4, Ar-H), 7.74 (1H, d, J 7.7, Ar-H), 7.58-
7.52 (3H, m, Ar-H), 7.42 (1H, t, J 7.9, Ar-H), 6.54 (1H, s, pyrazole-H), 2.31 (3H, s, CH3). tR 
(HPLC) 3.88 min. 
 
Thiazole-2-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 233 (JCC-CRT-252) 
 
Pale orange solid (14.2 mg, 49% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
9.95 (1H, s, NH), 8.53 (1H, s, Ar-H), 8.11 (1H, s, thiazole-H), 8.05 (2H, dd, J 7.7, 1.6, Ar-H), 
7.88 (2H, m, thiazole-H), 7.85 (1H, d, J 1.0, Ar-H), 7.73 (1H, d, J 7.8, Ar-H), 7.58-7.52 (3H, 
m, Ar-H), 7.42 (1H, t, J 7.9, Ar-H). tR (HPLC) 3.72 min. 
 
1-Methyl-1H-imidazole-2-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 234 
(JCC-CRT-256) 
 
White solid (5.7 mg, 20% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 10.42 
(1H, s, NH), 8.54 (1H, t, J 1.7, Ar-H), 8.11 (1H, s, thiazole-H), 8.05 (2H, dd, J 7.8, 1.7, Ar-H), 
7.85 (1H, dd, J 8.1, 1.2, Ar-H), 7.76 (1H, d, J 7.8, Ar-H), 7.58-7.52 (3H, m, Ar-H), 7.47 (1H, 
br s, imidazole-H), 7.44 (1H, t, J 7.9, Ar-H), 7.11 (1H, d, J 0.8, imidazole-H), 4.02 (3H, s, 
CH3). tR (HPLC) 4.09 min. 
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[1,2,3]Thiadiazole-4-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 235 (JCC-
CRT-257) 
 
Off-white solid (3.8 mg, 13% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
11.08 (1H, s, NH), 9.87 (1H, s, thiadiazole-H), 8.61 (1H, s, Ar-H), 8.15 (1H, s, thiazole-H), 
8.06 (2H, dd, J 7.8, 1.6, Ar-H), 7.91 (1H, dd, J 8.0, 1.2, Ar-H), 7.82 (1H, d, J 7.8, Ar-H), 
7.59-7.52 (3H, m, Ar-H), 7.49 (1H, t, J 7.9, Ar-H). tR (HPLC) 4.02 min. 
 
5-Isopropyl-2H-pyrazole-3-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 236 
(JCC-CRT-259) 
 
Off-white solid (7.7 mg, 25% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
13.12 (1H, s, pyrazole-NH), 10.04 (1H, s, CONH), 8.52 (1H, s, Ar-H), 8.11 (1H, s, thiazole-
H), 8.05 (2H, dd, J 7.6, 1.5, Ar-H), 7.85 (1H, dd, J 8.1, 1.1, Ar-H), 7.74 (1H, d, J 7.7, Ar-H), 
7.58-7.52 (3H, m, Ar-H), 7.42 (1H, t, J 7.9, Ar-H), 6.57 (1H, s, pyrazole-H), 3.03 (1H, sept, J 
6.9, CH(CH3)2), 1.27 (6H, d, J 6.9, CH(CH3)2). tR (HPLC) 4.20 min. 
 
1-Methyl-1H-indazole-3-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 237 
(JCC-CRT-260) 
 
Off-white solid (6.1 mg, 19% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.45 (1H, s, NH), 8.62 (1H, s, Ar-H), 8.27 (1H, d, J 8.0, Ar-H), 8.14 (1H, s, thiazole-H), 
8.07 (2H, s, Ar-H), 7.95 (1H, d, J 7.7, Ar-H), 7.84-7.75 (2H, m, Ar-H), 7.61-7.43 (5H, m, Ar-
H), 7.35 (1H, s, Ar-H), 4.23 (3H, s, CH3). tR (HPLC) 5.14 min.  
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6-Hydroxy-pyridine-2-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 238 
(JCC-CRT-284) 
 
Orange solid (10.8 mg, 36% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
11.33 (1H, s, pyridone-NH), 10.37 (1H, s, NH), 8.46 (1H, s, Ar-H), 8.17 (1H, s, thiazole-H), 
8.05 (2H, dd, J 7.8, 1.6, Ar-H), 7.85 (1H, dd, J 8.1, 1.3, Ar-H), 7.83-7.78 (2H, m, pyridone-H, 
Ar-H), 7.59-7.52 (3H, m, Ar-H), 7.51-7.42 (2H, m, pyridone-H, Ar-H), 6.84 (1H, d, J 8.4, 
pyridone-H). tR (HPLC) 3.86 min. 
 
2-Chloro-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-benzamide, 239 (JCC-CRT-229) 
 
Off-white crystalline solid (17.4 mg, 56% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, 
DMSO-d6) 10.65 (1H, s. NH), 8.45 (1H, t, J 1.7, Ar-H), 8.13 (1H, s, thiazole-H), 8.07-7.99 
(2H, m, Ar-H), 7.77 (2H, dd, J 8.0, 1.8, Ar-H), 7.66-7.42 (8H, m, Ar-H). tR (HPLC) 3.58 min. 
 
2-Oxo-1,2-dihydro-pyridine-3-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 
240 (JCC-CRT-233) 
 
Red solid (6.2 mg, 21% yield, ca. 80% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 12.46 
(1H, s, pyridone-NH), 8.48 (1H, dd, J 7.2, 2.2, pyridone-H), 8.33 (1H, s, Ar-H), 8.22 (1H, s, 
thiazole-H), 8.08-7.98 (2H, m, Ar-H), 7.85 (1H, dd, J 6.2, 2.2, Ar-H), 7.81-7.72 (2H, m, 
pyridone-H, Ar-H), 7.57-7.51 (3H, m, Ar-H), 7.47 (1H, t, J 7.9, Ar-H), 6.58 (1H, m, 
pyridone-H). tR (HPLC) 3.44 min. 
 
4-Cyano-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-benzamide, 241 (JCC-CRT-236) 
 
Pale orange solid (15.2 mg, 50% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.65 (1H, s, NH), 8.51-8.43 (1H, m, Ar-H), 8.19-8.13 (3H, m, 2 × Ar-H, thiazole-H), 8.07-
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8.01 (4H, m, Ar-H), 7.88-7.83 (1H, m, Ar-H), 7.82-7.77 (1H, m, Ar-H), 7.57-7.51 (3H, m, 
Ar-H), 7.52-7.44 (1H, m, Ar-H). tR (HPLC) 3.56 min. 
 
3-Cyano-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-benzamide, 242 (JCC-CRT-238) 
 
Off-white solid (11.3 mg, 37% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.58 (1H, s, NH), 8.47 (2H, s, Ar-H), 8.33-8.28 (1H, m, Ar-H), 8.16 (1H, s, thiazole-H), 
8.11-8.07 (1H, m, Ar-H), 8.07-8.01 (2H, m, Ar-H), 7.90-7.85 (1H, m, Ar-H), 7.82-7.74 (2H, 
m, Ar-H), 7.59-7.52 (3H, m, Ar-H), 7.52-7.45 (1H, m, Ar-H). tR (HPLC) 3.58 min. 
 
2-Methoxy-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-5-sulfamoyl-benzamide, 243 (JCC-CRT-
262) 
 
White solid (14.3 mg, 39% yield, ca. 80% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.40 (1H, s, CONH), 8.43 (1H, s, Ar-H), 8.15 (1H, s, thiazole-H), 8.07 (1H, d, J 2.4, Ar-H), 
8.06-8.02 (2H, m, Ar-H), 7.94 (1H, dd, J 8.7, 2.4, Ar-H), 7.80-7.73 (2H, m, Ar-H), 7.59-7.49 
(4H, m, Ar-H), 7.46 (1H, t, J 7.9, Ar-H), 7.37 (2H, s, SO2NH2), 3.98 (3H, s, CH3). tR (HPLC) 
3.39 min. 
 
2,5-Dimethoxy-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-benzamide, 244 (JCC-CRT-263) 
 
Pale yellow solid (7.9 mg, 24% yield, ca. 80% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.28 (1H, s, NH), 8.46 (1H, s, Ar-H), 8.14 (1H, s, thiazole-H), 8.06-8.00 (2H, m, Ar-H), 
7.79-7.71 (2H, m, Ar-H), 7.53 (3H, dd, J 12.7, 6.1, Ar-H), 7.45 (1H, t, J 7.9, Ar-H), 7.25 (1H, 
d, J 3.0, Ar-H), 7.14 (1H, d, J 9.0, Ar-H), 7.09 (1H, dd, J 9.0, 3.1, Ar-H), 3.89 (3H, s, CH3), 
3.77 (3H, s, CH3). tR (HPLC) 3.73 min. 
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2-Chloro-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-nicotinamide, 245 (JCC-CRT-265) 
 
Pale yellow needles (16.4 mg, 52% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, 
DMSO-d6) 10.80 (1H, s, NH), 8.56 (1H, dd, J 4.9, 1.9, pyridine-H), 8.42 (1H, s, Ar-H), 8.16 
(1H, s, thiazole-H), 8.13 (1H, dd, J 7.6, 1.9, pyridine-H), 8.05-8.01 (2H, m, Ar-H), 7.81-7.75 
(2H, m, Ar-H), 7.59 (1H, dd, J 7.6, 4.9, pyridine-H), 7.56-7.51 (3H, m, Ar-H), 7.48 (1H, t, J 
7.9, Ar-H). tR (HPLC) 3.46 min. 
 
4-Acetylamino-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-benzamide, 246 (JCC-CRT-268) 
 
Pale orange solid (12.1 mg, 37% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.27 (1H, s, NH), 10.25 (1H, s, NH), 8.47 (1H, s, Ar-H), 8.13 (1H, s, thiazole-H), 8.06-8.03 
(2H, m, Ar-H), 8.00-7.96 (2H, m, Ar-H), 7.87-7.82 (1H, m, Ar-H), 7.77-7.71 (3H, m, Ar-H), 
7.56-7.51 (3H, m, Ar-H), 7.45 (1H, t, J 8.0, Ar-H), 2.67 (3H, s, CH3). tR (HPLC) 3.49 min. 
 
4-Dimethylamino-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-benzamide, 247 (JCC-CRT-270) 
 
Orange solid (9.3 mg, 29% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.02 (1H, s, NH), 8.47 (1H, t, J 1.7, Ar-H), 8.11 (1H, s, thiazole-H), 8.05 (2H, dd, J 7.8, 1.6, 
Ar-H), 7.93 (2H, d, J 9.0, Ar-H), 7.84 (1H, dd, J 8.0, 1.2, Ar-H), 7.74-7.69 (1H, m, Ar-H), 
7.57-7.51 (3H, m, Ar-H), 7.42 (1H, t, J 7.9, Ar-H), 6.78 (2H, d, J 9.0, Ar-H), 3.01 (6H, s, 
N(CH3)2). tR (HPLC) 3.64 min. 
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1-Methyl-piperidine-4-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 248 
(JCC-CRT-271) 
 
Off-white solid (7.6 mg, 25% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.01 (1H, s, NH), 8.35-8.27 (1H, m, Ar-H), 8.10 (1H, s, thiazole-H), 8.03 (2H, dd, J 7.8, 1.7, 
Ar-H), 7.70-7.64 (2H, m, Ar-H), 7.58-7.50 (3H, m, Ar-H), 7.38 (1H, t, J 7.9, Ar-H), 2.83 (2H, 
d, J 11.3, NCH2), 2.35-2.25 (1H, m, COCH), 2.16 (3H, s, NCH3), 1.92-1.81 (2H, m, NCH2), 
1.81-1.73 (2H, m, NCH2CH2), 1.73-1.61 (2H, m, NCH2CH2). tR (HPLC) 3.44 min. 
 
Benzo[1,3]dioxole-5-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 249 (JCC-
CRT-273) 
 
Pale orange solid (9.9 mg, 31% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.22 (1H, s, NH), 8.46 (1H, t, J 1.7, Ar-H), 8.13 (1H, s, thiazole-H), 8.05 (2H, dd, J 7.8, 1.7, 
Ar-H), 7.83 (1H, dd, J 8.1, 1.2, Ar-H), 7.75 (1H, d, J 7.8, Ar-H), 7.64 (1H, dd, J 8.2, 1.8, Ar-
H), 7.57 (1H, d, J 1.8, Ar-H), 7.56-7.51 (3H, m, Ar-H), 7.45 (1H, t, J 7.9, Ar-H), 7.08 (1H, d, 
J 8.2, Ar-H), 6.15 (2H, s, CH2). tR (HPLC) 3.61 min. 
 
4-Methoxy-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-benzamide, 250 (JCC-CRT-274) 
 
Pale yellow solid (5.0 mg, 16% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.24 (1H, s, NH), 8.47 (1H, t, J 1.8, Ar-H), 8.13 (1H, s, thiazole-H), 8.05-8.00 (4H, m, Ar-
H), 7.87-7.82 (1H, m, Ar-H), 7.77-7.72 (1H, m, Ar-H), 7.56-7.52 (3H, m, Ar-H), 7.45 (1H, t, 
J 7.9, Ar-H), 7.10-7.06 (2H, m, Ar-H), 3.85 (3H, s, CH3). tR (HPLC) 3.61 min. 
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2-(4-Methoxy-phenyl)-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-acetamide, 251 (JCC-CRT-
275) 
 
Off-white solid (9.6 mg, 30% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.27 (1H, s, NH), 8.29 (1H, t, J 1.7, Ar-H), 8.10 (1H, s, thiazole-H), 8.04-8.01 (2H, m, Ar-
H), 7.71-7.65 (2H, m, Ar-H), 7.55-7.51 (3H, m, Ar-H), 7.39 (1H, t, J 7.9, Ar-H), 7.28 (2H, d, 
J 8.6, Ar-H), 6.92-6.88 (2H, m, Ar-H), 3.73 (3H, s, CH3), 3.60 (2H, s, CH2). tR (HPLC) 3.59 
min. 
 
4-Hydroxymethyl-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-benzamide, 252 (JCC-CRT-277) 
 
Pale brown solid (7.0 mg, 22%, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 10.34 
(1H, s, NH), 8.48 (1H, t, J 1.8, Ar-H), 8.13 (1H, s, thiazole-H), 8.08-8.03 (2H, m, Ar-H), 7.99 
(2H, d, J 8.3, Ar-H), 7.88-7.84 (1H, m, Ar-H), 7.79-7.74 (1H, m, Ar-H), 7.57-7.52 (3H, m, 
Ar-H), 7.50-7.43 (3H, m, Ar-H), 5.35 (1H, t, J 5.8, OH), 4.60 (2H, d, J 5.8, CH2). tR (HPLC) 
3.46 min. 
 
4-Methyl-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-benzamide, 253 (JCC-CRT-278) 
 
Off-white solid (2.3 mg, 8% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.35 (1H, s, NH), 8.47 (1H, t, J 1.8, Ar-H), 8.13 (1H, s, thiazole-H), 8.05 (2H, dd, J 7.9, 1.7, 
Ar-H), 7.87-7.82 (2H, m, Ar-H), 7.82-7.79 (1H, m, Ar-H), 7.78-7.74 (1H, m, Ar-H), 7.57-
7.51 (3H, m, Ar-H), 7.48-7.42 (3H, m, Ar-H), 2.42 (3H, s, CH3). tR (HPLC) 4.47 min. 
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4-Methanesulfonylamino-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-benzamide, 254 (JCC-
CRT-280) 
 
Off-white solid (3.3 mg, 9% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.29 (1H, s, CONH), 10.21 (1H, s, SO2NH), 8.46 (1H, t, J 1.7, Ar-H), 8.13 (1H, s, thiazole-
H), 8.05 (2H, dd, J 7.9, 1.7, Ar-H), 8.00 (2H, d, J 8.7, Ar-H), 7.85-7.82 (1H, m, Ar-H), 7.78-
7.74 (1H, m, Ar-H), 7.58-7.52 (3H, m, Ar-H), 7.45 (1H, t, J 7.9, Ar-H), 7.32 (2H, d, J 8.7, Ar-
H), 3.11 (3H, s, CH3). tR (HPLC) 3.77 min. 
 
2-(2-Methoxy-phenyl)-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-acetamide, 255 (JCC-CRT-
285) 
 
White solid (2.4 mg, 7% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 10.20 
(1H, s, NH), 8.33 (1H, s, Ar-H), 8.10 (1H, s, thiazole-H), 8.02 (2H, dd, J 7.8, 1.6, Ar-H), 7.67 
(2H, dd, J 12.9, 8.6, Ar-H), 7.57-7.50 (3H, m, Ar-H), 7.39 (1H, t, J 7.9, Ar-H), 7.24 (2H, d, J 
7.5, Ar-H), 6.99 (1H, d, J 7.9, Ar-H), 6.95-6.88 (1H, m, Ar-H), 3.78 (3H, s, CH3), 3.67 (2H, s, 
CH2). tR (HPLC) 4.12 min. 
 
Benzo[b]thiophene-2-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 256 (JCC-
CRT-242) 
 
Off-white solid (15.7 mg, 38% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.68 (1H, s, NH), 8.48 (1H, t, J 1.8, Ar-H), 8.45 (1H, s, Ar-H), 8.17 (1H, s, thiazole-H), 
8.11-8.01 (4H, m, Ar-H), 7.89-7.85 (1H, m, Ar-H), 7.81-7.78 (1H, m, Ar-H), 7.57-7.52 (3H, 
m, Ar-H), 7.52-7.46 (3H, m, Ar-H). tR (HPLC) 3.76 min. 
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1H-Indole-2-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 257 (JCC-CRT-
248) 
 
Pale orange solid (11.0 mg, 28% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
11.81 (1H, s, indole-NH), 10.39 (1H, s, CONH), 8.52 (1H, t, J 1.7, Ar-H), 8.15 (1H, s, 
thiazole-H), 8.06 (2H, dd, J 7.9, 1.6, Ar-H), 7.95-7.88 (1H, m, Ar-H), 7.79-7.72 (1H, m, Ar-
H), 7.70 (1H, d, J 7.9, Ar-H), 7.58-7.47 (6H, m, Ar-H), 7.27-7.19 (1H, m, Ar-H), 7.12-7.04 
(1H, m, Ar-H). tR (HPLC) 3.64 min. 
 
Ten further compounds were successfully synthesised, but the purification was not sufficient 
for assignment of the 
1
H-NMR data. These compounds were tested in the enzyme assays. 
– N-[3-(2-Phenyl-thiazol-4-yl)-phenyl]-phthalamic acid methyl ester, 258 (JCC-CRT-
228) 
 
– 3-Phenyl-isoxazole-5-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 259 
(JCC-CRT-255) 
 
– 5-(4-Chloro-phenyl)-isoxazole-3-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-
amide, 260 (JCC-CRT-261) 
 
– 5-Fluoro-2-methoxy-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-benzamide, 261 (JCC-
CRT-264) 
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– 5-Ethoxy-2-hydroxy-N-[3-(2-phenyl-thiazol-4-yl)-phenyl]-benzamide, 262 (JCC-
CRT-266) 
 
– N-[3-(2-Phenyl-thiazol-4-yl)-phenyl]-4-sulfamoyl-benzamide, 263 (JCC-CRT-269) 
 
– 2,2-Difluoro-cyclopropanecarboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 
264 (JCC-CRT-272) 
 
– 5-Phenyl-isoxazole-4-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 265 
(JCC-CRT-241) 
 
– 3-Isopropyl-1H-pyrazole-4-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 
266 (JCC-CRT-243) 
 
– 5-Isopropyl-isoxazole-3-carboxylic acid [3-(2-phenyl-thiazol-4-yl)-phenyl]-amide, 
267 (JCC-CRT-244) 
 
 
Parallel Synthesis: General Procedure for Buchwald-Hartwig Couplings of Aniline 166 
 
 
A solution of aniline 166 (20 mg, 100 μmol), aryl halide (100 μmol), NaOtBu (19.6 mg, 200 
μmol), Xantphos (5.8 mg, 10 μmol) and Pd(dba)2 (2.9 mg, 5 μmol) in dioxane (1.5 mL) was 
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heated (MW, 150 °C, 15 min). Upon cooling, H2O (2 mL) was added and the aqueous layer 
extracted with CH2Cl2 (5 mL), the solvent removed in vacuo and the product purified by 
HPLC under basic conditions. 
 
[3-(2-Phenyl-thiazol-4-yl)-phenyl]-pyridin-2-yl-amine, 268 (JCC-CRT-324) 
 
Orange gum (6.2 mg, 19% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 9.18 
(1H, s, NH), 8.25 (1H, t, J 1.8, Ar-H), 8.19 (1H, dd, J 5.2, 1.5, pyridine-H), 8.07 (1H, s, 
thiazole-H), 8.04 (2H, dd, J 7.8, 1.5, Ar-H), 7.88 (1H, dd, J 8.3, 1.5, pyridine-H), 7.62-7.50 
(5H, m), 7.36 (1H, t, J 7.9, Ar-H), 6.88 (1H, d, J 8.3, pyridine-H), 6.80-6.72 (1H, m, pyridine-
H). tR (HPLC) 5.88 min. 
 
(6-Methoxy-pyridin-2-yl)-[3-(2-phenyl-thiazol-4-yl)-phenyl]-amine, 269 (JCC-CRT-331) 
 
Red gum (20.4 mg, 57% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 9.20 
(1H, s, NH), 8.57 (1H, t, J 1.8, Ar-H), 8.07 (1H, s, thiazole-H), 8.03-7.99 (2H, m, Ar-H), 
7.65-7.60 (1H, m, pyridine-H), 7.58-7.47 (5H, m, Ar-H), 7.35 (1H, t, J 7.9, Ar-H), 6.44 (1H, d, 
J 7.8, pyridine-H), 6.17 (1H, d, J 7.8, pyridine-H), 3.92 (3H, s, CH3). tR (HPLC) 5.79 min. 
 
(6-Methoxy-pyridin-3-yl)-[3-(2-phenyl-thiazol-4-yl)-phenyl]-amine, 270 (JCC-CRT-332) 
 
Red gum (17.6 mg, 49% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 8.13 
(1H, s, Ar-H), 8.06 (1H, s, thiazole-H), 8.03 (1H, d, J 2.7, Ar-H), 8.02-7.98 (2H, m, Ar-H, 
NH), 7.65-7.62 (1H, m, pyridine-H), 7.58 (1H, dd, J 8.8, 2.9, Ar-H), 7.54-7.50 (3H, m, Ar-H), 
7.43-7.39 (1H, m, Ar-H), 7.28 (1H, t, J 7.8, Ar-H), 6.92 (1H, dd, J 7.8, 1.7, pyridine-H), 6.81 
(1H, d, J 7.8, pyridine-H), 3.83 (3H, s, OCH3). tR (HPLC) 5.12 min. 
 
(6-Methyl-pyridazin-3-yl)-[3-(2-phenyl-thiazol-4-yl)-phenyl]-amine, 271 (JCC-CRT-334) 
 
Light brown solid (6.7 mg, 19% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
9.28 (1H, s, NH), 8.29 (1H, t, J 1.9, Ar-H), 8.09 (1H, s, thiazole-H), 8.05-8.02 (2H, m, Ar-H), 
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7.92 (1H, dd, J 8.2, 1.5, Ar-H), 7.60-7.52 (4H, m, Ar-H), 7.41 (1H, t, J 7.9, Ar-H), 7.35 (1H, 
d, J 9.1, pyridazine-H), 7.11 (1H, d, J 9.1, pyridazine-H), 2.48 (3H, s). tR (HPLC) 3.29 min. 
 
[3-(2-Phenyl-thiazol-4-yl)-phenyl]-pyrimidin-2-yl-amine, 272 (JCC-CRT-338) 
 
Off-white solid (7.6 mg, 23% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
9.72 (1H, s, NH), 8.51 (2H, d, J 4.8, pyrimidine-H), 8.43 (1H, t, J 1.8, Ar-H), 8.06 (1H, s, 
thiazole-H), 8.04 (2H, dd, J 7.8, 1.6, Ar-H), 7.83 (1H, dd, J 8.2, 1.4, Ar-H), 7.65-7.59 (1H, m, 
Ar-H), 7.58-7.52 (3H, m, Ar-H), 7.38 (1H, t, J 7.9, Ar-H), 6.86 (1H, t, J 4.8, pyrimidine-H). 
tR (HPLC) 4.70 min. 
 
[3-(2-Phenyl-thiazol-4-yl)-phenyl]-(3-trifluoromethyl-pyridin-2-yl)-amine, 273 (JCC-
CRT-339) 
 
Orange solid (3.6 mg, 9% yield, ca. 60% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 8.38-
8.35 (1H, m, pyridine-H), 8.25 (1H, s, NH), 8.15 (1H, t, J 1.9, Ar-H), 8.13 (1H, s, thiazole-H), 
8.03 (2H, dd, J 7.9, 1.7, Ar-H), 8.01-7.98 (1H, m, pyridine-H), 7.75-7.72 (1H, m, Ar-H), 7.57-
7.52 (4H, m, Ar-H), 7.40 (1H, t, J 7.9, Ar-H), 6.97 (1H, dd, J 7.8, 5.0, pyridine-H). tR (HPLC) 
5.62 min. 
 
(4-Fluoro-pyridin-2-yl)-[3-(2-phenyl-thiazol-4-yl)-phenyl]-amine, 274 (JCC-CRT-340) 
 
Off-white solid (12.5 mg, 36% yield, ca. 60% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
9.40 (1H, s, NH), 8.24-8.19 (2H, m, Ar-H, pyridine-H), 8.10 (1H, s, thiazole-H), 8.03 (2H, dd, 
J 7.8, 1.6, Ar-H), 7.84 (1H, dd, J 7.7, 1.7, Ar-H), 7.61-7.51 (4H, m, Ar-H), 7.39 (1H, t, J 7.9, 
Ar-H), 6.73-6.67 (1H, m, pyridine-H), 6.63 (1H, dd, J 11.8, 2.2, pyridine-H). tR (HPLC) 4.83 
min. 
 
One further compound was successfully synthesised, but the purification was not sufficient 
for assignment of the 
1
H-NMR data. This compound was tested in the enzyme assays. 
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– [3-(2-Phenyl-thiazol-4-yl)-phenyl]-thieno[3,2-d]pyrimidin-4-yl-amine, 275 (JCC-
CRT-341) 
 
 
Parallel Synthesis: General Procedure for Buchwald-Hartwig Couplings of Bromide 93 
 
 
A solution of bromide 93 (27 mg, 100 μmol), amine (200 μmol), NaOtBu (19.6 mg, 200 
μmol), Xantphos (5.8 mg, 10 μmol) and Pd2(dba)3 (4.6 mg, 5 μmol) in dioxane (1.0 mL) was 
heated (MW, 150 °C, 20 min). Upon cooling, the reaction mixture was partitioned between 
H2O (2 mL) and CH2Cl2 (5 mL), the organic layer separated, the solvent removed in vacuo 
and the product purified by HPLC under acidic conditions. 
 
4-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-morpholine, 276 (JCC-CRT-346) 
 
Red gum (2.2 mg, 8% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 7.81 (2H, 
d, J 8.9, Ar-H), 7.02 (2H, d, J 8.9, Ar-H), 6.25 (1H, s, thiazole-H), 3.81 (3H, s, CH3), 3.77-
3.70 (4H, m, 2 × OCH2), 3.26-3.19 (4H, m, 2 × NCH2). tR (HPLC) 3.31 min. 
 
[2-(4-Methoxy-phenyl)-thiazol-4-yl]-pyridin-3-yl-amine, 277 (JCC-CRT-351) 
 
Dark orange gum (0.7 mg, 3% yield, ca. 75% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
9.71 (1H, s, NH), 8.74 (1H, d, J 2.6, pyridine-H), 8.17 (1H, dd, J 5.1, 1.0, pyridine-H), 8.03 
(1H, dd, J 8.4, 1.6, pyridine-H), 7.92-7.86 (2H, m, Ar-H), 7.58 (1H, dd, J 8.4, 5.1, pyridine-
H), 7.11-7.04 (2H, m, Ar-H), 6.81 (1H, s, thiazole-H), 3.83 (3H, s, CH3). tR (HPLC) 3.24 min. 
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[2-(4-Methoxy-phenyl)-thiazol-4-yl]-pyridin-4-yl-amine, 278 (JCC-CRT-352) 
 
Dark orange gum (2.9 mg, 10% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.85 (1H, s, NH), 8.35 (2H, d, J 7.0, pyridine-H), 7.92 (2H, d, J 8.8, Ar-H), 7.53 (2H, d, J 
7.0, pyridine-H), 7.15 (1H, s, thiazole-H), 7.08 (2H, d, J 8.8, Ar-H), 3.84 (3H, s, CH3). tR 
(HPLC) 3.23 min. 
 
(3-Methoxy-phenyl)-[2-(4-methoxy-phenyl)-thiazol-4-yl]-amine, 279 (JCC-CRT-357) 
 
Brown gum (3.0 mg, 10% yield, ca. 60% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 8.99 
(1H, s, NH), 7.91-7.81 (2H, m, Ar-H), 7.13 (1H, t, J 8.2, Ar-H), 7.09-7.04 (2H, m, Ar-H), 
6.91 (1H, t, J 2.2, Ar-H), 6.83 (1H, dd, J 8.2, 1.6, Ar-H), 6.62 (1H, s, thiazole-H), 6.39 (1H, 
dd, J 8.2, 2.2, Ar-H), 3.82 (3H, s, CH3), 3.73 (3H, s, CH3). tR (HPLC) 3.53 min. 
 
(2-Methoxy-phenyl)-[2-(4-methoxy-phenyl)-thiazol-4-yl]-amine, 280 (JCC-CRT-358) 
 
Brown solid (2.5 mg, 8% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 7.89-
7.82 (2H, m, Ar-H), 7.79 (1H, s, NH), 7.64 (1H, dd, J 7.9, 1.6, Ar-H), 7.08-7.03 (2H, m, Ar-
H), 6.99 (1H, dd, J 7.9, 1.6, Ar-H), 6.93-6.80 (2H, m, Ar-H), 6.69 (1H, s, thiazole-H), 3.86 
(3H, s, CH3), 3.82 (3H, s, CH3). tR (HPLC) 3.69 min. 
 
[2-(4-Methoxy-phenyl)-thiazol-4-yl]-p-tolyl-amine, 281 (JCC-CRT-359) 
 
Brown solid (3.6 mg, 12% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 8.86 
(1H, s, NH), 7.88-7.81 (2H, m, Ar-H), 7.16 (2H, d, J 8.5, Ar-H), 7.08-7.02 (4H, m, Ar-H), 
6.53 (1H, s, thiazole-H), 3.82 (3H, s, OCH3), 2.22 (3H, s, ArCH3). tR (HPLC) 3.66 min. 
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(4-Methoxy-phenyl)-[2-(4-methoxy-phenyl)-thiazol-4-yl]-amine, 282 (JCC-CRT-367) 
 
Brown solid (2.3 mg, 7% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 8.71 
(1H, s, NH), 7.90-7.80 (2H, m, Ar-H), 7.25-7.18 (2H, m, Ar-H), 7.05 (2H, d, J 9.0, Ar-H), 
6.86 (2H, d, J 9.0, Ar-H), 6.42 (1H, s, thiazole-H), 3.82 (3H, s, CH3), 3.70 (3H, s, CH3). tR 
(HPLC) 4.00 min. 
 
N-(4-[2-(4-Methoxy-phenyl)-thiazol-4-ylamino]-phenyl)-acetamide, 283 (JCC-CRT-370) 
 
Brown solid (5.6 mg, 17% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 9.75 
(1H, s, CONH), 8.89 (1H, s, NH), 7.88-7.83 (2H, m, Ar-H), 7.44 (2H, d, J 9.0, Ar-H), 7.20 
(2H, d, J 9.0, Ar-H), 7.09-7.04 (2H, m, Ar-H), 6.53 (1H, s, thiazole-H), 3.82 (3H, s, OCH3), 
2.00 (3H, s, COCH3). tR (HPLC) 4.66 min. 
 
(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-[2-(4-methoxy-phenyl)-thiazol-4-yl]-amine, 284 
(JCC-CRT-374) 
 
Brown solid (5.7 mg, 17% yield, ca. 75% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 8.72 
(1H, s, NH), 7.86-7.80 (2H, m, Ar-H), 7.07-7.04 (2H, m, Ar-H), 6.84 (1H, d, J 2.2, Ar-H), 
6.75-6.71 (2H, m, Ar-H), 6.44 (1H, s, thiazole-H), 4.23-4.16 (4H, m, 2 × CH2), 3.82 (3H, s, 
CH3). tR (HPLC) 3.66 min. 
 
[2-(4-Methoxy-phenyl)-thiazol-4-yl]-(3-trifluoromethyl-phenyl)-amine, 285 (JCC-CRT-
376) 
 
Dark red gum (11.1 mg, 32% yield, ca. 80% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
9.39 (1H, s, NH), 7.89-7.84 (2H, m, Ar-H), 7.68 (1H, s, ArH), 7.54 (1H, d, J 9.9, ArH), 7.45 
(1H, t, J 7.9, ArH), 7.14-7.04 (3H, m, Ar-H), 6.72 (1H, s, thiazole-H), 3.82 (3H, s, CH3). tR 
(HPLC) 3.86 min. 
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[2-(4-Methoxy-phenyl)-thiazol-4-yl]-(4-trifluoromethyl-phenyl)-amine, 286 (JCC-CRT-
377) 
 
Light brown solid (4.3 mg, 12% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
9.52 (1H, s, NH), 7.91-7.85 (2H, m, Ar-H), 7.56 (2H, d, J 8.7, Ar-H), 7.42 (2H, d, J 8.6, Ar-
H), 7.11-7.03 (2H, m, Ar-H), 6.81 (1H, s, thiazole-H), 3.83 (3H, s, CH3). tR (HPLC) 3.90 min. 
 
(3,5-Bis-trifluoromethyl-phenyl)-[2-(4-methoxy-phenyl)-thiazol-4-yl]-amine, 287 (JCC-
CRT-378) 
 
Dark orange solid (5.6 mg, 13% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
9.81 (1H, s, NH), 7.95 (2H, s, Ar-H), 7.90-7.82 (2H, m, Ar-H), 7.39 (1H, s, Ar-H), 7.13-7.05 
(2H, m, Ar-H), 6.82 (1H, s, thiazole-H), 3.83 (3H, s, CH3). tR (HPLC) 4.22 min. 
 
(4-Isopropyl-phenyl)-[2-(4-methoxy-phenyl)-thiazol-4-yl]-amine, 288 (JCC-CRT-384) 
 
Brown solid (10.3 mg, 32% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
8.87 (1H, s, NH), 7.89-7.82 (2H, m, Ar-H), 7.25-7.18 (2H, m, Ar-H), 7.15-7.11 (2H, m, Ar-
H), 7.09-7.05 (2H, m, Ar-H), 6.55 (1H, s, thiazole-H), 3.84 (3H, s, OCH3), 2.82 (1H, hept, J 
7.0, CH(CH3)2), 1.19 (6H, d, J 7.0, CH(CH3)2). tR (HPLC) 3.89 min. 
 
Five further compounds were successfully synthesised, but the purification was not sufficient 
for assignment of the 
1
H-NMR data. These compounds were tested in the enzyme assays. 
– 4-([2-(4-Methoxy-phenyl)-thiazol-4-ylamino]-methyl)-benzenesulfonamide, 289 
(JCC-CRT-373) 
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– Biphenyl-3-yl-[2-(4-methoxy-phenyl)-thiazol-4-yl]-amine, 290 (JCC-CRT-380) 
 
– (3,4-Dimethyl-phenyl)-[2-(4-methoxy-phenyl)-thiazol-4-yl]-amine, 291 (JCC-CRT-
381) 
 
– (1H-Indol-5-yl)-[2-(4-methoxy-phenyl)-thiazol-4-yl]-amine, 292 (JCC-CRT-382) 
 
–  (3,4-Dichloro-phenyl)-[2-(4-methoxy-phenyl)-thiazol-4-yl]-amine, 293 (JCC-CRT-
383) 
 
 
Parallel Synthesis: General Procedure for Aminothiazole Synthesis 
 
 
A solution of thiourea (100 μmol) and α-bromo ketone (100 μmol) in EtOH (0.5 mL) was 
heated (MW, 160 °C, 10 min). Upon cooling, the product was purified by HPLC under acidic 
conditions. 
 
[4-(3-Methoxy-phenyl)-thiazol-2-yl]-(3-trifluoromethyl-phenyl)-amine, 294 (JCC-CRT-
307) 
 
Orange gum (26.3 mg, 75% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.68 (1H, s, NH), 8.53 (1H, s, thiazole-H), 7.74 (1H, d, J 8.3, Ar-H), 7.57 (1H, t, J 8.0, Ar-
H), 7.52-7.49 (2H, m, Ar-H), 7.47 (1H, s, Ar-H), 7.35 (1H, t, J 8.0, Ar-H), 7.30 (1H, d, J 7.7, 
Ar-H), 6.92-6.87 (1H, m, Ar-H), 3.82 (3H, s, CH3). tR (HPLC) 4.34 min. 
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[4-(4-Trifluoromethoxy-phenyl)-thiazol-2-yl]-(3-trifluoromethyl-phenyl)-amine, 295 
(JCC-CRT-308) 
 
Orange gum (26.4 mg, 65% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.70 (1H, s, NH), 8.28 (1H, s, thiazole-H), 8.05-8.00 (2H, m, Ar-H), 7.91 (1H, d, J 9.4, Ar-
H), 7.57 (1H, t, J 8.0, Ar-H), 7.52 (1H, s, Ar-H), 7.44 (2H, d, J 8.1, Ar-H), 7.30 (1H, d, J 7.8, 
Ar-H). tR (HPLC) 4.98 min. 
 
[4-(4-Difluoromethoxy-phenyl)-thiazol-2-yl]-(3-trifluoromethyl-phenyl)-amine, 296 
(JCC-CRT-309) 
 
Orange gum (37.6 mg, 98% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.68 (1H, s, NH), 8.34 (1H, s, thiazole-H), 7.99-7.94 (2H, m, Ar-H), 7.88 (1H, d, J 9.5, Ar-
H), 7.57 (1H, t, J 8.0, Ar-H), 7.43 (1H, s, Ar-H), 7.30 (1H, t, J 74.1, OCHF2), 7.29 (1H, d, J 
7.6, Ar-H), 7.26 (2H, d, J 8.7, Ar-H). tR (HPLC) 4.00 min. 
 
(4-Benzofuran-5-yl-thiazol-2-yl)-(3-trifluoromethyl-phenyl)-amine, 297 (JCC-CRT-313) 
 
Orange gum (10.7 mg, 30% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.66 (1H, s, NH), 8.35 (1H, s, thiazole-H), 8.20 (1H, d, J 1.5, Ar-H), 8.03 (1H, d, J 2.1, Ar-
H), 7.95-7.88 (2H, m, Ar-H), 7.66 (1H, d, J 8.7, Ar-H), 7.59 (1H, t, J 8.0, Ar-H), 7.41 (1H, s, 
Ar-H), 7.30 (1H, d, J 7.7, Ar-H), 7.01-7.00 (1H, m, Ar-H). tR (HPLC) 4.36 min. 
 
[4-(4-Methoxy-phenyl)-thiazol-2-yl]-pyridin-4-yl-amine, 298 (JCC-CRT-315) 
 
Pale yellow gum (11.3 mg, 40% yield, ca. 98% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
8.42 (2H, d, J 6.3, pyridine-H), 8.14 (1H, s, NH), 7.88 (2H, d, J 8.8, Ar-H), 7.70 (2H, d, J 6.3, 
pyridine-H), 7.35 (1H, s, thiazole-H), 7.01 (2H, d, J 8.8, Ar-H), 3.80 (3H, s, CH3). tR (HPLC) 
1.79 min. 
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3-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine, 299 
229
 
 
A suspension of 3-aminobenzeneboronic acid monohydrate (2.30 g, 14.8 mmol), pinacol 
(2.11 g, 17.8 mmol) and MgSO4 (3.57 g, 29.7 mmol) in CH2Cl2 (15 mL) was stirred at r.t. for 
20 h, before being filtered and the solvent removed in vacuo. Column chromatography eluting 
with EtOAc/petrol (1:3) afforded the title compound as a white amorphous solid (3.24 g, 
100%), mp 90-92 °C; Rf 0.30 (EtOAc/petrol 1:3); δH (400 MHz, DMSO-d6) 7.23-7.12 (3H, m, 
Ar-H), 6.78 (1H, ddd, J 7.6, 2.4, 1.1, Ar-H), 3.62 (2H, br s, NH2), 1.33 (12H, s, 4 × CH3); m/z 
(CI) 439 (100%), 438 (68), 220 (MH
+
, 77), 219 (MH
+
, 85). Found MH
+
, 220.1501. 
C12H19BNO2 requires 220.1509. Data is in agreement with the literature.
229
 
 
Furan-2-carboxylic acid [3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-amide, 
300 
 
2-Furoyl chloride (0.90 mL, 9.13 mmol) was added dropwise to a stirred solution of pinacol 
boronate 299 (2.00 g, 9.13 mmol) and Et3N (2.55 mL, 18.3 mmol) in THF (40 mL) at 0 °C. 
The resulting white suspension was stirred for 3 h, filtered and the solvent removed in vacuo. 
Column chromatography eluting with EtOAc/petrol (1:3 → 1:1) afforded the title compound 
as a white solid (2.83 g, 99%), υmax (neat)/cm
-1
 1665, 1583, 1539, 1352; δH (400 MHz, CDCl3) 
8.11 (1H, br s, NH), 8.06 (1H, d, J 8.1, furan 5-H), 7.75 (1H, s, Ar-H), 7.55 (1H, d, J 7.3, Ar-
H), 7.46 (1H, s, Ar-H), 7.37 (1H, t, J 7.7, Ar-H), 7.20 (1H, d, J 3.4, furan 3-H), 6.52 (1H, dd, 
J 3.4, 1.7, furan 4-H), 1.32 (12H, s, 4 × CH3); δC (101 MHz, CDCl3) 156.2, 148.0, 144.4, 
137.1, 130.9, 128.9, 125.9, 123.1, 115.4, 112.8, 84.2, 77.4, 25.1; m/z (CI) 331 (MNH4
+
, 87%), 
330 (MNH4
+
, 22), 314 (MH
+
, 100), 313 (MH
+
, 48), 274 (29). Found MH
+
, 314.1563. 
C17H21BNO4 requires 314.1564. 
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Parallel Synthesis: General Procedure for One-Pot, Consecutive Suzuki Couplings 
 
A solution of 2,4-dibromothiazole 94 (24 mg, 100 μmol), boronic acid (100 μmol), K2CO3 
(41.5 mg, 300 μmol) and Pd(PPh3)4 (3.5 mg, 3 μmol) in DME/H2O (4:1, 1 mL) was heated 
(MW, 140 °C, 15 min). Upon cooling, boronic ester 300 (35 mg, 150 μmol) and Pd(PPh3)4 
(3.5 mg, 3 μmol) were added and the reaction mixture heated (MW, 160 °C, 20 min). Upon 
cooling, H2O (5 mL) was added and the aqueous layer extracted with CH2Cl2 (10 mL), the 
solvent removed in vacuo and the product purified by HPLC under acidic conditions. 
 
Furan-2-carboxylic acid (3-[2-(4-methoxy-phenyl)-thiazol-4-yl]-phenyl)-amide, 301 
(JCC-CRT-398B) 
 
Brown solid (11.3 mg, 30% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.32 (1H, s, NH), 8.44-8.41 (1H, m, Ar-H), 8.02 (1H, s, thiazole-H), 7.99 (1H, s, furan-H), 
7.97-7.95 (2H, m, Ar-H), 7.83-7.79 (1H, m, Ar-H), 7.76-7.72 (1H, m, Ar-H), 7.43 (1H, t, J 
8.0, Ar-H), 7.41-7.39 (1H, m, furan-H), 7.10 (2H, d, J 8.8, Ar-H), 6.72 (1H, dd, J 3.5, 1.8, 
furan-H), 3.84 (3H, s, CH3). tR (HPLC) 3.99 min. 
 
Furan-2-carboxylic acid (3-[2-(4-methanesulfonyl-phenyl)-thiazol-4-yl]-phenyl)-amide, 
302 (JCC-CRT-402) 
 
White solid (10.7 mg, 25% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.34 (1H, s, NH), 8.46 (1H, t, J 1.8, Ar-H), 8.32-8.26 (3H, m, 2 × Ar-H, thiazole-H), 8.13-
8.07 (2H, m, Ar-H, furan-H), 7.97-7.95 (1H, m, Ar-H), 7.86-7.81 (1H, m, Ar-H), 7.80-7.76 
(1H, m, Ar-H), 7.46 (1H, t, J 7.9, Ar-H), 7.41-7.38 (1H, m, furan-H), 6.73 (1H, dd, J 3.5, 1.7, 
furan-H), 3.30 (3H, s, CH3). tR (HPLC) 3.39 min. 
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Furan-2-carboxylic acid (3-[2-(3-carbamoyl-phenyl)-thiazol-4-yl]-phenyl)-amide, 303 
(JCC-CRT-403) 
 
Off-white solid (8.8 mg, 23% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.35 (1H, s, NH), 8.50 (1H, t, J 1.7, Ar-H), 8.43 (1H, t, J 1.8, Ar-H), 8.23-8.15 (3H, m, 
thiazole-H, 2 × Ar-H), 8.03-7.99 (1H, m, furan-H), 7.97-7.95 (1H, m, Ar-H), 7.87-7.83 (1H, 
m, Ar-H), 7.80-7.76 (1H, m, Ar-H), 7.46 (1H, t, J 7.9, Ar-H), 7.42-7.39 (1H, m, furan-H), 
6.72 (1H, dd, J 3.4, 1.9, furan-H). tR (HPLC) 3.36 min. 
 
Furan-2-carboxylic acid (3-[2-(4-methoxymethyl-phenyl)-thiazol-4-yl]-phenyl)-amide, 
304 (JCC-CRT-404) 
 
Off-white solid (14.7 mg, 38% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.32 (1H, s, NH), 8.44 (1H, t, J 1.8, Ar-H), 8.11 (1H, s, thiazole-H), 8.05-8.00 (2H, m, Ar-
H), 7.96-7.95 (1H, m, furan-H), 7.85-7.80 (1H, m, Ar-H), 7.77-7.74 (1H, m, Ar-H), 7.49 (2H, 
d, J 8.1, Ar-H), 7.44 (1H, t, J 7.9, Ar-H), 7.40 (1H, d, J 3.4, furan-H), 6.72 (1H, dd, J 3.4, 1.7, 
furan-H), 4.49 (2H, s, CH2), 3.34 (3H, s, CH3). tR (HPLC) 3.89 min. 
 
Furan-2-carboxylic acid (3-[2-(3-methanesulfonylamino-phenyl)-thiazol-4-yl]-phenyl)-
amide, 305 (JCC-CRT-406) 
 
Orange solid (18.6 mg, 42% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.33 (1H, s, NH), 8.42 (1H, t, J 1.8, Ar-H), 8.13 (1H, s, thiazole-H), 7.97-7.95 (1H, m, Ar-
H), 7.90 (1H, t, J 1.9, furan-H), 7.80 (1H, dd, J 8.2, 1.2, Ar-H), 7.78-7.73 (2H, m, Ar-H), 7.46 
(1H, t, J 7.9, Ar-H), 7.40-7.35 (3H, m, 2 × Ar-H, furan-H), 6.72 (1H, dd, J 3.5, 1.9, furan-H), 
3.06 (3H, s, CH3). tR (HPLC) 3.04 min. 
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Furan-2-carboxylic acid (3-[2-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazin-7-yl)-thiazol-
4-yl]-phenyl)-amide, 306 (JCC-CRT-407) 
 
Orange gum (6.2 mg, 15% yield, ca. 70% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.29 (1H, s, NH), 8.40 (1H, t, J 1.8, Ar-H), 7.97-7.95 (1H, m, furan-H), 7.91 (1H, s, 
thiazole-H), 7.83-7.79 (1H, m, Ar-H), 7.74-7.69 (1H, m, Ar-H), 7.47-7.41 (2H, m, Ar-H), 
7.40-7.38 (1H, m, furan-H), 7.33 (1H, d, J 2.0, Ar-H), 6.78 (1H, d, J 8.4, Ar-H), 6.72 (1H, dd, 
J 3.5, 1.7, furan-H), 4.30-4.24 (2H, m, OCH2), 3.39-3.33 (2H, m, NCH2), 2.93 (3H, s, CH3). 
tR (HPLC) 3.95 min. 
 
Furan-2-carboxylic acid (3-[2-(4-carbamoyl-phenyl)-thiazol-4-yl]-phenyl)-amide, 307 
(JCC-CRT-408) 
 
White solid (8.0 mg, 21% yield, ca. 60% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 10.33 
(1H, s, NH), 8.45 (1H, t, J 1.8, Ar-H), 8.20 (1H, s, thiazole-H), 8.12 (2H, d, J 8.4, Ar-H), 8.04 
(2H, d, J 8.4, Ar-H), 7.97-7.95 (1H, m, furan-H), 7.87-7.82 (1H, m, Ar-H), 7.79-7.75 (1H, m, 
Ar-H), 7.46 (1H, t, J 7.9, Ar-H), 7.40 (1H, dd, J 4.2, 1.0, furan-H), 6.73 (1H, dd, J 3.5, 1.9, 
furan-H). tR (HPLC) 3.35 min. 
 
Furan-2-carboxylic acid (3-[2-(2-methoxy-phenyl)-thiazol-4-yl]-phenyl)-amide, 308 
(JCC-CRT-409) 
 
Light brown solid (10.7 mg, 28% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-
d6) 10.32 (1H, s, NH), 8.52-8.41 (2H, m, Ar-H), 8.13 (1H, s, thiazole-H), 7.96 (1H, s, furan-
H), 7.80 (2H, dd, J 16.0, 7.8, Ar-H), 7.51 (1H, t, J 7.8, Ar-H), 7.44 (1H, t, J 7.9, Ar-H), 7.40 
(1H, d, J 2.7, furan-H), 7.28 (1H, d, J 8.3, Ar-H), 7.17 (1H, t, J 7.5, Ar-H), 6.77-6.66 (1H, m, 
furan-H), 4.05 (3H, s, CH3). tR (HPLC) 3.98 min. 
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Furan-2-carboxylic acid [3-(2-p-tolyl-thiazol-4-yl)-phenyl]-amide, 309 (JCC-CRT-410) 
 
Light brown solid (13.7 mg, 38% yield, ca. 90% purity by 
1
H-NMR), δH (400 MHz, DMSO-
d6) 10.33 (1H, s, NH), 8.43 (1H, s, Ar-H), 8.08 (1H, s, thiazole-H), 7.99-7.90 (3H, m, 2 × Ar-
H, furan-H), 7.82 (1H, d, J 8.1, Ar-H), 7.75 (1H, d, J 7.6, Ar-H), 7.44 (1H, t, J 8.0, Ar-H), 
7.40 (1H, d, J 3.1, furan-H), 7.36 (2H, d, J 7.8, Ar-H), 6.73 (1H, s, furan-H), 2.38 (3H, s, 
CH3). tR (HPLC) 4.15 min. 
 
Furan-2-carboxylic acid (3-[2-(3-hydroxy-phenyl)-thiazol-4-yl]-phenyl)-amide, 310 
(JCC-CRT-411) 
 
Off-white solid (13.8 mg, 38% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.34 (1H, s, NH), 9.86 (1H, s, OH), 8.45 (1H, s, Ar-H), 8.10 (1H, s, thiazole-H), 7.96 (1H, s, 
furan-H), 7.80 (1H, d, J 8.1, Ar-H), 7.74 (1H, d, J 7.6, Ar-H), 7.49-7.42 (3H, m, Ar-H), 7.40 
(1H, d, J 2.9, furan-H), 7.34 (1H, t, J 7.7, Ar-H), 6.91 (1H, d, J 7.8, Ar-H), 6.73 (1H, d, J 1.5, 
furan-H). tR (HPLC) 3.53 min. 
 
Furan-2-carboxylic acid (3-[2-(4-hydroxy-phenyl)-thiazol-4-yl]-phenyl)-amide, 311 
(JCC-CRT-412) 
 
Light brown solid (7.9 mg, 22% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.31 (1H, s, NH), 10.04 (1H, s, OH), 8.42 (1H, s, Ar-H), 7.97 (2H, m, thiazole-H, furan-H), 
7.87 (2H, d, J 7.8, Ar-H), 7.80 (1H, d, J 8.1, Ar-H), 7.73 (1H, d, J 7.7, Ar-H), 7.43 (1H, t, J 
8.1, Ar-H), 7.39 (1H, d, J 2.7, furan-H), 6.91 (2H, d, J 7.8, Ar-H), 6.72 (1H, s, furan-H). tR 
(HPLC) 3.33 min. 
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Furan-2-carboxylic acid (3-[2-(3-methoxy-phenyl)-thiazol-4-yl]-phenyl)-amide, 312 
(JCC-CRT-413) 
 
Off-white solid (14.8 mg, 39% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.33 (1H, s, NH), 8.43 (1H, s, Ar-H), 8.13 (1H, s, thiazole-H), 7.96 (1H, s, furan-H), 7.83 
(1H, d, J 8.2, Ar-H), 7.76 (1H, d, J 7.5, Ar-H), 7.60 (1H, d, J 7.6, Ar-H), 7.56 (1H, s, Ar-H), 
7.46 (2H, q, J 8.1, Ar-H), 7.40 (1H, d, J 3.1, furan-H), 7.11 (1H, d, J 8.2, Ar-H), 6.72 (1H, s, 
furan-H), 3.87 (3H, s, CH3). tR (HPLC) 4.00 min. 
 
Furan-2-carboxylic acid [3-(2-o-tolyl-thiazol-4-yl)-phenyl]-amide, 313 (JCC-CRT-414) 
 
Light brown solid (13.7 mg, 38% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-
d6) 10.32 (1H, s, NH), 8.44 (1H, s, Ar-H), 8.18 (1H, s, thiazole-H), 7.96 (1H, s, furan-H), 7.82 
(2H, t, J 9.2, Ar-H), 7.75 (1H, d, J 7.7, Ar-H), 7.48-7.34 (5H, m, 4 × Ar-H, furan-H), 6.72 
(1H, s, furan-H), 2.65 (3H, s, CH3). tR (HPLC) 4.08 min. 
 
Furan-2-carboxylic acid (3-[2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-phenyl)-amide, 
314 (JCC-CRT-415) 
 
Off-white solid (11.4 mg, 28% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.36 (1H, s, NH), 8.47 (1H, s, Ar-H), 8.30-8.21 (3H, m, thiazole-H, 2 × Ar-H), 7.97 (1H, s, 
furan-H), 7.92 (2H, d, J 8.0, Ar-H), 7.83 (1H, d, J 8.0, Ar-H), 7.77 (1H, d, J 7.6, Ar-H), 7.46 
(1H, t, J 7.9, Ar-H), 7.40 (1H, d, J 2.8, furan-H), 6.76-6.70 (1H, m, furan-H). tR (HPLC) 4.18 
min. 
 
Furan-2-carboxylic acid [3-(2-m-tolyl-thiazol-4-yl)-phenyl]-amide, 315 (JCC-CRT-416) 
 
White solid (10.8 mg, 30% yield, ca. 95% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.33 (1H, s, NH), 8.42 (1H, s, Ar-H), 8.12 (1H, s, thiazole-H), 7.96 (1H, s, furan-H), 7.90-
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7.80 (3H, m, Ar-H), 7.76 (1H, d, J 7.6, Ar-H), 7.48-7.37 (3H, m, 2 × Ar-H, furan-H), 7.34 
(1H, d, J 7.4, Ar-H), 6.73 (1H, s, furan-H), 2.42 (3H, s, CH3). tR (HPLC) 4.15 min. 
 
Furan-2-carboxylic acid (3-[2-(3-trifluoromethyl-phenyl)-thiazol-4-yl]-phenyl)-amide, 
316 (JCC-CRT-417) 
 
Pale brown solid (2.5 mg, 6% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.34 (1H, s, NH), 8.43 (1H, s, Ar-H), 8.33 (2H, s, Ar-H), 8.24 (1H, s, thiazole-H), 7.97 (1H, 
s, furan-H), 7.91 (1H, d, J 7.7, Ar-H), 7.88-7.75 (3H, m, Ar-H), 7.46 (1H, t, J 7.8, Ar-H), 7.39 
(1H, d, J 3.2, furan-H), 6.73 (1H, s, furan-H). tR (HPLC) 4.19 min. 
 
Furan-2-carboxylic acid (3-[2-(6-dimethylamino-pyridin-3-yl)-thiazol-4-yl]-phenyl)-
amide, 317 (JCC-CRT-421) 
 
Yellow solid (11.2 mg, 29% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.31 (1H, s, NH), 8.79-8.69 (1H, m, pyridine-H), 8.40 (1H, s, Ar-H), 8.08 (1H, d, J 9.1, 
pyridine-H), 7.95 (2H, m, thiazole-H, furan-H), 7.81 (1H, d, J 8.0, Ar-H), 7.77-7.70 (1H, m, 
Ar-H), 7.43 (1H, t, J 8.1, Ar-H), 7.39 (1H, d, J 2.8, furan-H), 6.77 (1H, d, J 9.1, pyridine-H), 
6.74-6.71 (1H, m, furan-H), 3.12 (3H, s, CH3), 3.10 (3H, s, CH3). tR (HPLC) 3.99 min. 
 
4-(4-(3-[(Furan-2-carbonyl)-amino]-phenyl)-thiazol-2-yl)-benzoic acid methyl ester, 318 
(JCC-CRT-424 
 
White solid (8.8 mg, 22% yield, ca. 85% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 10.34 
(1H, s, NH), 8.45 (1H, t, J 1.8, Ar-H), 8.24 (1H, s, thiazole-H), 8.21-8.16 (2H, m, Ar-H), 
8.14-8.10 (2H, m, Ar-H), 7.98-7.95 (1H, m, furan-H), 7.86-7.81 (1H, m, Ar-H), 7.80-7.75 (1H, 
m, Ar-H), 7.46 (1H, t, J 7.9, Ar-H), 7.41-7.38 (1H, m, furan-H), 6.73 (1H, dd, J 3.5, 1.7, 
furan-H), 3.90 (3H, s, CH3). tR (HPLC) 4.05 min. 
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Furan-2-carboxylic acid (3-[2-(2,5-dimethoxy-phenyl)-thiazol-4-yl]-phenyl)-amide, 319 
(JCC-CRT-430 
 
Brown solid (11.1 mg, 27% yield, ca. 80% purity by 
1
H-NMR), δH (400 MHz, DMSO-d6) 
10.31 (1H, s, NH), 8.45 (1H, t, J 1.8, Ar-H), 8.12 (1H, s, thiazole-H), 7.98 (1H, d, J 3.2, 
furan-H), 7.96 (1H, dd, J 3.3, 2.4, Ar-H), 7.85-7.80 (1H, m, Ar-H), 7.80-7.76 (1H, m, Ar-H), 
7.44 (1H, t, J 7.9, Ar-H), 7.41-7.38 (1H, m, furan-H), 7.22 (1H, d, J 9.1, Ar-H), 7.10 (1H, dd, 
J 9.1, 3.2, Ar-H), 6.72 (1H, dd, J 3.5, 1.6, furan-H), 3.99 (3H, s, CH3), 3.83 (3H, s, CH3). tR 
(HPLC) 3.92 min. 
 
Fifteen further compounds were successfully synthesised, but the purification was not 
sufficient for assignment of the 
1
H-NMR data. These compounds were tested in the enzyme 
assays. 
– Furan-2-carboxylic acid (3-[2-(4-fluoro-phenyl)-thiazol-4-yl]-phenyl)-amide, 320 
(JCC-CRT-398A) 
 
– Furan-2-carboxylic acid [3-(2-pyrimidin-5-yl-thiazol-4-yl)-phenyl]-amide, 321 (JCC-
CRT-398C) 
 
– Furan-2-carboxylic acid (3-[2-(4-methanesulfonylamino-phenyl)-thiazol-4-yl]-
phenyl)-amide, 322 (JCC-CRT-405) 
 
– Furan-2-carboxylic acid (3-[2-(2-methoxy-pyrimidin-4-yl)-thiazol-4-yl]-phenyl)-
amide, 323 (JCC-CRT-418) 
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– Furan-2-carboxylic acid (3-[2-(2-methoxy-5-methyl-phenyl)-thiazol-4-yl]-phenyl)-
amide, 324 (JCC-CRT-419) 
 
– 3-(4-(3-[(Furan-2-carbonyl)-amino]-phenyl)-thiazol-2-yl)-benzoic acid ethyl ester, 325 
(JCC-CRT-423) 
 
– Furan-2-carboxylic acid [3-(2-furan-2-yl-thiazol-4-yl)-phenyl]-amide, 326 (JCC-CRT-
427 
 
– Furan-2-carboxylic acid (3-[2-(2-methyl-2H-pyrazol-3-yl)-thiazol-4-yl]-phenyl)-
amide, 327 (JCC-CRT-428 
 
– Furan-2-carboxylic acid [3-(2-quinolin-2-yl-thiazol-4-yl)-phenyl]-amide, 328 (JCC-
CRT-429 
 
– Furan-2-carboxylic acid (3-[2-(3-acetylamino-phenyl)-thiazol-4-yl]-phenyl)-amide, 
329 (JCC-CRT-431 
 
– Furan-2-carboxylic acid (3-[2-(4-acetylamino-phenyl)-thiazol-4-yl]-phenyl)-amide, 
330 (JCC-CRT-432) 
 
– Furan-2-carboxylic acid (3-[2-(3-morpholin-4-yl-phenyl)-thiazol-4-yl]-phenyl)-amide, 
331 (JCC-CRT-437) 
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– Furan-2-carboxylic acid (3-[2-(1H-indol-6-yl)-thiazol-4-yl]-phenyl)-amide, 332 (JCC-
CRT-438) 
 
– Furan-2-carboxylic acid (3-(2-[6-(4-methyl-piperazin-1-yl)-pyridin-3-yl]-thiazol-4-
yl)-phenyl)-amide, 333 (JCC-CRT-439) 
 
– Furan-2-carboxylic acid (3-[2-(3-piperidin-1-ylmethyl-phenyl)-thiazol-4-yl]-phenyl)-
amide, 334 (JCC-CRT-440) 
 
 
N-Propargyl-furan-2-carboxamide, 370 
230
 
 
Furoyl chloride (1.00 mL, 10.2 mmol) was added dropwise to a stirred solution of 
propargylamine (720 μL, 11.2 mmol) and Et3N (1.70 mL, 12.2 mmol) in CH2Cl2 (40 mL) at 
0 °C, and the reaction mixture was allowed to warm to r.t. and stirred for 5 h. The reaction 
mixture was then sequentially washed with 1 M HCl (50 mL) and sat. aq. NaHCO3 (50 mL), 
dried (Na2SO4) and the solvent removed in vacuo to give the title compound as colourless 
rods (1.39 g, 92%), mp 90-91.5 °C; υmax (neat)/cm
-1
 3295, 2360, 1647, 1592, 1519, 1470; δH 
(400 MHz, CDCl3) 7.45-7.39 (1H, m, furan 5-H), 7.13-7.09 (1H, m, furan 3-H), 6.54 (1H, br s, 
NH), 6.47 (1H, dd, J 3.4, 1.9, furan 4-H), 4.20 (2H, dd, J 5.5, 2.6, CH2), 2.25 (1H, t, J 2.6, 
C≡CH); δC (101 MHz, CDCl3) 157.9, 147.4, 144.2, 114.8, 112.2, 79.3, 71.8, 28.9; m/z (ES) 
154 (20%), 150 (MH
+
, 100). Found MH
+
, 150.0549. C8H8NO2 requires 150.0555. Data is in 
agreement with the literature.
230
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Furan-2-carboxylic acid [(E)-3-(2-phenyl-thiazol-4-yl)-allyl]-amide, 372 
 
According to the method of Pietruszka,
231
 to a stirred solution of BH3.SMe2 (290 μL, 3.0 
mmol) in THF (3 mL) at 0 °C was added cyclohexene (0.61 mL, 6.0 mmol) dropwise, and the 
reaction mixture warmed to r.t. and stirred for 2 h to form a white precipitate. N-propargyl-
furan-2-carboxamide 370 (447 mg, 3.0 mmol) was then added at 0 °C, and the reaction 
mixture stirred for a further 1.5 h at r.t. to become a clear yellow solution. A solution of 
trimethylamine-N-oxide (451 mg, 6.0 mmol) in CH2Cl2 (3 mL) was then added, and the 
reaction mixture stirred for 2 h before the addition of pinacol (355 mg, 3.0 mmol), whereupon 
the reaction was stirred overnight. The solvent was removed in vacuo to give a yellow oil, and 
partial purification by column chromatography eluting with EtOAc/hexane (1:3 → 2:3) 
afforded crude boronate 371 as a pale yellow oil (683 mg), which was used directly in the 
next reaction. 
 
A portion of the crude boronate 371 (171 mg, 0.62 mmol) was added to a stirred solution of 4-
bromo-2-phenylthiazole (96) (50 mg, 0.21 mmol) and K2CO3 (73 mg, 0.53 mmol) in degassed 
DME/H2O (4:1, 3 mL), followed by Pd(PPh3)4 (7.3 mg, 0.006 mmol) and the reaction mixture 
stirred at reflux for 24 h. Upon cooling, EtOAc (10 mL) and H2O (10 mL) were added, and 
the aqueous layer extracted with EtOAc (3 × 10 mL). The combined organic layers were dried 
(Na2SO4) and the solvent removed in vacuo to give a brown oil. Partial purification by 
column chromatography eluting with EtOAc/hexane (1:4 → 1:1) gave the title compound as a 
colourless oil (51 mg, 62% over 2 steps, >80% purity by 
1
H-NMR with pinacol as the major 
contaminant), Rf 0.4 (EtOAc/hexane 1:1); υmax (neat)/cm
-1
 1647, 1593, 1522, 1476, 1294; δH 
(400 MHz, CDCl3) 7.96-7.92 (2H, m, Ar 2-H, 6-H), 7.42-7.38 (4H, m, Ar 3-H, 4-H, 5-H, 
furan 5-H), 7.12 (1H, d, J 3.3, furan 3-H), 7.03 (1H, s, thiazole-H), 6.72 (1H, dt, J 15.5, 6.0, 
CH2C(H)=C), 6.60 (1H, dt, J 15.5, 1.0, CH2C(H)=CH), 6.56 (1H, br s, NH), 6.47 (1H, dd, J 
3.5, 1.7, furan 4-H), 4.23 (2H, td, J 6.0, 1.0, CH2C(H)=C); δC (101 MHz, CDCl3) 168.3, 158.4, 
154.2, 148.1, 144.1, 133.7, 130.3, 129.1, 128.7, 126.8, 125.3, 115.3, 114.5, 112.3, 40.9; m/z 
(ES) 643 (38%), 492 (27), 470 (34), 333 (59), 311 (MH
+
, 100). Found MH
+
, 311.0851. 
C17H15N2O2S requires 311.0854. 
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2-Diazoacetylfuran, 373
232
  
 
Trimethylsilyldiazomethane (2 M in hexanes, 1.53 mL, 3.1 mmol) was added dropwise to a 
stirred solution of 2-furoyl chloride (200 μL, 2.0 mmol) and Et3N (0.43 mL, 3.1 mmol) in 
CH2Cl2 at 0 °C, and the reaction mixture allowed to warm to r.t. and stirred for 24 h. Sat. aq. 
NaHCO3 (40 mL) was added, and the aqueous layer extracted with CH2Cl2 (3 × 30 mL). The 
combined organic layers were washed with brine (40 mL), dried (Na2SO4) and the solvent 
removed in vacuo to give a yellow oil. Column chromatography eluting with EtOAc/hexane 
(1:3) afforded the title compound as a yellow oil which became a pale yellow solid on storage 
at -20 °C (202 mg, 73%), Rf 0.33 (EtOAc/hexane 1:3); δH (400 MHz, CDCl3) 7.48-7.46 (1H, 
m, furan 5-H), 7.13-7.11 (1H, m, furan 3-H), 6.52 (1H, dd, J 3.5, 1.8, furan 4-H), 5.86 (1H, s 
CHN2); m/z (CI) 154 (37%), 137 (MH
+
, 44), 106 (100). Found MH
+
, 137.0350. C6H5N2O2 
requires 137.0351. Data is in agreement with the literature.
232
 
 
2-Bromo-1-furan-2-yl-ethanone, 374 
233
 
 
According to the method of Pallavicini,
234
 HBr (2 M in H2O, 1 mL) was added dropwise to a 
stirred yellow solution of diazoketone 373 (89 mg, 0.65 mmol) in Et2O at 0 °C, causing 
effervescence and loss of the yellow colour. The reaction mixture was stirred for 30 min at 
0 °C and 1 h at r.t. before being partitioned between Et2O (20 mL) and sat. aq. NaHCO3 (40 
mL). The aqueous layer was extracted with Et2O (3 × 20 mL), the combined organic layers 
dried (MgSO4) and the solvent removed in vacuo. Column chromatography eluting with 
EtOAc/hexane (1:4 → 1:3) afforded the title compound as a colourless oil (110 mg, 94%), Rf 
0.36 (Et2O/petrol 1:3); δH (400 MHz, CDCl3) 7.61 (1H, d, J 1.5, furan 5-H), 7.30 (1H, d, J 3.8, 
furan 3-H), 6.56 (1H, dd, J 3.8, 1.5, furan 4-H), 4.28 (2H, s, CH2); δC (101 MHz, CDCl3) 
180.5, 150.5, 147.5, 119.3, 113.0, 30.2; m/z (CI) 208 (MNH4
+
, 100%), 206 (MNH4
+
, 100), 
190 (MH
+
, 32), 188 (MH
+
, 32), 95 (72). Found MH
+
, 205.9814. C6H9NO2Br requires 
205.9817. Data is in agreement with the literature.
233
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1-Furan-2-yl-2-[3-(2-phenyl-thiazol-4-yl)-phenylamino]-ethanone, 375 
 
A mixture of bromoketone 374 (29 mg, 0.16 mmol), aniline 166 (37 mg, 0.15 mmol) and 
NaHCO3 (15 mg, 0.18 mmol) in DMF (1 mL) was stirred at r.t. for 3 d. EtOAc (10 mL) was 
added and extracted with 50% brine (3 × 20 mL). The organic layer was dried (MgSO4) and 
the solvent removed in vacuo and purification by column chromatography eluting with 
EtOAc/hexane (1:3 → 1:1) afforded the title compound as a colourless oil (31 mg, 59%), Rf 
0.28 (EtOAc/hexane 1:3); υmax (neat)/cm
-1
 1761, 1681, 1607, 1572, 1467; δH (400 MHz, 
CDCl3) 8.06-8.00 (2H, m Ar-H), 7.64-7.59 (1H, m, furan 5-H), 7.48-7.39 (6H, m, 4 × Ar-H, 
thiazole-H, NH), 7.36 (1H, d, J 7.7, Ar-H), 7.33 (1H, d, J 3.6, furan 3-H), 7.27 (1H, t, J 6.5, 
Ar-H), 6.75 (1H, dd, J 8.0, 1.7, Ar-H), 6.57 (1H, dd, J 3.6, 1.6, furan 4-H), 4.58 (2H, s, CH2); 
δC (101 MHz, CDCl3) 184.5, 167.9, 156.5, 151.3, 147.0, 146.9, 135.7, 133.9, 130.2, 129.9, 
129.1, 126.9, 117.9, 117.2, 113.9, 113.1, 112.8, 112.1, 50.7; m/z (ES) 399 (12%), 383 (30), 
362 (28), 361 (MH
+
, 100). Found MH
+
, 361.1006. C21H17N2O2S requires 361.1011. 
 
Benzamide, 377
235
 
 
According to the method of Reuman,
236
 benzoyl chloride (20.0 mL, 174 mmol) was added 
slowly to a stirred solution of NH3 (ca. 14 M in H2O, 49.6 mL, 694 mmol) in H2O (250 mL), 
and the reaction mixture stirred at r.t. for 18 h. The resulting white precipitate was collected 
by filtration and dried in vacuo to give the title compound as colourless plates (17.2 g, 82%), 
mp 133-134.5 °C; δH (400 MHz, CDCl3) 7.83-7.76 (2H, m, Ar-H), 7.54-7.48 (1H, m, Ar-H), 
7.46-7.39 (2H, m, Ar-H), 6.16 (2H, br s, NH2). m/z (ES) 268 (48%), 163 (100), 122 (MH
+
, 88), 
118 (43). Found MH
+
, 122.0604. C7H8NO requires 122.0606. Data is in agreement with the 
literature.
235
 
 
Thiobenzamide, 378
237
  
 
Adapted from the method of Colabufo,
238
 a suspension of benzamide (2.72 g, 22.5 mmol) and 
Lawesson’s reagent (10.0 g, 24.7 mmol) in THF (250 mL) was stirred at reflux for 5 h to give 
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a clear, deep yellow solution. The solvent was removed in vacuo, and the residue was taken 
up in EtOAc (100 mL) and washed with 1 M HCl (2 × 100 mL). The aqueous layers were 
basified with Na2CO3 and extracted with EtOAc (3 × 100 mL). The organic layers before and 
after the acid wash were found to both contain the product by TLC, so were combined, dried 
(Na2SO4) and the solvent removed in vacuo to give a yellow solid. Column chromatography 
eluting with EtOAc/hexane (1:3 → 1:1) afforded the title compound as yellow needles (2.55 g, 
83%), mp 123-125 °C; Rf 0.51 (EtOAc/hexane 1:1); δH (400 MHz, CDCl3) 7.89-7.82 (2H, m, 
Ar-H), 7.68 (1H, br s, NH), 7.50 (1H, t, J 7.4, Ar-H), 7.39 (2H, t, J 7.7, Ar-H), 7.19 (1H, br s, 
NH). m/z (ES) 138 (MH
+
, 100%), 121 (41). Found MH
+
, 138.0372. C7H8NS requires 
138.0377. Data is in agreement with the literature.
237
 
 
4-Phthalimido-2-butanone, 379
239
 
 
According to the method of Timmerman,
239
 NaOEt (410 mg, 6.0 mmol) was added to a stirred 
suspension of phthalimide (17.7 g, 120 mmol) and 1-buten-3-one (10.0 mL, 120 mmol) in 
EtOH/EtOAc (1:4, 150 mL), and the reaction mixture was stirred at reflux for 4.5 h to give an 
almost clear solution. The solvent was removed in vacuo and the residue recrystallised from 
96% EtOH to give the title compound as a white crystalline powder (24.7 g, 95%), mp 112.5-
115 °C; δH (400 MHz, CDCl3) 7.83-7.79 (2H, m, Ar 3-H, 6-H), 7.70-7.67 (2H, m Ar 4-H, 5-
H), 3.96-3.90 (2H, m, NCH2), 2.88-2.82 (2H, m, COCH2), 2.16 (3H, s, CH3); m/z (ES) 309 
(13%), 282 (17), 281 (MH
+
, 100), 240 (14), 218 (37). Found MH
+
, 218.0819. C12H12NO3 
requires 218.0817. Data is in agreement with the literature.
239
 
 
2-[2-(2-Phenyl-thiazol-4-yl)-ethyl]-isoindole-1,3-dione, 380 
240
  
 
Bromine (0.71 mL, 13.8 mmol) was added to a stirred solution of ketone 379 (3.00 g, 13.8 
mmol) in MeOH (20 mL) at 0 °C, and the reaction mixture stirred at r.t. for 5 h to give a 
yellow precipitate. Sat. aq. NaHCO3 (40 mL) was added and extracted with EtOAc (3 × 50 
mL). The combined organic layers were washed with sat. aq. Na2S2O3 (20 mL), dried 
(Na2SO4) and the solvent removed in vacuo. Partial purification by column chromatography 
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eluting with EtOAc/hexane (1:3 → 1:1) afforded the crude bromoketone as a white solid 
(4.04 g), which was used directly in the subsequent thiazole formation. 
 
A solution of bromoketone (2.86 g, 9.67 mmol) and thiobenzamide (1.33 g, 9.67 mmol) in 
EtOH (35 mL) was heated to reflux for 5 h, cooled and the solvent removed in vacuo. The 
residue was partitioned between EtOAc (50 mL) and sat. aq. NaHCO3 (50 mL), the aqueous 
layer was extracted with EtOAc (3 × 50 mL), the combined organic layers dried (MgSO4) and 
the solvent removed in vacuo. Column chromatography eluting with EtOAc/hexane (1:5 → 
1:2) afforded the title compound as a white solid (1.07 g, 33% over 2 steps), mp 118-120 °C; 
δH (400 MHz, CDCl3) 7.80-7.77 (2H, m, phthalimide 3-H, 6-H), 7.76-7.72 (2H, m, 
phthalimide 4-H, 5-H), 7.68-7.63 (2H, m, Ar-H), 7.34-7.29 (3H, m, Ar-H), 6.96 (1H, s, 
thiazole-H), 4.08 (2H, t, J 7.0, NCH2), 3.20 (2H, t, J 7.0, NCH2CH2); m/z (CI) 336 (40%), 335 
(MH
+
, 100), 189 (22). Found MH
+
, 335.0861. C19H15N2O2S requires 335.0854. Data is in 
agreement with the literature.
240  
 
Furan-2-carboxylic acid [2-(2-phenyl-thiazol-4-yl)-ethyl]-amide, 381 
 
A solution of thiazole 380 (288 mg, 0.86 mmol) and hydrazine hydrate (70 μL, 1.72 mmol) in 
MeOH (15 mL) was heated to reflux for 6 h. After cooling, addition of EtOAc (10 mL) 
resulted in precipitation of the phthalazinedione by-product as a white solid, which was 
removed by filtration, washing with EtOAc. The solvent was removed in vacuo and the 
residue partitioned between CH2Cl2 (50 mL) and 1 M HCl (50 mL). The aqueous layer was 
basified with Na2CO3 and extracted with CH2Cl2 (3 × 50 mL). The combined organic layers 
were dried (MgSO4) and the solvent removed in vacuo to give the crude amine as a colourless 
oil (91 mg, 52%), which was used directly in the subsequent reaction. 
  
To a solution of this amine (69 mg, 0.34 mmol) and Et3N (142 μL, 1.02 mmol) in CH2Cl2 (2 
mL) at 0 °C was added 2-furoyl chloride (37 μL, 0.37 mmol), and the reaction stirred at r.t. 
for 5 h. EtOAc (15 mL) was added and extracted with sat. aq. NaHCO3 (15 mL) and 1 M HCl 
(15 mL). The organic layer was dried (MgSO4), the solvent removed in vacuo and purification 
by column chromatography eluting with EtOAc/hexane (1:1) afforded the title compound as a 
white semi-solid (55 mg, 54%), Rf (EtOAc/hexane 1:1); υmax (neat)/cm
-1
 3308, 1647, 1594, 
1515, 1475; δH (400 MHz, CDCl3) 8.01-7.95 (2H, m, Ar-H), 7.66 (1H, br s, NH), 7.45-7.39 
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(4H, m, furan 5-H, 3  Ar-H), 7.09 (1H, d, J 3.4, furan 3-H), 6.98 (1H, s, thiazole-H), 6.46 
(1H, dd, J 3.5, 1.7, furan 4-H), 3.79 (2H, m, NCH2), 3.06 (2H, t, J 6.2, NCH2CH2); δC (101 
MHz, CDCl3) 168.5, 158.6, 155.6, 148.6, 143.8, 133.7, 130.3, 129.1, 126.6, 114.6, 114.0, 
112.3, 38.8, 31.0; m/z (ES) 620 (15%), 619 (38), 362 (14), 321 (46), 299 (MH
+
, 100). Found 
MH
+
, 299.0853. C16H15N2O2S requires 299.0854.  
 
2-Phenyl-thiazole-4-carbonitrile 
241
  
 
A mixture of 4-bromothiazole 96 (360 mg, 1.5 mmol), Zn(CN)2 (264 mg, 2.25 mmol) and 
Pd(dppf)Cl2 (33 mg, 0.045 mmol) in DMF (5 mL) was heated in a microwave reactor at 
220 °C for 10 min. The reaction mixture was then filtered through Celite
®
 and partitioned 
between EtOAc (20 mL) and H2O (20 mL). The aqueous layer was extracted with EtOAc (3 × 
20 mL) and the combined organic layers dried (MgSO4) and the solvent removed in vacuo. 
Column chromatography eluting with EtOAc/hexane (0:1 → 1:4) afforded the title compound 
as a white solid (110 mg, 39%), mp 97-99 °C; δH (400 MHz, CDCl3) 7.95 (1H, s, thiazole-H), 
7.95-7.91 (2H, m, Ar-H), 7.49-7.43 (3H, m, Ar-H); δC (101 MHz, CDCl3) 170.1, 132.0, 131.6, 
130.1, 129.4, 127.7, 127.1, 114.3; m/z (CI) 204 (23%), 188 (28), 187 (MH
+
, 100), 186 (29). 
Found MH
+
, 187.0325. C10H7N2S requires 187.0330. Data is in agreement with the 
literature.
241 
 
Furan-2-carboxylic acid (2-phenyl-thiazol-4-ylmethyl)-amide, 383  
 
To a solution of nitrile 382 (99 mg, 0.53 mmol) in THF (6 mL) was added LiAlH4 (1 M in 
Et2O, 1.60 mL, 1.60 mmol). The reaction mixture was heated to reflux for 45 min, before 
being allowed to cool and carefully quenched with H2O (0.5 mL). 2 M NaOH (10 mL), H2O 
(2 mL) and EtOAc (20 mL) were added and the reaction mixture stirred vigorously for 30 min 
before being filtered through Celite
®
, washing with EtOAc. The organic layer was washed 
with brine (20 mL), dried (MgSO4) and the solvent removed in vacuo to give the crude amine 
as a colourless oil (100 mg), which was used without purification. δH (400 MHz, CDCl3) 
7.93-7.86 (2H, m, Ar-H), 7.42-7.35 (3H, m, Ar-H), 7.05 (1H, s, thiazole-H), 3.99 (2H, s, CH2), 
2.64 (2H, br s, NH2). 
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To a solution of this amine (50 mg, 0.27 mmol) and Et3N (74 μL, 0.53 mmol) in CH2Cl2 (1.5 
mL) at 0 °C was added 2-furoyl chloride (29 μL, 0.29 mmol), and the reaction stirred at r.t. 
for 24 h. EtOAc (15 mL) was added and the organic layer extracted with 1 M HCl (15 mL) 
and sat. aq. NaHCO3 (15 mL) before being dried (MgSO4) and the solvent removed in vacuo. 
Column chromatography eluting with EtOAc/hexane (1:2 → 1:1) afforded the title compound 
as an orange gum (74 mg, 99% over 2 steps). Rf 0.27 (EtOAc/hexane 1:1); υmax (neat)/cm
-1
 
3304, 1655, 1593, 1523, 1475; δH (400 MHz, CDCl3) 7.93-7.89 (2H, m, Ar-H), 7.42-7.38 (4H, 
m, 3 × Ar-H, furan 5-H), 7.17 (1H, s, thiazole-H), 7.11 (1H, br s, NH), 7.11 (1H, d, J 3.4, 
furan 3-H), 6.45 (1H, dd, J 3.5, 1.7, furan 4-H), 4.73 (2H, d, J 5.8, CH2); δC (101 MHz, 
CDCl3) 168.9, 158.4, 153.7, 148.0, 144.2, 133.5, 130.4, 129.1, 126.7, 115.7, 114.6, 112.3, 
39.4; m/z (ES) 348 (52%), 307 (53), 285 (MH
+
, 100). Found MH
+
, 285.0700. C15H13N2O2S 
requires 285.0698. 
 
2-Bromocyclohexanone, 385 
242
 
 
Adapted from the method of Easter,
243
 bromine (1.48 mL, 29.0 mmol) was added slowly to a 
stirred solution of cyclohexanone (3.00 mL, 29.0 mmol) in MeOH (20 mL) at -10 °C, and the 
reaction mixture was allowed to warm to r.t. and stirred for 6 h. H2O (20 mL) was then added 
and the reaction mixture left stirring overnight to give a light brown solution. Brine (20 mL) 
and EtOAc (40 mL) were added, the aqueous layer extracted with EtOAc (3 × 40 mL), the 
combined organic layers dried (Na2SO4) and the solvent removed in vacuo to give a brown oil. 
Column chromatography eluting with EtOAc/hexane (1:4 → 1:3) afforded the title compound 
as a colourless oil (3.92 g, 77%), Rf 0.45 (EtOAc/hexane 1:3); δH (400 MHz, CDCl3) 4.44-
4.39 (1H, m, CHBr), 3.01-2.91 (1H, m, CH2CO), 2.36-2.26 (2H, m, CH2), 2.25-2.16 (1H, m, 
CH2CO), 2.07-1.88 (2H, m, CH2), 1.85-1.66 (2H, m, CH2). Data is in agreement with the 
literature.
242
 
 
Furan-2-carboxylic acid amide, 386 
244
  
 
According to the method of Reuman,
236
 2-furoyl chloride (1.00 mL, 10.2 mmol) was added 
slowly to a stirred solution of NH3 (ca. 14 M in H2O, 2.4 mL, 40.6 mmol) in H2O (6 mL), and 
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the reaction mixture stirred at r.t. for 1.5 h. The resulting white precipitate was collected by 
filtration and dried in vacuo overnight to give the title compound as colourless rods (855 mg, 
76%), mp 135-137 °C; δH (400 MHz, CDCl3) 7.46-7.43 (1H, m, furan 5-H), 7.14 (1H, d, J 3.4, 
furan 3-H), 6.49 (1H, dd, J 3.4, 1.7, furan 4-H), 6.27 (1H, br s, NH), 6.08 (1H, br s, NH). m/z 
(ES) 223 (22%), 129 (100), 112 (MH
+
, 74). Found MH
+
, 112.0394. C5H6NO2 requires 
112.0399. Data is in agreement with the literature.
244
 
 
3-Chlorobenzamide, 387
245,246
 
 
According to the method of Reuman,
236
 3-chlorobenzoyl chloride (10.0 mL, 78.1 mmol) was 
added slowly to a stirred solution of NH3 (ca. 14 M in H2O, 22.3 mL, 312 mmol) in H2O (120 
mL), and the reaction mixture stirred at r.t. for 5 h. The resulting white precipitate was 
collected by filtration and dried in vacuo overnight to give the title compound as colourless 
plates (12.2 g, 97%), mp 139.5-140 °C; δH (400 MHz, CDCl3) 7.79 (1H, t, J 1.9, Ar-H), 7.68-
7.63 (1H, m, Ar-H), 7.49 (1H, ddd, J 8.2, 1.9, 1.0, Ar-H), 7.37 (1H, t, J 7.9, Ar-H), 6.07 (1H, 
br s, NH), 5.94 (1H, br s, NH). m/z (ES) 199 (34%), 197 (100), 156 (MH
+
, 45). Found MH
+
, 
156.0213. C7H7NOCl requires 156.0216. Data is in agreement with the literature.
245,246
 
 
3-Chloro-thiobenzamide, 388 
240
 
 
Adapted from the method of Colabufo,
238
 a suspension of 3-chlorobenzamide (3.50 g, 22.5 
mmol) and Lawesson’s reagent (10.0 g, 24.7 mmol) in THF (250 mL) was stirred at reflux for 
5 h to give a clear, deep yellow solution. The solvent was removed in vacuo, and the residue 
was partitioned between EtOAc (50 mL) and sat. aq. NaHCO3 (50 mL). The aqueous layers 
were extracted with EtOAc (3 × 50 mL), the organic layers combined, dried (Na2SO4) and the 
solvent removed in vacuo to give a yellow solid. Column chromatography eluting with 
EtOAc/hexane (1:3 → 1:2) afforded the title compound as yellow rods (3.33 g, 86%), mp 
120-120.5 °C; Rf 0.61 (EtOAc/hexane 1:1); δH (400 MHz, CDCl3) 7.89-7.82 (2H, m, Ar-H), 
7.68 (1H, br s, NH), 7.50 (1H, t, J 7.4, Ar-H), 7.39 (2H, t, J 7.7, Ar-H), 7.19 (1H, br s, NH). 
m/z (ES) 138 (MH
+
, 100%), 121 (41). Found MH
+
, 138.0372. C7H8NS requires 138.0377. 
Data is in agreement with the literature.
240
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2-(3-Chloro-phenyl)-4,5,6,7-tetrahydro-benzothiazole, 389 
 
A solution of thiobenzamide 388 (795 mg, 4.64 mmol) and bromide 385 (820 mg, 4.64 mmol) 
in EtOH (15 mL) was heated at reflux for 6.5 h, cooled and the solvent removed in vacuo. 
The residue was dissolved in a small volume of acetone and poured into Et2O to give a white 
precipitate. Column chromatography eluting with hexane afforded the title compound as a 
white solid (696 mg, 60%), mp 78-80 °C; Rf 0.70 (EtOAc/hexane 1:3); υmax (neat)/cm
-1
 3005, 
2949, 2375, 2201, 1801, 1603; δH (400 MHz, CDCl3) 8.42 (1H, dt, J 6.9, 1.7, Ar-H), 8.08-
8.05 (1H, m, Ar-H), 7.57-7.49 (2H, m, Ar-H), 3.21 (2H, t, J 4.7, NCCH2), 2.85 (2H, t J 4.6, 
SCCH2), 1.98-1.88 (4H, m, 2 × CH2); δC (101 MHz, CDCl3) 166.2, 146.1, 136.1, 133.8, 132.1, 
131.6, 127.9, 126.7, 117.4, 24.4, 23.7, 22.4, 21.3; m/z (CI) 252 (59%), 251 (40), 250 (MH
+
, 
100). Found MH
+
, 250.0458. C13H13NSCl requires 250.0457. 
 
Furan-2-carboxylic acid [3-(4,5,6,7-tetrahydro-benzothiazol-2-yl)-phenyl]-amide, 390 
 
According to the method of Fors,
168
 a solution of Pd(OAc)2 (1.1 mg, 1 mol%), BrettPhos (5.9 
mg, 2.2 mol%) in degassed 
t
BuOH (1 mL) containing H2O (4 mol%) was heated to 110 °C for 
2 min, before being cooled to r.t. This activated catalyst solution was then added to chloride 
389 (125 mg, 0.50 mmol), amide 386 (83 mg, 0.75 mmol) and finely ground K3PO4 (173 mg, 
0.75 mmol). The resulting suspension was stirred at 110 °C for 14 h before being cooled to r.t. 
and partitioned between EtOAc (10 mL) and H2O (10 mL). The aqueous layer was extracted 
with EtOAc (10 mL), the combined organic layers dried (MgSO4) and the solvent removed in 
vacuo. Column chromatography eluting with EtOAc/hexane (1:4 → 1:1) afforded the title 
compound as a white amorphous solid (140 mg, 86%), mp 124-125 °C; Rf 0.38 
(EtOAc/hexane 1:1); υmax (neat)/cm
-1
 3275, 2933, 1662, 1608, 1594, 1580, 1543, 1494, 1473; 
δH (400 MHz, CDCl3) 8.32 (1H, s, NH), 8.01 (1H, t, J 1.6, Ar-H), 7.86 (1H, dd, J 8.1, 1.4, Ar-
H), 7.57 (1H, d, J 7.9, Ar-H), 7.42 (1H, d, J 0.7, furan 5-H), 7.32 (1H, t, J 7.9, Ar-H), 7.18 
(1H, d, J 3.5, furan 3-H), 6.48 (1H, dd, J 3.5, 1.7, furan 4-H), 2.76 (4H, dt, J 9.8, 4.4, thiazole-
CH2), 1.88-1.77 (4H, m, 2 × CH2); δC (101 MHz, CDCl3) 163.9, 156.3, 151.5, 147.7, 144.5, 
138.2, 134.8, 129.7, 129.7, 122.2, 121.0, 117.3, 115.4, 112.6, 26.9, 23.7, 23.4, 23.0; m/z (ES) 
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388 (8%), 347 (22), 327 (8), 326 (21), 325 (MH
+
, 100). Found MH
+
, 325.0999. C18H17N2O2S 
requires 325.1011; 
 
(2,4-Dichloro-thiazol-5-yl)-methanol, 392 
169
 
 
According to the method of Kerdesky,
169
 to a stirred suspension of 2,4-thiazolidinedione (3.00 
g, 90% purity, 25.9 mmol) in POCl3 (10.7 mL, 116.4 mmol) was added dropwise DMF (2.04 
mL, 26.4 mmol) and the reaction mixture stirred at 85 °C for 1 h, then at reflux for 8 h. After 
cooling to r.t., the mixture was poured onto ice and extracted with EtOAc (2 × 100 mL). The 
combined organic layers were washed with NaHCO3 (100 mL), dried (MgSO4) and the 
solvent removed in vacuo. Partial purification by column chromatography eluting with 
EtOAc/hexane (0:1 → 1:19) afforded the slightly crude intermediate aldehyde as a white solid 
(2.32 g). To a solution of a portion of this material (2.00 g) in MeOH (20 mL) at 0 °C was 
added portionwise NaBH4 (416 mg, 11 mmol). The reaction was allowed to warm to r.t. and 
stirred for 4 h to give a green solution. The solvent was removed in vacuo and the residue 
partitioned between CH2Cl2 (20 mL) and sat aq. NH4Cl (20 mL). The aqueous layer was 
extracted with CH2Cl2 (3 × 20 mL), the combined organic layers dried (MgSO4) and the 
solvent removed in vacuo. Column chromatography eluting with EtOAc/hexane (1:3) 
afforded the title compound as a pale green amorphous solid (1.41 g, 30% over 2 steps), mp 
50-51 °C; Rf 0.11 (EtOAc/hexane 1:9); δH (400 MHz, CDCl3) 4.75 (2H, d, J 5.9, CH2O), 2.90 
(1H, t, J 5.9, OH); δC (101 MHz, CDCl3) 151.2, 133.8, 133.4, 56.9; m/z (CI) 203 (MNH4
+
, 
32%), 201 (MNH4
+
, 40), 186 (MH
+
, 80), 184 (MH
+
, 100). Found MH
+
, 183.9391. 
C4H4NOSCl2 requires 183.9391. Data is in agreement with the literature.
169
 
 
2-Phenyl-thiazole-5-carbaldehyde, 393 
247
 
 
A stirred solution of dichlorothiazole 392 (100 mg, 0.54 mmol), phenylboronic acid (79 mg, 
0.65 mmol), K2CO3 (187 mg, 1.35 mmol) and Pd(PPh3)4 (15 mg, 0.022 mmol) in DME/H2O 
(3 mL, 4:1) was heated to 100 °C for 14 h. The reaction mixture was partitioned between H2O 
(20 mL) and EtOAc (20 mL), and the aqueous layer was extracted with EtOAc (2 × 20 mL). 
The combined organic layers were dried (MgSO4) and the solvent removed in vacuo. Column 
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chromatography eluting with EtOAc/hexane (0:1 → 1:4) afforded the title compound as an 
off-white amorphous solid (77 mg, 75%), mp 93-95 °C; Rf 0.43 (EtOAc/hexane 1:3); υmax 
(neat)/cm
-1
 3056, 2835, 1673, 1653, 1508, 1452; δH (400 MHz, CDCl3) 10.00 (1H, s, CHO), 
8.39 (1H, s, thiazole-H), 8.00-7.95 (2H, m, Ar-H), 7.49-7.40 (3H, m, Ar-H); δC (101 MHz, 
CDCl3) 182.3, 175.7, 152.5, 139.0, 132.7, 132.0, 129.4, 127.4; m/z (ES) 231 (7%), 224 (9), 
196 (7), 191 (21), 190 (MH
+
, 100). Found MH
+
, 190.0323. C10H8NOS requires 190.0320. 
Data is in agreement with the literature.
247
  
 
Pyrazine-2-carbonyl chloride, 399 
248
  
 
To a stirred suspension of pyrazine-2-carboxylic acid (1.50 g, 12.1 mmol) and oxalyl chloride 
(3.07 mL, 36.3 mmol) in CH2Cl2 (100 mL) was added DMF (3 drops), causing vigorous 
effervescence at the surface of the suspended particles. After 5.5 h at r.t., the solvent was 
removed in vacuo to give the title compound as a purple powder, which was stored under Ar 
at -20 °C and used without purification in subsequent steps. δH (400 MHz, CDCl3) 9.30 (1H, d, 
J 1.3, pyrazine 3-H), 8.86 (1H, d, J 2.4, pyrazine 5-H), 8.81-8.79 (1H, m, pyrazine 6-H); δC 
(101 MHz, CDCl3) 169.1, 149.4, 146.0, 145.0, 144.6. Data is in agreement with the 
literature.
248
  
 
2-Chloro-1-(4-fluoro-phenyl)-propan-1-one, 400 
249
 
 
According to the method of Burpitt,
249
 to a stirred suspension of AlCl3 (4.12 g, 30.9 mmol) in 
CH2Cl2 (18 mL) was added dropwise a solution of 2-chloropropionyl chloride (3.00 mL, 30.9 
mmol) in CH2Cl2 (6 mL) and the reaction mixture stirred for 10 min. A solution of 
fluorobenzene (2.90 mL, 30.9 mmol) in CH2Cl2 (6 mL) was then added dropwise to give a 
clear orange solution, which was stirred at r.t. for 2.5 h. The reaction mixture was then 
cautiously poured onto HCl/ice (100 mL), stirred for 15 min and extracted with CH2Cl2 (3 × 
75 mL). The combined organic layers were washed with 2 M NaOH (2 × 50 mL), H2O (50 
mL) and brine (100 mL), dried (MgSO4) and the solvent removed in vacuo to give the title 
compound as a pale yellow oil which solidified on storage at -20 °C to an off-white solid 
(5.42 g, 94%), δH (400 MHz, CDCl3) 8.07-8.00 (2H, m, Ar-H), 7.18-7.11 (2H, m, Ar-H), 5.17 
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(1H, q, J 7.0, CHCl), 1.72 (3H, d, J 7.0, CH3); m/z (CI) 206 (36%), 204 (MH
+
, 100), 123 
(100), 52 (57). Found MH
+
, 204.0586. C9H12NOClF requires 204.0591. Data is in agreement 
with the literature.
249
 
 
4-(4-Fluoro-phenyl)-5-methyl-thiazol-2-ylamine, 401 
250
 
 
A mixture of chloroketone 400 (3.00 g, 16.1 mmol) and thiourea (2.45 g, 32.2 mmol) in EtOH 
(60 mL) was heated to reflux for 2 h to give a pale yellow solution. The solvent was removed 
in vacuo and the residue partitioned between EtOAc (50 mL) and 50% sat. aq. NaHCO3 (100 
mL). The aqueous layer was extracted with EtOAc (3 × 50 mL), the combined organic layers 
washed with brine (100 mL), dried (MgSO4) and the solvent removed in vacuo. Column 
chromatography eluting with EtOAc/hexane (1:3 → 1:1) afforded the title compound as pale 
yellow plates (3.32 g, 99%), mp 133.5-134 °C, Rf 0.24 (EtOAc/hexane 1:3); δH (400 MHz, 
CDCl3) 7.53-7.47 (2H, m, Ar-H), 7.09-7.02 (2H, m, Ar-H), 4.87 (2H, br s, NH2), 2.35 (3H, s, 
CH3); m/z (CI) 209 (MH
+
, 100%), 210 (27), 52 (40). Found MH
+
, 209.0543. C10H10FN2S 
requires 209.0549. Data is in agreement with the literature.
250,251
  
 
Pyrazine-2-carboxylic acid [4-(4-fluoro-phenyl)-5-methyl-thiazol-2-yl]-amide, 396 
 
To a stirred solution of aminothiazole 401 (200 mg, 0.96 mmol) and DMAP (118 mg, 0.96 
mmol) in CH2Cl2 (10 mL) was added acid chloride 399 (161 mg, 1.15 mmol) and the reaction 
stirred at r.t. for 16 h. The reaction mixture was partitioned between EtOAc (100 mL) and 50% 
sat. aq. NaHCO3 (100 mL). The aqueous layer was extracted with EtOAc (2 × 100 mL), the 
combined organic layers were dried (MgSO4) and the solvent removed in vacuo to give a 
yellow solid. Recrystallisation from EtOAc gave the title compound as yellow crystals (224 
mg, 74%), mp >250 °C; υmax (neat)/cm
-1
 3297, 3127, 1757, 1612, 1517, 1500, 1318, 1258; δH 
(400 MHz, DMSO-d6) 12.44 (1H, s, NH), 9.31 (1H, d, J 1.5, pyrazine 3-H), 8.95 (1H, d, J 2.4, 
pyrazine 5-H), 8.83 (1H, dd, J 2.4, 1.5, pyrazine 6-H), 7.76-7.70 (2H, m, Ar-H), 7.34-7.27 
(2H, m, Ar-H), 2.52 (3H, s, CH3); Sufficient concentration in solution could not be achieved 
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for a fully-resolved 
13
C spectrum; δF (377 MHz, DMSO-d6) -114.52; m/z (ES) 315 (MH
+
, 
100%), 282 (65), 240 (36), 160 (35). Found 315.0724. C15H12N4OSF requires 315.0716. 
 
2-Chloro-1-(4-fluoro-phenyl)-ethanone, 404
252
 
 
According to the method of Burpitt,
249
 to a stirred suspension of AlCl3 (4.12 g, 30.9 mmol) in 
CH2Cl2 (18 mL) was added dropwise a solution of chloroacetyl chloride (2.46 mL, 30.9 mmol) 
in CH2Cl2 (6 mL) and the reaction mixture stirred for 10 min. A solution of fluorobenzene 
(2.90 mL, 30.9 mmol) in CH2Cl2 (6 mL) was then added dropwise to give a clear orange 
solution, which was stirred at r.t. for 3 h. The reaction mixture was then cautiously poured 
onto HCl/ice (100 mL), stirred for 15 min and extracted with CH2Cl2 (3 × 75 mL). The 
combined organic layers were washed with 2 M NaOH (2 × 50 mL), H2O (50 mL) and brine 
(100 mL), dried (MgSO4) and the solvent removed in vacuo to give the title compound as a 
white solid (4.80 g, 90%), mp 46-47.5 °C, δH (400 MHz, CDCl3) 8.02-7.95 (2H, m, Ar-H), 
7.24-7.18 (2H, m. Ar-H), 4.64 (2H, s, CH2Cl); m/z (CI) 192 (MH
+
, 20%), 190 (MH
+
, 62), 123 
(44), 52 (100). Found MH
+
, 190.0437. C8H10NOClF requires 190.0435. Data is in agreement 
with the literature.
252
 
 
4-(4-Fluoro-phenyl)-thiazol-2-ylamine, 405 
253
 
 
A mixture of chloroketone 404 (2.78 g, 16.1 mmol) and thiourea (2.45 g, 32.2 mmol) in EtOH 
(60 mL) was heated to reflux for 2 h to give a pale yellow solution. The solvent was removed 
and the residue partitioned between EtOAc (50 mL), 50% sat. aq. NaHCO3 (100 mL). The 
aqueous layer was extracted with EtOAc (3 × 50 mL), the combined organic layers washed 
with brine (100 mL), dried (MgSO4) and the solvent removed in vacuo to give an orange solid. 
Column chromatography eluting with EtOAc/hexane (1:3 → 1:1) afforded the title compound 
as colourless rods (2.96 g, 95%), mp 111-114 °C; Rf 0.32 (EtOAc/hexane 1:3); δH (400 MHz, 
CDCl3) 7.76-7.69 (2H, m, Ar-H), 7.08-7.00 (2H, m, Ar-H), 6.63 (1H, s, thiazole-H), 5.08 (2H, 
br s, NH2); m/z (CI) 197 (19%), 196 (32), 195 (MH
+
, 100), 194 (20). Found MH
+
, 195.0393. 
C9H8N2SF requires 195.0392. Data is in agreement with the literature.
253
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5-Fluoro-4-(4-fluoro-phenyl)-thiazol-2-ylamine, 406 
 
Selectfluor
®
 (1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoro-borate, 
401 mg, 1.13 mmol) was added in one portion to a stirred solution of aminothiazole 405 (200 
mg, 1.03 mmol) in MeCN (5 mL) at 0 °C and the resulting orange solution allowed to warm 
to r.t. over 14 h. The reaction mixture was partitioned between EtOAc (20 mL) and H2O (10 
mL), the aqueous layer extracted with EtOAc (20 mL), the combined organic layers dried 
(MgSO4) and the solvent removed in vacuo. Column chromatography eluting with 
EtOAc/hexane (1:3 → 2:3) afforded the title compound as off-white amorphous crystals (122 
mg, 56%), mp 126-128 °C, Rf 0.32 (EtOAc/hexane 1:3); υmax (neat)/cm
-1
 3459, 3284, 3122, 
1636, 1605, 1587, 1541, 1505; δH (400 MHz, CDCl3) 7.76-7.70 (2H, m, Ar-H), 7.10-7.03 (2H, 
m, Ar-H), 4.99 (2H, br s, NH2); δC (101 MHz, CDCl3) 162.0 (dd, J 248.6, 2.3), 155.3 (d, J 
10.6), 147.8 (dd, J 297.0, 1.9), 129.0 (d, J 3.5), 128.7 (dd, J 8.0, 6.2), 128.4 (dd, J 5.7, 3.4) 
115.5 (d, J 21.6); δF (376 MHz, CDCl3) -113.7, -154.3; m/z (CI) 215 (13%), 214 (20), 213 
(MH
+
, 100), 212 (13), 195 (8). Found MH
+
, 213.0306. C9H7N2SF2 requires 213.0298. 
 
3-Bromo-[1,2,4]thiadiazol-5-ylamine, 408 
172
 
 
According to the method of Wehn,
172
 a mixture of 3-bromo-5-chloro-[1,2,4]thiadiazole (2.00 
g, 10.0 mmol) and ethanolic ammonia (2 M, 10.0 mL, 20.1 mmol) was heated in a sealed tube 
at 70 °C for 6 h, forming a white precipitate. After cooling to 0 °C, the reaction mixture was 
taken up in EtOAc (25 mL) and washed with H2O (25 mL) and brine (25 mL). The organic 
layer was dried (MgSO4) and the solvent removed in vacuo to give the title compound as a 
white solid (1.51 g, 84%), mp >250 °C; δH (400 MHz, DMSO-d6) 8.48 (2H, br s, NH2); m/z 
(CI) 182 (MH
+
, 100%), 180 (MH
+
, 100), 119 (33), 52 (28). Found MH
+
, 179.9235. 
C2H3N3BrS requires 179.9231. Data is in agreement with the literature.
172
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 (3-Bromo-[1,2,4]thiadiazol-5-yl)-carbamic acid tert-butyl ester, 410 
172
 
 
According to the method of Wehn,
172
 a solution of amine 408 (1.50 g, 8.34 mmol), di-tert-
butyl dicarbonate (2.55 g, 11.7 mmol) and DMAP (102 mg, 0.83 mmol) in THF (20 mL) was 
stirred at 70 °C for 40 h. The solvent was removed in vacuo and purification by column 
chromatography eluting with EtOAc/hexane (0:1 → 1:3) afforded the title compound as 
colourless amorphous crystals (2.15 g, 92%), mp 92-94 °C; δH (400 MHz, CDCl3) 10.66 (1H, 
s, NH), 1.55 (9H, s, C(CH3)3); m/z (CI) 282 (MH
+
, 100%), 280 (MH
+
, 100), 219 (5), 217 (5). 
Found MH
+
, 279.9761. C7H11N3O2BrS requires 279.9755. Data is in agreement with the 
literature.
172
 
 
(3-(4-Fluoro-phenyl)-[1,2,4]thiadiazol-5-yl)-carbamic acid tert-butyl ester, 411 
 
According to the method of Wehn,
172
 a mixture of bromide 410 (560 mg, 2.0 mmol), 4-
fluorophenylboronic acid (364 mg, 2.6 mmol), CsF (638 mg, 4.2 mmol) and PdCl2[P
t
Bu2(p-
NMe2-C6H4]2 (71 mg, 0.10 mmol) in degassed dioxane/H2O (6.6 mL, 10:1) was stirred at 
80 °C for 24 h to give a red solution. The reaction mixture was diluted with EtOAc (100 mL), 
washed with H2O (2 × 20 mL) and brine (20 mL), the organic layer dried (MgSO4) and the 
solvent removed in vacuo. Column chromatography eluting with EtOAc/hexane (1:10 → 1:2) 
followed by trituration with hexane afforded the title compound as white amorphous crystals 
(465 mg, 79%), mp 161-164 °C; υmax (neat)/cm
-1
 3204, 2985, 1713, 1549, 1243, 1153, 1129; 
δH (400 MHz, CDCl3) 11.01 (1H, s, NH), 8.17 (2H, dd, J 8.3, 5.6, Ar-H), 7.11 (2H, t, J 8.6, 
Ar-H), 1.26 (9H, s, C(CH3)3); δC (101 MHz, CDCl3) 178.7, 166.8, 164.3 (d, J 250.4), 153.0, 
130.3 (d, J 8.4), 129.18, 115.8 (d, J 21.5), 84.2, 27.9; m/z (ES) 297 (13%), 296 (MH
+
, 96), 
281 (30), 240 (100). Found MH
+
, 296.0864. C13H15N3O2SF requires 296.0869.  
 
3-(4-Fluoro-phenyl)-[1,2,4]thiadiazol-5-ylamine, 412 
 
According to the method of Wehn,
172
 a mixture of carbamate 411 (150 mg, 0.51 mmol), TFA 
(1.5 mL) and anisole (0.1 mL) in CH2Cl2 (3 mL) was stirred at r.t. for 4.5 h. The solvent was 
- 239 - 
 
removed and the residue partitioned between sat. aq. NaHCO3 (5 mL) and CH2Cl2 (20 mL). 
The aqueous layer was extracted with CH2Cl2 (2 × 20 mL), the combined organic layers dried 
(MgSO4) and the solvent removed in vacuo. Column chromatography eluting with 
EtOAc/hexane (1:3 → 1:1) afforded the title compound as a white amorphous solid (95 mg, 
96%), mp 153-155 °C; υmax (neat)/cm
-1
 3286, 3125, 1643, 1600, 1548, 1459; δH (400 MHz, 
MeOD) 8.14-8.08 (2H, m, Ar-H), 7.17-7.10 (2H, m, Ar-H); δC (101 MHz, MeOD) 185.9, 
169.9, 165.4 (d, J 248.8), 131.2 (d, J 8.7), 131.1 (d, J 2.9), 116.4 (d, J 22.4); δF (377 MHz, 
MeOD) -113.1; m/z (ES) 237 (47%), 198 (8), 197 (11), 196 (MH
+
, 100). Found MH
+
, 
196.0340. C8H7N3SF requires 196.0345.  
 
(3-Trifluoromethyl-phenyl)-thiourea, 415 
176
  
 
According to the method of Rasmussen,
176
 benzoyl chloride (12.08 mL, 104 mmol) was 
added slowly to a solution of ammonium thiocyanate (9.14 g, 120 mmol) in acetone (90 mL). 
The reaction mixture was stirred at reflux for 15 min, before the heating was stopped to allow 
rapid addition of 3-trifluoromethylaniline (10.0 mL, 80.06 mmol) in acetone (10 mL). The 
reaction mixture was heated to reflux for a further 30 min before being cooled to r.t. and 
poured onto a large excess of ice with vigorous stirring to cause precipitation of a yellow solid, 
which was collected under vacuum. This crude benzoylthiourea was added in one portion to a 
stirred solution of 5% NaOH (160 mL) at 80 °C. The reaction mixture was stirred for 25 min 
before being cooled to r.t. and poured into ice-cold 1 M HCl (200 mL) to give a white 
precipitate. The pH was adjusted to ca. 9 with Na2CO3 to remove benzoic acid, and the white 
solid filtered under vacuum to give the title compound as amorphous colourless crystals 
(17.46 g, 99%), mp 105-107 °C, δH (400 MHz, DMSO-d6) 8.05-7.94 (1H, m, Ar 2-H), 7.68 
(1H, d, J 8.0, Ar 4-H), 7.54 (1H, t, J 7.9, Ar 5-H), 7.43 (1H, d, J 7.8, Ar 6-H); δF (377 MHz, 
DMSO-d6) -61.4; m/z (CI) 222 (23%), 221 (MH
+
, 100). Found MH
+
, 221.0355. C8H8N2SF3 
requires 221.0360. Data is in agreement with the literature.
176
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 (4-Chloro-thiazol-2-yl)-(3-trifluoromethyl-phenyl)-amine, 417 
 
According to the method of Mahboobi,
177
 ethyl bromoacetate (2.31 mL, 20.8 mmol) was 
added to a stirred solution of thiourea 415 (3.52 g, 16.0 mmol) in EtOH (60 mL) at 50 °C. The 
reaction mixture was stirred for 18 h, before being cooled whereupon the solvent was 
removed in vacuo. Partial purification by column chromatography eluting with EtOAc/petrol 
(1:4 → 1:1) afforded the intermediate thiazolone 416 as an off-white solid (1.352 g), which 
was used directly in the subsequent chlorination. 
 
A portion of thiazolone 416 (520 mg, 2.0 mmol) was added to a stirred solution of POCl3 
(1.12 mL, 12.0 mmol), dimethylaniline (250 μL, 2.0 mmol) and TBAB (1.61 g, 5.0 mmol) in 
MeCN (20 mL). The reaction mixture was stirred at reflux for 4 h, before being cooled and 
the solvent removed in vacuo. The residue was partitioned between EtOAc (20 mL) and H2O 
(20 mL), the aqueous layers extracted with EtOAc (3 × 20 mL), the combined organic layers 
dried (MgSO4) and the solvent removed in vacuo. Column chromatography eluting with 
EtOAc/petrol (1:5 → 1:3) afforded the title compound as off-white needles (208 mg, 12% 
over 2 steps), mp 140-143 °C; Rf 0.51 (EtOAc/petrol 1:3); υmax (neat)/cm
-1
 1603, 1557, 1464, 
1421; δH (400 MHz, DMSO-d6) 8.03 (1H, s, Ar 2-H), 7.77 (1H, d, J 8.1, Ar 4-H), 7.55 (1H, t, 
J 8.0, Ar 5-H), 7.30 (1H, d, J 7.6, Ar 6-H), 6.94 (1H, s, thiazole-H); δC (101 MHz, DMSO-d6) 
162.7, 141.0, 132.9, 130.3, 129.8 (q, J 31.5), 124.2 (q, J 272.2), 120.6, 118.0, 112.9, 103.2; δF 
(377 MHz, DMSO-d6) -61.40; m/z (CI) 280 (50%), 279 (MH
+
, 100). Found MH
+
, 278.9966. 
C10H7N2SClF3 requires 278.9971. 
 
[4-(4-Methoxy-phenyl)-thiazol-2-yl]-(3-trifluoromethyl-phenyl)-amine, 87  
 
 
Bromine (0.68 mL, 13.3 mmol) was added dropwise to a solution of 4-methoxyacetophenone 
(2.00 g, 13.3 mmol) in Et2O (20 mL). The resulting suspension was stirred at r.t. for 16 h 
before being poured into 30 mL sat. aq. NaHCO3. The organic layer was washed with sat. aq. 
NaHCO3 (30 mL) and H2O (30 mL), dried (MgSO4) and the solvent removed in vacuo to give 
the crude bromide intermediate as a white solid. This was added to a solution of thiourea 415 
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(2.93 g, 13.3 mmol) in EtOH (30 mL) and the reaction mixture stirred at reflux for 2.5 h. The 
solvent was removed in vacuo and the residue recrystallised from EtOH to give the title 
compound as yellow needles (2.90 g, 63% over 2 steps), mp 171-172 °C; υmax (neat)/cm
-1
 
1611, 1583, 1565, 1532, 1511; δH (400 MHz, DMSO-d6) 8.40 (1H, s, Ar 2-H), 7.90-7.83 (3H, 
m, Ar 4-H, 3’-H, 5’H), 7.57 (1H, t, J 8.0, Ar 5-H), 7.29 (1H, d, J 7.7, Ar 6-H), 7.26 (1H, s, 
thiazole-H), 7.00 (2H, d, J 8.8, Ar 2’-H, 6’-H), 3.79 (3H, s, CH3); δC (101 MHz, DMSO-d6) 
162.8, 159.4, 150.1, 142.2, 130.6, 130.1 (q, J 31.7), 127.6, 127.4, 124.8 (q, J 271.4) 117.6, 
114.5, 114.3, 113.1, 102.2, 55.6; δF (377 MHz, DMSO-d6) -61.41; m/z (CI) 353 (20%), 352 
(50), 351 (MH
+
, 100), 350 (17). Found MH
+
, 351.0772. C17H14N2OSF3 requires 351.0779. 
 
N-(4-Oxo-4,5-dihydro-thiazol-2-yl)-acetamide, 420 
254
 
 
According to the method of Novartis,
188
 a stirred suspension of pseudothiohydantoin (3.89 g, 
33.5 mmol) in Ac2O (4.11 mL, 43.5 mmol) and pyridine (35 mL) was heated to reflux for 1.5 
h, cooled to r.t. and filtered, washing with Et2O, to give the title compound as light brown 
needles (3.48 g, 66%), mp > 250 °C; δH (400 MHz, DMSO-d6) 3.83 (2H, s, CH2) 2.17 (3H, s, 
CH3); m/z (CI) 176 (68%), 159 (MH
+
, 100). Found MH
+
, 159.0230. C5H7N2O2S requires 
159.0228. Data is in agreement with the literature.
254
 
 
N-(4-Chloro-thiazol-2-yl)-acetamide, 421 
188
 
 
According to the method of Novartis,
188
 a suspension of acetamide 420 (1.74 g, 11.0 mmol) in 
POCl3 (20 mL) was heated to reflux for 20 min before being cooled to r.t. whereupon the 
reaction mixture was poured carefully onto ice/H2O, washing with EtOH. The resulting 
solution was neutralised with solid Na2CO3 and extracted with EtOAc (3 × 20 mL). The 
combined organic layers were dried (MgSO4) and the solvent removed in vacuo to give the 
title compound as an orange amorphous solid (1.82 g, 94%), mp 149-151 °C; δH (400 MHz, 
CDCl3) 6.72 (1H, s, thiazole-H), 2.32 (3H, s, CH3); δC (101 MHz, CDCl3) 169.1, 159.7, 134.2, 
107.9, 23.6; m/z (CI) 196 (22%), 194 (43), 179 (55), 177 (MH
+
, 100). Found MH
+
, 176.9888. 
C5H6N2OSCl requires 250.0457. Data is in agreement with the literature.
188
  
 
- 242 - 
 
(4-Oxo-4,5-dihydro-thiazol-2-yl)-carbamic acid tert-butyl ester, 423 
189
 
 
According to the method of Reiter,
189
 a stirred suspension of pseudothiohydantoin (5.82 g, 
50.0 mmol) and di-tert-butyl dicarbonate (21.8 g, 100 mmol) in THF (200 mL) was heated at 
65 °C for 60 h, before being allowed to cool to r.t. and filtered. The solvent was removed in 
vacuo to give a white powder, which was suspended in hexane and filtered to give the title 
compound as a white powder (4.85 g, 45%), mp >250 °C; δH (400 MHz, CDCl3) 3.75 (2H, s, 
CH2), 1.53 (9H, s, C(CH3)3); δC (101 MHz, CDCl3) 183.7, 182.9, 153.8, 84.6, 36.5, 28.1; m/z 
(CI) 217 (MH
+
, 100%), 134 (53), 117 (66). Found MH
+
, 217.0655. C8H13N2O3S requires 
217.0647. 
 
Trifluoro-methanesulfonic acid 2-tert-butoxycarbonylamino-thiazol-4-yl ester, 424 
189
 
 
According to the method of Reiter,
189
 to a stirred solution of thiazolone 423 (1.08 g, 5.00 
mmol) and 2,6-lutidine (1.75 mL, 15.0 mmol) in CH2Cl2 (50 mL) at 0 °C was added dropwise 
Tf2O (1.68 mL, 10.0 mmol). The reaction mixture stirred at this temperature for 1 h before 
being poured into sat. aq. NH4Cl (100 mL). The organic layer was washed with sat. aq. 
NaHCO3 (100 mL), dried (MgSO4) and the solvent removed in vacuo to give a red oil. 
Column chromatography eluting with EtOAc/hexane (0:1 → 1:4) afforded the title compound 
as amorphous crystals (1.65 g, 95%), mp 94-96 °C, Rf 0.60 (EtOAc/hexane 1:3); δH (400 
MHz, CDCl3) 8.81 (1H, s, NH), 6.60 (1H, s, thiazole-H), 1.52 (9H, s, C(CH3)3); δC (101 MHz, 
CDCl3) 159.2, 152.4, 146.7, 118.8 (q, J 321), 99.3, 83.9, 28.2; δF (377 MHz, CDCl3) -72.6; 
m/z (CI) 367 (28%), 366 (MNH4
+
, 100), 349 (MH
+
, 39), 310 (43). Found MH
+
, 349.0144. 
C9H12N2O5S2F3 requires 349.0140. 
 
4-(4-Methoxy-phenyl)-thiazol-2-ylamine, 425 
255
 
 
To a stirred solution of 4-methoxy-acetophenone (10.0 g, 66.6 mmol) in Et2O (100 mL) was 
added slowly bromine (3.41 mL, 66.6 mmol), and the reaction mixture stirred at r.t. for 20 h. 
Further bromine (1.70 mL, 33.3 mmol) was added and the reaction stirred for an additional 1 
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h before being poured into sat. aq. NaHCO3 (150 mL). The organic layer was washed with sat. 
aq. NaHCO3 (100 mL) and H2O (100 mL), dried (MgSO4) and the solvent removed in vacuo 
to give a white solid, which was dissolved in EtOH (250 mL). To this solution was added 
thiourea (10.14 g, 133 mmol), and the mixture was heated to reflux for 2 h. The solvent was 
removed and the residue taken up in EtOAc (300 mL), which was washed with H2O (2 × 100 
mL) and brine (100 mL). The organic layer was dried (MgSO4), the solvent removed in vacuo 
and the residue recrystallised from EtOAc to give the title compound as yellow rods (6.51 g, 
47% over 2 steps), mp 217-219 °C; δH (400 MHz, DMSO-d6) 7.74-7.70 (2H, m, Ar-H), 7.01 
(2H, s, NH2), 6.94-6.89 (2H, m, Ar-H), 6.80 (1H, s, thiazole-H), 3.76 (3H, s, CH3); δC (101 
MHz, DMSO-d6) 168.1, 158.5, 149.7, 127.9, 126.8, 113.8, 99.3, 55.1; m/z (CI) 209 (10%), 
208 (22), 207 (MH
+
, 100). Found MH
+
, 207.0591. C10H11N2OS requires 207.0592. Data is in 
agreement with the literature.
255
 
 
2-Iodo-2',4',6'-triisopropyl-3,6-dimethoxy-biphenyl, 427 
192
 
 
According to the method of Fors,
192
 to a stirred suspension of Mg turnings (746 mg, 30.7 
mmol) in THF (60 mL) was added 2-bromo-1,3,5-triisopropyl-benzene (6.14 mL, 25.6 mmol). 
The reaction mixture was heated to reflux and 1,2-dibromoethane (20 μL, 0.2 μmol) was 
added. The reaction mixture was stirred at reflux for 1 h before being cooled to r.t. to give a 
solution of Grignard reagent 426. 
 
n
BuLi (2.5 M in hexanes, 10.2 mL, 25.6 mmol) was added dropwise to a stirred solution of 
1,4-dimethoxy-2-fluorobenzene (3.41 mL, 25.6 mmol) in THF (150 mL) at -78 °C. The 
reaction was stirred for 30 min at this temperature, before Grignard reagent 426 was 
introduced dropwise by cannula. The reaction mixture was stirred for a further 1 h at -78 °C 
and then for 1.5 h at r.t. before being cooled to 0 °C. A solution of iodine (7.79 g, 30.7 mmol) 
in THF (30 mL) was added dropwise, and the resulting dark red solution was stirred at r.t. for 
1 h. The solvent was removed in vacuo and the residue partitioned between CH2Cl2 (100 mL) 
and sat. aq. Na2SO3 (100 mL). The aqueous layer was extracted with CH2Cl2 (50 mL), and the 
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combined organic layers washed with brine (100 mL), dried (MgSO4) and the solvent 
removed in vacuo to give a light brown solid. Recrystallisation from EtOAc gave the title 
compound as white plates (3.03 g, 25%), mp 206.5-208 °C; δH (400 MHz, CDCl3) 7.02 (2H, s, 
Ar-H), 6.87 (1H, d, J 8.9, Ar-H), 6.79 (1H, d, J 8.9, Ar-H), 3.87 (3H, s, OCH3), 3.64 (3H, s, 
OCH3), 2.93 (1H, hept, J 6.9, CH(CH3)2), 2.34 (2H, hept, J 6.9, 2 × CH(CH3)2), 1.29 (6H, d, J 
6.9, CH(CH3)2), 1.16 (6H, d, J 6.9, CH(CH3)2), 0.98 (6H, d, J 6.9, CH(CH3)2); m/z (CI) 485 
(45%), 484 (MNH4
+
, 100), 437 (23), 436 (82). Found MNH4
+
, 484.1723. C23H35NO2I requires 
484.1713. Data is in agreement with the literature.
192
  
 
Dicyclohexyl-(2',4',6'-triisopropyl-3,6-dimethoxy-biphenyl-2-yl)-phosphane, 428 
192
 
 
According to the method of Fors,
192
 to a stirred solution of biphenyl iodide 427 (1.00 g, 2.15 
mmol) in THF (10 mL) at -78 °C was added 
n
BuLi (2.5 M in hexane, 944 µL, 2.36 mmol) 
dropwise over 10 min. The reaction mixture was stirred at -78 °C for 30 min before 
chlorodicyclohexylphosphine (499 µL, 2.26 mmol) was added dropwise over 10 min. The 
reaction mixture was stirred for a further 1 h at -78 °C and for 1.5 h at r.t. before being filtered 
through a plug of Celite
®
 layered over a plug of silica, washing with EtOAc. The solvent was 
removed in vacuo and the resulting white solid recrystallised from acetone to give the title 
compound as white amorphous crystals (914 mg, 79%), mp 188-190 °C; δH (400 MHz, CDCl3) 
6.94 (2H, s, Ar-H), 6.83 (1H, d, J 8.9, Ar-H), 6.76 (1H, d, J 8.9, Ar-H), 3.80 (3H, s, OCH3), 
3.54 (3H, s, OCH3), 2.91 (1H, hept, J 6.9, CH(CH3)2), 2.40 (2H, hept, J 6.9, 2 × CH(CH3)2), 
2.23-2.12 (2H, m, 2 × PCH), 1.84-1.75 (2H, m, Cy-H), 1.72-1.55 (6H, m, Cy-H), 1.42-0.87 
(12H, m, Cy-H), 1.29 (6H, d, J 6.9, CH(CH3)2), 1.18 (6H, d, J 6.9, CH(CH3)2), 0.91 (6H, d, J 
6.9, CH(CH3)2); m/z (ES) 553 (3%), 539 (8), 538 (32), 537 (MH
+
, 100). Found MH
+
, 
537.3854. C35H54O2P requires 537.3861. Data is in agreement with the literature.
192
  
 
2-Phenylamino-thiazol-4-one, 432 
256
 
 
A mixture of phenylthiourea (80%, 7.42 g, 39.0 mmol) and ethyl bromoacetate (4.33 mL, 
39.0 mmol) in EtOH (120 mL) was stirred at 50 °C for 1 h to give an orange solution. Upon 
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cooling, the solvent was removed in vacuo and the residue partitioned between CH2Cl2 (200 
mL) and sat. aq. NaHCO3 (100 mL). The aqueous layer was extracted with CH2Cl2 (100 mL), 
the combined organic layers dried (MgSO4) and the solvent removed in vacuo to give an 
orange solid. Column chromatography eluting with EtOAc/hexane (1:2 → 1:0) afforded the 
title compound as pale orange plates (5.93 g, 79%), mp 186-188 °C; Rf 0.4 (EtOAc/hexane 
1:1); δH (400 MHz, DMSO-d6) (mixture of tautomers) 11.74 (0.5H, s, NH), 11.16 (0.5H, s, 
NH), 7.70 (1H, d, J 7.2, Ar-H), 7.37 (2H, d, J 6.4, Ar-H), 7.15 (1H, t, J 7.2, Ar-H), 7.00 (1H, 
d, J 6.4, Ar-H), 4.01 (1H, s, CHH), 3.96 (1H, s, CHH); m/z (CI) 210 (24%), 194 (25), 193 
(MH
+
, 100), 102 (43), 85 (30). Found MH
+
, 193.0435. C9H9N2OS requires 193.0436. Data is 
in agreement with the literature.
256
 
 
Trifluoro-methanesulfonic acid 2-phenylamino-thiazol-4-yl ester, 433 
 
To a stirred solution of aminothiazolone 432 (1.92 g, 10.0 mmol) and Et3N (4.18 mL, 30.0 
mmol) in CH2Cl2 (150 mL) at 0 °C was added dropwise Tf2O (2.52 mL, 15.0 mmol). The 
reaction mixture was stirred for 30 min before dropwise addition of further Tf2O (0.84 mL, 
5.0 mmol) and stirring for an additional 30 min. The reaction mixture was then poured into sat. 
aq. NH4Cl (100 mL), the organic layer was washed with sat. aq. NaHCO3 (100 mL), dried 
(MgSO4) and the solvent removed in vacuo to give a red oil. Column chromatography eluting 
with EtOAc/hexane (1:10 → 1:4) afforded the title compound as off-white cubes (2.62 g, 
85%), mp 58-61 °C, Rf 0.54 (EtOAc/hexane 1:3); υmax (neat)/cm
-1
 1603, 1530, 1495, 1210, 
1134; δH (400 MHz, CDCl3) 7.96 (1H, s, NH), 7.38 (2H, t, J 7.7, Ar-H), 7.31 (2H, d, J 7.7, 
Ar-H), 7.15 (1H, t, J 7.2, Ar-H), 6.29 (1H, s, thiazole-H); δC (101 MHz, CDCl3) 164.0, 146.8, 
139.0, 129.9, 124.9, 119.8, 118.8 (q, J 321.2), 93.1; δF (377 MHz, CDCl3) -72.6; m/z (ES) 367 
(28%), 366 (12), 326 (14), 325 (MH
+
, 100), 245 (38). Found MH
+
, 324.9930. C10H8N2O3S2F3 
requires 324.9928. 
 
General procedure for aminothiazolone synthesis 
 
To a stirred suspension of the 1-substituted thiourea (1.0 eq.) and NaOAc (1.5 eq.) in EtOH 
(ca. 0.3 M) was added the bromoacetate (1.05 eq.) and the reaction mixture heated at reflux 
until completion (1-5 h). The solvent was removed in vacuo, the residue dissolved in EtOAc, 
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the organic layer washed with sat. aq. NaHCO3, dried (MgSO4) and the solvent removed in 
vacuo. The crude product was purified by column chromatography or recrystallisation. 
 
5-Methyl-2-phenylamino-thiazol-4-one, 437 
256
  
 
According to the general procedure, a suspension of phenylthiourea (2.00 g, 80% grade, 10.5 
mmol), methyl 2-bromopropionate (1.23 mL, 11.1 mmol) and NaOAc (1.30 g, 15.8 mmol) in 
EtOH (30 mL) was heated at reflux for 4 h. Column chromatography eluting with 
EtOAc/hexane (1:2 → 1:1) gave the title compound as a white powder (1.91 g, 88%), mp 
137-139 °C, δH (400 MHz, CDCl3) 11.84 (1H, br s, NH), 7.35 (2H, t, J 7.7, Ar-H), 7.29 (2H, 
d, J 7.4, Ar-H), 7.19 (1H, t, J 7.2, Ar-H), 4.08 (1H, q, J 7.3, CHCH3), 1.59 (3H, d, J 7.3, CH3); 
δC (101 MHz, CDCl3) 183.0, 169.6, 141.8, 129.4, 126.3, 122.8, 46.5, 19.0; m/z (ES) 270 
(19%), 248 (4), 224 (2), 207 (MH
+
, 100). Found MH
+
, 207.0588. C10H11N2OS requires 
207.0590. Data is in agreement with the literature.
192
 
 
5-Phenyl-2-phenylamino-thiazol-4-one, 438 
256
  
 
According to the general procedure, a suspension of phenylthiourea (2.00 g, 80% grade, 10.5 
mmol), 2-bromo phenylacetic acid (2.38 g, 11.1 mmol) and NaOAc (1.30 g, 15.8 mmol) in 
EtOH (150 mL) was heated at reflux for 2.5 h. Recrystallisation (EtOAc) gave the title 
compound as colourless plates (2.39 g, 85%), mp 192-193 °C, δH (400 MHz, CDCl3) 11.59 
(1H, br s, NH), 7.76 (1H, d, J 8.0, Ar-H), 7.45-7.30 (7H, m, Ar-H), 7.18 (1H, q, J 7.6, Ar-H), 
7.09 (1H, d, J 7.7, Ar-H), 5.56 (1H, s, SCH). m/z (ES) 332 (22%), 270 (15), 269 (MH
+
, 100), 
224 (12), 196 (10). Found MH
+
, 269.0753. C15H13N2OS requires 269.0749. Data is in 
agreement with the literature.
192
 
 
5-Fluoro-2-phenylamino-thiazol-4-one, 439 
 
According to the general procedure, a suspension of phenylthiourea (2.00 g, 80% grade, 10.5 
mmol), ethyl bromofluoroacetate (1.31 mL, 11.1 mmol) and NaOAc (1.30 g, 15.8 mmol) in 
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EtOH (30 mL) was heated at reflux for 3 h, before addition of further ethyl 
bromofluoroacetate (0.31 mL, 0.24 mmol) and heating for an additional 1 h. Column 
chromatography eluting with EtOAc/hexane (0:1 → 2:1) followed by recrystallisation (EtOAc) 
gave the title compound as a pale orange powder (1.15 g, 52%), mp 163-164 °C; υmax 
(neat)/cm
-1
 3277, 3213, 2994, 1698, 1633, 1570, 1490, 1448; δH (400 MHz, DMSO-d6) 
(mixture of tautomers) 11.95 (1H, br s, NH), 7.70 (1H, d, J 7.9, Ar-H), 7.43 and 7.40 (1H, 2 × 
t, J 7.8, Ar-H), 7.26-7.18 (1H, m, Ar-H), 7.01 (1H, d, J 7.7, Ar-H), 6.73 and 6.70 (1H, 2 × d, J 
56.6, CHF). δC (101 MHz, DMSO-d6) (mixture of tautomers) 183.6, 183.4, 174.2, 138.0, 
129.5, 129.2, 125.8, 125.5, 121.5, 121.1, 96.7 (d, J 222), 93.5 (d, J 222). δF (377 MHz, 
DMSO-d6) (mixture of tautomers) -157.6 (br s), -160.2 (d, J 56.6); m/z (ES) 252 (32%), 224 
(4), 211 (MH
+
, 100), 196 (8). Found MH
+
, 211.0351. C9H8N2OFS requires 211.0341. 
 
2-Allylamino-thiazol-4-one, 440  
 
According to the general procedure, a suspension of 1-allyl-2-thiourea (500 mg, 4.30 mmol), 
ethyl bromoacetate (0.50 mL, 4.52 mmol) and NaOAc (529 mg, 6.45 mmol) in EtOH (12 mL) 
was heated at reflux for 1 h. Column chromatography eluting with EtOAc/hexane (1:2 → 1:1) 
gave the title compound as a colourless oil (405 mg, 60%), υmax (neat)/cm
-1
 3290, 1713, 1607, 
1422, 1384, 1335; δH (400 MHz, CDCl3) 7.82 (1H, br s, NH), 5.77 (1H, ddd, J 22.6, 10.7, 5.6, 
NHCH2CH), 5.19-5.09 (2H, m, C=CH2), 4.28 (2H, d, J 5.7, NHCH2), 3.84 (2H, s, SCH2); δC 
(101 MHz, CDCl3) 171.3, 160.0, 130.7, 118.0, 44.1, 34.0; m/z (ES) 159 (5%), 158 (8), 157 
(MH
+
, 100). Found MH
+
, 157.0430. C6H9N2OS requires 157.0436.  
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13 Biochemistry – Materials and Methods 
 
Recombinant DNA Techniques 
 
Transformation of Bacterial Cells (Electroporation) 
 
Plasmid DNA (1 μg) was added to competent E. coli DH5α or BL21 cells and the mixture 
electroporated at 2.2 kV using a BioRad Gene Pulser. Following addition of LB (1 mL), the 
resulting suspension was centrifuged (13 krpm) and 800 μL of the supernatant removed. 
Following resuspension of the pellet, the mixture was spread onto antibiotic-supplemented 
agar plates and incubated at 37 °C for 14-24 h. 
 
Enzymatic Digestion of DNA 
 
A mixture of DNA (0.5 μg), the chosen restriction enzymes (total of 1 μL) and the appropriate 
10 × restriction buffer (1 μL) was made up to 10 μL using sterile water and incubated at 37 °C 
for 30 min. For larger volume digests, the quantity of restriction enzyme and subsequent 
incubation time was proportionately increased. For mini-prep DNA digests, 5 μL DNA was 
used along with loading buffer supplemented with RNase A (10 μg/mL). 
 
Agarose Gel Electrophoresis 
 
A suspension of 1% (w/v) agarose in TAE buffer was heated to solution, and upon partial 
cooling ethidium bromide (1 μg/mL) was added before the gel was allowed to set. The 
samples were added in 5 × TAE loading buffer and electrophoresed at 80 mA for 45-60 min. 
Visualisation was performed using UV-C for non-preparative samples or UV-A for 
preparative samples.  
 
Gene Clean DNA Purification 
 
The excised agarose gel bands were incubated with an approximately equal volume of 6 M 
NaI at 65 °C for 5 min. The resulting solution was mixed with glass-milk beads (5 μL) on ice 
for 5 min prior to brief centrifugation (13 krpm, 1 s). The pellet was washed with gene clean 
solution (3 × 500 μL) and resuspended in water (20 μL). Further incubation at 65 °C for 2 min 
was followed by a final centrifugation as before to give the desired DNA solution. 
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Jetsorb Purification 
 
The excised agarose gel bands were incubated with Jetsorb Buffer 1 (300 μL) and Jetsorb 
beads (10 μL) at 65 ºC for 15 min. The resulting suspension was briefly centrifuged at (13 
krpm, 1 s) and the pellet washed with Jetsorb Buffer 1 (300 μL), Jetsorb Buffer 2 (2 × 300 μL) 
and resuspended in water (20 μL). Further incubation at 65 °C for 5 min was followed by a 
final centrifugation as before to give the desired DNA solution.  
 
DNA Ligation 
 
A mixture of purified DNA (16 μL), the chosen DNA ligase (1 μL) and the appropriate 10 × 
ligation buffer (2 μL) was made up to 20 μL using sterile water and incubated at 37 °C for a 
minimum of 3 h, prior to gene clean purification. 
 
PCR Reaction 
 
A mixture of the DNA template (1 μL), the 5’- and 3’-primers (each 1 μL), the mutation-
bearing oligonucleotide (1 μL) and standard PCR components (see Section 15.1) was made up 
to 50 μL with sterile water. PCR was run under conditions dictated by the properties of the 
oligonucleotides used (typical conditions: 15 s, 98 °C; 15 s, 52 °C; 25 cycles), and the 
resulting mixtures were separated by agarose gel electrophoresis.  
 
DNA Sequencing 
 
DNA sequencing was performed commercially by Cogenics. 
 
 
Preparation of Plasmid DNA 
 
Small Scale Preparation of Plasmid DNA (Mini-Prep) 
 
A single colony was removed from the culture plate and added to antibiotic-supplemented LB 
(2 mL) before incubation at 37 °C for 8-12 h in a shaker. A portion (1.5 mL) was centrifuged 
at 13 krpm for 20 s and the resulting pellet resuspended in Solution I (100 μL). The cells were 
then lysed by addition of Solution II (200 μL) and the mixture neutralised by addition of 
Solution III (150 μL). Following centrifugation at 13 krpm for 5 min, the DNA was 
precipitated from the supernatant using NaOAc, pH 5.2 (50 μL) and ethanol (1 mL). 
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Following centrifugation at 13 krpm for 5 min, the resultant pellet was suspended in sterile 
water (50 μL). 
 
Large Scale Preparation of Plasmid DNA (Maxi-Prep) 
 
The 2 mL culture obtained in the above procedure following incubation was added to 
antibiotic-supplemented LB (200 mL) and further incubated at 37 °C for 16 h in a shaker. 
Centrifugation of the resulting suspension at 5 krpm for 5 min at 4 °C was followed by 
resuspension in Solution I (100 μL). Subsequent addition of Solution II (200 μL) and Solution 
III (150 μL) as above was followed by further centrifugation at 9 krpm for 5 min at 4 °C. 
Addition of 
i
PrOH (45 mL) was followed by further centrifugation (9 krpm, 5 min, 4 °C) and 
the resulting DNA pellet was resuspended in sterile water (3 mL) and ice-cold 5 M LiCl (4 
mL). Following incubation on ice for 5 min, centrifugation at 13 krpm for 5 min removed any 
contaminating RNA. Addition of cold ethanol (14 mL) to the supernatant again precipitated 
the DNA and, following centrifugation at 13 krpm for 5 min at 4 °C, the pellet was 
resuspended in sterile water (600 μL). Incubation of this solution with RNase A (10 μL) at 
37 °C for 15 min destroyed any remaining RNA, and contaminating protein was denatured by 
the addition of 1:1 (v/v) phenol/chloroform. Following centrifugation at 13 kprm for 5 min, 
the aqueous layer from this mixture was removed and further extracted with chloroform to 
remove any remaining phenol. Finally, addition of 3 M NaOAc, pH 5.2 (50 μL) and ethanol 
(1 mL) precipitated the purified DNA, and following centrifugation at 13 krpm for 5 min, the 
pellet was resuspended in an appropriate quantity of sterile water to give a concentration of ca. 
1 μg/μL, as determined by UV absorbance (260 nm). 
 
 
Protein Analysis 
 
SDS-Polyacrylamide Gel Electrophoresis 
 
10% SDS-PAGE gels were prepared using standard techniques (see Section 15.1 for gel 
constituents), and the protein samples loaded in SDS loading buffer. Electrophoresis was 
performed using SDS running buffer at 200V for ca. 1 h. Visualisation of the protein bands 
was performed by incubation with either Coomassie blue staining solution for ca. 1-2 h, 
(before being incubated in destaining solution overnight) or Instant Blue
TM
 staining solution 
for 10-20 min. 
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Protein Purification 
 
Purification via GST-Tag Chelation 
 
Antibiotic-supplemented LB (100-3000 mL) was added to a small culture (10-100 mL, 
prepared as above) and the suspension incubated at 37 °C for 1 h in a shaker. Addition of 1 M 
IPTG (0.1% total volume) induced protein expression, and the culture was incubated at 18 or 
37 °C for 4-16 h in a shaker. Centrifugation of the culture at 5 krpm for 5 min at 4 °C was 
followed by resuspension of the cell pellet in NETN (10 mL). Sonication of this suspension to 
lyse the cells (18W, 2 × 30 s, 0 °C) was followed by centrifugation at 9 krpm for 5 min at 
4 °C. The supernatant was added to glutathione-sepharose beads (250 μL, pre-equilibrated by 
washing with NETN) and the resulting suspension mixed by inversion for 1 h at 4 °C. 
Centrifugation at 2 krpm for 1 min at 4 °C gave the pellet of beads, which was washed with 
NETN (3 × 10 mL) and resuspended (NETN, 1 mL) prior to a final centrifugation at 13 krpm, 
for 1 s. The volume of NETN was reduced to approximately 150 μL and an equal volume of 
80% glycerol was added. The resulting mixture was kept on ice for 30 min, with frequent 
mixing by inversion, before storage at -20 °C. 
 
Purification via 2-stage Chromatography 
 
Antibiotic-supplemented LB (100-3000 mL) was added to a small culture (10-100 mL, 
prepared as above) and the suspension incubated at 37 °C for 1 h in a shaker. Addition of 1 M 
IPTG (0.1% total volume) induced protein expression, and the culture was incubated at 18 or 
37 °C for 4-16 h in a shaker. Centrifugation of the culture at 5 krpm for 5 min at 4 °C was 
followed by resuspension of the cell pellet in Buffer A (10 mL). Sonication of this suspension 
to lyse the cells (18W, 2 × 30 s, 0 °C) was followed by centrifugation at 9 krpm for 5 min at 
4 °C. The supernatant was syringe-filtered (0.45 μm) and added to Sepharose SP Fast Flow 
beads (3 mL), pre-equilibrated by washing with Buffer A (15 mL). The suspension was mixed 
by inversion (1 h, 4 °C) and then loaded into a column. The protein was eluted with Buffer A 
plus an increasing linear gradient of NaCl (0-0.5 M). Fractions found in an assay to contain 
high levels of cdc25 were concentrated using a centrifugal filter (Amicon
®
 Ultra-4, 10,000 
NMWL, Millipore). The retentate was then loaded onto a packed gel filtration column 
(Sephadex G-50) and eluted with Buffer B. Fractions found in a fluorimetric assay to contain 
high levels of cdc25 were concentrated as before.  
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Phosphatase Assays 
 
OMFP Fluorimetric Assay 
 
The phosphatase activities of cdc25A, B and C, VHR, PTP1B, MKP-5 and AP were measured 
in Microfluor black 96-well plates in a buffer with final concentration of 400 µM OMFP, 100 
mM Tris pH 8.0, 150 mM NaCl, 1 mM EDTA, 0.1% BME, 5% DMSO. The enzyme 
concentrations for cdc25A, B and C, VHR, PTP1B and MKP-5 were 50-125 ng/well, and the 
inhibitors were tested at concentrations up to 100 µM following 15 min pre-incubation with 
the enzyme. The fluorescence reading was measured using a Cary Eclipse fluorimeter 
(excitation 471 nm, emission 530 nm) over a period of 20-60 min at 25 ºC. 
 
The phosphatase activity of MKP-3 (as a stoichiometric complex with ERK2) was measured 
in clear 96-well plates in a buffer with final concentration of 20 mM PNPP, 50 mM imidazole 
pH 7.5 and 10 mM DTT. The enzyme concentration was 5 µg/well, and the inhibitors were 
tested at concentrations up to 100 µM. The colourimetric reading was measured at 405 nm 
over a period of 60 min at 25 ºC. 
 
 
13.1 Preparation of Constructs 
 
N-GST-cat.cdc25A-pGEX-KG was created by sub-cloning the cdc25A catalytic fragment from 
cat.cdc25A-pRSETA
119
 into pGEX-KG using BamHI and EcoRI. 
 
cat.cdc25A(F432A)-pET21a was created by two-step site-directed mutagenesis of N-GST-
cat.cdc25A-pGEX-KG and sub-cloning the fragment into pET21a using BamHI and HindIII. 
– 5’ end created from pGEX 5’ primer (5'-CAGCAAGTATATAGCATGGC-3’) and 
mutagenic 3’ primer (5'-GGGACCTCTCTCACTCGAGGCCTCGCAGTGAAAC-3’) 
– 3’ end created from pGEX 3’ primer (5'-GAGGTTTTCACCGTCATCAACC-3’) and 
mutagenic 5’ primer (5'-GTTTCACTGCGAGGCCTCGAGTGAGAGAGGTCCC-3’)  
 
cat.cdc25A(R439A)-pET21a was created by two-step site-directed mutagenesis of N-GST-
cat.cdc25A-pGEX-KG and sub-cloning the fragment into pET21a using BamHI and HindIII. 
– 5’ end created from pGEX 5’ primer (5'-CAGCAAGTATATAGCATGGC-3’) and 
mutagenic 3’ primer (5'-CACATACCGGCACATGGCCGGCCCTCTCTCAGA-3’) 
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– 3’ end created from pGEX 3’ primer (5'-
CACATACCGGCACATGGCCGGCCCTCTCTCAGA-3’) and mutagenic 5’ primer (5'-
TCTGAGAGAGGGCCGGCCATGTGCCGGTATGTG-3’)  
 
cat.cdc25A(R439D)-pET21a was created by two-step site-directed mutagenesis of N-GST-
cat.cdc25A-pGEX-KG and sub-cloning the fragment into pET21a using BamHI and HindIII. 
– 5’ end created from pGEX 5’ primer (5'-CAGCAAGTATATAGCATGGC-3’) and 
mutagenic 3’ primer (5’-CACATACCGGCACATGTCCGGACCTCTCTCAGA-3’) 
– 3’ end created from pGEX 3’ primer (5'-
CACATACCGGCACATGGCCGGCCCTCTCTCAGA-3’) and mutagenic 5’ primer (5'-
TCTGAGAGAGGTCCGGACATGTGCCGGTATGTG-3’)  
 
cat.cdc25A-pET21a was created by sub-cloning the cdc25A catalytic fragment from N-GST-
cat.cdc25A-pGEX-KG into pET21a using BamHI and HindIII. 
 
cat.cdc25B-pET21a was created by sub-cloning the cdc25B catalytic fragment from 
cat.cdc25B-pGEM-T
119
 into pET21a using BamHI and XhoI. 
 
cat.cdc25C-pGEM-T was created by truncation of cdc25C-pOTB7
119
 using PCR primers 5'-
GGATCCATGTCTACGGAACTCTTCTCATCC-3’ and 5'-CTCGAGTCATGGGCTCATGTCCTTCACC-3’ 
and ligation of the fragment into pGEM-T.  
 
cat.cdc25C-pET21a was created by sub-cloning the cdc25C catalytic fragment from 
cat.cdc25C-pGEM-T into pET21a using BamHI and XhoI. 
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15  Appendix 
 
15.1 Solution Constitutions 
 
Assay Buffer 100 mM Tris pH 8, 150 mM NaCl, 1 mM EDTA, 0.1% BME 
Buffer A 25 mM Tris pH 7.5, 2 mM DTT, 1 mM EDTA 
Buffer B 25 mM Tris pH 7.5, 2 mM DTT, 1 mM EDTA, 200 mM NaCl 
Coomassie destaining solution 10% (v/v) AcOH, 10% (v/v/) MeOH 
Coomassie staining solution 0.25% (w/v) Coomassie blue dye, 10% (v/v) AcOH, 10% (v/v) MeOH  
Gene clean solution 10mM Tris HCl, 50 mM NaCl, 2.5 mM EDTA, 50% v/v EtOH, pH 7.5 
KOD DNA polymerase 2.5 U μL-1 KOD, 50 mM Tris-HCl, 50 mM KCl, 1 mM DTT, 0.1 mM 
EDTA, 50% (v/v) glycerol, 0.1% (v/v) NP40, 0.1% (v/v) Tween, pH 8.0 
KOD buffer 1 1.2 M Tris-HCl, 100 mM KCl, 60 mM (NH4)2SO4, 1% (v/v) Triton X-
100, 0.01% (w/v) BSA, pH 8.0 
KOD buffer 2 1.2 M Tris-HCl, 100 mM KCl, 60 mM (NH4)2SO4, 1% (v/v) Triton X-
100, 0.01% (w/v) BSA, pH 8.8 
LB 1% (w/v) bactotryptone, 1% (w/v) NaCl, 0.5% (w/v) bactoyeast extract, 
pH 7.0 
M9 micronutrients (per 100 mL) 
 
conc. HCl (8 mL), FeCl2.4H2O (5 g), CaCl2.2H2O (184 mg), H3BO3 (64 
mg), MnCl2.4H2O (40 mg), CoCl2.6H2O (18 mg), CuCl2.2H2O (4 mg), 
ZnCl2 (340 mg), Na2MoO4.2H2O (605 mg) 
M9 minimal medium (per litre)  Na2HPO4 (12.8 g), KH2PO4 (3.0 g), NaCl (0.5 g), NH4Cl (1.0 g), 
glucose (2.0 g), MgSO4.7H2O (0.494 g), CaCl2.H2O (0.015 g), thiamine 
(0.01 g), FeSO4.7H2O (0.01 g), pH 7.4 
M9 vitamins (per litre) biotin (1.1 mg), folic acid (1.1 mg), para-aminobenzoic acid (110 mg), 
riboflavin (110 mg), pantothenic acid (220 mg), pyridoxine HCl (220 
mg), thiamine HCl (220 mg), niacinamide (220 mg), ethanol (500 mL) 
NETN 0.5% (v/v) NP40, 20 mM Tris-HCl, 250 mM NaCl, 1 mM EDTA 
KOD PCR components KOD buffer 1 (5 μL), 25 mM MgCl2 (4 μL), 2 mM dNTPs (5 μL), KOD 
DNA polymerase (0.5 μL) 
Taq PCR components Taq buffer (5 μL), 25 mM MgCl2 (4 μL), 100 mM dNTP (2 μL), Taq 
DNA polymerase (2 μL) 
5 × SDS loading buffer 0.16 M Tris-HCl, pH 6.8, 24% (v/v) glycerol, 5% SDS, 12.5% (v/v) 
BME, 0.1% (w/v) bromophenol blue 
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SDS-PAGE stacking gel 0.1% (v/v) SDS, 5% (v/v) acrylamide, 0.1 M Tris-HCl, pH 6.8 
SDS-PAGE resolving gel 0.2% (v/v) SDS, 10% (v/v) acrylamide, 0.4 M Tris-HCl, pH 8.8 
SDS running buffer 7.8 mM Tris-HCl, 80 mM glycine, 10% (v/v) MeOH, 10% (w/v) SDS 
Solution I 50 mM glucose, 25 mM Tris-HCl, 10 mM EDTA, pH 8 
Solution II 0.2 M NaOH, 1% SDS solution 
Solution III 3 M KOAc, 5 M glacial acetic acid 
TAE 40 mM Tris-acetate, 1 mM EDTA, pH 8.0 
TAE loading buffer TAE + 0.04% (w/v) bromophenol blue, 2.5% (w/v) ficoll 
Taq buffer 100 mM Tris-HCl, 500 mM KCl, 0.8% (v/v) NP40, pH 8.8 
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15.2 Parallel Synthesis – Attempted Reactions 
 
Suzuki coupling (boronic acids or esters) 
 
Successful reactions: 
 
4-pyridyl 4-acetaminophenyl 
2-trifluoromethylphenyl 4-N-Tosyl-aminophenyl 
4-(1-pyrazolylmethyl)-phenyl 2-methoxy-3-hydroxy-4-chlorophenyl 
3-acetamidophenyl 2-pyrrolyl (N-Boc) 
4-(SO2NEt)-phenyl 4-amino-2-fluorophenyl 
4-pyridyl (2-methyl) 2-(N-mesyl)-aminophenyl 
2-mesylphenyl 3-pyridyl (5-fluoro) 
3-mesylphenyl 3-isopropoxy- 4-methoxyphenyl 
3- (1-piperidinylmethyl)phenyl 4-SO2N(cyclopropyl)-phenyl 
5-indolyl 5-(2-aminopyrimidinyl) 
3-fluoro-4-methylphenyl 5-(2-dimethylamino)pyridyl 
4-SO2N(benzyl)phenyl 3-(1-phenyl)pyrazolyl 
3-methoxy-5-fluorophenyl 3-(CO2Et) phenyl 
3-morpholino-phenyl 4-quinolyl 
4-indazolyl 4-(2-dimethylaminoethoxy)phenyl 
2-hydroxy-4-fluorophenyl 3-(5-phenyl)pyrazolyl 
5-(2-methoxy)-pyrimidyl 4-(N-mesyl)aminophenyl 
2-furyl 3-nitrophenyl 
3-carboxyphenyl 4-(1-(2-morpholinoethyl)-)pyrazolyl 
4-(1-isobutyl)-pyrazolyl 4-amino-3-methoxylphenyl 
4-(1-benzyl)-pyrazolyl 4-(1-(thiophen-2-ylmethyl)-pyrazolyl 
5-indazolyl  
 
Unsuccessful reactions: 
 
4-pyrazolyl (3,5-dimethyl, N-Boc) 5-indolyl (N-benzenesulfonyl) 
2-N-Boc-aminophenyl 5-Indolyl (N-Tosyl) 
trans-styryl 4-pyridyl (2,3-dichloro) 
7-benzomorpholine (N-methyl) 2-benzothiophene 
2-methoxy-5-isopropylphenyl 2-isopropoxy-5-fluorophenyl 
2-trifluoromethoxyphenyl 3-pyridyl (2-chloro-4-methyl) 
3-pyridyl (2,6-difluoro) 4-phenoxyphenyl 
4-isoxazolyl 4-(4-methoxybenzyloxy)-phenyl 
4-ethoxy(2-piperidinyl)phenyl 3-pyridyl (5-CO2Et) 
3-pyridyl (4- N-methylpiperazine) 4-pyridyl (3-morpholine) 
3-fluoro-4-(CO2NHNH2)phenyl 5-cyano-benzothiophene 
3-methoxy-4-(N-Boc)aminophenyl 3-indolyl (N-benzenesulfonyl) 
5-(2-cyano)pyrimidinyl 4-(N-succinic acid)phenyl 
8-quinolyl 5-benzimidazolyl 
4-(CONH2)phenyl 5-pyrimidyl 
4-(aminomethyl)-phenyl 4-(3,5-dimethyl)-pyrazolyl 
2-aminophenyl 3-pyridyl (4-methoxy) 
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Aminocarbonylation (amines) 
 
Successful reactions: 
 
 
Unsuccessful reactions: 
 
4-trifluoromethyl aniline  2-aminoimidazole hemisulfate 
4-amino-5-imidazole carboxamide 5-aminosalicyclic acid 
3-amino-5-methylisoxazole 2-amino-5-(4-methoxyphenyl)-1,3,4-thiadiazole 
aminopyrazine 3-amino-1-benzofuran-2-carbonitrile 
3-amino-2-pyrazinecarboxylic acid 3-(trifluoromethyl)-1H-pyrazol-5-amine 
3-aminopyridine-2-carboxylic acid methyl ester D-p-hydroxyphenylglycine methylester 
2-aminobenzimidazole 2-amino-4-tert-butylthiazole 
trifluoromethoxyphenylethylamine 5-amino-1H-[1,2,4]-triazole-3-carboxylic acid methyl ester 
 
 
Aniline Amides (acid chlorides) 
 
Successful reactions: 
 
o-anisoyl chloride benzoyl chloride 
trimethylacetyl chloride acetyl chloride 
o-toluyl chloride propionyl chloride 
isobutyryl chloride cyclopropane carbonyl chloride 
isovaleryl chloride cyclopentane carbonyl chloride 
4-methyloxazole-5-carbonyl chloride nicotinoyl chloride 
isonicotinoyl chloride phenylacetyl chloride 
2-thiophene carbonyl chloride 2-furoyl chloride 
1,5-dimethyl-1H-pyrazole-3-carbonyl chloride 3-methylisoxazole-5-carbonyl chloride 
3-chlorobenzoyl chloride 3,4,5-trimethoxybenzoyl chloride 
2-methyl-2H-pyrazole-3-carbonyl chloride 4-chlorobenzoyl chloride 
p-toluoyl chloride 4-isopropoxybenzoyl chloride 
5-methyl-isoxazole-3-carbonyl chloride 3,5-dimethylisoxazole-4-carbonyl chloride 
5-methyl-4-isoxazole carbonyl chloride  
 
Unsuccessful reactions: 
 
1-methyl-1H-imidazole-5-carbonyl chloride 2,3-dihydro-1,4-benzodioxine-5-carbonyl chloride 
2-methyl-1,3-thiazole-4-carbonyl chloride 4-isopropylbenzoyl chloride 
2,5-dimethyloxazole-4-carbonyl chloride  
 
 
 
 
 
 
 
 
 
morpholine 4-(aminomethyl)pyridine 
4-anisidine isopropylamine  
2-amino-5-ethyl-1,3,4-thiadiazole 4-(3-aminopropyl)morpholine 
1-(3-aminopropyl)-imidazole  cyclohexylamine  
3-(2-thienyl)-1H-pyrazol-5-amine 3-amino-2-pyridinol 
tetrahydrofurfurylamine  2-methoxyethylamine  
4-amino-2-chloropyridine R-1-(4-fluorophenyl)ethylamine 
(1R,2R)-(-)-trans-1-amino-2-indanol 2-aminoethylmethylsulfone  
methyl 4-(aminomethyl)benzoate   
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Aniline amides (carboxylic acids) 
 
Successful reactions: 
 
2-chlorobenzoic acid mono-methyl phthalate 
(S)-(-)-2-pyrrolidine-5-carboxylic acid picolinic acid 
2-hydroxynicotinic acid 2-pyrazinecarboxylic acid 
6-hydroxynicotinic acid 4-cyanobenzoic acid 
4-pyridazinecarboxylic acid 3-cyanobenzoic acid 
5-phenyl-4-isoxazolecarboyxlic acid thianaphthene-2-carboxylic acid 
3-isopropylpyrazole-4-carboxylic acid 5-isopropylisoxazole-3-carboxylic acid 
3-methylpyrazole-5-carboxylic acid 4-methyl-5-thiazole carboxylic acid 
indole-2-carboxylic acid 5-methyl-1H-pyrazole-3-carboxylic acid 
2,4-dimethylthiazole-5-carboxylic acid 3-phenylisoxazole-5-carboxylic acid 
1-methyl-1H-imidazole-2-carboxylic acid [1,2,3]thiadiazole-4-carboxylic acid 
1-methylindazole-3-carboxylic acid 3-isopropylpyrazole-5-carboxylic acid 
2-methoxy-5-sulfamoylbenzoic acid 5-(4-chlorophenyl)-isoxazole-3-carboxylic acid 
5-fluoro-2-methoxybenzoic acid 2,5-dimethoxybenzoic acid 
5-ethoxysalicyclic acid 2-chloronicotinic acid 
4-acetamidobenzoic acid 4-carboxybenzenesulfonamide 
4-dimethylaminobenzoic acid 1-methylpiperidine-4-carboxylic acid hydrochloride 
2,2-difluorocyclopropanecarboxylic acid piperonylic acid 
4-methoxybenzoic acid 4-methoxyphenylacetic acid 
4-toluic acid 4-hydroxymethylbenzoic acid 
4-[(methylsulfonyl)amino]benzoic acid 2-methoxyphenylacetic acid 
6-hydroxypyridine-2-carboxylic acid 2-thiazolecarboxylic acid 
 
Unsuccessful reactions: 
 
4-imidazoleacetic acid hydrochloride 3-methylsalicyclic acid 
1,3-dimethyl-1H-pyrazole-5-carboxylic acid 4-methanesulfonylmethylbenzoic acid 
2-cyanobenzoic acid 3-morpholin-4-yl-propionic acid 
2-pyrrolidin-1-yl-propionic acid hydrochloride indan-2-carboxylic acid 
2,6-dimethylbenzoic acid 5-isopropylisoxazole-4-carboxylic acid 
1-methyl-1H-imidazole-4-carboxylic acid 3-hydroxybenzoic acid 
3-hydroxypicolinic acid 4-pyrazolecarboxylic acid 
salicyclic acid 1-piperidinepropionic acid 
 
 
Sulfonamides (sulfonyl chlorides) 
 
Successful reactions: 
 
methanesulfonyl chloride 4-methoxybenzenesulfonyl chloride 
1-butanesulfonyl chloride 2-fluorobenzenesulfonyl chloride 
3,5-dimethylisoxazole-4-sulfonyl chloride 4-(chlorosulfonyl)benzoic acid 
phenylmethanesulfonyl chloride 2,3-dihydro-1,4-benzodioxine-6-sulfonyl chloride 
2-phenylethanesulfonyl chloride thiophene-2-sulfonyl chloride 
tetrahydrothiophene-3-sulfonyl chloride 1,1-dioxide 1-methyl-1H-pyrazole-3-sulfonyl chloride 
2-oxo-2,3-dihydro-1,3-benzoxazole-6-sulfonyl chloride furan-2-sulfonyl chloride 
furan-3-sulfonyl chloride 1-methylimidazole-4-sulfonyl chloride 
1,5-dimethyl-1H-pyrazole-4-sulfonyl chloride 2H-[1,2,4]-triazole-3-sulfonyl chloride 
 
Unsuccessful reactions: 
 
pyridine-3-sulfonyl chloride hydrochloride methyl-3-(chlorosulfonyl)-2,2-dimethylpropanoate 
5-methyl-4-isoxazolesulfonyl chloride 4-chlorosulfonylpyrazole 
3-chlorobenzenesulfonyl chloride  
 
 
 
- 272 - 
 
Ureas (isocyanates) 
 
Successful reactions: 
 
phenylisocyanate  ethylisocyanate  
benzylisocyanate  cyclohexylisocyanate  
tert-butylisocyanate  3-chlorophenylisocyanate 
2-chlorophenylisocyanate  3-cyanophenylisocyanate 
3-methoxyphenylisocyanate  4-methoxyphenylisocyanate  
2-methoxyphenylisocyanate trimethylsilylisocyanate 
 
Unsuccessful reactions: 
 
4-chlorophenylisocyanate  
 
 
Buchwald-Hartwig couplings (halides) 
 
Successful reactions: 
 
2-bromopyridine 2-bromo-6-methoxypyridine 
3-bromo-6-methoxypyridine 3-chloro-6-methylpyridazine 
2-bromopyrimidine 2-chloro-3-trifluoromethylpyridine 
2-chloro-4-fluoropyridine 4-chlorothienylpyrimidine 
 
Unsuccessful reactions: 
 
5-bromo-2-cyanopyrimidine 3-bromo-5-(CO2Me)-1-methylpyrrole 
3-bromo-5-cyanopyridine 4-bromo-1-methylpyrazole 
2-bromo-6-(CO2Me)-pyridine 4-bromo-2-methoxythiazole 
7-bromoindole 2-bromo-5-(CO2Et)-thiophene 
2-bromo-4-methylanisole  
 
 
Buchwald-Hartwig couplings (amines) 
 
Successful reactions: 
 
morpholine 3-aminopyridine 
4-aminopyridine 3-anisidine 
2-anisidine 4-toluidine 
4-anisidine 4-aminoacetanilide 
3-trifluoroaniline 4-trifluoroaniline 
3,5-di-(trifluoro)aniline 4-isopropylaniline 
N-(3-aminophenyl)-methanesulfonamide 3-aminobiphenyl 
3,4-dimethylaniline 5-aminoindole 
3,4-dichloroaniline 6-amino-1,4-benzodioxane 
 
Unsuccessful reactions: 
 
4-piperidinecarboxamide benzylamine 
N-(3-aminopropyl)-2-pyrrolidinone 4-methoxybenzylamine 
2-aminomethylpyridine 2-(2-aminoethyl)-1-methylpyrrolidine 
furfurylamine 4-(3-aminopropyl)morpholine 
4-aminophenol 2-oxopiperazine 
N-methylbenzylamine 3-aminobenzoic acid 
4-amino-5-imidazolecarboxamide 5-amino-3-methylisoxazole 
N,N-dimethyl-4-phenylene diamine tryptamine 
anthranilic acid 2-(2-furyl)-1H-pyrazole-5-amine 
2-methoxybenzylamine 6-aminoindazole 
3-cyclopropyl-1H-pyrazole-5-amine  
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One-pot consecutive Suzuki couplings (boronic acids or esters) 
 
Successful reactions: 
 
4-methoxyphenyl 4-(methanesulfonyl)phenyl 
3-aminocarbonylphenyl 4-(methoxymethyl)phenyl 
3-(methanesulfonylamino)phenyl 7-(4-methyl-3,4-dihydro-2H-1,4-benzoxazinyl) 
4-aminocarbonylphenyl 2-methoxyphenyl 
4-tolyl 3-hydroxyphenyl 
4-hydroxyphenyl 3-methoxyphenyl 
2-tolyl 4-trifluorophenyl 
3-tolyl 3-trifluorophenyl 
5-(2-N,N-dimethylaminopyridinyl) 4-(methoxycarbonyl)phenyl 
2,5-dimethoxyphenyl 4-fluorophenyl 
5-pyrimidinyl 4-(methanesulfonylamino)phenyl 
5-(2-methoxypyrimidyl) 2-methoxy-5-methylphenyl 
3-(ethoxycarbonyl)phenyl 2-furyl 
5-(1-methylpyrazolyl) 3-quinolinyl 
3-acetamidophenyl 4-acetamidophenyl 
4-morpholinophenyl 5-indolyl 
5-(2-N-methylpiperazinyl-pyridinyl) 3-(piperidin-1-ylmethyl)phenyl 
 
Unsuccessful reactions: 
 
benzyl 4-(hydroxymethyl)phenyl 
3-thienyl 5-(2,4-dimethoxypyrimidinyl) 
4-carboxylphenyl 4-pyrazolyl 
3,5-dimethylisoxazolyl 5-(2-cyanopyrimidinyl) 
4-indazolyl 3-(4-methoxypyridinyl) 
4-(SO2N-cyclopropyl)phenyl 5-(2-aminopyrimidinyl) 
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15.3 Full In Vitro Phosphatase Assay Results for Synthesised Compounds 
 
The table below gives abbreviated initial assay data for all the compounds both synthesised 
and tested in this project, shown in the order tested. The standard error for each activity or 
IC50 measurement is omitted for clarity and brevity. 
 
 Cdc25A VHR 
 Activity (%)  Activity (%)  
ID 50 µM 10 µM IC50 (µM) 50 µM 10 µM IC50 (µM) 
JCC-CRT-161 33 100  24 106  
JCC-CRT-166 25 101  43 125  
JCC-CRT-167 -3 91 11.0 6 93 10.5 
JCC-CRT-168 59 100  83 118  
JCC-CRT-172 54 111  43 118  
JCC-CRT-179 48 107  46 129  
JCC-CRT-180 25 85 10.8 32 114 16.2 
JCC-CRT-181 90 110  97 145  
JCC-CRT-231 104 109  102 136  
JCC-CRT-232 39 111 16.8 22 117 17.8 
JCC-CRT-234 54 98  27 127 100 
JCC-CRT-235 14 110 21.0 38 122 23.1 
JCC-CRT-237 127 109  117 126  
JCC-CRT-245 22 108 23.1 19 122 16.7 
JCC-CRT-249 76 128  52 101  
JCC-CRT-250 67 130  95 128  
JCC-CRT-251 20 113 13.3 -9 72 15.4 
JCC-CRT-252 100 137  51 117  
JCC-CRT-256 100 132  86 132  
JCC-CRT-257 26 111 28.1 50 128  
JCC-CRT-259 12 100 15.0 13 103 21.9 
JCC-CRT-260 14 112 12.4 2 92 16.1 
JCC-CRT-284 -11 42 1.17 -13 27 2.60 
JCC-CRT-10 68 127  92 92  
JCC-CRT-13 56 126  54 99  
JCC-CRT-16 65 100  44 51 25.1 
JCC-CRT-17 76 89  -11 -16 16.7 
JCC-CRT-22 18 104 31.5 5 55 39.0 
JCC-CRT-23 76 107  6 35 25.1 
JCC-CRT-24 36 69 25.6 15 52 12.6 
JCC-CRT-27 70 133  99 119  
JCC-CRT-29 39 103 22.5 -2 62 20.5 
JCC-CRT-30 75 128  4 58 26.6 
JCC-CRT-31 89 123  107 84  
JCC-CRT-32 62 96  14 62 16.6 
JCC-CRT-34 23 109 100 84 88  
JCC-CRT-35 86 151  75 103  
JCC-CRT-36 119 129  212 138  
JCC-CRT-51 80 135  34 99 75 
JCC-CRT-54 124 127  131 125  
JCC-CRT-55 97 115  87 82  
JCC-CRT-56 46 97  -14 18 15.7 
JCC-CRT-57 46 103 75 52 75 9.65 
JCC-CRT-59 37 109 16.7 69 149  
JCC-CRT-60 70 106  95 116  
JCC-CRT-62 50 61 24.4 58 102  
JCC-CRT-63 74 123  86 114  
JCC-CRT-65 86 99  92 108  
JCC-CRT-67 87 105  98 88  
JCC-CRT-68 112 112  109 142  
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JCC-CRT-69 81 112  69 94  
JCC-CRT-71 135 145  188 108  
JCC-CRT-72 62 123  65 73  
JCC-CRT-73 64 86  -3 36 15.6 
JCC-CRT-74 94 119  85 100  
JCC-CRT-75 57 128  14 70 15.6 
JCC-CRT-77 21 111 24.9 84 84  
JCC-CRT-92 38 130 40.4 57 112  
JCC-CRT-95 89 122  91 117  
JCC-CRT-97 91 116  62 126  
JCC-CRT-99 50 95 14.5 69 102  
JCC-CRT-100 71 132  72 92  
JCC-CRT-101 155 146  180 109  
JCC-CRT-102 84 139  66 99  
JCC-CRT-103 80 143  5 110 13.3 
JCC-CRT-106 46 129 100 7 61 10.7 
JCC-CRT-109 97 140  -7 41 18.9 
JCC-CRT-113 40 101 48.0 27 104 8.85 
JCC-CRT-80 105 136  64 92  
JCC-CRT-81 111 141  71 128  
JCC-CRT-307    62 135  
JCC-CRT-308    -11 79 39.6 
JCC-CRT-309    -11 114 36.4 
JCC-CRT-313    1 91 45.1 
JCC-CRT-315    9 123 100 
JCC-CRT-83 194 143  135 151  
JCC-CRT-84 109 119  103 137  
JCC-CRT-85 110 122  41 124 75 
JCC-CRT-114 44 105 50.8 44 111 17.0 
JCC-CRT-115 121 172  127 121  
JCC-CRT-117 88 135  109 124  
JCC-CRT-118 106 167  101 158  
JCC-CRT-119 62 139  80 107  
JCC-CRT-129 50 161 18.1 45 134 5.29 
JCC-CRT-130 61 104  96 107  
JCC-CRT-131 117 178  87 94  
JCC-CRT-132 45 98  12 77  
JCC-CRT-136 61 132  23 72 39.4 
JCC-CRT-139 39 133  63 122  
JCC-CRT-140 101 155  101 98  
JCC-CRT-142 66 109  26 125 33.9 
JCC-CRT-143 134 217  135 125  
JCC-CRT-151 89 126  91 111  
JCC-CRT-152 106 152  33 51 22.0 
JCC-CRT-153 33 112 25.1 41 84 16.0 
JCC-CRT-154 227 264  107 101  
JCC-CRT-155 77 127  74 69  
JCC-CRT-156 172 293  19 70 75 
JCC-CRT-157 38 87 75 71 115  
JCC-CRT-158 56 95  6 114 42.2 
JCC-CRT-159 62 86  83 107  
JCC-CRT-160 64 91  132 129  
JCC-CRT-162 41 84 26.6 108 135  
JCC-CRT-163 107 164  168 229  
JCC-CRT-164 31 19 46.9 54 76 17.7 
JCC-CRT-165 61 89  105 109  
JCC-CRT-169 27 17 39.5 130 153  
JCC-CRT-171 74 116  141 172  
JCC-CRT-173 52 62 26.6 121 126  
JCC-CRT-174 64 87  128 153  
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JCC-CRT-175 75 84  129 157  
JCC-CRT-228 100 170  167 193  
JCC-CRT-229 61 62  71 68  
JCC-CRT-233 80 92  19 67 5.26 
JCC-CRT-236 75 62  59 49 14.7 
JCC-CRT-238 55 83  43 74  
JCC-CRT-255 85 80  90 128  
JCC-CRT-261 74 84  88 151  
JCC-CRT-262 36 78 21.6 40 91 30.8 
JCC-CRT-263 92 91  124 135  
JCC-CRT-264 81 90  111 107  
JCC-CRT-265 93 113  35 95 46.7 
JCC-CRT-266 79 72  83 83  
JCC-CRT-268 99 144  121 150  
JCC-CRT-269 38 145  85 176  
JCC-CRT-270 82 101  54 112  
JCC-CRT-271 166 170  209 195  
JCC-CRT-272 75 107  -12 127  
JCC-CRT-273 53 64  78 89  
JCC-CRT-274 61 78  88 131  
JCC-CRT-275 28 32 51.4 43 57 20.2 
JCC-CRT-277 98 132  131 190  
JCC-CRT-278 46 76 46.5 85 114  
JCC-CRT-280 40 75 9.44 104 135  
JCC-CRT-285 53 62  92 122  
JCC-CRT-206 19 58 23.7 61 103  
JCC-CRT-207 36 91 20.0 26 134 12.6 
JCC-CRT-208 37 57 14.9 26 121 8.50 
JCC-CRT-209 47 58  82 130  
JCC-CRT-210 52 89  18 56 22.5 
JCC-CRT-211 27 47 26.1 15 86 9.23 
JCC-CRT-212 37 57 32.1 65 98  
JCC-CRT-214 26 55 28.6 71 109  
JCC-CRT-215 25 85 47.9 43 111 7.03 
JCC-CRT-216 35 43 45.1 57 108  
JCC-CRT-217 125 86  135 155  
JCC-CRT-218 36 41 18.2 42 74 5.59 
JCC-CRT-183 10 105  39 124  
JCC-CRT-184 31 57 100 37 44 22.8 
JCC-CRT-185 21 47 150 48 56 42.2 
JCC-CRT-186 23 68  6 10  
JCC-CRT-189 25 70  38 84  
JCC-CRT-190 50 72  65 52 39.8 
JCC-CRT-191 23 67 150 196 167  
JCC-CRT-192 -1 11  54 65  
JCC-CRT-193 -5 10 100 16 24 9.29 
JCC-CRT-194 52 75  14 90 75 
JCC-CRT-195 12 29 47.2 -6 6 13.3 
JCC-CRT-197 -7 10 3.21 16 21 11.7 
JCC-CRT-199 23 127 34.4 91 112  
JCC-CRT-200 -8 22 26.5 7 48 17.5 
JCC-CRT-201 -5 95 75 -10 40 13.1 
JCC-CRT-203 7 80 58.4 9 77 22.4 
JCC-CRT-204 49 100  91 120  
JCC-CRT-205 39 57 300 75 118  
JCC-CRT-241 -3 3  26 82  
JCC-CRT-242 8 23 75 56 67  
JCC-CRT-243 53 137  18 102  
JCC-CRT-244 89 81  78 78  
JCC-CRT-248 18 42 30.3 2 21 10.3 
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JCC-CRT-324 18 48 75 10 30 25.8 
JCC-CRT-331 43 77 200 21 32 38.9 
JCC-CRT-332 51 85  22 61 53.8 
JCC-CRT-334 33 132 29.7 24 54 20.6 
JCC-CRT-338 20 83 50 -12 38 50 
JCC-CRT-339 29 114 100 54 110  
JCC-CRT-340 38 79 47.1 61 51 50 
JCC-CRT-341 15 115  -3 84  
JCC-CRT-346 12 90 100 10 85 26.8 
JCC-CRT-351 14 53 33.4 15 71 7.13 
JCC-CRT-352 30 184 200 89 130  
JCC-CRT-357 27 83 60 53 111  
JCC-CRT-358 76 90  39 80 45.0 
JCC-CRT-359 79 124  87 98  
JCC-CRT-367 79 86  28 84 26.9 
JCC-CRT-370 104 119  41 91 13.3 
JCC-CRT-373 96 124  34 112 14.6 
JCC-CRT-374 126 127  25 89 30.9 
JCC-CRT-376 62 107 50.6 57 79  
JCC-CRT-377 89 153  13 116 27.5 
JCC-CRT-378 63 100 21.0 84 81  
JCC-CRT-380 128 132  17 94 21.8 
JCC-CRT-381 95 107  10 64 30.9 
JCC-CRT-382 128 129  9 75 20.5 
JCC-CRT-383 101 102  -5 73 25.1 
JCC-CRT-384 122 156  110 113  
JCC-CRT-398A 69 103  57 49 29.1 
JCC-CRT-398B 96 109  32 75 27.1 
JCC-CRT-398C 92 98  67 84  
JCC-CRT-402 91 137  36 113 22.2 
JCC-CRT-403 67 142  36 87 27.6 
JCC-CRT-404 120 171  40 98 50.3 
JCC-CRT-405 61 119  12 77 28.7 
JCC-CRT-406 67 170  -8 97 16.2 
JCC-CRT-407 73 131  15 52 18.8 
JCC-CRT-408 71 145  27 123 12.6 
JCC-CRT-409 82 115  32 36 19.7 
JCC-CRT-410 80 137  52 94  
JCC-CRT-411 16 155 41.7 17 100 28.3 
JCC-CRT-412 5 146 39.4 10 112 27.2 
JCC-CRT-413 61 105 100 32 10 29.1 
JCC-CRT-414 138 166  24 59 39.6 
JCC-CRT-415 70 131  58 33 34.7 
JCC-CRT-416 110 179  13 42 28.3 
JCC-CRT-417 109 160  109 84  
JCC-CRT-418 159 209  7 141 32.1 
JCC-CRT-419 113 149  41 66 23.6 
JCC-CRT-421 218 231  126 182  
JCC-CRT-423 130 161  29 51 25.5 
JCC-CRT-424 154 174  45 92 14.2 
JCC-CRT-427 116 159  2 110 20.6 
JCC-CRT-428 165 177  0 36 13.6 
JCC-CRT-429 145 185  49 50 12.9 
JCC-CRT-430 166 231  29 81 13.8 
JCC-CRT-431 86 97  59 69  
JCC-CRT-432 127 140  78 147  
JCC-CRT-437 85 97  6 52 16.1 
JCC-CRT-438 64 85  -6 24 10.1 
JCC-CRT-439 229 195  148 138  
JCC-CRT-440 170 179  126 131  
 
